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Patient-Derived Colorectal Cancer Organoids Upregulate Revival Stem Cell Marker Genes
Following Chemotherapeutic Treatment
Reprinted from: J. Clin. Med. 2020, 9, 128, doi:10.3390/jcm9010128 . . . . . . . . . . . . . . . . . . 1
Claudia De Vitis, Giacomo Corleone, Valentina Salvati, Francesca Ascenzi, Matteo Pallocca, 
Francesca De Nicola, Maurizio Fanciulli, Simona di Martino, Sara Bruschini, 
Christian Napoli, Alberto Ricci, Massimiliano Bassi, Federico Venuta, 
Erino Angelo Rendina, Gennaro Ciliberto and Rita Mancini
B4GALT1 Is a New Candidate to Maintain the Stemness of Lung Cancer Stem Cells
Reprinted from: J. Clin. Med. 2019, 8, 1928, doi:10.3390/jcm8111928 . . . . . . . . . . . . . . . . . 15
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Preface to ”New Aspects of Cancer Stem Cell Biology:
Implications for Innovative Therapies”
The cancer stem cell (CSC) paradigm represents one of the most prominent breakthroughs of
the last decades in tumor biology. CSCs are broadly defined as a subpopulation of tumor cells
that, besides sharing some functional features with normal stem cells (self-renewal, low cycling
rate, and differentiation capacity), can drive tumor initiation, to rebuild the heterogeneity of the
original tumor, to evade the immune system, and to escape conventional treatments such as chemo-
and radiotherapy. In light of these properties, CSCs have been implicated in tumor metastasis
and recurrence. Nevertheless, the biological characteristics of CSCs, their molecular profile, their
contribution to cancer progression, and even their existence, remain matters of intense debate and
controversy among tumor biologists. The difficulty in achieving a better definition of CSC biology
may be explained by the plasticity of such a cell subpopulation. Indeed, the emerging view is that
CSCs represent a dynamic “state” of tumor cells that can acquire stemness-related properties under
specific circumstances, rather than referring to a well-defined group of cells.
Regardless of their origin, it is clear that designing novel anti-tumor treatments based on the
eradication of CSCs will only be possible upon unraveling the biological mechanisms that underlie
their pathogenic role in tumor progression and therapy resistance. The Special Issue on “New Aspects
of Cancer Stem Cell Biology: Implications for Innovative Therapies” will highlight recent insights into
CSC features that can make them an attractive target for novel therapeutic strategies.
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Abstract: Colorectal cancer stem cells have been proposed to drive disease progression, tumour
recurrence and chemoresistance. However, studies ablating leucine rich repeat containing G
protein-coupled receptor 5 (LGR5)-positive stem cells have shown that they are rapidly replenished in
primary tumours. Following injury in normal tissue, LGR5+ stem cells are replaced by a newly defined,
transient population of revival stem cells. We investigated whether markers of the revival stem
cell population are present in colorectal tumours and how this signature relates to chemoresistance.
We examined the expression of different stem cell markers in a cohort of patient-derived colorectal
cancer organoids and correlated expression with sensitivity to 5-fluorouracil (5-FU) treatment.
Our findings revealed that there was inter-tumour variability in the expression of stem cell markers.
Clusterin (CLU), a marker of the revival stem cell population, was significantly enriched following
5-FU treatment and expression correlated with the level of drug resistance. Patient outcome data
revealed that CLU expression is associated with both lower patient survival and an increase in disease
recurrence. This suggests that CLU is a marker of drug resistance and may identify cells that drive
colorectal cancer progression.
Keywords: bowel cancer; organoid; tumoroid; colorectal; colon; stem cell; chemotherapy resistance
1. Introduction
Colorectal cancer (CRC) is the most frequently diagnosed cancer of the digestive tract and
a principal cause of cancer-related deaths worldwide [1,2]. The majority of deaths from CRC can be
attributed to cancer recurrence after initial treatment, which presents as distant metastases in secondary
sites such as the liver or lung. If left untreated, the 5 year survival rate of patients with metastatic
CRC can be as low as 5% [3,4]. Combined chemotherapy treatment, which includes the commonly
J. Clin. Med. 2020, 9, 128; doi:10.3390/jcm9010128 www.mdpi.com/journal/jcm1
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used drug 5-fluorouracil (5-FU), can help to increase this survival rate [5,6]. However, development
of more targeted and personalised treatments are necessary to decrease overall CRC mortality [7].
Understanding the mechanisms underlying resistance to common treatments incorporating 5-FU is
complex and requires further elucidation in models that recapitulate the diversity of primary tumours
arising [8].
Cellular heterogeneity is a feature of CRC tumours, where only a subset of cells display
tumour-initiating activity [9,10]. The cancer stem cell (CSC) hypothesis supports a model where a small
population of stem cells drive tumour growth and metastasis and may even predict disease relapse [11].
Furthermore, CSCs may enter a quiescent state, rendering them inherently resistant to anti-proliferative
drugs. They may also stimulate tumour recurrence following therapy. [12]. CSC markers are promising
prognostic biomarkers and therapeutic targets. However, several studies have now demonstrated the
considerable plasticity of stem cell populations within tumours which creates further complexity when
targeting these cell populations [13,14]. Characterising the dynamics of these cell populations in response
to chemotherapeutic challenge is therefore of critical importance.
Normal intestinal crypt-based columnar (CBC) stem cell markers, including leucine rich repeat
containing G protein-coupled receptor 5 (LGR5) and EPH receptor B2 (EPHB2), have been shown
to be over-expressed in colorectal adenocarcinomas, and colorectal tumours that display a stem cell
signature correlate with a decrease in disease-free survival of patients and an increase in relapse [15,16].
However, specific targeted ablation of LGR5+ cells in cancerous tissues revealed that the LGR5+
stem cell population is dispensable for primary tumour maintenance [13,14,17]. This is also the case
when LGR5+ cells are deleted within the intestinal epithelium during normal homeostasis [17,18].
In normal tissues and tumours, it appears that cellular plasticity within intestinal cell populations
allows LGR5- progenitors to revert back into a stem-like state and reconstitute the ablated LGR5+
stem cells [13,14,17,18]. In normal tissue, a quiescent reserve population of stem cells marked by BMI1
polycomb ring finger proto-oncogene (BMI1) has been postulated to be activated upon damage and
regenerate lost Lgr5+ cells [18,19]. Whether a population of cells with these characteristics are present
in tumours is unclear. However, colon tumours with elevated levels of BMI1 have been associated
with reduced overall patient survival [20].
Recently, a novel unique stem cell population, marked by clusterin (CLU) and annexin A1 (ANXA1)
expression, has been identified by single cell RNA sequencing in normal mouse small intestinal tissue.
This stem cell pool is activated at the onset of tissue injury and repopulates the damaged small
intestinal crypts, including the LGR5+ stem cell population [21]. The exact role of this revival stem cell
population in a cancer context remains yet to be determined.
In this study, we aim to characterise the expression profile of the revival, CBC and quiescent stem
cell markers in colorectal cancer and examine how this expression is modified upon chemotherapeutic
treatment with 5-FU. To achieve this objective, we make use of patient-derived colorectal tumour
organoids that were generated from treatment-naïve patients. This enables analysis of expression
of stem cell markers in a cohort of organoid lines derived directly from patients. Subsequently,
we investigate how the profile of different stem cell markers correlates with resistance to therapy and
patient survival.
2. Experimental Section
2.1. Ethics and Consent
This study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Cabrini Human Research Ethics Committee (CHREC 04-19-01-15) and the Monash
Human Research Ethics Committee (MHREC ID 2518). Patient recruitment was led by the colorectal
surgeons in the Cabrini Monash University Department of Surgery. Tissue was obtained from treatment
naïve patients diagnosed with colorectal cancer undergoing surgical resection at the Cabrini Hospital,
Malvern, Australia. All subjects provided written informed consent.
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2.2. Patient Data
Patient information including clinical characteristics, treatment regimen and outcome data
(Table S1) was obtained from the prospectively maintained, clinician-led Cabrini Monash University
Department of Surgery colorectal neoplasia database (CMCND) [22]. This dataset has been adopted in
a minimum dataset format as the Binational Colorectal Cancer Audit of the Colorectal Surgical Society
of Australia and New Zealand (https://cssanz.org/bcca-database/).
2.3. Establishing Colorectal Cancer Organoids
CRC tissue specimens were cut into 5 mm pieces and washed eight times with 1×PBS supplemented
with antibiotics. Tissue fragments were digested with 0.125 mg/mL dispase type II (Sigma, St Louis,
MO, USA) and 1 mg/mL collagenase A (Roche Diagnostics, Mannheim, Germany) at 37 ◦C for 30 min
and then mechanically dissociated by repetitive pipetting in cold PBS. Cancer tissue fragments were
allowed to settle by gravity before supernatant was collected and pelleted by centrifugation at 240× g
for 5 min at 4 ◦C. The isolated cells/fragments were passed through a 70 μm cell strainer (Corning, NY,
USA), centrifuged and resuspended in Matrigel (Corning).
Matrigel containing cancer cell clusters were seeded into 24-well tissue culture plates (Thermo
Scientific Nunc, Foster City, CA, USA) and allowed to polymerize for 10 min at 37 ◦C. The cancer
cells were overlaid with 500 μL of culture medium composed of advanced Dulbecco’s modified Eagle
medium/F12 supplemented with 1X B27, Glutamax, 10 mM HEPES (all from Gibco, Waltham, MA,
USA), 100 μg/mL Primocin (InvivoGen, San Diego, CA, USA), 50 ng/mL recombinant human EGF
(Peprotech, Rochy Hill, NJ, USA), 10 nM Gastrin (Sigma), 500 nM A83-01 (Tocris Bioscience, Bristol,
UK), 1.25 mM N-acetylcysteine (Sigma), 10 mM nicotinamide (Sigma) and 100 ng/mL recombinant
human Noggin (Peprotech) or 10% Noggin conditioned media, 20% R-spondin1 conditioned media.
Following initial seeding of the cultures, 10 μM Y-27632 dihydrochloride kinase inhibitor (Tocris
Bioscience) was also added to the media for 2–3 days.
2.4. Organoid Drug Sensitivity Testing
After the establishment of cancer-derived organoids, organoids were dissociated using TrypLE Express
enzyme (Gibco) and re-seeded in Matrigel into a 48-well plate in triplicate. Organoids were cultured in
complete media until small organoids were formed. Reference viability values were determined at day 0
by adding 200 μL of 1X Presto Blue reagent (Invitrogen, Carlsbad, CA, USA) diluted in culture medium to
each well. Organoids were incubated for 45 min at 37 ◦C before the Presto Blue solution was removed into
a black microplate and the fluorescence was measured (excitation of 560 nm and an emission of 590 nm)
on the PHERAstar FS (BMG Labtech, Ortenberg, Germany). Complete media supplemented with 0, 0.1,
1, 10, 20 and 50 μm 5-fluorouracil (5-FU) (Sigma) was replaced onto the organoids at day 0 and day 2.
Cell viability was measured at day 5, as for day 0.
2.5. Histological Sections
Primary tissue samples were fixed in 4% paraformaldehyde (PFA) and embedded in paraffin
blocks. Mature organoids were fixed in 4% PFA before being dissociated from the Matrigel. Organoids
were collected into a tube and gently centrifuged before being embedded into low melting agarose
(2% diluted in PBS). The agarose blocks were processed before being embedded into paraffin. Sections
(4 μm) of both primary tissue and patint-matched organoids were subjected to routine haematoxylin
and eosin (H&E) staining.
2.6. Immunohistochemistry
The immunohistochemical procedure was conducted as previously described [23]. Briefly, slides
were deparaffinized in histosol and rehydrated in graded alcohols. Antigen retrieval was performed by
heating the slides for 10 min in a pressure cooker in 10 mM citrate buffer (pH = 6). Slides were blocked
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with CAS block (Invitrogen) for 1 h at room temperature. Sections were incubated overnight at 4 ◦C with
the primary antibody diluted in PBS containing 1% bovine serum albumin. The following antibodies
were used: anti-cleaved caspase 3 (Cell Signaling Technology, Danvers, MA, USA), anti-Cytokeratin
20 (Roche Ventana, Oro Valley, AZ, USA), anti-caudal type homeobox 2 (CDX2) (Abcam, Cambridge,
UK) and anti-LGR5 ([24] gift from Dr Melissa R. Junttila, GenenTech, South San Francisco, CA, USA)
(Table 1). For the detection of primary antibodies, sections were exposed to anti-goat or anti-rabbit
horseradish peroxidase coupled antibodies (Life technologies, Carlsbad, CA, USA) in PBS with 1%
bovine serum albumin for 1 h at room temperature. Peroxidase activity was detected with the 3,
3′-diaminobenzidine (DAB) liquid kit (Dako, Burlingame, CA, USA). Sections were counterstained
with haematoxylin, dehydrated and mounted. Imaging was carried out using a Zeiss Axio Imager
running ZEN digital imaging software (Carl Zeiss, Oberkochen, Germany).
Table 1. List of antibodies used for immunohistochemistry.
Antibodies/Dye Host Dilution Supplier Cat/Lot number
Primary
Cleaved Caspase 3 (Asp175) Rabbit 1:250 Cell Signaling 9661S
Cytokeratin 20 (CK20) (SP33) Rabbit 1:1 Roche Ventana 790-4431
Caudal type homeobox 2 (CDX2) Rabbit 1:1000 Abcam Ab76541
Leucine rich repeat containing G
protein-coupled receptor 5 (LGR5) Rabbit 1:200 Genentech n/a
Secondary
Anti-rabbit horseradish peroxidase Goat 1:200 Life Technologies G21234
2.7. Quantitative RT–PCR Analysis
Total RNA was isolated from tumour-derived organoids using the RNeasy Micro kit (Qiagen,
Hilden, Germany). cDNA was synthesized from 400 ng of total RNA using QuantiTect Reverse
Transcription Kit (Qiagen). Quantitative PCR was performed in technical triplicates on a LightCycler
480 II (Roche) using QuantiNova SYBR® Green PCR Kit with thermal cycle as follows: 95 ◦C for 10 min,
45 cycles of 95 ◦C for 20 s, 60 ◦C for 30 s followed by 72 ◦C for 40 s. The average expression levels
(2−ΔCt) for each gene was calculated relative to beta-2-microglobulin and β-actin expression levels.
The primers used in the current study are listed in Table 2.
Table 2. List of primers used for qPCR analysis.
Gene Forward Primer Sequences Reverse Primer Sequences Product Length (bp)
ACTB CTGGCACCACACCTTCTACAATG GGTCTCAAACATGATCTGGGTC 124
ANXA1 TTTGCAAGAAGGTAGAGATAAAGAC GGATGACTTCACAGTTTGAACAT 121
B2M GTGCTCGCGCTACTCTCTC GTCAACTTCAATGTCGGAT 142
BMI1 GGTACTTCATTGATGCCACAACC CTGGTCTTGTGAACTTGGACATC 104
CLU CAGGCCATGGACATCCACTT GTCATCGTCGCCTTCTCGTA 78
EPHB2 TTGGGCTCTCACGCTTTCTA AGGTGAACTTCCGGTACTGG 120
Ki67 CAGCACCTGCTTGTTTGGAAG TAATATTGCCTCCTGCTCATGGAT 109
KRT20 CTGAGGTTCAACTAACGGAGCTG AACAGCGACTGGAGGTTGGCTA 129
LGR5 CCTTCCAACCTCAGCGTCTT AGGGATTGAAGGCTTCGCAA 250
2.8. Survival Analysis
The survival analysis of The Cancer Genome Atlas (TCGA) data were performed using online
tools OncoLnc (http://www.oncolnc.org/) [25] and SurvExpress (http://bioinformatica.mty.itesm.mx/
SurvExpress) [26]. In OncoLnc, the correlation between CLU expression and prognosis of patient were
analysed with the upper and lower 25 percentile of CLU expression in colon adenocarcinoma (COAD)
patients (n = 220). Survival rate is represented by Kaplan−Meier plot and analysed using Log-rank
test. In SurvExpress, Cox survival analysis with CLU expression was performed in Colon GSE41258
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database (n = 244) and censored with both survival and recurrence data. A value of p < 0.05 was
considered to be significant.
3. Results
3.1. Patient-Derived Colorectal Cancer Organoids Recapitulate the Histopathological Characteristics of Their
Primary Tumours and Display Inter-Tumoural Heterogeneity in Stem Cell Signatures
In order to determine whether CRC patient-derived colorectal cancer organoids (PDCOs) are
robust models for examining the expression pattern of stem cell markers, we first compared the
biological characteristics of primary tumours and their matched PDCOs. Histological analysis of
10 primary tumours and their respective PDCOs (Figure 1A) was conducted by a trained pathologist.
The histological profile of the primary tumour was generally well maintained in PDCOs, with organoids
typically having a more cuboidal appearance, but present otherwise similar cellular morphology to
the primary specimen. The primary tumour in patient 30T is a moderately differentiated colonic
adenocarcinoma with the PDCO displaying a more cuboidal appearance with less nuclear pleomorphism
evident. In tissue from 38T, the primary tumour is a well differentiated colonic adenocarcinoma and
matched PDCOs appear more cuboidal and show less nuclear stratification, but are otherwise similar
(Figure 1A). The primary tumour in 53T represents an intramucosal adenocarcinoma with luminal
necrosis. Similar cell morphology and luminal necrosis is evident in the PDCO section (Figure 1A).
In 63T, the primary tumour is a moderately differentiated adenocarcinoma displaying cuboidal cell
morphology with PDCOs closely resembling this morphology (Figure 1A).
Commonly used for differential diagnosis of colorectal cancer, caudal type homeobox 2 (CDX2)
is a transcription factor critical for intestinal development that is highly expressed in normal and
neoplastic intestinal epithelium [27,28]. To confirm whether intestinal identity of epithelial tissue is
maintained under culture conditions, we compared the expression of CDX2 in primary tumour and
PDCOs. Strong and diffuse nuclear staining of CDX2+ was observed in all 10 paired primary tumour
and PDCO sections, confirming the intestinal origin of these adenocarcinomas is maintained in culture.
Representative images of CDX2+ staining are provided in Figure 1B.
The ability of PDCOs to recapitulate the profile of stem and differentiated cell populations of the
primary tumour was examined by immunohistochemical analysis. The number of LGR5+ cells as well
as the cytoplasmic staining intensity were variable across the primary tumour specimens. However,
the levels of expression between the primary tumour and matched PDCO were comparable. Similarly,
positive immunostaining for cytokeratin 20 (CK20), the protein encoded by the Keratin 20 (KRT20)
gene, was observed in the cytoplasm and/or cell membrane of the PDCOs and the abundance of CK20+
cells closely resembled that of the patient-matched primary tumour. Representative images of LGR5
and CK20 staining are illustrated in Figure 1C.
To more broadly assess the expression profiles of stem cell markers in CRC, we performed
qRT-PCR analysis on 10 PDCO lines, analysing basal expression levels of CBC stem cell markers LGR5
and EPHB2, a quiescent stem cell marker BMI1, recently identified revival stem cell markers CLU
and ANXA1, and a marker of differentiated intestinal cells, Keratin 20 (KRT20) (Figure 1D). These
results were consistent with the immunostaining for LGR5 and CK20 (Figure 1C) and revealed unique
expression profiles for each of the 10 PDCO lines. Given that it has previously been reported that
aggressive CRCs are enriched in intestinal stem cell marker expression and this is predictive of relapse
in CRC patients [16], we were interested in investigating whether the differential expression profiles of
the PDCOs were predictive of chemotherapeutic drug response.
5
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Figure 1. Patient-derived cancer organoids recapitulate the histopathological characteristics of their
primary tumours and inter-tumoural heterogeneity in stem cell signatures. (A): Haematoxylin and eosin
(H&E) staining of sectioned tissue from primary colorectal adenocarcinoma and patient-derived cancer
organoids derived from the same tumour. Scale bar, 400 μm. (B): Immunohistochemical detection of
CDX2 (marker of adenocarcinomas of intestinal origin) in primary colorectal adenocarcinoma compared
to patient-derived colorectal cancer organoids (PDCOs). Scale bar, 400 μm. (C): Immunohistochemical
detection of LGR5 (CBC stem cell marker) and CK20 (intestinal epithelial marker) in the colorectal
adenocarcinomas and PDCOs. Scale bar, 400 μm. (D): The expression levels (2−ΔCt) for LGR5, EPHB2,
BMI1, CLU, ANXA1 and KRT20 were calculated relative to beta-2-microglobulin andβ-actin by qRT-PCR
in individual PDCO lines.
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3.2. Elevated Expression of a Subset of Stem Cell Markers Correlates with Resistance to Chemotherapy
PDCOs from six treatment-naïve CRC patients with stage III (present in local lymph nodes) and IV
(spread to distant organs) disease were treated with an increasing dose of common chemotherapeutic,
5-fluorouracil (5-FU). The 5-FU serves as the main backbone of adjuvant chemotherapy regimens
for the treatment of CRC. Cell viability was assessed five days following initial treatment and was
analysed by the slope of the dose-response curve (Figure 2A,B), and area under the curve (AUC)
analysis (Figure 2C). The PDCOs display differential responses to 5-FU treatment including distinct
phenotypic changes in organoids that are responsive to drug treatment (ORG54T) and those that are
less sensitive to treatment (ORG64T) (Representative images; Figure 2A). The presence of cleaved
caspase-3-positive apoptotic cells in 5FU-treated PDCO 54T further illustrates sensitivity to treatment
compared with the absence of staining in treatment resistant PDCO 64T (Figure 2A, right panel).
To determine whether basal expression levels of stem cell markers in PDCOs are predictive of
resistance to chemotherapeutic drug treatment, gene expression analysis (Figure 1D) was correlated with
AUC (Figure 2C). We identified an inverse correlation with marker of intestinal differentiation, KRT20
(p = 0.008). High KRT20 expression was significantly associated with lower AUC values, conferring
sensitivity to treatment. There is also a strong positive correlation with revival stem cell gene CLU, when
CLU expression in PDCO 54T was eliminated as an outlier from analysis which fall away from the 95%
prediction interval of the best-fit line. High expression of CLU was significantly correlated with high
AUC values (R2 = 0.885; p = 0.004).
Following treatment with chemotherapeutic drug 5-FU, we analysed PDCO expression profiles
for stem cell markers from the same six patient lines (Figure 2E). We performed qRT-PCR analysis of
PDCOs five days following initial treatment with 0, 1 and 10 μM 5-FU. We observed a modest decrease in
LGR5 expression at 1 μM (0.88-fold decrease; p = 0.0115). There was upregulation of expression at 10 μM
for both BMI1 (1.5-fold increase; p < 0.0001) and KRT20 (2.4-fold increase; p < 0.0001). However, it was
revival stem cell-associated genes CLU and ANXA1 that were the most significantly upregulated, with
expression robustly increasing up to 5-fold between the untreated (0 μM) and 10 μM treated PDCOs.
We further explored the prognostic relevance of CLU expression in CRC using the OncoLnc
online system to analyse colon adenocarcinoma patient data from TCGA. Kaplan–Meier survival
analysis revealed increased expression of CLU was associated with poorer survival outcomes (p = 0.0286)
(Figure 3A). Using the SurvExpress online tool, we evaluated differences in overall survival and
recurrence-free survival between the predicted high-risk and low-risk groups in the Sheffer series
(GSE41258). The high-risk group that had decreased overall survival and increased disease recurrence
was associated with significantly higher expression of CLU (p= 0.032 and 0.024 respectively) (Figure 3B,C),
which is in line with previous observations [29,30].
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Figure 2. Elevated expression of a subset of stem cell markers correlates with resistance to chemotherapy.
(A): Representative brightfield images of patient-derived cancer organoids (PDCOs) in response to
chemotherapeutic treatment with 5-fluorouracil (5-FU) and the immunohistochemical detection of the
active cleaved form of caspase 3 (apoptotic marker) in 10 μM treated PDCOs. Scale bar, 500 μm. (B):
Dose-response curve of PDCOs in response to chemotherapeutic treatment with 5-FU (n= 6, mean ± SEM).
(C): Area under the curve (AUC) analysis of 5-FU sensitivity in six patient-derived tumoroids. (D):
Linear regression correlation analysis between the expression of stem cell marker genes and AUC
showing the best-fit line (solid line) and 95% prediction interval (dash-line). (E): Expression of stem
cell marker genes in PDCOs in response to an increasing dose of 5-FU. Fold change is calculated by the
average gene expression levels (2−ΔCt) relative to the vehicle control (n = 6, mean ± SEM). In each graph,
asterisks indicate pairs of means (compared to vehicle control) that were significantly different using
Mann–Whitney test (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
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Figure 3. CLU expression in colon adenocarcinoma patients is associated with decreased overall survival.
(A): Kaplan–Meier survival plot comparing The Cancer Genome Atlas (TCGA) colon adenocarcinoma
patients with high (n = 110) and low (n = 110) expression of CLU using the OncoLnc tool. The associated
log-rank p-value is 0.0286. (B): Kaplan–Meier survival plot for high- (red, n = 121) and low- (green,
n = 122) risk groups in GSE41258 database by SurvExpress tool shows cumulative survival against time
(months) and the box plot shows the corresponding CLU expression across groups. The number of
individuals, the number of censored, and the CI of each risk group are shown in the top-right insets.
Censoring samples are shown as “+” marks. (C): Kaplan–Meier survival plot for high- (red, n = 95)
and low- (green, n = 94) risk groups in GSE41258 database by SurvExpress tool shows cumulative
recurrence-free survival against time (months) and the box plot shows the corresponding CLU expression
across groups. The number of individuals, the number of censored, and the CI of each risk group are
shown in the top-right insets. Censoring samples are shown as “+” marks.
4. Discussion
The initial objective of this study was to profile the expression of stem cell markers in a cohort of
colorectal cancer-derived organoid cultures from different patients. We first determined how faithfully
the organoids replicated the histological features of the primary tumour from which they were derived.
The overall morphological features and level of differentiation was maintained in the PDCOs with
some tumours displaying a moderate degree of differentiation and others with a more differentiated
phenotype. This is consistent with previous studies conducted on PDCOs which suggest most epithelial
features of the primary tumours are present in vitro [31–34]. All of the PDCOs were positive for the
definitive intestinal marker CDX2 [28,35] and the expression of the CBC stem cell marker, LGR5 [36,37]
and the cytokeratin marker CK20 was similar in the primary tissue and organoids. Some organoids
displayed more widespread expression and this was reflected in the corresponding primary tissue,
while others showed little expression of LGR5. This indicated that the PDCOs were closely modelling
the epithelial features of the tumours from which they were derived. Subsequently, we examined
individual PDCOs for the expression of stem cell markers. The results revealed considerable inter-tumour
variability of expression of the different markers. Overall, this suggests marked heterogeneity between
9
J. Clin. Med. 2020, 9, 128
individual PDCOs. All of the cultures utilised in our study were derived from patient tumours naïve
to treatment, so these initial results represent cellular expression without the selective pressure of
chemotherapeutic treatment.
Using knowledge of the behaviour of different stem cell populations in normal tissue, we predicted
that there may be a difference in the expression of the repertoire of markers following exposure to
5-FU. We treated each of the PDCO lines with 5-FU and measured cell viability to determine relative
sensitivity and correlated this with the stem cell expression signatures. LGR5 clearly did not correlate
with resistance to 5-FU. LGR5+ cells are extremely susceptible to damage induced by chemotherapy
or radiation in normal mouse tissue and rapidly undergo apoptosis [17–19]. This is also observed in
LGR5+ cells in primary intestinal tumours in mice and human colorectal tumours [13,14]. This suggests
the susceptibility to treatment observed here and in other studies is a conserved feature of LGR5+ cells
in both normal tissue and tumours. In contrast, markers of both quiescent reserve cells and the newly
described revival stem cells were enriched upon exposure to 5-FU in PDCOs. In mouse models, BMI1+
cells appear to be more resistant to injury and lineage tracing experiments have revealed these cells are
activated to replenish lost LGR5+ cells [18]. Revival stem cells cannot be detected in normal tissue
and are only identified in a mouse injury model, where damage-induced revival stem cells are also
capable of reconstituting LGR5+ stem cells and regenerating the intestinal epithelium [21]. Our study
shows for the first time that a revival stem cell signature strongly correlates with chemoresistance
in PDCOs and suggests that the process of re-population of LGR5+ cells observed in normal tissue,
may also operate with a similar mechanism in human cancer. It remains to be elucidated whether
a comparable hierarchical relationship between LGR5+ cells and CLU+ cells is conserved in human
intestinal cancer tissues.
Patient-derived models of cancer, including PDCOs show great promise in trialling therapies
before they reach the patient and evidence supporting how accurately these ex vivo models can predict
patient response is beginning to emerge [32,38–42]. A recent report showed convincing data from ten
patients that a viability assay could be used to predict patient response to irinotecan-based therapies
using CRC-derived PDCOs [39]. However, the same testing protocol was not predictive for patient
outcomes following treatment with 5-FU plus oxaliplatin. How predictive PDCO testing is for a range
of therapies and what the most effective testing regime to implement is still being investigated. Here,
we used PDCO testing to look at how markers of different stem cell populations behave following
5-FU treatment and identified CLU, a marker of the revival stem cell population, as being enriched.
Interestingly, both the patients from whom PDCO cultures 64T and 67T were derived, which were most
resistant in our assay of sensitivity to 5-FU, have progressive disease. These PDCOs also exhibited the
highest levels of CLU expression following treatment. Although the sample size is limited, this provides
the basis for future studies on the role of revival stem cells in progressive disease in colorectal cancer
patients. This cell type may be a potential therapeutic target and a marker of drug resistance.
5. Conclusions
Our study demonstrates that PDCOs are relevant in vitro models for studying the heterogeneity of
stem cell populations represented in the primary tumours. We show that there is considerable variation
between individual PDCOs in the repertoire of stem cell markers present. We have identified that
CLU, a marker of the revival stem cell population, is enriched in PDCOs resistant to 5-FU and this is
consistent with overall patient data showing that CLU correlates with lower survival and an increase in
disease recurrence.
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Abstract: Background: According to the cancer stem cells (CSCs) hypothesis, a population of cancer
cells with stem cell properties is responsible for tumor propagation, drug resistance, and disease
recurrence. Study of the mechanisms responsible for lung CSCs propagation is expected to provide
better understanding of cancer biology and new opportunities for therapy. Methods: The Lung
Adenocarcinoma (LUAD) NCI-H460 cell line was grown either as 2D or as 3D cultures. Transcriptomic
and genome-wide chromatin accessibility studies of 2D vs. 3D cultures were carried out using
RNA-sequencing and Assay for Transposase Accessible Chromatin with high-throughput sequencing
(ATAC-seq), respectively. Reverse transcription polymerase chain reaction (RT-PCR) was also carried
out on RNA extracted from primary cultures derived from malignant pleural effusions to validate
RNA-seq results. Results: RNA-seq and ATAC-seq data disentangled transcriptional and genome
accessibility variability of 3D vs. 2D cultures in NCI-H460 cells. The examination of genomic
landscape of genes upregulated in 3D vs. 2D cultures led to the identification of 2D cultures led to the
identification of Beta-1,4-galactosyltranferase 1 (B4GALT1) as the top candidate. B4GALT1 as the top
candidate. B4GALT1 was validated as a stemness factor, since its silencing caused strong inhibition
of 3D spheroid formation. Conclusion: Combined transcriptomic and chromatin accessibility study
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of 3D vs. 2D LUAD cultures led to the identification of B4GALT1 as a new factor involved in the
propagation and maintenance of LUAD CSCs.
Keywords: cancer stem cells; genome-wide; transcriptome; lung cancer; ATAC-seq; RNA-seq; CSCs;
NSCLC; B4GALT1; LUAD
1. Introduction
Lung cancer is the leading cause of cancer mortality worldwide [1]. Lung cancer can be divided
into two major types, non-small cell lung cancer (NSCLC), which accounts for 80% of cases, and
small cell lung cancer (SCLC). There are two main subtypes of NSCLC: Adenocarcinoma (LUAD) and
squamous cell carcinoma (LUSC), of which LUAD is the most common [2,3]. The five-year survival
rate of patients with advanced lung cancer remains very low, in spite of the introduction of targeted
therapies for patients with specific genetic alterations such as EGFR mutations, or ALK and ROS
translocations, and, more recently, of immunotherapy with anti-PD1 or anti-PD-L1 antibodies as first
or second line therapy [4–7]. Unfortunately, failure of immunotherapy in NSCLC still occurs in a high
proportion of cases because several factors, both tumor intrinsic and tumor extrinsic, are responsible
for drug resistance [8,9]. In this scenario, lung cancer, and in particular its most frequent form LUAD,
remains a highly unmet medical need in search of a deeper understanding of mechanisms of drug
resistance and of the identification of new targets for more efficient therapy.
A widely accepted concept is that tumor cells are organized as a hierarchical population sustained
by a subset of cells called Cancer Stem Cells (CSCs) capable of both symmetrical and asymmetrical
divisions [10]. CSCs are resistant to conventional drugs and are responsible for tumor relapse after
therapy. For these reasons, CSCs have been the object of intense study over the last two decades in the
attempt to identify mechanisms responsible for their propagation and of ways to inhibit their growth.
Our group previously described a protocol able to propagate LUAD as 3D spheroids obtained
either from malignant pleural effusions (MPEs) or from stable cell lines [11]. We showed that
3D spheroids are highly enriched in cells with stemness markers, including upregulation of
Nanog, Oct4, SOX2, and ALDH1A1 activity [12,13]. Enrichment of CSCs was confirmed in
transplantation studies in immune-deficient mice showing high rates of tumor engraftment [11,13].
Spheroids showed upregulation of the expression of a key protein in lipid metabolism, namely,
Stearoyl–CoA–desaturase 1 (SCD1), the key factor in the biogenesis of monounsaturated fatty acids
as precursors of phospholipids [14,15]. SCD1 pharmacological inhibition determined a decreased
efficiency of 3D spheroid formation accompanied by a negative impact on the architecture of 3D
spheroids. Moreover, SCD1 depletion induced a reduction in ALDH1A1 activity, a marker of cancer
stem cells, determining apoptosis specifically in ALDH1A1-positive cells. Silencing of SCD1 impaired
in vivo tumorigenicity of 3D lung cancer stem cells [11,16]. We also observed that LUAD 3D spheroids
treated with an SCD1 inhibitor reverted resistance to cisplatin. Finally, SCD1 expression correlated
with poor survival and worse clinical outcome [17]. Mechanistically, SCD1 inhibition induced the
inactivation of β-catenin and YAP/TAZ signalling pathways [18]. Based on these observations and on
those of several other laboratories, we consider the 3D spheroid assay a valuable approach to identify
factors responsible for the maintenance and propagation of lung CSCs [19]. An intrinsic feature of
CSCs is considered to be their plasticity, i.e., their ability to change their physiological properties,
which has been linked to epigenetic reprogramming [20–22].
In this context, the study of epigenetic alterations in CSCs acquires particular relevance [23],
also because epigenetic alterations might deregulate signalling pathways controlling self-renewal
and differentiation, including Wnt, Myc, Notch, and Hedgehog pathways [24,25]. Many epigenetic
studies on lung cancer focused on the methylation level of DNA [26,27]. Likewise, post-translational
modifications of histone proteins are known to influence chromatin accessibility to transcription factors
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and complex gene expression machinery [28–30]. In recent years, ATAC-seq has been developed as
an emerging technology able to provide a fast and sensitive analysis of the epigenome. ATAC-seq
allows to obtain a chromatin accessibility map of the entire genome in order to identify functional
gene-regulatory regions [31,32]. Hence, the intersection of transcriptomic analysis and of chromatin
accessibility through ATAC-seq can provide a unique opportunity to better identify CSC-specific
changes in gene regulatory networks.
In the present study, we have applied this approach to identify regulatory principles responsible
for CSCs maintenance. For this purpose, we used the 3D spheroid assay on the MPEs derived LUAD
cell line NCI-H460 and intersected transcriptomic with epigenetic signatures of CSCs-enriched (3D
cultures) vs. differentiated cells (2D cultures) by RNA-seq and ATAC-seq, respectively. Interestingly,
we observed that 3D cultures of NCI-H460 cells are characterized by the activation of pathways enriched
of genes responsible for Epithelial to Mesenchymal Transition (EMT). Furthermore, we singled out
and validated the role of the B4GALT1 as an emerging gene in CSCs propagation and as a target for
their inhibition.
2. Materials and Methods
2.1. Cell Cultures
Established human NSCLC cell NCI-H460 was obtained from the American Type Culture
Collection (ATCC, Manassasn, VA, USA) and was cultured according to the manufacturer’s instructions.
BBIRE T-238 and BBIRE T-248 primary cultures were isolates from Malignant Pleural Effusion (MPEs) of
patients with LUAD, as previously described [11,13]. The study was approved by the Ethics Committee
(protocol number 1032/17). Cells in adherent condition were cultured in RPMI-1640 supplemented with
10% FBS, 1% L–Glutammine and 1% Penicillin/Streptomycin (Sigma, St. Louis, MO, USA), while 3D
cultures in suspension were obtained as previously described [11,13,18]. Briefly, 20,000 cells/mL were
resuspended in an appropriate amount of Spheroid Medium and seeded onto Ultralow Attachment
plates (Corning Costar, MA, USA) to form 3D structures. After 4 days, the number of 3D spheres in
single wells of a 96 well low attachment culture plate were counted, and their volume was estimated
using Image J Software v1.50i. Cells were routinely checked for mycoplasma contamination by PCR.
2.2. RNA-Sequencing and Bioinformatic Analysis
Total RNA was extracted from NCI-H460 2D and 3D cells cultures, using Qiazol (Qiagen, Hilden,
Germany), purified from DNA contamination through a DNase I (Qiagen) digestion step, and further
enriched by Qiagen RNeasy columns profiling (Qiagen). Quantity and integrity of the extracted
RNA were assessed by Nanodrop Spectrophotometer (Nanodrop Technologies LCC, Thermofisher,
Waltham, MA, USA) and by Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA),
respectively. All RNA used for subsequent library preparation had an RNA integrity number greater
than9.0. RNA libraries for sequencing were generated in triplicate using the same amount of RNA
for each sample according to the standard Illumina TrueSeq Stranded Total RNA kit with an initial
ribosomal depletion step using Ribo Zero Gold (Illumina, San Diego, CA, USA). The libraries were
quantified by qPCR and sequenced in paired-end mode (2 × 75 bp) with NextSeq 500 (Illumina).
Each sample was generated with the Illumina platform. A pre-step for quality control was performed
to assess sequence data quality and to discard low quality reads [33]. Paired 75 bp long reads
were quality checked and processed using Kallisto v0.46.0 [34] with parameters: “quant -t 8 -b 30”
to the genome Ensemble GRCh38.96 [35] downloaded from https://github.com/pachterlab/kallisto-
transcriptome-indices/releases/download/ensembl-96/homo_sapiens.tar.gz. Differential expression
data were obtained running the R package Sleuth v0.27.3 [36] following the pipeline suggested in the
Sleuth manual available https://pachterlab.github.io/sleuth_walkthroughs/trapnell/analysis.html using
both available Likely ratio [37] and Wald tests [38]. Differentially expressed genes were considered
those with FDR < 0.001 in both tests and B value over 0.3 for upregulation and less than −0.3 for
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downregulation. Volcano plots were drawn with an in-house R script (R v3.6.1). Gene set enrichment
analysis was performed, submitting the top 100 significant genes to the hallmark.MSigDB [39] available
in ShinyGo v0.60 [40] and plotted with an in-house R script.
2.3. Transcriptome Analyses of Public Datasets
TCGA cohort coupled with GTEx cohort was used to run a pan-cancer, LUAD, and LUSC specific
analysis of the gene B4GALT1 expression. Box-plots and overall survival analysis were obtained using
GEPIA v1 [41] (http://gepia.cancer-pku.cn/index.html) selecting default parameters. The Kaplan–Meier
overall survival analysis of pooled B4GALT1 and SCD1 genes expression data was performed by
re-analysis of the TCGA dataset available in Kaplan–Meier plotter [42,43] of 513 (LUAD) and 501 (LUSC)
patients, respectively, with default parameters. Gene expression data were scaled in log2(TPM+1).
2.4. Assay for Transposase Accessible Chromatin with High-Throughput Sequencing (ATAC) and
Bioinformatic Analysis
To profile open chromatin, we used the ATAC-seq protocol developed by Buenrostro et al.,
with minor modifications [44]. 50,000 NCI–H460 2D and 3D cells were washed once with 1x PBS
and centrifuged at 500× g for 5 min at 4 ◦C. The cell pellet was lysed in ice-cold lysis buffer (10 mM
Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% IGEPAL CA–630) to isolate the nuclei. The nuclei
were centrifuged at 500× g for 5 min at 4 ◦C and subsequently resuspended on ice in 50 μL transposase
reaction buffer containing 2.5 μL of Tn5 transposase and 25 μL of 2xTD buffer (Nextera DNA Sample
preparation kit from Illumina). After incubation at 37 ◦C for 30 min, the samples were purified with
MiniElute PCR Purification Kit (Qiagen), eluting in 10 μL elution buffer (10 mM Tris–HCl pH 8).
To amplify transposed DNA fragments, we used NEBNext High-Fidelity 2x PCR Master Mix (New
England Labs, Ipswich, MA, USA) and the Customized Nextera PCR Primers. Libraries were purified
by adding Agencourt Ampure XP (Beckman, Brea, CA, USA) magnetic beads (1:1 ratio) to remove
remaining adapters (left side selection) and double purified (1:0.5 and 1:1.15 ratio) for right side
selection. Libraries were controlled using a High Sensitivity DNA Kit on a Bioanalyzer. Each library
was then paired-end sequenced (2 × 75 bp) on a NextSeq 500 instrument (Illumina). Paired-end
75 bp long reads were quality checked using FASTQC and aligned to Hg38 using Bowtie v 2.3.4.2
setting: “mode = local and p = 6”. The aligned reads were processed by Samtools v1.9 to be converted
in BAM format then sorted and indexed. Peaks were called by MACS2 v2.1.2 with parameters
“nomodel–shift–100–extsize 200–B–SPMR–call–summits”. Peaks with a –log10(q-value) lower than
2.0 were discarded. Peaks in bdg format were converted in bw format using bedGraphToBigWig v4
tool available on https://www.encodeproject.org/software/bedgraphtobigwig/. All peaks matching
blacklisted regions were discarded from further processing. After peak generation, an in-house
pipeline based on BEDTOOLS v2.25.0 and custom BASH scripts were developed to build a master
list of accessible sites by pooling the significant peaks of all the sample dataset. The master list of
accessible sites was produced with a multistep procedure: 1. To identify the common overlapping
signal amongst all the samples, promoter peaks were intersected using BEDTOOLS multiinter. 2. The
book-ended regions from the core signal file were merged using BEDTOOLS merge, then intersected
with the original peak calls and sorted.
2.5. Comparative Analysis of DNA Accessibility
Differential analysis of the two groups (3D vs. 2D signals) was obtained using an in-house
script which deploys edgeR suite (v3.28.0) [45]. Data were processed and normalized with the TMM
method [46]. The differential comparison was performed using an in-house script which relies on the
edgeR “exactTest” function (v3.28.0). Data were further adjusted for Benjamini Hochberg correction.
The sites showing FDR < 0.05 were considered significant. Boxplot of differential enriched sites
enrichment was performed with an in-house script. To show normalized read count differences
observed between 3D and 2D culture, we developed an R script to build a heatmap showing differences
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between our groups. We centered the data to the row mean and fixed the color palette from the lowest
to the highest value. Centered data were hierarchically clustered (Pearson distance, average linkage)
using the hclust package. Results were visualized using heatmap.2 available in the gplot R package
(v3.0.1.1).
2.6. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated by Trizol (Thermofisher) following the manufacturer’s instructions.
First-strand cDNA was synthesized with PrimeScript RT reagent Kit, genomic DNA contamination is
eliminated with gDNA Eraser (Takara Bio Inc, Kusatsu, Prefettura di Shiga, Japan). The cDNA was used
for RT-PCR experiments carried out in a 7500 StepOnePlus (Applied Biosystems, Foster City, CA, USA)
as previously described [47,48]. Primers for B4GALT1: 5′-CTATATCTCGCCCAAATGCTG-3′ (forward)
and 5′-GTGCAATTCGGTCAAACCTC-3′ (reverse), and other primers are previously described [18].
The relative amount of all mRNAs was calculated using the comparative method (2−ΔΔCt) after
normalization to H3. Three independent experimental replicates were performed.
2.7. siRNA Transfection
NCI-H460 cells were transfected with siRNA of B4GALT (s5726; Thermofisher) or control siRNA
(Santa Cruz, CA, USA). DNA transfections were done with Lipofectamine RNAiMAX Reagents
(Invitrogen Co, Carlsad, CA, USA) according to the manufacturer’s instructions.
2.8. Aldehyde Dehydrogenase (ALDH) Activity Assays
ALDH activity was performed with Activity kit (ab155893, Abcam, Cambridge, UK), in 3D
transfected cells. Following the manufacturer’s recommendation, NADH standard and sample
were added into a 96 well plate in duplicate. Subsequently, 50 μL of the Reaction mix, containing
Acetaldehyde and ALDH substrate, were added to each well. Finally, it was incubated for 20–60 min at
room temperature and measured at OD 450 nm. The activity was calculated according to the datasheet.
2.9. Statistical Analysis
All experiments were performed in triplicate and the statistical was carried out to GraphPad
Prism v6.0 software. Group comparison were performed by Student’s test and values were expressed
as mean ± Standard Error of Measurement (SEM).
3. Results
3.1. A Combinatorial Approach to Identify Gene Expression Features of Cancer Stem Cells (CSC)-Enriched
Lung Adenocarcinoma (LUAD) Cell Cultures
In order to characterize regulatory cues responsible for orchestrating gene expression in CSCs,
we used the approach described in Figure 1. The stable LUAD cell line NCI–H460 derived from
MPEs was grown either in standard 2D attachment conditions or as 3D cultures enriched of CSCs
markers [16,47] (Figure 1A). For transcriptomic analysis, RNA was extracted from both types of
cultures. In parallel, in order to achieve genome-wide chromatin accessibility maps and to identify
active gene regulatory regions, nuclei were isolated from both 2D and 3D cultures, chromatin was
extracted and subjected to ATAC-seq (see materials and methods) (Figure 1B).
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(A) (B) 
Figure 1. Graphical overview of the investigation. (A) 2D and 3D cell cultures were obtained from
the stable NCI–H460 cell line obtained from the malignant pleural effusion of a lung adenocarcinoma
(LUAD) patient. Total RNA was extracted and subjected to RNA-seq. Nuclei were isolated and
processed to perform ATAC-seq. (B) Computational workflow developed to identify differentially
expressed genes, pathways and biological processes in 3D compared to 2D cell cultures.
Transcriptomics technologies and chromatin accessibility assays are powerful tools to infer active
cell regulatory states by analyzing the relative number of transcripts (Figure 1) and cis-regulatory
activity, respectively. Although there are several difficulties in linearly correlating the activity of
cis-regulatory regions with the relative production of gene transcripts, numerous studies [49–51]
revealed that the large majority of regulatory elements are strongly linked to RNA production and occur
in the proximity (within 50 kb) to the closest Transcriptional Start Sites (TSS). Thus, we took advantage
of these observations and assayed the differences of RNA abundance and active chromatin accessibility
sites in 3D vs. 2D cultures obtained from stable NCI–H460 cell line in a unique computational workflow.
Each set of data was analyzed first individually then jointly to better identify gene regulatory elements
capable of simultaneously controlling key cellular pathways specifically activated in CSC-enriched
cell cultures.
3.2. Integrative RNA-seq and ATAC-seq Analysis Reveals Overarching Transcriptomic Features of Cancer Stem
Cells (CSC)-Enriched LUAD Cell Cultures
RNA sequencing analysis revealed a global transcriptional rewiring from 2D to 3D cultures.
The differential analysis revealed 3095 genes significantly enriched (FDR < 10−3) (detailed in Figure 2A,
Figure S1, Table S1) of which 1854 were downregulated and 1241 upregulated in 3D spheroids. To gain
insights into the functional role of the differentially expressed transcripts, we computationally predicted
the impact in their relative abundance to the cell physiological state (Figure 2B). Not unexpectedly,
gene set enrichment analysis of the differentially regulated genes in the two systems revealed the
emergence of a vastly different regulatory landscape. In particular, the 3D spheroids cell population
exhibited a significant enrichment of gene pathways involved in oncogenesis and cancer progression,
including EMT (FDR < 10−13), Hypoxia (FDR < 10−10), Cholesterol homeostasis (FDR < 10−5),
and Apoptosis (FDR < 10−4) (Figure 2B).
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(A) (B) 
Figure 2. Analysis of 2D vs. 3D culture transcriptomes. (A) Volcano plot of over-expressed or
under-expressed genes in 3D transcriptome vs. 2D. (blue: significantly under-expressed transcripts;
red: significantly over-expressed transcripts). (B) Functional enrichment for upregulated genes in
3D cultures.
Among the most significant upregulated genes, we identified 3 different isoforms of CD55 a
well-known protein coding gene frequently linked to cancer aggressiveness in many carcinomas.
Surprisingly, among the top 10% genes exhibiting the most significant transcript abundance
shift (Table S1), we found the gene B4GALT1. Notably, B4GALT1 protein has been previously
associated with multi-drug-resistant cell phenotype in human leukemia [52] and other haematological
malignancies [53,54]. On the other side, genes significantly downregulated were associated with MYC
and E2F target genes (Figure S2). Importantly, our transcriptomic data further support the model
of cancer aggressiveness recently proposed by Padmanaban et al. [55] in which significant loss of
E–cadherin transcription (CDH1 gene) guides the upregulation of the transforming growth factor-β
(TGFβ) expression (see Table S1) as a requirement for metastatic invasion.
Then, ATAC-seq data were utilized to determine genome-wide chromatin accessibility of 3D vs.
2D NCI–H460 cells. DNA nucleosome-free regions store regulatory information in the form of active
regulatory elements, including enhancers and promoters. These elements are highly plastic and act
as essential players in guiding cell phenotypic states. The analysis revealed only 404 genomic loci
(FDR < 0.05) significantly different between the two groups (see Figure 3A,B) of which 236 were closed









Figure 3. Analysis of DNA accessibility in 3D vs. 2D cultures. (A) ATAC-seq signal enrichment
of normalized read counts at differential accessible sites in 3D vs. 2D (red = open; blue = closed).
(B) Heatmap of differential chromatin accessibility sites (N = 404) showing the cell condition specificity
of 2D and 3D ATAC-seq peaks. (C) Regulatory landscape of B4GALT1 locus. Peaks represent Assay
for Transposase Accessible Chromatin with high-throughput sequencing (ATAC-seq) raw signals.
(D) Reverse transcription polymerase chain reaction (RT-PCR) validation level of B4GALT1 upregulated
in 3D cells compared to 2D culture in NCI-H460 (stable lung cell line) and BBIRE T-238, BBIRE T248
(primary lung cell lines). H3 reference gene have been used for normalization. Bars represent the mean
of three biological replicates and technical replicates with their corresponding standard error of the
mean (SEM). *** p < 0.0002; * p < 0.02; ** p < 0.0085.
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Recent observations [56,57] confirmed the notion that the signal intensity of ATAC-seq is linearly
dependent on the number of cells contributing to the signal. On the basis of this, we observed that
the normalized signal of the open sites in 3D cells was consistently doubling the signal of sites only
accessible in 2D cells, thus implying that 3D cultures are composed of a more homogeneous cell
population compared to the 2D culture signal (Figure S3, Table S2). Finally, we tested the relationship
between gene expression and chromatin openness among each gene-specific neighborhood (|50 kb| to
the TSS) to identify regulatory patterns exhibiting both significant changes in transcriptomic abundance
and chromatin plasticity (Figure S4). By integrating RNA-seq and ATAC-seq data, we found that
only a small proportion of differential ATAC-seq signal was occurring within |50 kb| from the TSSs of
differentially regulated genes (Table S3). However, the largest proportion of promoters associated with
expressed genes were consistently accessible to regulatory factors in both groups, suggesting active
transcription (Figure S5). These data imply that the differential abundance of transcripts in 3D vs. 2D
cultures does not depend only on chromatin shifts in the vast majority of cases, but may be favored by
other mechanisms whose further investigation could shed light on their identity (Table S2). Examining
the genomic landscape of the genes upregulated in 3D, we identified B4GALT1 as the top candidate.
Interestingly, the B4GALT1 locus presents three regulatory sites (Figure 3C) differentially opened in 3D
vs. 2D cell cultures. These regulatory sites may represent active enhancers; however, no previously
published data annotate these genomic sites as regulatory regions, and further investigations need to
be conducted to confirm this hypothesis.
In order to confirm B4GALT1 upregulation in LUAD 3D spheroids we carried out qRT-PCR assays
on RNA extracted from 2D vs. 3D cultures of NCI–H460 cells and from two additional primary LUAD
cell lines isolated from malignant pleural effusions in our laboratory (BBIRE–T238 and BB–IRE T–248).
The results (Figure 3D) show that B4GALT1 is strongly upregulated in 3D cultures in all cases analyzed.
3.3. Validation of B4GALT1 as Novel Factor Responsible for the Propagation of Lung Adenocarcinoma (LUAD)
Cancer Stem Cells (CSCs)
As shown in the previous paragraph, the combined RNA-seq/ATAC-seq analysis of 3D vs. 2D
cultures of NCI–H460 cells highlighted B4GALT1 as one of the top genes overexpressed in CSCs
enriched 3D cultures with a corresponding highly opened chromatin structure of its gene regulatory
domains. In order to validate B4GALT1 as a critical factor for CSC propagation and a potential target
for intervention, we carried out a series of analyses. We first performed an explorative analysis of
B4GALT1 expression by interrogating TCGA and GTEx dataset. Remarkably, 84% of cancer types
exhibit upregulation of B4GALT1 expression compared to healthy tissues, including both lung cancers
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Figure 4. B4GALT1 gene expression and survival analysis in lung adenocarcinoma (LUAD) and lung
squamous cell carcinoma (LUSC) patients. (A) On the left panel is shown a Box Plot of B4GALT1
expression in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Each dot
represents a patient. (red: cancer tissues; grey: healthy tissues). On the right panel is shown a survival
curves depict the B4GALT1 prognostic value in LUAD (N = 239 high expression tissues +239 low
expression tissues) and LUSC cohort (N = 241 high expression +241 low expression). Comparison of
survival curves was performed using a log-rank (Mantel–Cox) test. HR = Hazard ration. Dotted lines
represent the 95% of Confidence Interval. (B) Kaplan–Meier curves depict the cumulative prognostic
value of B4GALT1 and SCD1 gene expressions in LUAD (N = 250 high expression tissues + 254
low expression tissues) and LUSC (N = 153 high expression tissues + 342 low expression tissues)
Abbreviations: LUAD, lung adenocarcinoma; LUSC lung squamous cell carcinoma; num, number;
T, tumor; N, normal.
These data were consistent with Immunohistochemistry of normal and pathologic tissues available
on the Human Protein Atlas data portal [58]. Consistent with these predictions, a meta-analysis of
the TCGA datasets re-computed from raw RNA-seq by XENA project revealed that higher expression
of B4GALT1 mRNA is linked with poor survival in many cancers (data not shown). In particular,
LUAD patients with higher expression of B4GALT1 at diagnosis have a significantly worse outcome;
conversely, this is not occurring in LUSC patients (Figure 4A). In agreement, a meta-analysis of pooled
B4GALT1 and SCD1 mRNA expression data from TCGA conducted to similar results (Figure 4B),
thus suggesting a potential co-regulatory activity in tumor progression of SCD1 and B4GALT1 genes.
Furthermore, in order to assess the role of B4GALT1 in the generation of 3D spheroids we
transfected a B4GALT1 siRNA in NCI–H460 lung cancer cells. Transient knockdown of B4GALT1
strongly impaired 3D spheroids formation, both as to number and size (Figure 5A,B). The role of
B4GALT1 in the propagation of lung CSCs enriched cell cultures was confirmed by the demonstration
that its depletion reduced the expression level of other stemness markers such as Oct4, Sox2, and Nanog
compared to scramble siRNA (Figure 5C). Moreover, the silencing of B4GALT1 affected SCD1 mRNA
levels in 3D cells. To further confirm the role of B4GALT1 in CSCs, ALDH activity was also evaluated.
As shown in Figure 5D, inhibition of B4GALT1 resulted in a significant reduction of ALDH activity
in 3D cells, as well as a decrease of Nanog protein expression compared to control scrambled siRNA
(data not shown). These results taken together suggest that B4GALT1 plays an important role in the
propagation and maintenance of CSC-enriched LUAD cell cultures.
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Figure 5. Knockdown of B4GALT1 RNA decreases the 3D structure formation and the expression
of stemness markers. (A) Representative images of silencing of B4GALT1 reduction of 3D structure
formation potential compared to the scramble of H460 cells. Scale bar = 100 μm. (B) Graphs show
that silencing of B4GALT1 in 3D induces a decrease of volume and number of 3D spheroids. Number
and volume of the 3D cells counted in each well after four days of culture. (C) Validation of B4GALT1
silencing in 3D cells, the results show a strongly decreases of stemness markers mRNA levels, such as
Oct4, Sox2, Nanog, and SCD1. Expression of each gene was normalized to that of H3. (D) ALDH
activity decrease substantially in 3D siB4GALT1 vs. Scramble cells. Experiments were performed in
triplicate, and the background interference and the blank value were subtracted from the absorbance of
the samples. In the bar plots, the mean ± standard error of mean (SEM) was shown from at least three
independent experiments * p< 0.05, **p< 0.005, **** p< 0.0001 (vs. scramble).
4. Discussion
In this study, in order to better identify transcriptional cues active in lung adenocarcinoma
stem cells, we sought to link genes undergoing expression changes to their regulatory elements by
leveraging RNA-seq and ATAC-seq data obtained from 2D and CSC-enriched 3D cell cultures. Indeed,
the parallel profiling of gene expression and chromatin accessibility within the same cell bulk is
a well-described approach to reveal causal regulatory relationships [59]. In this respect, our data
revealed a global shift of gene expression which was accompanied by discrete changes in chromatin
accessibility. Using a rigorous and conservative computational strategy, we identified more than 3000
differentially regulated transcripts and approximately 400 cis-regulatory regions affected in the passage
from 2D to 3D cultures. In this regard, modifications of chromatin openness are linked to the activation
and inhibition of regulatory pathways able to confer a selective growth advantage to cancer cells.
Regulatory regions such as enhancers are key distal cis-regulatory elements that elevate the expression
of nearby genes, independently from the distance to the target gene or orientation [60,61]. Our data
predict that significant chromatin openness changes might collectively affect several hundreds of genes.
Interestingly, both sets of differentially opened regulatory regions and RNA transcribed enrich for
“cell migration” and “EMT pathways”, which are both distinctive features of cancer stem cells [62,63],
and which we know from previous studies to be enriched in 3D vs. 2D cultures [64–68].
One of the most exciting findings of our combined transcriptomic and epigenomic analysis was
the identification of B4GALT1 as one of the top candidates. Indeed, besides being one of the most
highly transcriptionally upregulated genes in 3D cultures, the B4GALT1 locus shows three genomic
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regions located downstream the transcriptional start site whose chromatin is accessible only in 3D
cultures as compared with 2D cultures.
We believe these are regulatory regions which may act as enhancers. Further studies are needed to
confirm this hypothesis. An apparent limitation of our study is that we have applied our approach so
far only to one LUAD cell line. However, we are confident that our observation about the involvement
of B4GALT1 is of more general significance because of various reasons. Firstly, B4GALT1 transcriptional
upregulation in 3D LUAD spheroids was confirmed by RT-PCR, not only in NCI–H460 but also in
other LUAD primary cells, generated in our laboratory from malignant pleural effusions of LUAD
patients. Secondly, our meta-analysis of TCGA datasets revealed that overexpression of B4GALT1 is
linked to poorer survival in LUAD patients.
B4GALT1 has been reported before to facilitate cancer cell proliferation, invasiveness,
and metastasis in several cancer types [69,70]. However, we provide the first evidence that this
gene may be involved in the propagation of cancer stem cells, namely in lung cancer. In this respect
the previous observation in hematologic cancers that B4GALT1 is responsible for drug resistance by
regulating the expression of P-gp and MDR- associated protein [52,69] acquires particular relevance
given the known ability of CSCs to be drug resistant [71,72].
We have observed that B4GALT1 silencing potently inhibits the 3D spheroid formation and
impairs the expression of a set of stem cell markers. Hence, we believe that B4GALT1 is needed for
lung CSCs propagation. At the moment the mechanism by which B4GALT1 activity facilitates lung
CSCs propagation can only be the object of speculations. The enzyme catalyzes the transfer of galactose
from UDP–Galactose to N-linked sugar chains of glycoproteins and is therefore important for the
biosynthesis of glycoconjugates which may be required to facilitate the formation and maintenance
of cell–cell contact and resistance to anoikis during the formation of 3D structures in non-adherent
conditions. Further studies are required to investigate about this possibility.
Finally, B4GALT1 expression is somehow linked in LUAD to the expression of SCD1, which has
been the object of intense studies by our group and other laboratories in recent years. TCGA data clearly
show that co-overexpression of B4GALT1 and SCD1 is a negative prognostic factor. Furthermore,
our silencing data demonstrate that inhibiting the expression of B4GALT1 strongly reduces SCD1
expression in LUAD 3D spheroids. We tend to believe that this is not a direct effect, but rather an
indirect consequence of decreased survival of lung CSCs linked to the absent expression of B4GALT1.
5. Conclusions
In conclusion, our study proposes for the first time the involvement of B4GALT1 in lung CSCs
maintenance and propagation. Therefore, this enzyme can become a new potential target of intervention.
It will be important in the future to assess the effect of in vivo inhibition of B4GALT1 in LUAD tumor
growth either alone or combined with inhibitors of other CSC-enriched targets, such as SCD1.
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Abstract: Potentially malignant oral lesions, mainly leukoplakia, are common. Malignant transformation
varies widely, even in the absence of histological features such as dysplasia. Hence, there is a
need for novel biomarker-based systems to more accurately predict the risk of cancer progression.
The pluripotency transcription factor SOX2 is frequently overexpressed in cancers, including oral
squamous cell carcinoma (OSCC), thereby providing a link between malignancy and stemness.
This study investigates the clinical relevance of SOX2 protein expression in early stages of oral
carcinogenesis as a cancer risk biomarker, and also its impact on prognosis and disease outcome at late
stages of OSCC progression. SOX2 expression was evaluated by immunohistochemistry in 55 patients
with oral epithelial dysplasia, and in 125 patients with OSCC, and correlated with clinicopathological
data and outcomes. Nuclear SOX2 expression was detected in four (7%) cases of oral epithelial
dysplasia, using a cut-off of 10% stained nuclei, and in 16 (29%) cases when any positive nuclei was
evaluated. Univariate analysis showed that SOX2 expression and histopathological grading were
significantly associated with oral cancer risk; and both were found to be significant independent
predictors in the multivariate analysis. Nuclear SOX2 expression was also found in 49 (39%) OSCC
cases, was more frequent in early tumor stages and N0 cases, and was associated with a better survival.
In conclusion, SOX2 expression emerges as an independent predictor of oral cancer risk in patients with
oral leukoplakia. These findings underscore the relevant role of SOX2 in early oral tumorigenesis rather
than in tumor progression.
Keywords: oral cancer risk; oral epithelial dysplasia; SOX2; immunohistochemistry; oral squamous
cell carcinoma
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1. Introduction
Squamous cell carcinoma (SCC) of the oral cavity (OSCC) afflicts about 300,400 new cases and
causes 145,400 deaths worldwide each year [1], with a predilection for South Asian and Southeast
Asian populations [2]. According to the World Health Organization (WHO) mortality projections,
there is an estimate of 679,941 mouth and oropharynx cancer-related deaths by 2060 [3]. OSCC shows
an aggressive growth pattern with a high degree of local invasiveness and a propensity to metastasize
to the cervical lymph nodes, even in early stages. In fact, metastases to neck lymph nodes occur in 40%
of cases, which remain the main factor associated with poor prognosis [4]. Additionally, between 26%
and 80% of patients with early-stage OSCC develop locoregional recurrence or distant metastasis [4].
Despite aggressive treatment, the prognosis of this disease remains dismal, with a five-year survival
rate at around 55%–60% [2].
OSCC may develop from an apparently normal oral mucosa or from oral potentially malignant
disorders (OPMDs), mainly oral leukoplakia (OLK), which shows a malignant transformation rate of
0.1% to 36% [5]. All premalignant lesions, such as OLK, erythroplakia, submucosal fibrosis, or oral
lichen planus, may harbor many genetic alterations present in OSCC [6].
Oral cancer exhibits cellular heterogeneity and is composed by three different types of cells
including highly differentiated bulk tumor cells, transit cells with maximum proliferation capacity, and
a small subpopulation of cells with elevated self-renewal capacity and plasticity called cancer stem
cells (CSCs) [7]. The CSCs are capable of long-term self-renewal and generation of the phenotypically
diverse tumor cell population [8], and may be responsible for the genesis, anchorage-independent
growth, cellular migration, and metastatic spread of the tumor [9,10]. Meantime, investigations by
Takahashi and Yamanaka [11] revealed that the expression of four transcription factors (SOX2, Oct4,
c-Myc, and Klf4) was sufficient to reprogram differentiated cells into induced pluripotent stem cells
(iPSCs). One of these genes, the so-called sex-determining region Y (SRY)-related high-mobility-group
(HMG)-box 2 (SOX2), located on chromosome 3q26, is implicated in the maintenance of embryonic stem
cell pluripotency [12]. Numerous evidences indicate that SOX2 is involved in tumorigenesis, thereby
acting as a link between malignancy and stemness [13]. Moreover, the proliferation of CSCs in head
and neck SCC was inhibited both in vitro and in vivo when SOX2 was suppressed by all-trans-retinoic
acid [14]. The degree of similarity to OSCC found in premalignant lesions depend upon the presence
of atypia; however, individual lesions exhibit molecular genetic traits in common with OSCC, even in
the absence of histologically-defined dysplasia [15]. Hence, better biomarker-based detection systems
need to be developed to more accurately predict the risk of cancer progression in potentially malignant
oral disorders.
It has been described that OLK lesions show higher expression of SOX2 than normal oral mucosa,
suggesting its contribution to the pathogenesis of OSCC [16]. Consequently, SOX2 could be a potentially
useful predictor of cancer risk in the oral cavity. SOX2 is mainly expressed in CSCs [13], and is one
of the amplified genes in OSCC, where its expression has been closely associated with lymph node
metastasis [17] and poor prognosis [18]. In marked contrast, several studies have demonstrated that
increased levels of SOX2 were significantly associated with better prognosis in patients with OSCC, and
also in squamous cell lung cancer [19,20]. Therefore, the role of SOX2 expression in OSCC prognosis
remains controversial.
This prompted us to perform a thorough study to investigate the clinical significance of SOX2
in the development and progression of OSCC. To accomplish this, the expression pattern of SOX2
was evaluated at different stages of oral tumorigenesis, from potentially malignant oral disorders
(i.e., oral epithelial dysplastic lesions) to invasive carcinomas, to ascertain its contribution to tumor
initiation and malignant transformation, and also late stages of disease progression.
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2. Materials and Methods
2.1. Patients and Tissue Specimens
Surgical tissue specimens from 55 patients who were diagnosed with oral mucosa dysplasia at
the Hospital Universitario Central de Asturias between 2000 and 2005 were retrospectively collected.
All selected patients met the following inclusion criteria: (i) pathological diagnosis of oral epithelial
dysplasia; (ii) lesions of the oral mucosa (leukoplakia); (iii) no previous history of head and neck cancer,
(iv) complete excisional biopsy of the lesion; and (v) a minimum follow-up of five years (or until
progression). Patients were followed up as previously described [21].
In addition, surgical tissue specimens from 125 patients with histologically-confirmed OSCC
surgically treated at the Hospital Universitario Central de Asturias between 1996 and 2007
were retrospectively collected, in accordance to approved institutional review board guidelines.
All experimental procedures were conducted in accordance to the Declaration of Helsinki and
approved by the Institutional Ethics Committee of the Hospital Universitario Central de Asturias and
by the Regional (CEIC) from Principado de Asturias (date of approval 5th of May 2016; approval
number: 70/16) for the project PI16/00280. Informed consent was obtained from all patients.
Tissue samples and data from donors were provided by the Principado de Asturias BioBank
(PT17/0015/0023), integrated in the Spanish National Biobanks Network, and processed following
standard operating procedures with the appropriate approval of the Ethical and Scientific Committees.
Representative tissue samples were obtained from archival, formalin-fixed, paraffin-embedded blocks
and the histological diagnosis was confirmed by an experienced pathologist.
2.2. Tissue Microarray (TMA) Construction
As previously described [21], three representative tissue cores (1 mm diameter) were taken
from each tumor block to construct OSCC TMAs. Each TMA block also included three cores of
normal epithelium as an internal control. These samples were obtained from non-oncological patients
undergoing oral surgery.
2.3. Immunohistochemistry (IHC)
The TMAs were cut into 3 μm sections and dried on Flex IHC microscope slides (DakoCytomation,
Glostrup, Denmark). Antigen retrieval was performed by heating the sections with Envision Flex Target
Retrieval solution, high pH (Dako, Glostrup, Denmark). Staining was done at room temperature on an
automatic staining workstation (Dako Autostainer Plus, Glostrup, Denmark) with anti-SOX2 rabbit
polyclonal antibody (AB5603, Merck Millipore, Darmstadt, Germany) at 1:1000 dilution using the Dako
EnVision Flex + Visualization System (Dako Autostainer, Glostrup, Denmark) and diaminobenzidine
chromogen as substrate. Counterstaining with hematoxylin was the final step.
The IHC results were independently evaluated by two observers (JPR, and JMG-P), blinded to
clinical data. SOX2 staining was evaluated as the percentage of cells with nuclear staining in the
dysplastic epithelium or in the tumor tissue. SOX2 staining scores were classified as negative or
positive staining on the basis of values below or above the median value of 10%. Since CSC-like
subpopulations are usually limited to a very small percentage of cells, SOX2 staining in the dysplastic
areas was also scored considering any positive nuclei.
2.4. Statistical Analysis
Bivariate analysis byχ2 and Fisher’s exact tests were used for comparison between SOX2 expression
and clinicopathological categorical variables. Disease-specific survival (DSS) was determined from the
date of treatment completion to the death of the tumor. For time-to-event analysis, survival curves
were estimated using the Kaplan–Meier method. The log-rank test was used to compare the survival
curves. Hazard ratios (HRs) with their 95% confidence intervals (CIs) for clinicopathological variables
were calculated using univariate and multivariate Cox proportional hazards model. All tests were
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two-sided and P-values less than 0.05 were considered statistically significant. All statistical analyses
were performed using SPSS version 18 (IBM Co., Armonk, NY, USA).
3. Results
3.1. Clinicopathological Features and Follow-Up in Patients with Oral Epithelial Dysplasia
Twenty-six patients (47%) were men and the remaining 29 were women (53%), with a mean age
of 62.61 years (SD 12.56, range 39 to 83 years). Ten patients (18%) were smokers and four (7%) were
habitual alcohol drinkers. Forty-two of 55 premalignant lesions (76%) were classified as mild dysplasia,
six (11%) as moderate dysplasia, and the remaining seven (13%) as severe dysplasia, according to
the WHO classification [22]. During the follow-up period (mean: 85.47, SD: 44.41, median: 75, range:
four to 252 months), 12 (22%) of 55 patients developed an invasive OSCC. The most relevant clinical
and pathological characteristics are summarized in Table S1.
3.2. SOX2 Protein Expression in Oral Epithelial Dysplasia
Nuclear SOX2 expression was detected in four (7%) cases when a cut-off of 10% stained nuclei was
used (SOX2 > 10), and in 16 (29%) when any positive nuclei was applied (SOX2any). Normal adjacent
epithelia showed negative SOX2 expression (Figure 1A–C). SOX2 protein expression was found
to significantly increase with the grade of dysplasia (Table 1). In addition to the WHO three-tier
classification, the binary WHO grading system (low-grade vs. high-grade) was used and correlated
with SOX2 expression.
Figure 1. Immunohistochemical analysis of SOX2 expression in oral epithelial dysplasia.
Normal adjacent epithelia showed negative staining (A). Representative examples of oral dysplasia
showing negative (B) and positive nuclear SOX2 staining (C), and oral squamous cell carcinomas with
negative (D) and positive SOX2 staining (E). Magnification 20 ×; scale bar 200 μm.
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Table 1. Associations between SOX2 expression and patient characteristics.
Characteristics
SOX2 > 10% Positive Nuclei
Negative Positive
P SOX2 any Positive Nuclei
Negative Positive
P
Age (years), Mean (SD) 62.93 (12.69) 60.50 (13.20) 0.72 61.00 (12.69) 65.55 (12.35) 0.34
Gender, number (%)
• Female 27 (93) 2 (7)
1.00
22 (76) 7 (24)
0.39
• Male 24 (92) 2 (8) 17 (65) 9 (35)
Smoking, number (%)
• Yes 9 (90) 1 (10)
1.00
6 (60) 4 (40)
0.71
• No 18 (86) 3 (14) 14 (67) 7 (33)
Ethanol intake, number
(%)
• Yes 3 (75) 1 (25) 0.44 2 (50) 2 (50) 0.60
• No 24 (89) 3 (11) 18 (67) 9 (33)
Epithelial dysplasia
• Mild 42 (100) 0 (0)
0.001
33 (79) 9 (21)
0.055• Moderate 5 (83) 1 (17) 3 (50) 3 (50)
• Severe 4 (57) 3 (43) 3 (43) 4 (57)
Epithelial dysplasia
• Low-grade 42 (100) 0 (0)
0.002
33 (79) 9 (21)
0.02
• High-grade 9 (69) 4 (31) 6 (46) 7 (54)
There was a statistically significant correlation between the histopathological grade (both the WHO
histological classification and the binary dysplasia grading) and the risk of progression to oral cancer in
this cohort (log-rank test, P < 0.001; Figure 2A,B) (Table 2). In addition, positive SOX2 expression also
significantly predicted oral cancer risk either considering SOX2 > 10 (log-rank test, P = 0.02; Figure 2C)
or SOX2any (log-rank test, P = 0.01; Figure 2D) as cut-off points. Univariate Kaplan–Meier and Cox
analysis showed that the SOX2 expression and histological grading were significantly associated with
oral cancer risk (Table 3). When these factors were simultaneously analyzed using a multivariate
Cox analysis, only SOX2 expression calculated using SOX2any as the cut-off point and the dysplasia
grading were significant independent predictors of OSCC development (Table 4).
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Figure 2. Kaplan–Meier cancer-free survival curves in the cohort of 55 patients with oral epithelial
dysplasia categorized by the World Health Organization (WHO) histological grading (A), the binary
dysplasia grading (B), and SOX2 protein expression dichotomized using the cut-off values of SOX2
staining > 10% positive nuclei (C) or SOX2 staining any positive nuclei (D).
Table 2. Evolution of the premalignant lesions in relation to histopathological diagnosis and
SOX2 expression.
Variable Number of Cases (%) Progression to Carcinoma (%) P *
Histopathological diagnosis
<0.001• Low-grade dysplasia 42 (76) 2 (5)
• High-grade dysplasia 13 (24) 10 (77)
SOX2 > 10% positive nuclei
0.02• Negative 51 (93) 9 (18)
• Positive 4 (7) 3 (75)
SOX2 any positive nuclei
0.01• Negative 39 (71) 5 (13)
• Positive 16 (29) 7 (44)
* Fisher exact test.
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P Hazard Ratio 95% CI
Epithelial Dysplasia
< 0.001 19.08 4.09–89.01
• High-grade 13 3 (23) 100.69(54.14–147.24)
• Low-grade 42 40 (95) 181.59(170.21–192.98)
SOX2 > 10% positive nuclei
0.002 6.13 1.62–23.27• Positive 4 1 (25) 69.00 (26.18–111.81)
• Negative 51 42 (82) 191.80(152.14–231.47)
SOX2 any positive nuclei
0.002 5.75 1.68–19.74• Positive 16 9 (56) 90.40 (64.14–116.66)
• Negative 39 34 (87) 203.22(162.30–244.15)
P-values were estimated using the log-rank test.
Table 4. Multivariate Cox proportional hazards model to estimate oral cancer risk.
Variable P Hazard Ratio 95% CI
Histology (high-grade vs. low-grade) < 0.0001 21.88 4.13–116.07
SOX2 > 10% (positive vs. negative) 0.196 3.0 0.57–15.89
SOX2 any (positive vs. negative) 0.021 5.83 1.31–26.01
Similarly, we have recently reported a novel role for another pluripotency factor NANOG as a
cancer risk marker using the same subset of 55 patients with oral epithelial dysplasia [21]. Since SOX2
and NANOG are functionally-related proteins, this prompted us to assess the impact of combined
expression of SOX2 and NANOG in regards to malignization risk. Interestingly, results consistently
showed that patients harboring positive expression of SOX2 (either SOX2 > 10% or SOX2any) and
NANOG (either cytoplasmic or nuclear expression) significantly exhibited a much higher risk of
developing oral cancer, compared to patients with positive expression of either SOX2 or NANOG or
those patients with negative expression (Table 5).
Table 5. Univariate Cox cancer-free survival analysis in 55 patients with oral dysplasia categorized by






P Hazard Ratio 95% CI
SOX2 > 10% positive nuclei
and nuclear NANOG
• Both negative 51 42 (84) 191.80 (152.13–231.46)
0.003
Ref
• One positive 2 1 (50) 93.00 (32.01–153.98) 3.72 0.46–29.98
• Both positive 2 0 (0) 45.00 (8.00–97.92) 9.06 1.91–43.00
SOX2 > 10% positive nuclei
and cytoplasmic NANOG




• One positive 7 5 (71) 182.28 (101.53–263.03) 1.63 0.30–8.71
• Both positive 3 0 (0) 46.33 (15.66–76.99) 10.89 2.74–43.22
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P Hazard Ratio 95% CI
SOX2 any positive nuclei
and cytoplasmic NANOG
<
0.0005• Both negative 36 31 (86) 175.49 (158.40–192.57) Ref
• One positive 13 11 (85) 215.99 (170.17–261.81) 1.091 0.20–5.85
• Both positive 6 1 (17) 44.50 (21.60–67.40) 11.36 3.18–40.60
SOX2 any positive nuclei
and nuclear NANOG
<
0.0005• Both negative 39 34 (87) 203.22 (162.30–244.15) Ref
• One positive 14 9 (64) 97.76 (69.96–125.55) 4.62 1.23–17.29
• Both positive 2 0 (0) 45.00 (8.00–97.92) 14.82 2.69–81.56
3.3. Clinicopathological Features and Follow-Up in the Cohort of OSCC Patients
The mean and median follow-up times were 71.82 (SD: 57.55) and 61.0, respectively. Neck node
metastases were present in 49 (39%) cases, and local recurrences were found in 54 (43%) cases. No patient
had distant metastasis at the time of diagnosis. The five- and 10-year disease-specific survival rates
were 60% and 44%, respectively. The mean and median survival times were 132.74 months (95% CI:
113.25 to 152.22 months) and 141 months (95% CI: 102.40 to 179.59 months), respectively. The remaining
relevant clinical and pathological characteristics are summarized in Table S2.
3.4. SOX2 Protein Expression and Its Relation with Clinicopathological Variables and Follow-Up
Positive SOX2 staining was found in 49 (39%) cases located in the nucleus of tumor cells, whereas
stromal cells and normal epithelium showed negligible expression (Figure 1A,D,E). SOX2 expression
did not show any significant association with the clinicopathological variables studied (Table S3).
In the survival analysis, tumor size and local extension (pT), neck node status (pN), and stage were
significantly correlated to survival (Table S4). Positive SOX2 expression was associated with a longer
disease-specific survival, although differences did not reach statistical significance (log-rank test,
P = 0.07; Figure 3).
Figure 3. Kaplan–Meier disease-specific survival curves in the cohort of 125 patients with oral squamous
cell carcinoma dichotomized according to SOX2 staining (positive versus negative). P-values were
estimated using the log-rank test.
3.5. In Silico Analysis of SOX2 mRNA Expression and Copy Number Alterations using the Cancer Genome
Atlas (TCGA) Data
The role of SOX2 mRNA expression and copy number alterations in OSCC was investigated by
analyzing a subset of 172 OSCC patients from the TCGA Head and Neck Squamous Cell Carcinoma
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(HNSCC) cohort [23] using the platform cBioPortal (http://cbioportal.org/) [24]. As shown in Figure 4A,
SOX2 gene alterations were present in a total of 38 (22%) of 172 OSCC patients. Twenty-two (13%)
cases harbored SOX2 mRNA up-regulation as previously reported [21], and 23 (13%) cases harbored
SOX2 gene amplification. SOX2 mRNA levels were associated to copy number alterations (Figure 4B).
Overall, SOX2-amplified tumors showed higher mRNA levels; however, SOX2 amplification was only
concomitantly accompanied by gene expression up-regulation in eight cases (5%). The impact of SOX2
mRNA expression on OSCC patient survival was also assessed (Figure 4C). The median survival times
for patients with high (above the median) and low SOX2 mRNA levels (below the median) were 26.41
and 19.19 months, respectively, although differences did not reach statistical significance (P = 0.495,
log-rank test).
Figure 4. In silico analysis of mRNA expression and copy number alterations of SOX2 in the subset of
172 oral squamous cell carcinoma patients from The Cancer Genome Atlas (TCGA) Head and Neck
Squamous Cell Carcinoma cohort [23] using the platform cBioPortal. (A) Oncoprint and heatmap
representations showing the percentage of cases with SOX2 gene amplification, mutation, and mRNA
up-regulation. (B) SOX2 mRNA expression analysis in relation to the copy number alterations of
SOX2 gene (RNA seq V2 RSEM) values were Log2 transformed (y-axis). Whiskers plot (min. to max.)
with median values; ** P < 0.01 and *** P < 0.001, one-way ANOVA, Tukey’s test. (C) Kaplan–Meier
survival curves categorized by SOX2 mRNA expression (RNA seq V2 RSEM, z-score threshold ± 2)
dichotomized as high mRNA levels (above the median) versus low mRNA levels (below the median),
P-value estimated using the log-rank test.
4. Discussion
To the best of our knowledge this is the first study to investigate SOX2 protein expression along the
different stages of oral carcinogenesis, from potentially malignant oral disorders, such as leukoplakia,
to invasive carcinomas, to ascertain its contribution to tumor initiation and malignant transformation,
and also late stages of disease progression.
Cancer stem cells (CSCs) are defined as a small subpopulation of cells in the tumors that
possess the ability to initiate neoplasms and sustain tumor self-renewal [7]. SOX2 gene mapping
at 3q26 is frequently amplified in OSCC and other cancers. It has been established as an important
CSC marker and a key molecule in the development of tumorigenesis in various cancers [13] and
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thus proposed as an oncogene [25,26]. Arnold et al. [27] reported that epithelial adult stem cells
expressing SOX2 may be residual stem niches that originate from embryonic SOX2-positive tissue
progenitors. Cai et al. [28] investigated the roles of OCT4 and SOX2 in the reprogramming of oral
cancer stem cells. They immortalized oral epithelial cells by lentiviral transduction and found that
double-transduced OCT4+SOX2+ cells were able to trigger tumor formation in immunodeficient mice;
however, single-transduced OCT4+ or SOX2+ cells did not show tumorigenic capacity. They also stated
that oral carcinogenesis may derive from OCT4+SOX2+ reprogrammed stem cells, in which SOX2
plays a major role in the regulation of the CSC niche [28]. Accordingly, it has been proposed that, in
the absence of SOX2 expression, CSC self-renewal that sustains tumor growth could be abrogated,;
therefore, supporting SOX2 inhibition as a potentially relevant therapeutic target for oral cancer [28].
OLK is the most frequent potentially malignant disorder in the oral cavity. Histologic grading of
epithelial dysplasia in OLK is currently still the gold standard in the clinical practice to evaluate the
risk of progression to invasive carcinoma [16]. However, the accuracy of the various grading systems
so far developed have shown limited predictability, are largely subjective, and affected by a great inter-
and intra-examiner variability [29]. According to the WHO 2017 classification there is not a unique
criteria or grading system for oral epithelial dysplasia, and as a consequence diagnostic reproducibility
is still limited. In addition to the currently accepted WHO three-tier classification for oral epithelial
dysplasia, a binary grading system (low-grade vs. high-grade) has also been proposed [22]. However,
this binary system has not yet been validated for use in the oral cavity. It is; therefore, of paramount
importance to identify novel biomarkers that could provide complementary information to histology
to more accurately predict the risk of malignant transformation of OLK. SOX2 has been demonstrated
to play a central role in the maintenance of CSC pluripotency and self-renewal [27], thereby emerging
as a promising marker for oral carcinogenesis. Luiz et al. [16] conducted a retrospective study to
compare the expression of SOX2 in OLK with normal oral mucosa, and found that SOX2 expression
was higher in OLK, although the relationship with oral cancer risk was not evaluated.
The presence of dysplastic features in the epithelium of the oral cavity are thought to be relevant
to malignant transformation in OLK. In our study, patients harboring high-grade dysplasia indeed
showed a significantly higher risk of malignant progression (HR = 19.08). SOX2 expression was also
found to be a significant predictor of risk of cancer development (HRs of 6.13 and 5.75 depending
on the cut-off used). Furthermore, dysplasia grading and SOX2 expression were both found to be
significant independent predictors of oral cancer risk in multivariate analysis. Similarly, we recently
demonstrated that NANOG expression was a novel cancer risk marker using the same subset of
patients with oral epithelial dysplasia [21]. Importantly, this study further extends these data to show
that patients harboring positive expression of both SOX2 and NANOG significantly exhibited a much
higher risk of progression to oral cancer, thereby suggesting a cooperative oncogenic role of these two
proteins in oral pathogenesis and malignant transformation.
SOX2 expression has also been analyzed during tumor progression. Freier et al. [30] reported
SOX2 expression in 18% of OSCC, and other studies on SCC of larynx, pharynx, and oral cavity found
frequencies up to 86% [22,31–33]. In our cohort of 125 OSCC cases, positive SOX2 expression was
detected in 39% of cases, while the frequencies of SOX2 expression reported in a previous study,
performed at our laboratory for other head and neck subsites, were 38% in hypopharynx, 42% in
larynx, and 14% in sinonasal cancer. In consequence, SOX2 expression frequencies in the oral cavity
were similar to those observed in neighboring tissues such as hypopharynx and larynx, but much
higher than in the sinonasal tract. In silico analysis of RNAseq data in a subset of 172 OSCC patients
from the TCGA HNSCC cohort [23] further contributed to demonstrate that SOX2 mRNA levels were
up-regulated in 13% of OSCC patients. In addition, SOX2 gene amplification was also observed in 13%
of cases; however, only 5% of cases harboring SOX2 amplification were concomitantly accompanied
by increased gene expression, indicating that additional mechanisms must be contributing to SOX2
expression in OSCC. In this sense, there are various plausible transcriptional regulatory mechanisms,
such as the transcription factors OCT4 and YAP1 or the hypoxic factor HIF1α, found to modulate SOX2
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expression [34,35]. Moreover, SOX2 protein expression was detected at much higher percentages (38%)
in our OSCC cohort than SOX2 mRNA expression (13%), thereby suggesting the possible involvement
of post-transcriptional mechanisms. Similar observations have been reported for other CSC-related
factors, such as NANOG or PDPN, detected in over 30% of OSCC patients at the protein level [21,36]
compared to 3% at mRNA levels according to the TCGA data from 172 OSCC patients [21].
Studies published to date assessing the expression of SOX2 and its clinical and prognostic relevance
in OSCC have led to contradictory results. It has been reported that a high expression of SOX2 was
significantly associated with poorer survival in node-negative OSCC [18], while others [17,26,37] found
that a high expression of SOX2 correlated with lymph node metastasis. The latter could be explained
by the relevant role of SOX2 as an epithelial–mesenchymal transition (EMT) inducer, thereby acting
through the Wnt/β-catenin and phosphoinositide 3-kinase/protein kinase B signaling pathways [38,39]
to promote oncogenesis, invasion, and metastasis. Nonetheless, the opposite viewpoint is represented
by patients with early-stage OSCC, where upregulation of SOX2 has been correlated with a lower
incidence of lymph node metastasis [2,20]. These controversial results could be explained by the
heterogeneity of different tumors, as well as by different molecular mechanisms underlying the complex
process of metastasis. The majority of studies showed that SOX2 overexpression may promote cancer
progression; however, it has also been reported that SOX2 overexpression inhibits cell proliferation [13].
Furthermore, SOX2 is thought to stabilize stem cell phenotype and prevent EMT [40], and even more,
SOX2 could promote mesenchymal–epithelial transition (MET), attenuating the invasive phenotype [41].
In our study, the expression of SOX2 did not correlate to T classification, neck lymph node metastasis,
disease stage, histological grade, tumor recurrence, and second primary carcinomas development.
Most studies showed that the survival rate of OSCC patients harboring low levels of SOX2
increased compared to those with high levels of SOX2 [13], although Züllig et al. [20] and Fu et al. [2]
found that low expression of SOX2 was significantly associated with worse survival. Similarly, other
studies on SCC from various locations described an association of elevated SOX2 expression with
longer survival [19,42–44]. We herein observed that SOX2 expression was more frequently observed
in early tumor stages as well as in N0 cases, and patients with positive SOX2 expression exhibited
a better survival than those with negative expression, although differences did not reach statistical
significance (P = 0.07).
It is possible that all these contradictory results are related to methodological differences in SOX2
IHC scoring, as well as in the heterogeneity of patient populations or even in the morphological and
genetic heterogeneity observed in solid tumors. Another explanation may be that SOX2 copy number
gain and expression are early tumor-initiating events, but this gene can lose its relevance in conveying
an aggressive or metastasizing phenotype [22].
5. Conclusions
Together, our results reveal that SOX2 expression is a clinically relevant feature in early stages of
oral tumorigenesis, and provide original evidence of its potential utility as biomarker for oral cancer
risk assessment. According to these data, SOX2 expression emerges as an important determinant in
the pathogenesis of a subset of OSCC, thereby contributing to tumor initiation and acquisition of an
invasive phenotype rather than late stages of disease progression.
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Abstract: The frequent dysregulation of SRC family kinases (SFK) in multiple cancers prompted
various inhibitors to be actively tested in preclinical and clinical trials. Disappointingly, dasatinib and
saracatinib failed to demonstrate monotherapeutic efficacy in patients with head and neck squamous
cell carcinomas (HNSCC). Deeper functional and mechanistic knowledge of the actions of these
drugs is therefore needed to improve clinical outcome and to develop more efficient combinational
strategies. Even though the SFK inhibitors dasatinib and saracatinib robustly blocked cell migration
and invasion in HNSCC cell lines, this study unveils undesirable stem cell-promoting functions that
could explain the lack of clinical efficacy in HNSCC patients. These deleterious effects were targeted
by the mithramycin analog EC-8042 that efficiently eliminated cancer stem cells (CSC)-enriched
tumorsphere cultures as well as tumor bulk cells and demonstrated potent antitumor activity in vivo.
Furthermore, combination treatment of dasatinib with EC-8042 provided favorable complementary
anti-proliferative, anti-invasive, and anti-CSC functions without any noticeable adverse interactions
of both agents. These findings strongly support combinational strategies with EC-8042 for clinical
testing in HNSCC patients. These data may have implications on ongoing dasatinib-based trials.
Keywords: head and neck squamous cell carcinoma; SRC; dasatinib; saracatinib; cancer stem cells;
EC-8042
1. Introduction
Increased SRC expression and/or activity has been widely detected in a variety of human cancers,
including head and neck squamous cell carcinomas (HNSCC) [1–3]. It has been demonstrated that
aberrant SRC activity plays a central role in all stages of tumorigenesis from malignant transformation
to tumor progression and ultimately development of metastatic disease [4,5].
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SRC is a pleiotropic non-receptor tyrosine kinase that interacts with multiple receptor tyrosine
kinases and modulates multiple oncogenic signaling pathways [6,7], thereby regulating a variety
of cellular processes central to the malignant phenotype, including proliferation, survival, cell-cell
adhesion, motility, invasion, and angiogenesis [8,9]. SRC induces disruption of focal adhesions
by activation of focal adhesion kinase (FAK) [10]. FAK is associated with SRC in focal adhesions,
which results in the phosphorylation of FAK followed by downstream activation of the Ras-mediated
pathways [11]. In addition, SRC regulates the reorganization of the actin cytoskeleton through
phosphorylation of p190 [12] and cortactin (CTTN), which results in increased motility [13].
The frequent dysregulation of SRC family kinases (SFK) in a variety of human cancers has led
to a rapid development of multiple agents aimed at targeting SFK in cancer treatment [9]. Various
inhibitors, in particular dasatinib (BMS-354825) and saracatinib (AZD0530), have been the subject
of intense research in recent years [14–21]. Even though both drugs have proved powerful as
antitumor agents in preclinical settings, their clinical efficacy in cancer patients has been limited if
not disappointing [14–16,20,21]. In preclinical models of HNSCC, dasatinib and saracatinib showed
potent effects on proliferation, cell migration, and invasion [22,23]; however, both inhibitors failed
to demonstrate any significant activity as single agents in patients with recurrent and/or metastatic
HNSCC [24,25].
In light of these data, it becomes highly desirable to establish relevant response biomarkers to
improve patient stratification, treatment efficacy, and ultimately clinical outcome. In addition, a deeper
functional and mechanistic knowledge of the actions of these drugs on tumor cells will contribute to
deciphering not only anti-tumor functions but also unwanted pro-tumor actions, thus enabling the
development of combination strategies that may prevent potential deleterious activities and provide
anti-tumor complementary/synergistic strategies.
This study demonstrates that while dasatinib and saracatinib robustly blocked cell migration
and invasion in HNSCC cell lines, both were found to strikingly enhance cancer stem cells (CSC)
properties. These deleterious effects were effectively targeted by the low-toxicity mithramycin analog
(mithralog) EC-8042 [26], which has previously demonstrated anti-stemness activity in other cancer
cells [27]. Accordingly, EC-8042 efficiently inhibited the growth of both bulk tumor adherent cultures
and CSC-enriched tumorsphere cultures in HNSCC-derived cells and demonstrated a robust antitumor
activity in vivo. Moreover, combination treatment between dasatinib and EC-8042 benefits from
complementary anti-tumor properties provided by each compound without any noticeable adverse
interactions between them.
2. Materials and Methods
2.1. Drugs
EC-8042 (EntreChem, Oviedo, Spain), Dasatinib and Saracatinib (both from Selleck, Suffolk, UK)
were prepared as 10 mM solutions in sterile DMSO or water, maintained at −20 ◦C and brought to the
final concentration just before use.
2.2. Cell Culture
FaDu cells (male, hypopharyngeal squamous cell carcinoma) were purchased from the ATCC,
and the HNSCC cell line UT-SCC38 derived from a laryngeal squamous carcinoma (T2N0M0) was
kindly provided by R. Grenman (Department of Otolaryngology, University Central Hospital, Turku,
Finland) [28]. Cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL
penicillin, 200 mg/mL streptomycin, 2 mmol/L L-glutamine, 20 mmol/L HEPES (pH 7.3), and 100 mmol/L
non-essential amino acids. All the cells derived from HPV-negative primary HNSCC. All cell lines
were periodically tested for mycoplasma contamination by PCR using the Biotools Detection kit
(Madrid, Spain) specifically amplifying a conserved region of the mycoplasma 16S RNA gene. Cell
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line authentication was carried out by DNA (STR) profiling at the SCT Core Facilities (University of
Oviedo, Spain).
2.3. Western Blotting Analysis
Cells were lysed in Laemmli sample buffer and sonicated before centrifugation. Protein lysates were
separated by SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and transferred to nitrocellulose
membranes (Amersham Protran, GE Healthcare, Pittsburg, PA, USA). Subsequently, membranes were
blocked for 1 h with Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) and incubated
overnight with the indicated primary antibodies (Supplementary Methods) at 1:1000 dilution. The
IRDye Infrared Fluorescent secondary antibodies anti-Rabbit and anti-Mouse IRDye 800CW and IRDye
680RD (LI-COR Biosciences) were used for detection. Membranes were scanned with the Odyssey Fc
Dual-Mode Imaging System (LI-COR Biosciences) using the red (700 nm) and green (800 nm) channels,
and signal analysis was performed using Image Studio Lite software (LI-COR, Nebraska). Results
were normalized to GAPDH as loading control.
2.4. Cell Viability Assays
HNSCC cells were seeded into 96-well culture plates at a density of 2000 cells per well and
incubated overnight. Drugs were serially diluted in medium over a range of concentrations and
added to the cells. After 72 h treatment, cell viability was measured in quadruplicates using a MTS
assay (CellTiter 96 Aqueous One Solution Cell Proliferation Assay from Promega, Madison, WI, USA)
reading absorbance at 490 nm using a Synergy HT plate reader (BioTek, Winooski, VT, USA). The
existence of synergy in drug combinations was determined by calculating the combination index (CI)
as described in Supplementary Information.
2.5. Scratch-Induced Directional Migration Assay
Cells were plated in 24-well dishes with ibidi® culture inserts (ibidi LLC, Verona, WI, USA) at
80–90% confluence, and cell migration monitored as we previously described [29].
2.6. Three-Dimensional Spheroid Invasion Assays
Invasion assays using 3D spheroids were performed as previously described [30]. Cells were
suspended in DMEM plus 5% Methyl cellulose (Sigma, St Louis, MO, USA) to form cell spheroids by
serial pipetting into a non-adhesive Petri dish (2000 cells/spheroid), followed by overnight incubation
in an inverted position. The next day, each cell spheroid was individually transferred to a 96-well
plate, embedded into bovine collagen matrix (Advanced Biomatrix PureCol), and filled with 100 μL
of complete media containing or not containing drugs. Cell invasion was monitored using a Zeiss
Cell Observer Live Imaging microscope (Zeiss, Thornwood, NY, USA) and images acquired every
15 min for 24 h using a Zeiss AxioCam MRc camera. The invasive area was calculated as the difference
between the final area (t = 24 h) and the initial area (t = 0 h) using image J analysis program, and data
were normalized to control (vehicle-treated) cells. Three independent experiments were performed
using quadruplicates for each condition.
2.7. Tumorsphere Formation Assay
HNSCC-derived cells lines were plated at a density of 500 cells/mL in 6-well tissue culture
plates treated with a sterile solution of polyHEMA (10 g/L in 95% ethanol) (Sigma) to prevent cell
attachment. Cells were grown in DMEM-F12 (GE Healthcare) supplemented with 1% Glutamax and
2% B27 Supplement from Life Technologies (Rockford, IL, USA), 10 ng/mL human bFGF and 20 ng/mL
human EGF (PeproTech, London, UK) and 100 U/mL penicillin and 200 mg/mL streptomycin (Thermo,
Waltham, MA, USA).
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After 10–12 days, well-formed spheres were photographed in Leica Microsystems microscope
DMIL T coupled with a Leica DC500 High-resolution Digital Camera (Leica Microsystems, Barcelona,
Spain). Then, the tumorspheres were centrifuged at 300 rpm for 2 min, washed with PBS and either
collected for RNA extraction or disaggregated with Gibco trypsin (0.25%)/EDTA for 15 min to measure
cell viability by MTS.
2.8. RNA Extraction and Real-Time RT-PCR
Total RNA was extracted from HNSCC cells using Trizol reagent (Invitrogen Life Technologies,
Carlsbad, CA, USA), and gene expression was analyzed by real-time RT-PCR as we previously
reported [31] using SYBR Green Master Mix protocol (Applied Biosystems, Foster City, CA, USA) in a
StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Reactions were run
in triplicates using the specific primers detailed in Supplementary Table S1, and the ribosomal coding
gene RPL19 was used as endogenous control. The relative mRNA expression was calculated using the
2−ΔΔCT method, and the data were expressed as the fold-change normalized to RPL19 mRNA levels
and relative to control (vehicle-treated) cells.
2.9. In Vivo Treatments of FaDu Xenografts
All experimental protocols were performed in accordance with the institutional guidelines of
the University of Oviedo and approved by the Animal Research Ethical Committee of the University
of Oviedo prior to the study. Female athymic NMRI-nude mice of 6–7 weeks old (Janvier Labs, St
Berthevin, France) were subcutaneously inoculated (s.c.) with 1.5 × 106 FaDu cells mixed 1:1 with BD
Matrigel Matrix High Concentration (BD Biosciences, Erembodegem, Belgium) previously diluted 1:1
in culture medium. Once tumors reached ~200 mm3, mice were randomized into four treatment groups
(n = 10 per group): (i) vehicle (saline solution intravenously (i.v.) as vehicle for EC-8042 and tartaric
acid solution orally for dasatinib); (ii) dasatinib (10 mg/kg every day (16 doses) orally); (iii) EC-8042
(50 mg/kg every 7 days (4 doses) i.v.); and (iv) dasatinib plus EC-8042 combination.
Survival was represented using Kaplan–Meier analysis and the log-rank test to estimate significant
differences among groups (PAST 3.01 software, University of Oslo, Norway). Tumor growth and drug
efficacy (expressed as the percentage of tumor growth inhibition, %TGI) were calculated as indicated
in Supplementary Information.
2.10. Tumorsphere Formation and Immunohistochemical Analyses of Tumors from FaDu Xenografts.
Upon removal, tumor samples were weighted and a portion of some tumors was disaggregated
into single cell suspensions using MACS Tissue Dissociation Kit and the GentleMACS Dissociator
system (Miltenyi Biotec, Bergisch Gladbach, Germany) as previously described [27], in order to perform
tumorsphere formation assays after in vivo treatments. The remaining portion of the tumors were fixed
in formol, embedded in paraffin, cut into 4-μm sections, and stained with hematoxylin and eosin (H&E).
Immunohistochemical analyses were performed in an automatic workstation (Dako Autostainer Plus)
with anti-Ki67 (Clone MIB-1 Dako # JR626, Prediluted), anti-active PARP (Abcam # 32064, at 1:500),
anti-ALDH1 (BD Biosciences # 611195, at 1:500), anti-SOX2 (Merck Millipore # AB5603, at 1:1000), and
phospho-FAK (Y861) (Invitrogen # 44-626G, at 1:100) using the Dako EnVision Flex + Visualization
System (Dako Autostainer). The number of ALDH1-positive cells or SOX2-positive nuclei was counted
at 40× in five independent microscopic fields per tissue section, and the mean of five fields was
calculated for each treatment. p-FAK (Y861) staining intensity was evaluated, and the mean of five
fields was calculated for each treatment. Quantification of staining for Ki67 proliferation index (number
of positive cells per mm2) and cleaved PARP (number of positive cells per mm2) was automatically
performed using the ImageJ software (National Institutes of Health, Bethesda, MD, USA) in six random
images (×200) per sample.
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2.11. Statistical Analyses
Statistical analysis was performed using GraphPad Prism version 6.0 (Graphpad Software Inc, La
Jolla, CA, USA). Data are presented as the mean ± standard deviation (SD) of at least three independent
experiments unless otherwise stated. Statistical significance will be determined either using a Student’s
unpaired t-test with two-tailed distribution for comparison across two groups or one/two-way ANOVA
for comparing multiple samples/variables. In comparisons with control groups, the values of p < 0.05
were considered statistically significant (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).
3. Results
3.1. Dasatinib and Saracatinib Completely Blocked Migration and Invasion in HNSCC-Derived Cell Lines
We first evaluated the effect of dasatinib and saracatinib in the HNSCC-derived cell lines FaDu
and UT-SCC38. As expected, both compounds decreased the phosphorylation levels of SRC at tyrosine
418 (Y418) and FAK at Y861 in FaDu and UT-SCC38 cells (Supplementary Figure S1A,B). Phospho-SRC
Y418 levels rapidly decreased after 1 h treatment with saracatinib and dasatinib (Supplementary Figure
S1C), and the phosphorylation levels of its downstream target FAK Y861 were efficiently targeted
and durably reduced at 24 h. In addition, dasatinib (0.1 μM) and saracatinib (1 μM) completely
blocked cell migration and invasion into 3D collagen matrices in both cell lines (Figure 1A,B, and
Supplementary Materials: Videos S1 and S2). 24 h treatment with these concentrations of drugs had no
significant effect on cell viability in UT-SCC38 and led to a 20% decrease in FaDu cells (Supplementary
Figure S1D); however, this effect was very modest compared to the robust effects observed on cell
migration (>90%) and invasion (>70%). Altogether, these data indicate that the potent anti-invasive
effect observed upon dasatinib or saracatinib treatment cannot be attributed to the ability of these
drugs to decrease cell viability. Nonetheless, longer treatments for 72 h with saracatinib and dasatinib
led to a dose-dependent reduction of cell viability, with dasatinib having a more pronounced cytotoxic
effect (Figure 1C).
3.2. Dasatinib and Saracatinib Promoted CSC-Like Phenotypes in HNSCC Cells
CSCs have been recognized to play critical roles driving tumor initiation, progression, recurrence,
and treatment resistance. This prompted us to investigate whether dasatinib and saracatinib are able
to target CSCs in HNSCC cells.
Clonal sphere-forming ability in non-adherent serum-free culture conditions (tumorsphere
cultures) is a hallmark of self-renewal and CSC-related phenotype. Under these conditions, the
expression of well-known CSC markers such as ALDH1A1 and SOX2 [32] was consistently and
markedly enriched in FaDu and UT-SCC38 tumorspheres when compared to unselected adherent
cultures (Supplementary Figure S2). Notably, dasatinib and saracatinib failed to eliminate CSC-enriched
tumorsphere cultures of FaDu and UT-SCC38 cells (Figure 2A,B). Strikingly, we also found that both
drugs significantly increased the expression of ALDH1A1 and SOX2 at both mRNA and protein levels
(Figure 2C,D and Supplementary Figure S3A). Of note, specifically in UT-SCC38 cells, SOX2 expression
was not affected by dasatinib, and consistent results were obtained at both mRNA and protein level.
Nonetheless, NANOG1 and OCT4 levels also consistently increased upon dasatinib and saracatinib
treatment in these two HNSCC-derived cell lines (Figure 2D), in good agreement with the previous
paper by Koo et al. [33]. Furthermore, since the process of epithelial to mesenchymal transition
(EMT) is known to play a critical role as a driver of tumor cell invasion and metastatic spreading in
HNSCC [34–36], expression changes of EMT markers were also assessed. Our results consistently
showed that the expression levels of the epithelial marker E-Cadherin increased upon treatment
with dasatinib and saracatinib, while the expression of mesenchymal markers such as Vimentin and
Snail decreased, thereby indicating that both compounds inhibit EMT in these two HNSCC cell lines
(Supplementary Figure S4). In light of these data, the ability of dasatinib and saracatinib to revert EMT
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could be an additional mechanism (together with other invasion regulators targeted, e.g., SRC, FAK) to
explain the potent inhibitory effect on cell invasiveness exhibited by these drugs.
Figure 1. Effect of dasatinib and saracatinib on cell migration, invasion, and growth of head and
neck squamous cell carcinomas (HNSCC)-derived cell lines. (A) Wound healing assays in FaDu
and UT-SCC38 cells treated with either DMSO (vehicle), 0.1 μM dasatinib, or 1 μM saracatinib. The
percentage of cell migration (left panel) and representative images showing the initial scratch (t = 0)
area and the residual area at the final time (t = 15 h) in FaDu cells (right panel) are displayed.
Scale bars = 200 μm. Data are expressed relative to vehicle-treated cells (mean ± SD, Student’s t-test,
*** p < 0.001). (B) 3D spheroid invasion assays in FaDu cells treated for 24 h with either DMSO (vehicle),
0.1 μM dasatinib, or 1 μM saracatinib. The quantification of the invasive area at the indicated times
(left panel) and representative images of FaDu spheroids at initial (t = 0) and final time (t = 24 h) (right
panel) for the different treatments are displayed. Scale bars = 200 μm. Data are expressed relative to
DMSO-treated cells (mean ± SD, Student’s t-test, *** p < 0.001). (C) Cell viability of FaDu (left panel)
and UT-SCC38 (right panel) cells was measured by MTS assay after 72 h treatment with increasing
doses of either dasatinib or saracatinib. IC50 values are shown.
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Figure 2. Effect of dasatinib and saracatinib on the cancer stem cells (CSC) properties of HNSCC-derived
cell lines. (A,B) Cell viability (MTS assay) of UT-SCC38 and FaDu tumorspheres treated with increasing
concentrations of dasatinib or saracatinib for 72 h. Quantification of cell viability (A) and representative
images of FaDu tumorspheres upon the indicated treatments (B) are shown. (C,D) Analysis of the
protein (Western blotting; C and quantification of IRdye fluorescent signals are plotted in Supplementary
Figure S3A) and relative mRNA (RT-qPCR); (D) levels of the CSC-markers ALDH1A1, SOX2, OCT4,
and NANOG in FaDu and UT-SCC38 cells treated with increasing concentrations of dasatinib and
saracatinib for 72 h. Data were normalized to RPL19 levels and represented relative to vehicle-treated
cells (mean ± SD, Student’s t-test, ** p < 0.01, *** p < 0.001).
3.3. The Mithramycin Analog EC-8042 Effectively Abrogated the CSC Properties of HNSCC Cells
We next assessed the ability of the mithramycin analog EC-8042 to eradicate CSCs, since it has
been described to potently reduce CSCs viability and expression of CSC-related markers in other
cancers [27].
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EC-8042 showed a much more robust cytotoxic effect on adherent cultures than the two SRC
inhibitors (Figure 3A). Likewise, the treatment with EC-8042 was highly effective in reducing the
number, size and the viability of CSC-enriched tumorsphere cultures (Figure 3B,C). Furthermore,
pretreatment for 72 hours with EC-8042 (0.1 μM) but neither dasatinib (0.1 μM) nor saracatinib (1 μM)
was also able to significantly prevent tumorsphere formation in FaDu cells (Figure 3D). In addition, the
expression of the CSC-related markers ALDH1A1 and SOX2 was robustly and consistently reduced in
both FaDu and UT-SCC38 cells after treatment with EC-8042 (Figure 3E).
Figure 3. Effect of the mithralog EC-8042 on the viability and CSC properties of HNSCC-derived cell
lines. (A,B) Dose-response curves of the cell viability by MTS in UT-SCC38 and FaDu adherent cells (A)
or CSC-enriched tumorspheres (B) treated with increasing concentrations of EC-8042 for 72 h. IC50
values are shown. (C) Representative images of FaDu tumorspheres upon treatment for 72 h with
different doses of EC-8042. (D) Tumorsphere-forming ability of FaDu cells upon treatment for 72 h with
either DMSO (vehicle), 0.1 μM dasatinib, 1 μM saracatinib, or 0.1 μM EC-8042. (E) RT-qPCR analysis of
the CSC-markers ALDH1A1 and SOX2 in adherent cultures of FaDu and UTSCC38 cells treated with
increasing concentrations of EC-8042 for 72 h. Data are expressed relative to DMSO-treated cells (mean
± SD, Student’s t-test, * p < 0.05, ** p < 0.01, *** p < 0.001).
3.4. Combined Effects of Treatment with Dasatinib and EC-8042 in HNSCC Models
Next, we explored the effects of the combination treatment with dasatinib and EC-8042. First, we
analyzed the effect of the combination on the activation of key signaling targets for both drugs (Figure 4A
and Supplementary Figure S5). As shown previously in other tumor cell models [37], a 24-hour
treatment with dasatinib efficiently inhibited SRC phosphorylation at Y418 while upregulating total
SRC levels. SRC-dependent phosphorylation and activation of FAK at Y861, but not SRC-independent
autophosphorylation at Y397, was completely and durably inhibited by dasatinib without affecting
total FAK levels. The phosphorylation/activation of other downstream signaling targets, such as AKT
at S473 or p44/42-MAPK, was also inhibited by dasatinib treatment (Figure 4A). EC-8042 treatment
resulted in reduced levels of its target SP1 and also led to the down-regulation of both total FAK and
p-FAK (Y397) levels. Importantly, the combination of both drugs produced an additive inhibitory effect
on the phosphorylation/activation of most of the targets (Figure 4A).
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Figure 4. Functional effects of the combined treatment with dasatinib and EC-8042 in HNSCC cells.
(A) Western blotting analysis of the expression/phosphorylation levels of the indicated proteins in
FaDu cells treated for 24 h, 48 h, or 72 h with either 0.1 μM dasatinib or 0.1 μM EC-8042 alone, or
in combination. Quantification of IRdye fluorescent signals are plotted in Supplementary Figure S5.
(B,C) 3D spheroid invasion assay in FaDu cells treated for 24 h with 0.1 μM dasatinib, 0.1 μM
EC-8042 alone, or combination. The quantification of the invasive area at the indicated times (B)
and representative images of FaDu spheroids (C) at initial (t = 0) and final time (t = 24 h) for the
different treatments are shown. Scale bars = 200 μm. Data are expressed relative to vehicle-treated
cells (mean ± SD, Repeated Measures (RM)-one-way ANOVA, Tukey’s test, * p < 0.05 vs. DMSO and
EC-8042-treated cells). (D) Dose-response curves of cell viability by MTS in FaDu (upper panel) and
UT-SCC38 (lower panel) cells treated with the indicated combinations of drugs for 72 h. In these graphs
the dasatinib + EC-8042 series was normalized to the value observed after treatment with EC-8042 alone.
The effect of EC-8042 alone is subtracted from the combination values, thus showing the shift in the
IC50 of dasatinib due to the combination. (E) Cell viability of CSC-enriched FaDu tumorspheres treated
with 0.1 μM dasatinib, 0.1 μM EC-8042, or combination. Data are expressed relative to vehicle-treated
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cells (mean ± SD, one-way ANOVA, Tukey’s test, *** p < 0.001 vs. DMSO and dasatinib-treated cells).
(F) Western blotting (left panel) and (G) RT-qPCR analysis (right panel) of the indicated oncogenic
and CSC-related markers in adherent cultures of FaDu cells treated for 72 h with 0.1 μM dasatinib
or 0.1 μM EC-8042 alone, or in combination. mRNA levels were normalized to RPL19 levels and the
relative fold-change to vehicle-treated cells ± SD plotted, two-way ANOVA, Dunnett’s test, * p < 0.05,
** p < 0.01, *** p < 0.001 vs. DMSO (black) and dasatinib-treated cells (red). Quantification of the IRdye
fluorescent signals are plotted in Supplementary Figure S3B.
We next studied the ability of the combination to add jointly favorable anti-tumor effects with
respect to single treatments. First, we found that the combined treatment maintained the ability of
dasatinib to abolish invasion of HNSCC cells into 3D collagen matrices (Figure 4B,C, Supplementary
Videos S1–S4). In addition, cell survival curves normalized to the effect of EC-8042 alone showed that
the combination of dasatinib with EC-8042 did not produce a significant shift of the dasatinib IC50
values (Figure 4D). Furthermore, combination index values calculated according to the Chou and
Talalay method [38] for EC-8042 and dasatinib combination were close to 1 (Supplementary Figure
S6A), thus suggesting that this combination produce additive, rather than synergistic cytotoxic effects.
Moreover, the deleterious effects caused by dasatinib sustaining CSC-like phenotypes were
effectively counteracted by EC-8042 co-treatment, thereby reducing the viability of CSC-enriched
tumorspheres (Figure 4E) and the expression of various CSC-related factors such as ALDH1, SOX2,
NANOG, OCT4, c-MYC, or NOTCH1 at mRNA and protein level (Figure 4F,G and Supplementary
Figure S3B).
In addition, the effects of EC-8042 and combo treatments on the targeting of CSC subpopulations
were also monitored by flow cytometry using the SORE6 reporter system, which allows dynamic
monitoring of CSC subpopulation based on SOX2/OCT4 expression. This system has previously
demonstrated its ability to detect CSC subpopulations in different tumor types [39]. Thus, we generated
HNSCC-derived cell lines with stable expression of the SORE6 construct (UT-SCC38-SORE6-GFP
and FaDu-SORE6-GFP) or their corresponding controls without the SORE6 response element
(UT-SCC38-minCMV-GFP and FaDu-minCMV-GFP), which have been used as gating controls in
flow cytometry analyses. FaDu-SORE6-GFP and UT-SCC38-SORE6-GFP displayed 28% and 22%
of SORE6-positive cells, respectively. As expected for bona fide CSCs subpopulations, SORE-GFP+
subpopulations sorted from both cell lines by flow cytometry showed increased expression of SOX2 and
OCT4 and also increased ability to grow as tumorspheres (Supplementary Figure S7A,B). To analyze
the effect of the drugs on CSC subpopulations, cultures of SCC38-SORE6-GFP and FaDu-SORE6-GFP
cells were treated with dasatinib, EC-8042 and the combination for 72 h. As shown by flow cytometry
analysis, EC-8042 and the combined treatment, but not dasatinib alone, significantly decreased the
SORE-GFP+ subpopulation in both cell lines (Supplementary Figure S7C,D), thus confirming the ability
of EC-8042 alone or in combination with dasatinib to target CSC subpopulations in HNSCC cells.
Importantly, EC-8042 and the combined treatment demonstrated a profound antitumor activity
in vivo on FaDu xenografts compared to vehicle- and dasatinib alone-treated groups (Figure 5). Thus,
treatment with EC-8042 or EC-8042 plus dasatinib led to a significant reduction of tumor volume
growth, presenting TGI percentages of 43% and 61%, respectively, and also a significant increase in
survival (Figure 5A,B and Supplementary Figure S8A,B). Likewise, tumor weights in vehicle and
dasatinib series doubled those of EC-8042 and combination series (Figure 5C) and even the combination
regime was able to produce tumor regression in one case (Supplementary Figure S8A). Notably, none of
the treatments caused loss of weight (Supplementary Figure S8C) or any other adverse effects in treated
mice. In any case, a two-way ANOVA analysis of the relative tumor volumes at the experimental end
point (Figure 5B) or the tumor weights (Figure 5C) show that the interaction between dasatinib and
EC-8042 is considered not significant (Supplementary Figure S6B–D) and therefore, no synergistic
effect was expected [40] in line with the CI values calculated in in vitro assays.
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Figure 5. Effect of combination treatment with dasatinib and EC-8042 in FaDu xenografts. Mice with
established FaDu xenografts were randomly assigned to four different treatment groups (n = 10 tumors
per group) and treated with saline buffer intravenously (i.v.) and/or tartaric acid (orally) (control),
dasatinib (orally) at a dose of 10 mg/Kg every day (16 doses), EC-8042 (i.v.) at a dose of 50 mg/Kg every
7 days (4 doses), or the dasatinib plus EC-8042 combination (combo). Animals were sacrificed 4 h after
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the last treatment with dasatinib and 24 h after treatment with EC-8042. (A) Curves representing
the mean tumor volume of FaDu xenografts during the treatments. Drug efficacy expressed as the
percentage of tumor growth inhibition (%TGI) at the end of the experiment is indicated. Mean ± SD
(n = 10 per treatment group), RM-one-way ANOVA, Tukey’s test, * p < 0.05, ** p < 0.01 vs. control
(black) and dasatinib-treated mice (red). (B,C) Distribution of tumor volumes (B) and tumor weights
(C) at the end of the experiment. Mean ± SD (n = 10 per group), one-way ANOVA, Tukey’s test, p < 0.05
between the indicated groups. (D) For the evaluation of CSC subpopulations after drug treatments,
xenograft tumors were harvested and dissociated into single cells to assess the tumorsphere-forming
ability after in vivo drug treatment. Mean ± SD (n = 3 per group), one-way ANOVA, Tukey’s test.
(E) Representative images and (F–J) graphs of the immunohistochemical analysis of Ki67, cleaved
PARP, ALDH1, SOX2, and phospho-FAK (Y861) in paraffin-embedded tumors from FaDu xenografts
after in vivo treatment with the indicated drugs. Scale bars = 100 μm. Mean ± SD (n = 5 per group),
one-way ANOVA, Tukey’s test, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control (black),
dasatinib-(red) or EC-8042-treated (blue) mice.
The ability of drugs to target CSC subpopulations was also examined after in vivo treatments.
Thus, a cohort of xenograft tumors was harvested at the end of the treatments, disaggregated into
single cells and assayed for tumorsphere formation. Whilst tumorsphere formation slightly increased
in dasatinib-treated tumors, we found an inhibition of tumorsphere-forming ability in tumors treated
with EC-8042 alone, which reached statistical significance in combination with dasatinib (Figure 5D).
Furthermore, immunohistochemical analysis also confirmed a significant decrease in the expression of
both CSC markers ALDH1A1 and SOX2 in EC-8042-treated and combo-treated tumors (Figure 5E–G).
We also found that EC-8042 and combination treatment led to a significant decrease in the percentage
of Ki67-positive cells, as well as a significant increase in apoptotic cell death (cleaved-PARP staining)
(Figure 5E,H,I). In addition, FAK (Y861) phosphorylation levels significantly diminished in dasatinib-
and combo-treated tumors, as expected (Figure 5E,J). Taken together, these results demonstrate that
EC-8042 and combination treatment efficiently targeted CSC properties and showed robust in vivo
anti-tumor effects mainly due to reduced cell proliferation and increased apoptotic cell death.
Overall, we show evidence that HNSCC cells treated with a combination of dasatinib and EC-8042
benefit from favorable anti-tumor properties of both drugs while preventing the adverse pro-stemness
effects induced by dasatinib. Even though our findings indicate the presence of additive cytotoxic
effect in vitro but not in vivo synergistic effect, the combined treatment keeps the ability of dasatinib to
abrogate relevant pro-tumor signaling (i.e., SRC/FAK signaling) and abolish invasive potential, while
adding the potent capacity of EC-8042 to target CSC subpopulations and inhibit tumor growth, without
any noticeable adverse interactions of both agents.
4. Discussion
Dasatinib and saracatinib have proven powerful antitumor activity in preclinical settings but
rather limited clinical efficacy in cancer patients [14–16,21,22]. In the context of HNSCC, both drugs
have failed to demonstrate any significant activity as single agents in patients with recurrent and/or
metastatic disease [24,25]. We herein provide interesting new data uncovering important deleterious
activities of dasatinib and saracatinib sustaining stem cell-like properties in HNSCC cell lines, which
could be a plausible underlying reason to explain their lack of clinical efficacy as monotherapeutic
agents in HNSCC patients.
Complete eradication of tumors requires therapies able to effectively eliminate the CSC
subpopulations responsible for treatment resistance, relapse, and metastasis [41–43]. Indeed, we found
that treatment of HNSCC cells with EC-8042, a mithramycin analog with reported anti-stemness
activity in sarcomas [27], resulted in a potent elimination of both adherent cell cultures (bulk tumor
population) and CSC-enriched tumorsphere cultures and demonstrated a robust antitumor activity
in vivo in HNSCC xenograft models. EC-8042 was found to induce its anti-oncogenic effects through
the inhibition of factors like SP1 [27]. In this regard, it has been demonstrated that SP1 is frequently
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upregulated in HNSCC and that a combined inhibition of SP1, using mithramycin, and TGFβ pathways
induced cell death and prevented HNSCC recurrence [44].
In marked contrast to EC-8042, dasatinib completely abolished cell invasion but induced only a
modest anti-proliferative effect in adherent HNSCC cultures. More importantly, dasatinib failed to
eliminate CSC-enriched tumorspheres or to prove any significant antitumor activity in FaDu xenografts.
In this line, it has been reported that dasatinib worsened the anti-tumor effects in combination with
cetuximab or cetuximab and radiation therapy in FaDu-derived tumors [45]. In addition, saracatinib did
not demonstrate a significant effect on HNSCC tumor growth in a mouse orthotopic model of tongue
squamous cell carcinoma but impaired perineural invasion and cervical lymph node metastasis [46].
Similarly, results from a randomized trial aimed to test the treatment with erlotinib, dasatinib, or
combination treatment in patients with operable HNSCC showed that erlotinib but not dasatinib
significantly reduced tumor size [47].
The study of the effect of dasatinib and EC-8042 combination in HNSCC models shows
non-synergistic but complementary effects, where both drugs exert complementary anti-tumor
properties without antagonizing each other. Remarkably, combined treatment of dasatinib with
EC-8042 efficiently counteracted the deleterious effects of dasatinib on CSC properties, thus showing
potent anti-proliferative, anti-stemness, and anti-invasive effects in HNSCC cells and significant
antitumor activity in xenografts. Clonal sphere-forming ability and also expression of well-known
CSC markers were consistently and dramatically reduced both in vitro and in vivo by treatment
with dasatinib and EC-8042, compared to dasatinib alone. Our results also evidenced additional
beneficial effects of combination treatment, such as combined targeting of several factors and signaling
pathways which are effectively inhibited by EC8042 (i.e., ALDH1, SOX2, NANOG, NOTCH1) and/or
dasatinib (i.e., SRC/FAK/ERK and PI3K/AKT pathways), as well as complementary anti-proliferative,
anti-stemness, and anti-invasive effects provided by each compound. It is therefore plausible that
combined targeting of these signaling pathways may result in reducing more effectively the CSC
subpopulations within the tumors.
The in vivo data clearly indicate that the reduction of tumor volume and weight observed
appears to be caused mainly by EC-8042. According to our in vitro data, this is likely due to the
potent anti-proliferative and cytotoxic effect of EC-8042 on both bulk tumor cells as well as CSC
subpopulations. Contrasting this, dasatinib but not EC-8042 demonstrated robust anti-migratory and
anti-invasive properties, and this beneficial effect was also observed by combined treatment in 3D
spheroid invasion assays, probably mediated by inhibition of SRC/FAK signaling pathway and/or EMT.
Notably, p-FAK Y861 was a major target of dasatinib but not EC-8042. Accordingly, p-FAK Y861 levels
were found to robustly diminish by dasatinib or combo treatment both in vitro and in vivo. In marked
contrast, p-FAK Y861 levels were not significantly affected by EC-8042 in vivo and only partially
reduced in vitro, whereas p-FAK Y397 as well as total FAK levels were mainly targeted and robustly
decreased by EC-8042. It seems quite reasonable to infer that this could exert a major influence on the
ability of tumors to invade and metastasize. Altogether, these data suggest that patients treated with
the combined treatment may benefit from the cytotoxic and anti-stemness effect of EC-8042 together
with the prevention of cancer cell migration and invasion due to dasatinib action. These properties
could be of particular importance for patients with advanced stages of disease who are at a higher risk
of metastatic dissemination.
In contrast to these findings, it has been reported that dasatinib was able to inhibit Sox2 expression
and tumorsphere formation in NSCLC cells [48,49]. These differences could be related to differences in
cell and/or tissue context, since we consistently observed that dasatinib reduced the phosphorylation
levels of SRC and also AKT whilst increasing endogenous Sox2 levels in HNSCC cells and also
Sox2/Oct4 reporter activity. This highlights the need to establish accurate markers of drug response
and adequate patient stratification to better select the patients who may benefit from the treatment
with dasatinib.
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5. Conclusions
This study unveils undesirable stem cell-promoting functions by dasatinib and saracatinib
that could explain the lack of clinical efficacy of both drugs in HNSCC patients. Supporting this
hypothesis, we show that HNSCC cells treated with a combination of dasatinib and EC-8042 benefit
from complementary anti-invasive, anti-proliferative and anti-CSC functions. This combination
counteracts the adverse pro-stemness effects induced by dasatinib and is therefore suggested as a
novel therapeutic strategy for clinical testing in HNSCC patients. According to these data, novel
combinational strategies with EC-8042 could contribute to improving treatment efficacy and long-term
clinical outcomes in HNSCC patients.
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Abstract: Tumor recurrence is now the leading cause of breast cancer-related death. These recurrences
are believed to arise from residual cancer stem cells that survive initial therapeutic intervention.
Therefore, a comprehensive understanding of cancer stem cell biology is needed to generate more
effective therapies. Here we investigate the association between dysregulation of lipid metabolism
and breast cancer stem cells. Focusing specifically on lipid droplets, we found that the lipid droplet
number correlates with stemness in a panel of breast cell lines. Using a flow cytometry-based method
developed for this study, we establish a means to isolate cells with augmented lipid droplet loads from
total populations and show that they are enriched in cancer stem cells. Furthermore, pharmacological
targeting of fatty acid metabolism reveals a metabolic addiction in a subset of cell lines. Our results
highlight a key role for the lipid metabolism in the maintenance of the breast cancer stem cell pool,
and as such, suggest it as a potential therapeutic target.
Keywords: cancer stem cells; breast cancer; lipid; metabolism; therapeutic resistance
1. Introduction
Despite advancements in early detection, the World Health Organization reports that over
0.5 million women still succumb to breast cancer every year. The majority of these deaths are attributed
to tumor recurrences, which are largely believed to arise from residual cancer stem cells (CSC)
that survive the initial therapeutic intervention [1]. According to the CSC model of tumorigenesis,
this population of cells is responsible for the origin, progression, and recurrence of the tumor,
and therefore, for any therapy to have success, it must be able to effectively target this population [2].
Despite their central role in the development of malignant disease, CSCs remain poorly characterized.
The characterization of this population has been hampered, in part, by the lack of robust markers for
their identification. Thus, highlighting the necessity to identify more robust markers and therapeutic
strategies for CSCs.
Given their central role in promoting tumor progression, the identification and characterization of
breast CSCs remain an active area of research. To date, most rely upon the combinatorial expression of
cell surface markers such as the cluster of differentiation (CD) 24 and CD44 for the identification of CSC
populations [3]. Recently, metabolic stem cell markers, such as cytoplasmic aldehyde dehydrogenase
(ALDH) A1 and A3 have been described as markers of adult stem cells and CSC in a number of tissue
types [4,5]. Aldehydes are generated by the metabolism of a wide variety of xenobiotic and endobiotic
compounds, including alcohols, amino acids, and anticancer drugs, as well as from lipid peroxidation.
Aldehyde dehydrogenases function as detoxifying enzymes through their role in metabolizing
aldehydes, thereby protecting cells from oxidative and electrophilic stress [6]. The finding that CSCs
can, in part, be identified by a metabolic marker has stimulated an interest in the characterization of
CSC metabolism.
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In order to meet the increased biochemical demands that accompany increased proliferation,
metabolic pathways are frequently dysregulated in cancer. The metabolic reprogramming that
accompanies cancer onset is now understood to be essential for the pathogenesis of the disease
and accordingly has been added to the list of cancer hallmarks [7,8]. Of the metabolic alterations
reported in cancer, none is better studied than aerobic glycolysis, the production of lactate from glucose
in the presence of oxygen [9,10]. Glycolytic metabolism has been shown to play an important role
in supporting stemness in several cancer types. However, it is becoming increasingly clear that in
addition to high glycolytic rates, tumorigenesis is supported by multiple aberrant metabolic processes,
including dysregulation of lipid metabolism [11].
A coordinated dysregulation of lipid metabolism is observed in nearly all cancer types. In addition
to fulfilling the basic requirements of structural lipids for membrane synthesis, lipids play important
roles as signaling molecules and contribute significantly to energy homeostasis. As lipid metabolism
affects multiple aspects of cellular biology, it is not surprising that alterations in lipid metabolism affect
a diverse range of cellular processes including, growth, proliferation, differentiation, and motility.
In order to fulfill their heightened demand for lipids, cancer cells increase their uptake of exogenous
fatty acids. This is achieved through increased surface expression of fatty acid translocase CD36.
Interestingly, elevated CD36 expression has been reported in metastasis-initiating cell populations and
is inversely correlated with survival prognosis [12]. Once taken up by the cells, the free fatty acids can be
shuttled into the mitochondria to produce energy equivalents through fatty acid beta-oxidation(FAO).
Maintenance of cellular energy stores by FAO has been shown to be fundamental to the survival
of CSCs in scarce nutrient environments [13]. Multiple reports have highlighted the importance of
increased exogenous fatty acid metabolism in CSCs [14].
In addition to the increased uptake of exogenous lipids, cancer cells also have the unique property
of being able to synthesize lipids. Whilst fatty acid biosynthesis is normally restricted to hepatocytes,
adipocytes, or mammary epithelium during lactation, several studies have now demonstrated the
ability of cancer cells to preform de novo fatty acid biosynthesis [15,16]. Indeed, the expression of
several enzymes involved in de novo fatty acid biosynthesis has been implicated in tumorigenesis and
the maintenance of stemness in CSCs [17,18].
On a cellular level, excess fatty acids, either exogenous fatty acids taken up by the cells or products
of de novo fatty acid biosynthesis, are processed into triacylglycerides and retained in specialized
storage organelles called lipid droplets [19]. Lipid droplets are endoplasmic reticulum (ER)-derived
organelles that are comprised of a phospholipid monolayer surrounding a core of neutral lipids,
primarily triglycerides and sterol esters. They have long been considered to function as a primary store
of energy but several recent reports have begun to highlight their role in a diverse range of cellular
functions including ER stress, ROS detoxification, and protein dynamics [20].
Our goal in this study is to assess lipid metabolism as a therapeutic target in a panel of breast
cancer cell lines. We report that stemness in breast cancer cell lines correlates with lipid droplet number.
In line with this, we devised a FACS based strategy to isolate lipid droplet enriched populations and
analyzed them for CSC markers. This analysis revealed that lipid droplethi populations increase CSC
markers, as well as increasing mammosphere-forming efficiency. Utilizing an inhibitor of fatty acid
biosynthesis, we were able to effectively target the stem cell population in a subset of breast cancer
cell lines, thus demonstrating the potential of lipid metabolism targeting compounds as adjuvants to
traditional therapies.
2. Experimental Section
2.1. Cell Lines and Culture Conditions
In this study, the following human breast cancer cell lines were used: BT474, MCF7, T47D,
and MDA-MB-231. BT474 cells were purchased from the Leibniz Institute DSMZ-German Collection
of Microorganisms and Cell Cultures and maintained in Roswell Park Memorial Institute, RPMI 1640,
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(Lonza, Basel, Switzerland) supplemented with 5% fetal bovine serum (Sigma-Aldrich, St. Louis,
MO, USA), 2 mM L-Glutamine (Euroclone, Milano, Italy), and 10 μg/mL human insulin (Sigma-Aldrich,
St. Louis, MO, USA). MCF7, T47D, and MDA-MB 231 were purchased from the National Cancer
Institute, Bethesda, MD, USA (NCI) and maintained in RPMI 1640 supplemented with 10% fetal bovine
serum and 2 mM L-Glutamine. All the cell lines were cultured at 37 ◦C in a humidified atmosphere,
5% CO2 incubator.
Additionally, two cell lines, representative of normal breast epithelium, HMEC (Cambrex,
East Rutherford, NJ, USA) and MCF10a (European Institute of Oncology, Milan, Italy) were used.
HMEC cells were cultured in RPMI 1640 with 10% FBS and 2 mM L-glutamine. MCF10a cells
were cultured in Dulbecco’s modified Eagle medium/nutrient mixture F-12 (DMEM-Ham’s F12),
(Sigma Aldrich, St. Louis, MO, USA) containing: 5% horse serum (Life Technologies, Carlsbad, CA,
USA), 10 μg/mL insulin, 20 ng/mL epidermal growth factor (Vinci Biochem, Florence, Italy), 500 ng/mL
hydrocortisone (Sigma Aldrich, St. Louis, MO, USA), 100 ng/mL cholera toxin (Sigma Aldrich, St. Louis,
MO, USA) and 2 mM L-glutamine.
2.2. 5-(Tetradecyloxy)-2-Furoic Acid (TOFA) Treatments
TOFA (Sigma-Aldrich, T6575, St. Louis, MO, USA) was resuspended in two milliliters of Dimethyl
sulfoxide (DMSO) and stored at −20 ◦C. Experiments in which cells were treated with TOFA, unless
otherwise specified, were cultured in the presence of 10 μM TOFA in their normal growth media for
forty-eight hours prior to initiating measurements or assays.
2.3. Growth Curves for TOFA Sensitivity
To assess the effects of TOFA on cell proliferation each cell line was seeded across five, 96-well plates
(CostarTM, Corning, NY, USA) at the following cell densities, expressed as cells per well: MDA-MB-231
0.5 × 104, MCF7 1 × 104, BT474 and T47D 1.5 × 104. Additional wells were filled with growth media
alone to act as plate blanks. All experimental conditions were set up in triplicate. Upon cell adhesion
and spreading, a single plate was taken from each set of five plates, fixed and stained.
Fixation was done by removing the culture media and adding 100 μL of 4% paraformaldehyde
solution, PFA, (HIMEDIA, Kennett Square, PA, USA) to each well for ten minutes. The PFA was then
removed and 100 μL of Crystal Violet solution (Merck KGaA, Darmstadt, Germany) was added to
each well. After twenty minutes, all non-cell associated Crystal Violet was removed by washing the
wells with water.
Cells in the remaining sets of four plates were treated with either growth media containing 0.13%
DMSO or growth media with 10 μM TOFA (Sigma-Aldrich, St. Louis, MO, USA) in DMSO. Every 24 h,
for 96 h, a single plate was removed from each set and processed as described above.
Once in the entire time course, five plates in total per cell line were processed and completely
dried. One hundred μL of acetic acid glacial was added to each well and incubated for twenty minutes
at room temperature. The log optical density (OD) of each experimental well was then measured at
a wavelength of 570 nm using a Wallace Victor 3TM multilabel reader (PerkinElmer Inc., Waltham,
MA, USA). Reported OD values were generated by subtracting the average of the three experimental
wells from the average of the three corresponding plate blank wells.
2.4. Fluorescence-Activated Cell Sorting
BODIPY™ 500/510 C1, C12 (4,4-Difluoro-5-Methyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Dodecanoic
Acid) (Molecular Probes, Eugene, OR, USA) stock solution, 1 mg/mL, was prepared in ethanol and
kept at −20 ◦C until used. For FACS sorting, the cells were incubated with 1 μg/mL BODIPY™,
following an overnight incubation; they were washed twice, trypsinized, resuspended in Phosphate
Buffered Saline(PBS) containing 2% FBS and 0.3% Gentamycin and sorted on a MoFlo Astrios cell
sorter (Beckman Coulter, Pasadena, CA, USA).
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2.5. FACS of Fatty Acid Loaded and TOFA Treated Cells
FACS analysis of fatty acid loaded cells was done by culturing cells to 30–40% confluence.
The normal growth media was then spiked with 100 μM oleic acid (Sigma-Aldrich, O1383, St. Louis,
MO, USA) and 50 μM palmitic acid (Sigma-Aldrich, P5585, St. Louis, MO, USA) for 48 h. Twelve hours
prior to FACS, cells were treated with Bodipy at 1 μg/mL. Immediately before FACS, cells were then
trypsinized and spun at 1200 rpm for five minutes. The pellet was gently washed with Dulbecco’s
Phosphate Buffered Saline (DPBS) and resuspended in DPBS containing 2%, 0.22 μm filtered, FBS.
FACS was conducted using Attune NxT (Thermofisher Scientific Inc., Waltham, MA, USA). FACS data
depicted represents analysis done on single, 4’,6-diamindino-2-phenylindole(DAPI)-negative cell
populations. FlowJo version 10.4.2 (BD Life Sciences, Franklin Lakes, NJ, USA) was used for
the analysis.
The same workflow, with the exception of the fatty acid loading step, was used to assess the
impact of TOFA treatment on the lipid droplet content of the experimental cell lines.
2.6. Nile Red Staining and Lipid Droplets Quantification Analysis
The Nile Red staining was performed as previously reported [21]. Briefly, Nile red (Molecular
Probes, Eugene, OR, USA) stock solution was made in DMSO at a concentration of 1 mg/mL. For cellular
staining, cells were seeded on poly-lysine coated coverslips and then fixed in paraformaldehyde,
4%, for fifteen minutes. After washing, the cells were incubated for ten minutes in Nile Red, 1 μL of
1 mg/mL Nile Red stock in 10 mL of 150 mM NaCl, protected from light. Nuclei were stained using
Dapi, and finally, coverslips were mounted onto glass slides.
Lipid droplet quantification was performed using a Fiji plug-in (developed by Martini E.).
Briefly, after manually delineating an Region of Interest (ROI) around the cells, the plugin identified
lipid droplets using the ImageJ’s Find Maxima2 algorithm on the maximum projection image after
background removal (using the rolling ball algorithm3) and noise reduction (with a median filter).
2.7. RNA Extraction and Quantitative RT-PCR Analysis
In order to perform the RT-PCR analysis, total RNA was first isolated using a trizol-chloroform
extraction with TRIzol reagent (Life Technologies, Carlsbad, CA, USA) and chloroform. For the
cells collected following cell sorting, RNA was extracted using the RNeasy mini kit (Qiagen,
Hilden, Germany). After the extraction, the RNA was quantified by NanoDrop to assess both
concentration and quality. Reverse transcription was performed using the SuperScript III reverse
transcriptase kit (Invitrogen, Carlsbad, CA, USA). Gene expression was analyzed using the TaqMan
gene expression analysis. The samples were amplified with primers for each gene; β-actin was used as
the housekeeping gene. The primer assay IDs used in these experiments were: ACTB, Hs99999903_m1;
SOX2, Hs01053049_s1; POU5F1, Hs00742896_s1; KLF4, Hs00358836_m1; ALDH1A1, Hs00946916_m1;
ALDH1A3, Hs00167476_m1.
2.8. Mammosphere Formation Assay from Cell Lines
The primary mammospheres were produced as previously described [22]. The mammosphere
media used in this assay was DMEM-F12 (Biowest, Nuaillé, France) supplemented with B27 supplement
(Invitrogen, Carlsbad, CA, USA) and EGF 20 ng/mL (Vinci Biochem, Florence, Italy). To prepare
non-adherent plates, standard 6-well plates were coated with 1 ml of 1% agarose solution in PBS.
To produce the 1% agarose solution, agarose powder was dissolved in PBS and autoclaved.
Briefly, cells were centrifuged at 580× g for two minutes and resuspended in 2 mL PBS. To avoid
cellular aggregates, a 22 G needle was used to syringe the cell suspension. We found out that
1 × 104 cells/well was a good seeding density for our cell lines. Cells were plated and incubated in
a 5% CO2 humidified incubator at 37 ◦C. After five days, all mammospheres larger than 50 μm were
counted and the mammosphere formation efficiency (MFE) was calculated using the following formula:
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mammosphere forming efficiency (%) = (number of mammospheres per well/number of cells seeded
per well) × 100.
2.9. Assessment of Lipid Droplet Content Using CD44/CD24 Stem Cell Markers
MDA-MB-231 and BT474 cell lines were cultured in 6-well plates (Falcon®, Ref no. 353046,
Corning, NY, USA). On the night prior to FACS analysis, cells were treated with BODIPY™ 500/510
C1, C12, as described in Section 2.4. Following incubation with BODIPYTM 500/510 C1, C12, the cells
were harvested and incubated in 500 μL of a 1× DPBS, 5% BSA, blocking buffer for forty-five minutes
at room temperature. The cells were then stained with Alexa Fluor® 647 mouse anti-human CD24
(BD Pharmingen, Material No. 561644, San Jose, CA, USA) and CD44-VioBlue® mouse anti-human
CD44 (Miltenyi Biotec, Order No. 130-113-899, Bergisch Gladbach, Germany) for thirty minutes on ice.
The antibody concentrations recommended on the accompanying data sheets were used for the stain.
Following staining, the cells were pelleted and washed three times with a 1× DPBS, 1% BSA solution,
prior to resuspension in a 1% FBS, 1× DPBS solution. The FACS was conducted using the Attune NxT
(Thermofisher Scientific Inc., Waltham, MA, USA). FACS data depicted represents analysis done on
single, propidium iodide negative, cell population. FlowJo version 10.4.2 (BD Life Sciences, Franklin
Lakes, NJ, USA) was used for the analysis.
2.10. Fatty Acid Oxidation Assay
MDA-MB-231, MCF7, T47D, and BT474 cell lines were seeded into 96-well plates (CostarTM,
Corning, NY, USA) at 7 × 104 cells per well and treated with either the vehicle or 10 μM TOFA in DMSO.
After approximately twenty hours, the cells were assessed using a fatty acid oxidation assay (Abcam,
ab217602, Cambridge, United Kingdom) used in conjunction with an extracellular O2 consumption
assay (Abcam, ab197243, Cambridge, UK). The protocols accompanying the assays were followed to
assess the cell lines after TOFA treatment. Experimental measurements were made using a Wallac
EnvisionTM 2104 multilabel reader (Perkin-Elmer, Waltham, MA, USA), maintained at 37 ◦C throughout
the course of the experiment. Excitation filter, UV (TRF) 340 and emission filter APC665 were used to
assess the status of the oxygen-sensing probe used for the assay. Measurements of the oxygen-sensing
probe were made every 90 s for one and a half hours.
2.11. Transmitted Light and Fluorescence Microscopy
Mammosphere images were acquired with an EVOS FL imaging system (Thermo Fisher Scientific,
Inc., Waltham, MA, USA) transmitted light microscope. Fluorescent images were acquired with
laser-scanning confocal microscopes: Leica TCS SP5 laser confocal scanner mounted on a Leica DMI
6000B inverted microscope equipped with motorized stage and HCX PL APO 63X/1.4NA oil immersion
objective (Leica Mikrosysteme Vertrieb GmbH, Wetzlar, Germany) and Leica TCS SP2 AOBS laser
confocal scanner mounted on a Leica DM IRE2 inverted microscope equipped with HCX PL APO
63X/1.4NA oil immersion objective (Leica Mikrosysteme Vertrieb GmbH, Wetzlar, Germany). For the
excitation of fluorochromes dyes, 405, 488, 561, and 633 nm laser lines were used on Leica TCS SP5
and Leica TCS SP2 AOBS. The following settings were maintained for fluorescent images acquisition:
digital zoom 2.5 and a 1024 × 1024 scan format.
2.12. Kaplan-Meier Plotter
Kaplan–Meier plots were generated using the Kaplan–Meier plotter found at http://kmplot.com/
analysis/index.php?p=background [23]. This is an online platform that enables the user to assess the
effect of 54,000 genes on survival in 21 cancer types. Prognostic values for PLIN2 mRNA (Affymetrix
ID 209122_at) expression was evaluated for a cohort of 3951 breast cancer patients.
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2.13. Statistical Analysis
All experiments were carried out at least three times unless otherwise indicated. Data were
analyzed using GraphPad Prism version 8 statistical software (GraphPad Software, San Diego,
CA, USA). Experimental results are reported as mean and standard deviation unless otherwise stated.
3. Results
3.1. Lipid Droplet Marker PLIN2 Expression Correlates with Disease Progression and Lipid Droplet Number
An increase in lipid droplet metabolism in therapeutic resistant cell populations has now been
reported for several solid tumors, including breast [24,25]. This led us to ask whether there was
a correlation between lipid droplets and disease progression in breast cancer. As a proxy for lipid
droplets, we chose to use a member of the perilipin family, Perilipin 2 (PLIN2), a lipid-droplet associated
structural protein. The over-expression of PLIN2 has previously been reported for several cancer
types, although its prognostic value is not clear. Therefore, we asked whether PLIN2 over-expression
has any prognostic value in breast cancer. Querying the Kaplan–Meier plotter [23], we have found
a significant negative correlation between PLIN2 expression and relapse-free survival in breast cancer
patients (Figure 1a). After stratifying for intrinsic breast cancer sub-type, we observed that the negative
correlation was maintained in basal, luminal A and luminal B subtypes, although interestingly not in
Her2+ breast cancers (Figure S1a).
Next, we set out to investigate whether PLIN2 expression correlates with an increase in lipid
droplet number across a panel of breast cancer cell lines. Cell lines were selected to represent the major
intrinsic subtypes as classified by their immuno-histological features are represented in Table 1.
We utilized 9-diethylamino-5H-benzo [alpha] phenoxazine-5-one (Nile Red) to assess the lipid
droplet content across the panel (Figure 1b). Quantification of the baseline lipid droplet numbers in
these cells revealed that although all breast cancer cell lines queried contain lipid droplets, BT474,
and MB-MDA-231 had a significantly higher number of lipid droplets in comparison to the other cell
lines tested (Figure 1c). Of note, we also quantified lipid droplet number in two control cell lines,
MCF10a and HMECs. Despite being models of “healthy mammary epithelium,” both cell lines had
an elevated number of lipid droplets in comparison to the cancer cell lines (Figure S1b).
It has yet to be determined whether the increase in lipid droplets that is associated with therapeutic
resistance is a consequence of a stress response or if it represents an enrichment of a therapy-resistant
sub-clonal population. Considering the CSC theory of therapeutic resistance, we were prompted
to ask whether there could be a correlation between lipid droplets and stemness. We began by
evaluating the expression of stemness markers utilizing quantitative PCR. We found that the baseline,
normalized values, of markers previously published to associated with CSCs including Octamer-binding
transcription factor 4 (POUF51), SRY(Sex-determining region Y)-box2 (SOX2), ALDH1A3, and Kruppel
-like factor 4 (KLF4) did not show a significant variation in between the cell lines tested (Figure S1c).
Notably, the expression of ALDH1A1, which was also included in the panel, was limited to BT474.
Breast CSCs can be enriched by culturing in non-adherent, non-differentiating culture conditions,
where they grow as small clusters of CSC derived cells referred to as mammospheres. To ask
whether there were discernible differences in CSC pools between the four cell lines, we performed
mammosphere formation efficiency assays. Despite similar overall levels in the expression of stem cell
markers, we observed clear variations in mammosphere formation efficiency between the four cell
lines (Figures 1d and S1d).
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Figure 1. Lipid droplets correlate with breast cancer progression and stemness. (a) The effect of
PLIN2 expression on relapse-free survival in breast cancer (b) Confocal imaging of Nile Red stained
BT474, MCF7, T47D, and MDA-MB-231. The scale bar represents 50 μm. (c) Quantification of lipid
droplets number/cell for 100 cells per cell line (right). (d) Mammosphere formation efficiency for the
four cell lines used in this study. (e) Confocal imaging of mammospheres stained with Nile Red, arrows
indicate lipid droplet enriched cells, scale bar represents 50 μm. Data are represented as mean ± SEM.
Significance was calculated using two-tailed t-tests. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
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Table 1. Molecular classification of breast cancer cell lines.
Classification ER PR HER2 Example Cell Lines [26,27]
Luminal A + +/- - MCF7, T47D, SUM185
Luminal B + +/- + BT474, MDA-MB-361
Claudin-low - - - MDA-MB-231, BT549
Basal - - - MDA-MB-468, SUM 190
HER2 - - + SKBR3, MDA-MB-453
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2. The cell lines
indicated in bold were used in this study.
The mammosphere formation assay suggested a correlation between lipid droplet number and
stemness, but we now wanted to demonstrate that lipid droplet enriched populations are indeed found
in mammospheres. Therefore we passaged mammospheres produced from MDA-MB-231 and BT474
for two generations and then visualized the lipid droplet containing cells using Nile Red. Interestingly,
we found a sub-population of cells within the mammospheres to be highly enriched in lipid droplets
(Figures 1e and S1e). Intriguingly, taken together, these observations suggested a link between lipid
droplet load and stemness in breast cancer-derived cell lines.
3.2. Lipid Droplets Increase Cell Complexity and Provide a Means to Isolate Individual Populations
These observations led us to ask whether CSCs were enriched in the population of cells harboring
high numbers of lipid droplets. To address this question, we needed a means to separate lipid
droplet-enriched from lipid droplet-depleted populations. Having shown that the accumulation
of lipid droplets within the cell is tractable through the use of lipid droplet specific dye Nile Red,
we reasoned that we could utilize cell fluorescent fatty acid analogs to sort lipid droplethi populations
from lipid dropletlo populations.
In order to develop a florescenence-activated cell sorting (FACS) based approach for cell sorting,
we needed a live cell marker of lipid droplets; we chose to use BODIPY™ 500/510(BODIPY™). BODIPY™
is a fluorescent fatty acid analog that can be used as a marker of lipid droplets and membranes [28].
To understand whether BODIPYTM would be suitable for a FACS based assay, we incubated cells in
growth media containing BODIPY™ and evaluated the resulting fluorescence signal using confocal
microscopy. Image analysis confirmed that the BODIPY™ was being taken up by the cells and
incorporated into the neutral lipid species (triglycerides or sterol esters) that are stored in cytoplasmic
lipid droplets. Additionally, membrane incorporation, whereas visible, was not the major contributor
to the signal (Figure 2a).
We then proceeded to test whether we could use a FACS-based strategy to identify lipid droplet
containing populations using BODIPY™. FACS-based analyses of the BODIPY™ loaded cells versus
non-loaded controls revealed a strong shift in the fluorescence signal following excitation at 488 nm for
all cell lines (Figure 2b). In order to demonstrate that the BODIPY™ signal being read by the FACS
is attributable to the lipid droplet concentration, we tested the system by pre-incubating the cells in
media containing additional fatty acids. The addition of exogenous fatty acids to the media resulted in
their uptake and metabolism leading to a dramatic increase in lipid droplet number (Figure S2a).
Accordingly, we observed not only a significant increase in BODIPY™ signal in cells that had been
pre-loaded with fatty acids but also a marked shift in the side scatter (SSC) measurements of the cells
(Figure 2b). SSC at FACS is used as an indicator of the internal complexity or granularity of the cell.
These parameters are often used to measure internal cellular components such as granules. Interestingly,
increasing the number of lipid droplets also resulted in an increase in the SSC measurements for the
treated population. Therefore, like granules, lipid droplets increase the complexity of the cytosol, in
a way that was distinguishable at FACS. Taken together, the BODIPY™ driven FACS based strategy
provided a robust method to stratify cells based on lipid droplet content.
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Figure 2. BODIPYTM based FACS protocol distinguishes lipid droplet enriched cells. (a) Confocal
imaging of BODIPYTM 500,510 loaded cells. Upper panels are representative images from each of
the four cell lines following a 12 h incubation with BODIPYTM, lower panel representative image
of cells incubated with palmitic acid, oleic acid and BODIPYTM. The scale bar represents 50 μm.
(b) Representative plots of BODIPYTM signal in cells, – BODIPYTM, + BODIPYTM, and fatty acid
loaded cells + BODIPYTM. The corresponding histograms represent the FITC (BODIPYTM) signal for
each condition.
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3.3. Lipid Droplets Correlate with Stemness in a Subset of Breast Cancers
The development of FACS based protocols for the identification and isolation of stem cells has been
instrumental in shaping our understanding of their contribution to development and pathogenesis.
In the breast, the cell population distinguished by CD24lo/−/CD44hi has been previously shown to be
highly enriched in CSCs both in primary patient material as well as in established breast cancer cell
lines [3,29]. The establishment of the BODIPYTM based FACS protocol described above now allowed
us to investigate whether CSCs populations, defined by CD24/CD44 levels, contain high levels of lipid
droplets. In agreement with our previous data, we observed a 2.5–2.7 fold increase BODIPYTM intensity
in the stem enriched CD24lo/−/CD44hi pool (Figures 3a and S3). In addition to the observed increase in
the BODIPYTM signal, we also detected increased cytosolic complexity (SSC) in the CD24lo/−/CD44hi
population. This is in accordance with the previous experiments that demonstrated that increasing
lipid droplet load led to an increase in SSC. These results further strengthened the earlier observation
that lipid droplet number correlates with stemness.
Figure 3. Lipid droplethi populations are enriched for stem cell markers in BT474 (a) FACS-based analysis
of CD44hi/CD24lo populations in BT474 and MDA-MB-231. Scatter plot showing the distribution of the
two surface markers (left), the histogram of MFI for BODIPYTM in CD44hi/CD24lo (red) versus total
population (black; middle), the dot plot to highlight SSC distribution of CD44hi/CD24lo (red) versus total
population (black). (b) Scatter plot for FITC (BODIPYTM) versus FSC illustrating the gating strategy
for FACS sort, with histogram for FITC (BODIPYTM) levels in sorted BT474 populations. Confocal
microscopy of Nile Red stained sorted populations. The scale bar represents 50 μm. (c) Quantitative
PCR to analyze the expression of a panel of genes associated with stemness for the three sorted
populations from BT474. Data are represented as geometric mean ± SD (d) Mammosphere formation
efficiency for the three sorted populations from BT474 (n = 7). Data are represented as geometric mean
± SD. Significance was calculated using the two-tailed t-test. * p < 0.05, ** p < 0.01, *** p < 0.001.
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Having established multiple correlations between lipid droplet number and stemness features,
we now wanted to demonstrate that populations of cells containing higher lipid droplet numbers
were indeed enriched in CSCs. In order to isolate lipid droplet enriched populations from the total
population, we applied the FACS based strategy described above. BT474 was chosen due to its
propensity to show enrichment in lipid droplet number and mammosphere-forming efficiency. Three
separate bins were created to enable sorting of the top (lipid droplethi) 5% and bottom (lipid dropletlo)
5% of cells based upon the BODIPY™ fluorescence intensity. Cells were additionally collected from the
average (lipid dropletave) BODIPY™ population to serve as a control group (Figure 3b). Following
sorting, cells were assessed for lipid droplet number by fluorescence microscopy. Nile Red was again
employed to visualize lipid droplets in the sorted cells. The staining confirmed enrichment of lipid
droplets in the lipid droplethi population.
We proceeded to characterize the three populations isolated from the BT474 cell line for stemness
traits. Quantitative PCR was performed for a panel of CSC markers. Interestingly, with the exception
of SOX2, we saw a marked increase across all stem cell markers in the lipid droplethi population
(Figure 3c), suggesting that the lipid droplethi population of BT474 was enriched for CSCs. Next,
we tested the three isolated populations in mammosphere formation assays. The results demonstrated
significant enrichment in mammosphere forming capacity in the lipid droplethi population (Figure 3d).
Taken together, there is strong evidence that lipid droplet enrichment correlates with CSC traits in the
BT474 breast cancer cell line.
3.4. Targeting Lipid Metabolism Directly Impact CSCs
Having observed an enhancement in the stem cell pool in lipid droplethi populations, we reasoned
that if we were able to effectively target this population, we should affect the overall fitness of the
cell lines. In order to target the metabolic pathways that lead to the accumulation of lipid droplets,
we choose to use 5-tetradecyloxy-2-furoic acid (TOFA), an inhibitor of acetyl-CoA carboxylase-α(ACCA).
Through inhibition of ACCA, the rate-limiting enzyme in long fatty acid biosynthesis, TOFA has been
shown to effectively block fatty acid biosynthesis, therefore limiting FA and lipid droplet accumulation
(Figure 4a and [30]). Therefore, we asked whether exposure to TOFA would impact lipid droplet level,
cellular proliferation, and/or stemness in our cell line panel.
We began by evaluating the effect of TOFA on lipid metabolism and total lipid droplet number in
our panel of cell lines. First, we evaluated the effects of TOFA treatment on FAO. With the exception of
MDA-MB-231, we found a significant decrease in FAO following 24 h of TOFA treatment (Figure S4a).
This could be attributed to the observed decrease in lipid droplets that were detected in the cells
following treatment with 10 uM TOFA (Figure 4b). For a more quantitative evaluation of the effect of
TOFA on the lipid droplet number across our cell lines, we used our previously established BODIPY
FACS protocol. This analysis confirmed the efficacy of TOFA in reducing the lipid droplets in the
cells post-treatment (Figure 4c). In line with the FAO and imaging data, MDA-MB-231 did not show
a significant reduction in lipid droplets following TOFA treatment, suggesting that MDA-MB-231 is not
reliant upon de novo fatty acid biosynthesis to meet its fatty acid requirements. Interestingly, BT474
did not have a significant shift in BODIPYTM signal following sorting. This was unexpected given
the clear differences seen both in the FAO levels and in the imaging. Despite the lack of change in
the overall BODIPYTM signal, we noticed a shift in cellular distribution in the SSC/FSC plots, which
suggested an increase in cell size following treatment. This increase in cell size, with the accompanying
increase in BODIPYTM labeled cellular membranes, could account for the lack of difference observed in
the histograms.
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Figure 4. TOFA treatment reveals lipid metabolic addiction in a panel of breast cancer cell lines.
(a) Schematic depicting the effects of TOFA treatment on lipid metabolism. (b) Confocal microscopy of
lipid droplets in the cell lines used in this study. Lipid droplets were visualized for control, vehicle,
and following 48 h of 10 μM TOFA treated with Nile Red. The scale bar represents 50 μm. (c) FACS
profile of cells treated with media, vehicle or TOFA for 48 h. From top to bottom, BODIPYTM signal
across the treatment groups, side scatter vs. forward scatter plots across the treatment groups. (d) Second
generation mammosphere forming efficiency for MDA-MB-231 and BT474 following pre-treatment
with TOFA, vehicle or regular growth media (n = 2). (e) Growth of each cell line over time in the
presence of 10 μM TOFA, vehicle or growth media. Significance was calculated using the two-tailed
t-test. * p < 0.05, ** p < 0.01, *** p < 0.001.
Having demonstrated that lipid droplet containing populations were enriched in CSCs, we asked
whether treatment with TOFA was sufficient to deplete the CSC populations in the cell lines that were
shown to respond to treatment. In order to address this, we performed a qPCR analysis on a panel
of stem cell-associated genes in control and treated populations. Despite the global effects on lipid
droplet number observed for BT474, T47D and MCF7, TOFA treatment only had marginal effects on
the expression of stemness related genes in MCF7 and T47D, while affecting BT474 more significantly
(Figure S4b). For a functional validation of these observations, we evaluated mammosphere forming
efficiency for both BT474 and MDA-MB-231 for the following conditions: control, vehicle-treated and
TOFA treated. Following 5 days of acute TOFA treatment, the surviving populations of BT474 and
MDA-MB-231 were washed in TOFA-free growth media to remove any residual TOFA. They were then
singularized and seeded in low adhesion, low differentiation conditions in the absence of TOFA and
evaluated for mammosphere formation efficiency (Figures 4d and S4c). In line with the qPCR data
and imaging data, we observed a significant decrease in second-generation mammosphere-forming
capacity for BT474, while MDA-MB-231 had no marked effect on mammosphere generation following
TOFA treatment.
74
J. Clin. Med. 2020, 9, 87
The observation that TOFA acts as a potent inhibitor of lipid metabolism and stemness in a subset
of cell lines prompted us to evaluate its impact upon proliferation. To do this, we monitored cell growth
for 96 h across three treatment groups: growth media, vehicle, and 10 uM TOFA. With the exception of
MDA-MB-231, TOFA treatment had a significant impact on the growth of all the cell lines in our panel,
severely impeding proliferation (Figure 4d). Although the mammosphere formation assay suggested
that TOFA negatively affected the stem cell pool in BT474, these results suggest a more global addiction
to the ACCA-mediated fatty acid metabolism that may extend beyond the stem cell pool in these lines.
4. Discussion
The resurgence of interest in tumor metabolism has largely focused on the dysregulation of
metabolic pathways in the primary tumor itself. However, there is increasing evidence that the
metabolic hallmarks of singular populations could play a role in determining their response to
therapeutic challenges. Indeed, over the past five years, numerous reports have emerged suggesting
that alterations in lipid metabolism correlate with resistance [24,31]. The mechanisms by which
dysregulated lipid metabolism contribute to resistance still remain largely unknown. In this study,
we investigated the relationship between lipid metabolism and stemness traits by interrogating a panel
of breast cancer cell lines.
One of the hallmarks of therapeutic resistant populations is an observed increase in cytoplasmic
lipid droplets. Lipid droplets are the lipid storage organelle of the cell, in which neutral lipids such as
triglycerides and sterol esters are sequestered. They are dynamic organelles that arise from pools of
lipids within the ER in response to stress or alterations in metabolism. The first association of lipid
droplets with tumor cells was first made over 50 years ago [32]. Recently, lipid droplets have been
shown to correlate with stemness in colorectal cancer [33]. Despite that, surprisingly few have focused
on the use of the lipid droplet as a biomarker in breast cancer.
The protein component of lipid droplets could be used as a proxy and facilitate their inclusion in
histopathological analyses. In this study, we have focused on PLIN2. PLIN2 is a member of the perilipin
family of proteins that includes PLIN2, -3, -4, and -5. This family of lipid-droplet associated proteins
plays an instrumental role in lipid droplet formation, stability and trafficking [19,34]. Querying the
Kaplan–Meier plotter, we observed a significant negative correlation between lipid droplet associated
protein PLIN2 expression level and relapse-free survival in breast cancer patients [23]. This observation
stimulated us to better understand the association. One of the outstanding questions in the field is
whether the lipid droplets that have been observed in therapeutic resistant cell populations are the result
of de novo synthesis in the face of a therapeutic challenge, or if they are an enrichment of a previously
metabolically distinct population of cells. The finding that PLIN2 expression in the primary tumor
correlates with a worse prognosis suggests that at least in a subset of patients, pre-existing alterations
in lipid metabolism could correlate with disease progression.
Interestingly, evaluation of a panel of breast cancer cell lines revealed distinct differences in
lipid droplet number between the cell lines. This is despite being maintained in similar media
conditions, at comparable confluency. It is interesting to note, as beautifully cataloged in a recent study,
that despite having been maintained for 40-plus years in culture, in non-physiological conditions,
the metabolic profiles of these cell lines have retained some significant differences, suggesting perhaps
a metabolic addiction [35]. In this regard, it is important to highlight that even within individual
cell lines, we observed a high degree of heterogeneity in terms of lipid droplet loading within the
population. This variation could reflect alterations in the cell cycle, or intriguingly, it could be a marker
of metabolically distinct clonal populations, among which CSCs within the cell lines themselves.
One of the most elusive, yet highly sought-after contributors to heterogeneity is the population of
CSCs. The CSC theory of tumor progression proposes that it is this population that resists therapeutic
intervention, and acts as the seed for tumor recurrence. Therefore, efficient targeting of this population
would lead to higher therapeutic efficacy and better long-term survival rates. However, for many
tumor types, we still lack robust markers to enable the identification and characterization of the CSC
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population. Interestingly, we observed a strong correlation between lipid droplet number and stemness
in the cell lines we used in this study.
Having devised a method to sort the population based upon lipid droplet number, we were able to
demonstrate an increase in mammosphere forming capacity and stem cell markers in the lipid droplethi
segment of the population. An additional characteristic of lipid droplet containing cells which emerged
from this study was the correlation between lipid droplets and increased cytosolic complexity, which
was detected as increased SSC at FACS. The demonstration that lipid droplets contribute to increased
side scatter provides an interesting stain-free mechanism to distinguish lipid droplethi populations.
Taken together, this data suggests that inclusion of lipid droplets into the current criteria for CSC
identification could provide an additional, low-cost parameter for stem cell identification.
We also demonstrate that this feature of CSC metabolism can be exploited in therapeutic settings
by targeting lipid metabolism. In line with previous reports for CRC, exposure to TOFA, an ACAA
targeting drug, profoundly impacted upon lipid droplet persistence in our panel of cell lines [36].
Treatment with TOFA severely affected proliferation in three out of the four lines tested. In the case of
BT474, for which we have shown a strong correlation between lipid droplet abundance and stemness,
TOFA mediated lipid droplet depletion also resulted in a decrease in the expression of several markers
of stemness. An interesting observation for further studies is the cell line MDA-MB-231 that appeared
to be largely resistant to treatment by TOFA, as seen by the lack of impact upon lipid droplets number as
quantified at FACS. In line with this, we observed no effect of TOFA treatment on viability or stemness
in the MDA-MB-231, despite observing a drastic effect in all other cell lines. This data suggests that
MDA-MB-231 is able to fulfill its fatty acid demands by other means. As TOFA specifically targets de
novo fatty biosynthesis, it would be informative to perform a more inclusive study, using a panel of
inhibitors targeting the various druggable components of the lipid droplet assembly cascade. However,
despite the lack of efficacy on MDA-MB-231, the efficacy of TOFA in inhibiting proliferation of the
other cell lines used in this study suggests that it would be interesting to explore the inclusion of lipid
metabolic targeting compounds into current therapeutic regimes.
5. Conclusions
In this study we demonstrated a correlation between lipid droplet number and stemness features in
a panel of breast cancer cell lines. Yet, our observations were limited to steady-state growth conditions.
There is ample literature addressing the induction of lipid droplet accumulation in response to cellular
stressors, including chemotherapeutic administration. Therefore, it would be critical to understand
if and how lipid droplet biosynthesis is dysregulated following therapeutic exposure. For example,
do lipid droplets accumulate in previously deplete populations? If so, what are the stress response
pathways governing the expansion? Are lipid droplets dispensable for survival? It is our hope that the
answers to these questions will reveal novel lipid metabolic targets in malignancy specific pathways.
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Abstract: Preclinical works have suggested cytotoxic chemotherapies may increase the number
of cancer stem cells (CSC) whereas angiogenesis inhibition may decrease CSC proliferation.
We developed a proof of concept clinical trial to explore bevacizumab activity on breast CSC.
Breast cancer patients requiring preoperative chemotherapy were included in this open-label,
randomized, prospective, multicenter phase II trial. All received FEC-docetaxel combination, and
patients randomized in the experimental arm received concomitant bevacizumab. The primary
endpoint was to describe ALDH1 (Aldehyde dehydrogenase 1) positive tumor cells rate before
treatment and after the fourth cycle. Secondary objectives included safety, pathological complete
response (pCR) rate, disease-free survival (DFS), relapse-free survival (RFS), and overall survival
(OS). Seventy-five patients were included. ALDH1+ cells rate increase was below the predefined 5%
threshold in both arms for the 32 patients with two time points available. Grade 3 or 4 adverse events
rates were similar in both arms. A non-significant increase in pCR was observed in the bevacizumab
arm (42.6% vs. 18.2%, p = 0.06), but survival was not improved (OS: p = 0.89; DFS: p = 0.45; and RFS:
p = 0.68). The increase of ALDH1+ tumor cells rate after bevacizumab-based chemotherapy was less
than 5%. However, as similar results were observed with chemotherapy alone, bevacizumab impact
on breast CSC cells cannot be confirmed.
Keywords: early breast cancer; bevacizumab; neoadjuvant chemotherapy; cancer stem cells; ALDH1
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1. Introduction
Breast cancer remains the first cancer in women in western countries [1]. Breast tumors can benefit
from neoadjuvant chemotherapy to enhance the rate of conservative surgery [2–5]. Preoperative
systemic treatments have also an impact on micro metastatic disease and have similar survival results
than adjuvant systemic treatments [5,6]. It is also a way to assess the efficacy of new drugs or
combinations and to develop translational research programs [7,8]. Major regimens used in this setting
are sequential combinations of anthracyclines and taxanes [9–12], with the addition of trastuzumab
and pertuzumab for HER2 (human epidermal growth factor receptor 2)-positive tumors [13,14].
Neoangiogenesis is a well-known hallmark of cancer [15], highly involved in tumorigenesis [16],
and balanced by activating and inhibiting signals. Dysregulation of the equilibrium leads to an
“angiogenic switch” allowing a tumor to grow over one to three mm [17]. The main pro-angiogenic
and most specific factor is the vascular endothelial growth factor (VEGF). VEGF proteins are
released by tumor cells, bind to their receptors (mainly VEGFR1 and VEGFR2), and are involved
in cell division, endothelial cell migration, extracellular matrix modifications, vessels permeability,
and vessels survival [18–20]. A combination of chemotherapy and an anti-VEGF monoclonal antibody
(bevacizumab) has been shown to improve progression-free survival in first-line metastatic breast
cancer [21–23] as well as pathological response rates after neoadjuvant treatment [24,25] but failed
to improve overall survival in both early and advanced settings. Similar results have been obtained
with other types of advanced cancer with improvements of progression-free survival with small or no
clinical impact on overall survival [26–29].
The cancer stem cell theory has been largely developed in the last decade to explain resistance to
cytotoxic agents [30]. Cancer stem cells display capacities of auto-renewal and differentiation and thus
can drive resistance and disease recurrences [31–33].
Cancer stem cells have been described to display higher enzymatic activity of aldehyde
dehydrogenase 1 (ALDH1) than differentiated cells, and can thus be identified using ALDH1 staining
in various cancer localizations, including breast cancer [34–38]. Brain tumors models developed from
cancer stem cells (CSC) synthetize higher levels of VEGF and can be inhibited with bevacizumab [39].
CSC secreting VEGF may also be localized in pro-angiogenic niches, with potentiation of antitumor
effects when combining cytotoxic chemotherapy to antiangiogenic treatments [40,41]. Concerning
breast cancer, in vitro models have suggested that CSCs express elevated levels of pro-angiogenic
factors including VEGF, and that bevacizumab can decrease this pro-angiogenic effect [42].
As chemotherapy alone enriches breast CSC population after neoadjuvant treatment [30],
we hypothesized that CSC inhibition by chemo-bevacizumab combinations can lead to a decrease or
a stabilization of CSC rate within breast tumors. Differentiated cancer cells should indeed be killed
by chemotherapy whereas CSC should be targeted by bevacizumab. We proposed to assess CSC
inhibition by a chemotherapy–bevacizumab combination compared to chemotherapy alone for breast
cancer patients treated in the neoadjuvant setting.
2. Experimental Section
2.1. Study Design
The AVASTEM trial (EudraCT Number: 2009-014773-40; ClinicalTrials.gov Identifier:
NCT01190345) was conducted as an open-label, randomized (2:1), prospective, multicenter, phase II
trial with chemotherapy with or without bevacizumab combination for the treatment of primary breast
cancer candidate to receive preoperative chemotherapy. Its primary objective was to evaluate cancer
stem cell (CSC) inhibition under treatment by assessing the percentage of residual ALDH1 positive
cells after the fourth treatment cycle.
Secondary objectives were safety (as assessed according to CTCAE v3.0 criteria), pathological
response (pCR) rate, disease-free survival (DFS), relapse-free survival (RFS), and overall survival (OS).
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2.2. Patients
This trial was conducted in three French tertiary comprehensive cancer centers (Institut Paoli
Calmettes, Marseille; Institut Curie, Paris; Institut Jean Godinot, Reims).
To be enrolled in this trial, patients had to have been diagnosed with a pathologically confirmed
breast cancer, SBR grade 2 or 3 (except for inflammatory breast tumors), tumor size over 3 cm.
Patients were 18 years or older; with a good performance status (ECOG ≤ 1); life expectancy of at least
3 months; adequate hematological, liver, and renal functions; without cardiac dysfunction (left ventricle
ejection fraction ≥ 55%). Exclusion criteria were breast cancers of lobular subtype (except for
HER2-positive, grade 3 or inflammatory breast tumors); prior treatment with bevacizumab; history of
invasive cancer within the last 5 years (except skin carcinoma and in situ cervix cancers with appropriate
treatment); uncontrolled high blood pressure (systolic > 150 mmHg and/or diastolic > 100 mmHg);
history of congestive heart failure, unstable angina, myocardial infarction within the past 6 months;
serious cardiac arrhythmia; thrombotic event within the last 6 months; history of coagulation
disorder; history of digestive or non-digestive fistula or digestive perforation within the last 6 months;
major surgery within the last 28 days; and history of anaphylaxis to monoclonal antibodies. All patients
were affiliated to, or beneficiated to, a national insurance regimen. Patients were enrolled after
signature of a written informed consent. All procedures were done in accordance with the 2008
Helsinki Declaration, after approval of the responsible ethics committees (institutional and national).
2.3. Treatments
Treatment scheme, dose reductions, and safety assessments were done according to
protocol recommendations.
Patients randomized in arm A (experimental treatment) received four 21-day cycles of FEC100 IV
infusions (5FU 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2) on day 1 plus
bevacizumab (15 mg/kg on day 1). They then received four 21-day cycles of docetaxel (100 mg/m2 on
day 1) plus bevacizumab (15 mg/kg on day 1). Patients randomized in the control arm only received
cytotoxic chemotherapy. Patients with HER2-positive tumors also received IV trastuzumab. No dose
reduction was allowed for bevacizumab, and toxicities were managed according to EMA (European
Medicines Agency) summary of product characteristics. Other drugs dose modifications were done in
accordance to EMA guidelines.
2.4. Randomization Process
A stratified permuted block randomization method was used to allocate patients in a 2:1 ratio to
receive FEC + bevacizumab or FEC alone. Block randomization lists were generated using a computer
algorithm with randomly selected block sizes to ensure reproducibility and constant ratio of patients
assigned between arms within blocks. The random allocation sequence and patients’ assignment
were performed by the biostatics unit from the Institut Paoli-Calmettes. Clinicians from the three
participating centers enrolled the patients.
2.5. Primary Objective Analysis
Breast CSC and progenitors can be identified by exploring the expression of an enzyme involved
in retinoic acid metabolism: ALDH1 [34,43]. CSC inhibition was assessed in the intention to treat
population as the percentage of ALDH1-positive cells identified using immunohistochemistry (IHC)
as previously described with the ALDH1 antibody (Becton Dickinson biosciences) used at a 1/50
dilution [34], both before treatment and after the fourth treatment cycle. All patients with ADLH1
assessment prior to and during treatment were included in primary objective analysis.
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2.6. Analysis of Safety Data
Safety assessments consisted of recording all adverse events (AEs) (CTCAE v3.0 criteria and
NYHA for cardiac AEs) and serious adverse events (SAEs) collected during the treatment period and
within 28 days after treatment completion. Cardiac AEs were collected for 12 months after treatment
discontinuation. The safety population was defined as the subjects who received at least a partial dose
of treatment.
2.7. Analysis of Clinical Efficacy Data
The efficacy population was defined as the group of subjects who received at least one
chemotherapy cycle. Pathological complete response after treatment was planned to be defined
according to Sataloff classification [44]. However, as most of recent literature data are mainly based on
the more consensual ypT0/is pN0 definition [45], we described both classifications. DFS was defined
as the time from treatment initiation to disease recurrence wherever the localization, secondary cancer
diagnosis, or death, whatever occurred first. RFS was defined as the time from treatment initiation to
disease recurrence or death. OS was defined as the time from treatment initiation to death, whatever
the cause.
2.8. Statistical Analysis
The number of subjects to be included in this trial was 75 with a 2:1 ratio (50 patients in the
experimental arm) to show that the increase of the percentage of ADLH1-positive cells was not upper
than 5% after the fourth treatment cycle in the experimental arm, with an 80% power and an alpha-risk
of 5%. An exact Wilcoxon rank-signed test was performed to confirm the rejection of the hypothesis
that ALDH1+ cells rate increase was upper than 5% after four chemotherapy cycles in the experimental
arm. p-Values, estimation of location parameters (Hodges Lehmann pseudo-median) and their one
sided 95% confidence intervals (CI) were determined using exactRankTests v0.8-29 R-package [46].
Descriptive statistics were used to summarize the frequency, severity, duration, and relationship
to treatment for all AEs occurring after the initiation of treatment. Categorical variables were
described using counts and frequencies, and quantitative variables were described using medians
and ranges. Patients’ characteristics were compared using exact Fisher’s tests for qualitative variables
and rank-Wilcoxon’s tests for quantitative variables. Hazard ratios are provided with their bilateral
confidence interval and Wald’s test p-value for significance. Follow-ups were estimated using the
inverse Kaplan–Meier method. Patients lost to follow-up or without event were censored at the date of
last news. Survival curves were estimated using the Kaplan–Meier method, and the median DFS, RFS,
and OS were calculated with their 95% confidence intervals. Both univariate and multivariate analyses
were conducted using Cox’s proportional hazard regression models including treatment arm, ADLH1
status at inclusion and pCR status as categorical explanatory variables. For Cox multivariate analysis,
all the delays were considered from surgery date instead of inclusion due to an adjustment on pCR
status (evaluated at surgery).
Except for the primary endpoint, all tests were two-sided. The level of statistical significance was
set at α = 0.05. Statistical analyses were carried out with the SAS® software version 9.3 (SAS Institute
Inc., Cary, NC, USA) and the R software version 3.0.3 (https://www.R-project.org/). This study was
performed according to the CONSORT statements [47], (see Supplementary checklist).
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3. Results
3.1. Population Description
Seventy-five patients were included from March 2010 to July 2012 (Figure 1). Follow-up was
stopped five years after inclusion of the last patients, i.e., in October 2017. Fifty patients received
the experimental treatment (arm A) and twenty-five were randomized in the control arm (arm B).
There was no imbalance between arms (Table 1). Median age at inclusion was 50.0 years for arm A
versus 49.8 for arm B. Ten patients had de novo metastatic breast cancer (arm A = 14%, arm B = 12%).
Out of non-metastatic cases, most of them were larger than 5cm (T3: 37.2% vs. 31.8%; T4a–b:
2.3% vs. 9.1%; T4d: 18.6% vs. 13.6%). There was a trend in higher rates of lymph node involvement for
non-metastatic patients included in arm B (N1: 52.4% vs. 77.3%; N2: 16.7% vs. 4.5%; N3: 2.4% vs. 9.1%;
p = 0.06). Pathologically-defined molecular subtypes were well balanced: fourteen cases (28%) were
HER2-positive in arm A (including 6 HR-positive and 8 HR-negative tumors) versus eight (32%) in
arm B (including 3 HR-positive and 5 HR-negative tumors). Triple negative tumors rates were also
similar for both arms (42.9% vs. 40%).
Figure 1. CONSORT flow diagram.
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Table 1. Clinical and pathological features at inclusion. When required, results are notified as N (% of




(N = 25) p-Value
Clinical features
Age at inclusion, years
(median, min–max) 50.0 (24.3–66.9) 49.8 (28.4–68.5) 0.47
Menopausal 9 (18) 6 (24) 0.55
Tumor size T2 21 (42) 10 (40) 1.00
T3 17 (34) 9 (36)
T4 12 (24) 6 (24)
Axillary lymph node positive 37 (75.5) 22 (88) 0.24
Metastatic disease at diagnosis 7 (14) 3 (12) 1
Pathological features
at diagnosis
HR status Positive 21 (42) 10 (40) 1
Negative 29 (58) 15 (60)
HER2 status Positive 14 (28) 8 (32) 0.86
Negative 35 (70) 17 (68)
Equivocal 1 (2)
Triple negative phenotype 21 (42.9) 10 (40) 1
SBR grade 1–2 12 (24) 9 (36) 0.41
3 37 (76) 16 (64)
Lymphovascular invasion
positive 6 (13) 1 (4) 0.41
3.2. Treatment Administration and Safety
More than 80% of patients received eight chemotherapy cycles (A: 88%, B: 84%). Only five patients
did not receive the four scheduled cycles of FEC. Seven patients (arm A) and 4 patients (arm B) did not
receive all the planned docetaxel infusions. All the patients in the experimental arm received at least
one cycle of bevacizumab. Out of them 43 (86%) received at least four cycles and 28 (56%) received the
eight planned bevacizumab courses.
Concerning safety (Table 2), 94% of patients included in the experimental arm and 88% in the
control arm experimented grade 3 to 4 adverse events. The most frequent were haematological
disorders with 46 to 48% of grade 3 to 4 neutropenia, with 34% of febrile neutropenia in arm A and 8%
in arm B. High grades of anaemia, asthenia, nausea, mucitis, and cutaneous disorders were also more
frequent in the experimental arm (18% vs. 4%, 14% vs. 4%, 10% vs. 0%, 22% vs. 8%, and 20% vs. 12%,
respectively). Regarding bevacizumab-related adverse events, severe high blood pressure increase
was observed for two patients (4%) in arm A (vs. 0 in arm B); three cases of thrombotic event were
observed for patients in arm A (none in the control arm).
No treatment-related death was reported during study duration.
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Table 2. Most common adverse events (Common Terminology Criteria for Adverse Events version 3.0).
Only adverse events (AEs) related to treatment and with an incidence ≥ 10% for all grades or ≥ 5% for
grade ≥ 3 are presented.
Bevacizumab Arm Control Arm
All Grades Grade ≥ 3 All Grades Grade ≥ 3
Adverse events N % N % N % N %
Haematological
Anaemia 13 26 9 18 5 20 1 4
Lymphopenia 9 18 9 18 6 24 6 24
Neutropenia 24 48 23 46 12 48 12 48
Febrile neutropenia 17 34 17 34 2 8 2 8
Non-haematological
Asthenia 37 74 7 14 18 72 1 4
Anorexia 9 18 2 4 4 16 1 4
Weight lost 13 26 0 0 1 4 0 0
Constipation 16 32 0 0 7 28 0 0
Diarrhoea 17 34 0 0 6 24 0 0
Nausea 43 86 5 10 20 80 0 0
Vomiting 18 36 3 6 2 8 0 0
Abdominal pain 7 14 1 2 2 8 0 0
Stomach pain 10 20 0 0 6 24 0 0
Dysphagia 8 16 0 0 1 4 0 0
Mucitis 39 78 11 22 17 68 2 8
Epistaxis 30 60 0 0 1 4 0 0
Arthralgia 10 20 1 2 11 44 1 4
Myalgia 18 36 0 0 12 48 0 0
Peripheral neuropathy 6 12 0 0 3 12 0 0
Cutaneous toxicities 43 86 10 20 21 84 3 12
Amenorrhea 10 20 5 10 9 36 6 24
High blood pressure 14 28 2 4 2 8 0 0
Headaches 15 30 0 0 1 4 0 0
3.3. Primary Endpoint: Percentage of ADLH1+ Cells
IHC analysis was performed to identify tumors with ALDH1 expression at inclusion. We evaluated
the percentage of ALDH1+ cells for each sample at inclusion and after the fourth chemotherapy cycle.
Absence of a large increase of ALDH1 expression was explored as a surrogate marker of CSC inhibition
due to chemotherapy-bevacizumab combination. ALDH1 data before and after four chemotherapy
cycles were available for 19 patients in arm A and 13 patients in arm B. The primary endpoint was thus
not evaluable in 43 patients, of whom 12 patients were excluded from the analysis set due to complete
remission at the end of the fourth cycle of chemotherapy (Figure 1). Most of the patients randomized
in the experimental arm with both biopsy analyses available experimented a low increase (<5%) or a
decrease of ALDH1+ cells rate (pseudo-median=−0.125, one-sided 95% CI (−∞–0), p = 0.001, Wilcoxon
test, N = 19), (Figure 2). ALDH1 expression was also significantly not higher after chemotherapy in the
control arm (pseudo-median = −0.25, one-sided 95% CI (−∞–0), p = 0.006, N = 13).
We then exploratory assessed ALDH1 expression levels on post-chemotherapy (after the 8th cycle)
samples. ALDH1 pseudo-median of difference between post-chemo and pre-chemo samples was
−0.125 (one-sided 95% CI (−∞–0), p < 0.001, N = 19) in the experimental arm versus −0.25 (one-sided
95% CI (−∞–10), p = 0.14, N = 7) for the chemotherapy only arm. When adding cases with complete
pathological response after chemotherapy to patients without high ALDH1+ rate increase, we observed
that these results were similar both for the experimental arm (pseudo-median = −0.125, one-sided
95% CI (−∞–0), p < 0.001, N = 37) and the control arm (pseudo-median = −0.25, one-sided 95% CI
(−∞–0), p = 0.016, N = 11).
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Figure 2. ADLH1 positive cells rates modifications after the first four cycles of treatment (each line
represents one patient). Red lines represent patients presenting an increase of ALDH1+ cells rate.
Blue lines represent patients presenting a decrease of ALDH1+ cells rate. Green lines represent patients
without ALDH1+ cells rate modification.
3.4. Efficacy
3.4.1. Efficacy for the Whole Population
Regarding pathological response after chemotherapy (Table 3), a not statistically significant
difference according to treatment arm was observed when using Sataloff classification (51.1% vs. 31.8%;
OR = 2.24, 95% CI (0.77–6.54), p = 0.14). When using the usual definition of pathological complete
response, there was a trend for pCR rate improvement for patients who received bevacizumab
(42.6% vs. 18.2%; OR = 3.33, 95% CI (0.98–11.38), p = 0.06).
Table 3. Pathological response rates. Results are notified as N (% of cases with data available).
Bevacizumab






Sataloff classification pCR 23 (51.1) 7 (31.8) 2.24 (0.77–6.54) 0.14
Non-pCR 22 (48.9) 15 (68.2)
Missing data 5 3
ypT0/is pN0 definition pCR 20 (42.6) 4 (18.2) 3.333 (0.98–11.38) 0.06
RD 27 (57.5) 18 (81.8)
Missing data 3 3
pCR: pathological complete response, RD: invasive residual disease in breast or lymph nodes.
Median follow-up was 60.9 months for the whole population (95% CI (60.4–61.8)) with no
difference according to treatment arm (61.3 months, 95% CI (60.2–62.5), for arm A vs. 60.6 months,
95% CI (60.2–61.6), for arm B). The 5-y OS was 86% (95% CI (75–92)) for the whole cohort and 90%
(95% CI (80–96)) for non-metastatic patients. There was no OS difference according to treatment arm
(5-y OS = 85% for arm A vs. 87% for arm B; p = 0.89; HR = 1.10, 95% CI (0.28–4.25)), (Figure 3A).
Considering non-metastatic patients, 5-y DFS was 73% (95% CI (60–82)) for the whole population,
without improvement for patients who received bevacizumab (5-y DFS = 76% for arm A vs. 65% for
arm B; p = 0.45; HR = 0.69, 95% CI (0.26–1.81)), (Figure 3B). Results were similar regarding RFS. Five-y
RFS was 76% for arm A vs. 70% for arm B (p = 0.68; HR = 0.81, 95% CI (0.29–2.23)), (Figure 3C).
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Figure 3. Kaplan–Meier curves. (A): Overall survival for the whole cohort. (B): Disease-free survival
for non-metastatic patients. (C): Relapse-free survival for non-metastatic patients.
3.4.2. Efficacy according to ALDH1 Status
At inclusion, 21 of 63 patients with analyzable samples were ADLH1+ (33% in both treatment
arms). ALDH1 status was also available for 32 patients after the fourth chemotherapy cycle.
Of them, twenty-two percent had ADLH1+ tumors. Among the six ALDH1+ cases at inclusion
in arm A, three were still ADLH1+ after four chemotherapy cycles (vs. three of four in arm
B). Two of 13 ADLH1− cases became ADLH1+ in arm A versus one of nine in arm B. ADLH1
status at inclusion was not correlated to pCR (ypT0/is pN0 definition) after neoadjuvant treatment:
OR (ALDH1− vs. ADLH1+) = 2.74, 95% CI (0.84–8.97), p = 0.10). Similar results were observed for
OS (HR = 0.69, 95% CI = (0.15–3.06), p = 0.62), DFS (HR = 0.94, 95% CI = (0.37–2.40), p = 0.90), and RFS
(HR = 1.10, 95% CI = (0.41–2.94), p = 0.85). Multivariate Cox regression analyses including ALDH1
status at inclusion, treatment arm, and pCR status failed to show survival benefits for ADLH1-positive
tumors (Tables S1–S3).
4. Discussion
This randomized prospective phase II trial aimed to bring evidences of CSCs inhibition using
a chemotherapy-bevacizumab combination. As hypothesized, we observed that ADLH1+ cells
rate was not increased above the predefined threshold for patients receiving bevacizumab-based
neoadjuvant chemotherapy. However, as similar results were obtained for the control group, an impact
of angiogenesis inhibition on the CSC population cannot be confirmed.
Contrarily to our initial hypothesis, some preclinical results published after initiation of our trial
intriguingly suggested that hypoxia generated by antiangiogenic agents, including bevacizumab,
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could stimulate the population of CSCs and contribute to the resistance of these drugs and the lack
of survival benefit provided by these compounds in breast cancer [48]. An increase in CSCs was
particularly noticeable when treatment was delivered in the context of large and established tumors,
a setting comparable to that of neoadjuvant treatment, most likely in relation to a greater overall
volume for hypoxia to occur. Nevertheless, these preclinical observations were not clearly validated
in vivo, and we did not observe CSCs stimulation during bevacizumab treatment in the present trial.
The ADLH1 status at inclusion, which can be seen as a surrogate of the CSC population,
was also neither prognostic nor predictive of pCR after treatment. These results are contradictory to
other published data. In a Japanese cohort of more than 100 breast cancers receiving preoperative
chemotherapy, ALDH1-positive cases were associated with a low pCR rate (9.5% vs. 32.2%; p = 0.037).
Analyses done before and after neoadjuvant chemotherapy showed an increase of the proportion of
ALDH1-positive tumor cells for patients who did not achieve pCR [49]. These results were confirmed
in another set of 119 patients receiving anthracyclines and taxanes before breast surgery, for whom
ALDH1 negativity at baseline was significantly associated with pCR, and ALDH1 expression was
increased after chemotherapy [50]. In this study, ALDH1 expression in the residual tumor was also
prognostic, with worse overall survival for ALDH1-positive cases. Similar results were observed in
a retrospective work including more than 650 breast cancer patients [51]. We did not find such a
correlation between ALDH1 expression at diagnosis and treatment efficacy in our study. Concerning
pCR, the results were inconclusive (p = 0.10) probably because of a lack of power, and this trial was
indeed not powered for pCR nor for survival analyses.
Pathological response rates were surprisingly high in our set with, according to the classification
used, 42 to 51% of pCR in the bevacizumab arm and 18 to 32% in the control arm. These rates decreased
our capacity to obtain post-treatment tumor samples for ALDH1 expression analysis. However,
even though high, these rates are in accordance to the data published during the last years for the
tumor phenotypes described in this set. Nearly 60% of patients included harbored HR-negative tumors,
including more than 40% with triple-negative cancer. Triple negative breast cancer is now known to
display higher rates of pCR, and our results are in accordance with what has been previously published
with pCR rates ranging from 25% to 60% [51–53].
In the GeparQuinto trial, exploring the addition of VEGF-R inhibition to anthracycline and
taxane-based neoadjuvant therapy, pCR rates in the TNBC subset were significantly higher with
bevacizumab (39.3% vs. 27.9%, p = 0.003) [53], with results close to what we observed in our cohort.
However, as we also notified, survival was not improved with the combination for TNBC (HR = 0.99
for DFS, p = 0.94; HR = 1.02 for OS, p = 0.89) nor for the whole HER2-negative cohort, (HR = 1.03 for
DFS, p= 0.78; HR = 0.97 for OS, p = 0.84) [54]. To avoid this issue of TNBC excess leading to high pCR
rates in both groups, we should have decreased the number of TNBC patients included. However,
this would have led to insufficient enrolment within the predefined inclusion period.
This trial has some limits which deserve to be underlined. Firstly, the definition of the main
endpoint was of importance at time of trial design but could be more criticized if this study takes
place in 2019. Improvement of the surrogate markers of CSCs could have allowed us to reach
our primary objective. Additional staining focused on the ALDH1A1 isoform, or other stem cells
markers such as CD44+/CD24− may be of interest [55,56]. However recent studies suggest that
CD44+ CD24− phenotype and ALDH1 phenotype may form part of two interconvert dynamic EMT
states. Mesenchymal-like CSCs (CD44+/CD24− are more quiescent whereas epithelial-like BCSCs
(ALDH1+) are more proliferative [57]. In the neoadjuvant setting, ALDH1 staining only displayed
a prognostic value for patients in terms of pCR or metastasis-free survival [58]. We thus chose to
monitor CSC during neoadjuvant chemotherapy using ALDH1 staining. The ALDEFLUOR assay,
based on the assessment of ALDH enzymatic activity, could also have been evaluated, but is very
unlikely to be developed in routine practice as it needs early processing of fresh tumor samples
and flow cytometry experiments [55]. Secondly, even though the randomization was of importance
to look for an association between bevacizumab treatment and CSC enrichment as suggested by
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Li et al. [30], the lack of blind could have had an impact on efficacy data, including our primary
endpoint. Thirdly, CSCs may not be a good candidate to predict neoadjuvant treatments efficacy.
We have recently described that pCR rates after chemotherapy and bevacizumab-based neoadjuvant
treatments in inflammatory breast cancer are correlated to circulating tumor cells (CTC) detection [59].
CTC-positive cases displayed worse three-year DFS (39% vs. 70%) and OS. CTC status at baseline was
an independent prognostic feature in multivariate analysis. A team from Harvard has also recently
reported that another type of tumor cells with (but not only with) CSC properties, called AKT1low
quiescent cancer cells, seem to be resistant to chemotherapy in the neoadjuvant setting for triple
negative breast cancer [60]. Concerning the current study, as it was designed as a proof of concept trial
with a biological primary endpoint, its sample-size was limited, response and survival endpoints were
secondary, and definitive conclusions related to bevacizumab contribution to treatment efficacy can
only be considered as preliminary. However, larger and more robust results have been published in
randomized trials evaluating adjuvant bevacizumab efficacy for early breast cancers [61]. These data
are in accordance with our results with no survival gain with bevacizumab-based combinations in
the (neo)adjuvant setting, despite higher rates of pathological response [24,25,54,62]. Similar results
have been obtained in the early setting for other tumor localizations, with no disease-free survival or
overall survival improvements [63,64]. Even though pCR has been widely described to be prognostic
in early breast cancer, survival gains secondary to treatment-induced pCR improvement is still debated.
A large meta-analysis published a few years ago thus showed that trials describing pCR gains did not
result in survival benefits, with the exception of the NOAH trial which introduced trastuzumab in the
preoperative systemic regimen for HER2-positive cases [45].
5. Conclusions
Bevacizumab impact on CSC was not higher than that of chemotherapy alone for the cases
enrolled in this trial. Moreover, despite that bevacizumab-chemotherapy combination enhanced pCR
rates compared to chemotherapy alone for breast cancer receiving neoadjuvant chemotherapy, it did
not improve survival. These observations warrant to be deeply explored in larger series and for
other tumor localizations for which bevacizumab is more widely used such as ovarian, colorectal,
and cervical cancers [27,28,65–67].
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Abstract: Background: Cancer stem cells (CSCs) promote tumor progression and distant metastasis
in breast cancer. Cadherin 11 (CDH11) is overexpressed in invasive breast cancer cells and implicated
in distant bone metastases in several cancers. The WNT signalling pathway regulates CSC activity.
Growing evidence suggest that cadherins play critical roles in WNT signalling pathway. However,
CDH11 role in canonical WNT signalling and CSCs in breast cancer is poorly understood. Methods:
We investigated the functional association between CDH11 and WNT signalling pathway in triple
negative breast cancer (TNBC), by analyzing their expression profile in the TCGA Breast Cancer
(BRCA) cohort and immunohistochemical (IHC) staining of TNBC samples. Results: We observed a
significant correlation between high CDH11 expression and poor prognosis in the basal and TNBC
subtypes. Also, CDH11 expression positively correlated with β-catenin, wingless type MMTV
integration site (WNT)2, and transcription factor (TCF)12 expression. IHC results showed CDH11
and β-catenin expression significantly correlated in TNBC patients (p < 0.05). We also showed
that siRNA-mediated loss-of-CDH11 (siCDH11) function decreases β-catenin, Met, c-Myc, and
matrix metalloproteinase (MMP)7 expression level in MDA-MB-231 and Hs578t. Interestingly,
immunofluorescence staining showed that siCDH11 reduced β-catenin nuclear localization and
attenuated TNBC cell migration, invasion and tumorsphere-formation. Of translational relevance,
siCDH11 exhibited significant anticancer efficacy in murine tumor xenograft models, as demonstrated
by reduced tumor-size, inhibited tumor growth and longer survival time. Conclusions: Our
findings indicate that by modulating β-catenin, CDH11 regulates the canonical WNT signalling
J. Clin. Med. 2019, 8, 148; doi:10.3390/jcm8020148 www.mdpi.com/journal/jcm95
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pathway. CDH11 inhibition suppresses the CSC-like phenotypes and tumor growth of TNBC cells
and represents a novel therapeutic approach in TNBC treatment.
Keywords: Cadherin 11; WNT signaling; β-catenin; cancer stem cells; TNBC
1. Introduction
Triple negative breast cancer (TNBC) constitutes 10−20% of all breast cancer cases and exhibits
more aggressive traits and worse patient prognosis than hormone receptor- and HER2- positive breast
cancer [1]. To date, TNBC lacks US-FDA-approved target therapy [1,2]. Chemotherapy remains the
primary treatment of choice. Despite a documented record of TNBC sensitive to chemotherapy, only
30% of such cases show pathologic complete responses, while the less- or non- sensitive patients
exhibit a high probability of developing distant metastases and relapses [2]. Metastatic breast cancer is
currently an incurable disease, with palliative treatment being the therapy of last resort to alleviate
pain, enhance quality of life and help patients live longer [3]. The discovery and development of novel
efficacious targeted therapy to treat TNBC and prevent metastatic breast disease are important issues.
Since the discovery of CSCs in solid tumors, namely, breast cancer in 2003 [4], there is growing
evidence of CSCs existence or presence in other solid tumors [5]. The CSCs possess self-renewal
capacity and differentiate into heterogeneous tumor cells. They have been implicated in metastatic
dissemination of cancerous cells in many cancer models including breast cancer and are shown to be
more resistant to chemotherapy and lead to cancer relapse [6]. Targeting these cells in cancer treatment
may be more beneficial for TNBC patients.
The WNT signalling pathway is a principal regulator of self-renewal and helps maintain the
undifferentiated state of normal mesenchymal stem cells and CSCs [7,8]. The presence of the WNT
ligand has been shown to promote β-catenin translocation to the nucleus and activate target gene of
WNT signalling pathway [9]. Knocking down β-catenin reduced stem cell-like cell population and their
chemoresistance to doxorubicin; the β-catenin-silenced TNBC cell lines generated smaller tumors than
control cells when inoculated into the mammary fat pad of tumor xenograft mice models [10]. In the
membrane, β-catenin binds to different cadherins in the adhesion junction complex and become stabilized;
however, β-catenin in the cytoplasm is degraded by the APC-Axin-GSK3β complex in the absence of
WNT ligands [11]. In fact, cadherins inhibit activation of the canonical WNT signalling pathway by
keeping β-catenin in the membrane. β-catenin translocation to the nucleus is prevented in the presence
of WNT ligands [12]. During epithelial-to-mesenchymal transition (EMT), cadherins act as a pool of
calcium-dependent adhesion-competent β-catenin, which is a principal mediator of canonical WNT
signalling activation, thus, depleting cadherins reduces β-catenin in the membrane and suppresses
WNT signalling activation despite the presence of β-catenin in the cytoplasm [13]. Cadherin 11, a type II
cadherin and mesenchymal protein marker, is overexpressed in the invasive breast cancers [14]. In prostate
and renal cancers, CDH11 plays an important role in distant bone metastasis. Expression of CDH11 in
metastatic bone tumors is higher than in primary tumor sites [15,16]. The brain, lungs, and bones are the
most common sites of distant metastasis in TNBC patients [17,18]. Interestingly, these organs have higher
expression of CDH11 than the breast itself in normal condition [19]. Inhibition of CDH11 in breast cancer
cell lines reduced migration and invasion ability [20], suggesting that it may play an important role in
TNBC metastasis.
In this present study, we hypothesized and validated our hypothesis that CDH11 regulates the
canonical WNT signalling pathway and the CSCs-like phenotypes. The inhibition of the CSCs-like
phenotypes of TNBC cells through CDH11 repression represents a novel therapeutic approach in
TNBC treatment. Thus, we highlight a novel aspect of TNBC biology and provide a molecular basis
for further exploration of CDH11-mediated anti-TNBC targeted therapy.
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2. Materials and Methods
2.1. Public Dataset Analyses
The TCGA Breast Cancer (BRCA) cohort datasets were downloaded from UCSC Xena Browser
platform. This cohort contains several datasets from 1247 samples of breast cancer patients. We also
made use of the TNBC cohort data of the Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) cohort dataset (n = 1904) downloaded from the European Genome-Phenome
archive (EGAS00000000098). The METABRIC study classifies breast tumors into subcategories, based
on genetic fingerprints and molecular signatures which are intended to help predict therapeutic
response and determine the optimal course of treatment. The gene expression RNAseq-IlluminaHiSeq
and Phenotypes datasets were downloaded and used for further analysis. The PAM50 mRNA
nature2012 clinical parameter was used for classifying breast cancer patients into luminal A, luminal B,
Her2-enriched and basal-like (BL) subgroups. The status of ER, PR and Her2 were used to determine
the triple negative breast cancer subgroup. To establish correlation between CDH11 and prognosis of
breast cancer patient for each subgroup, we performed Kaplan Meier (KM) overall survival analysis
using the “R2: Genomics Analysis and Visualization Platform”. For the low/high expression group
dichotomization, we did not use the traditional median or mean cutoff values, rather we employed a
bioinformatics approach using the automated ‘Kaplan scan’ cutoff function of the R2 genomic interface
platform. The ‘Kaplan scan’ generates a KM plot based on the most optimal mRNA cut-off expression
level to discriminate between a good (low expression) and bad (high expression) prognosis cohort.
This was followed by the Bonferroni test for statistical significance (p-value) of the KM plot.
2.2. Immunohistochemistry
Triple negative breast cancer tissue samples (n = 38) were obtained from the Shuang Ho Hospital
(SHH) breast cancer cohort. Ethical approval for the study was obtained from Joint Institutional
Review Board (JIRB) of the Taipei Medical University (approval number: N201603028). Tissue sections
(4 μm) were deparaffinized and rehydrated in gradually decreased concentration of methanol (100%,
95%, and 70%). Antigen retrieval was carried out by boiling slides in pressure cooker containing
TrilogyTM buffer (Sigma-920P-06, Cell Marque, Sigma-Aldrich, Inc. St. Louis, MO, USA) for 5 min,
and followed by incubation in hydrogen peroxide blocking solution (TA-125-H2O2Q, Thermo Fisher
Scientific, Waltham, MA, USA) for 10 min. Nonspecific binding was blocked with Ultra V Block
(TA-125-PBQ, Thermo Fisher Scientific, Waltham, MA, USA) for 10 min. The slides were incubated
in primary antibodies against cadherin 11 (polyclonal antibody, 71-7600, Thermo Fisher Scientific,
Waltham, MA, USA) and β-catenin (H-102: sc-7199, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
with working dilution 1:100 and 1:50, respectively for overnight at 4 ◦C. Later, tissue slides were
incubated in Primary Antibody Amplifier Quanto (TL-125-QPB, Thermo Fisher Scientific, Waltham,
MA, USA) for 10 min, in Horseradish peroxidase (HRP) Polymer Quanto (TL-125-QPH, Thermo Fisher
Scientific, Waltham, MA, USA) for 10 min and then in DAB Quanto Chromogen (TA-004-QHCX,
Thermo Fisher Scientific, Waltham, MA, USA) diluted 3:100 in DAB Quanto Substrate (TA-125-QHSX,
Thermo Fisher Scientific, Waltham, MA, USA) for 3 min. Slides were counterstained with hematoxylin.
The immunoreactive score system (IRS) was used to measure the expression level of protein of interest
as previously described [21]. For final analyses, negative-mild staining was categorized as “Low”
while moderate-strong positive staining was categorized as “High”.
2.3. Cell Culture
TNBC cell lines, MDA-MB-231 and Hs578T were purchased from American Type Culture Collection
(ATCC, Manassas, VA, USA). MDA-MB-231, derived from the pleural effusion and metastatic site of a
female patient with breast adenocarcinoma, constitutively express WNT7B, EGF and TGFα, and forms
poorly differentiated adenocarcinoma (grade III) in experimental mice models. Hs578T, however, is from
a female patient with primary breast carcinoma and is non-tumorigenic in immunosuppressed mice.
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The selection of the 2 cell lines provided a basis for phenotypic and functional comparison between
two variants of TNBC cells. The cell lines used in this study were periodically tested and confirmed to
be free from mycoplasma and/or cross-contamination with cells derived for a different origin during
laboratory manipulation or processing. Both cell lines were cultured in DMEM) (DML10-1000ML,
Caisson Labs, Smithfield, UT, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS),
100 IU/mL Penicillin and 100 μg/mL Streptomycin, in 5% CO2 humidified atmosphere at 37 ◦C.
For maintenance, both cell lines were sub-cultured every 48–72 h.
2.4. CDH11 Knockdown
For CDH11 loss-of-function studies, we used On-Target plus Human CDH11 siRNA-Smart
pool (L-013493-00-0005, Dharmacon, Lafayette, CO, US) that contains 4 siRNA mix. CDH11 #1:
5’-GUGAGAACAUCAUUACUUA-3’. CDH11 #2: 5’-GGACAUGGGUGGACACAUAUG-3’. CDH11 #3:
5’-GGAAAUAGCGCCAAGUUAG-3. CDH11 #4: 5’-CCUUAUGACUCCAUUCAAA-3’. A day before
transfection, MDA-MB-231 cell line was seeded into 6-well cell plate at a density of 3 × 105 cells/well in
DMEM containing 10% FBS without antibiotics. The Hs578t cell line was seeded in the same condition
except the density (2 × 105 cells/well). After 24 hours incubation, 30–40% confluent cells were transfected
with siRNA using Lipofectamine 3000 (L3000008, Thermo Fisher Scientific, Waltham, MA, USA) in
serum-free DMEM. 80 nM of siRNA was used as final concentration. Six hours after initial transfection,
the medium was replaced with fresh DMEM containing 10% FBS. Next day, cells were re-transfected with
same siRNA, following same transfection steps. The siRNA-transfected cells were incubated for 48 h
since the first transfection and used for western blot, and functional assays.
2.5. Western Blotting
Triple negative breast cancer cells were harvested by scraping method then lyzed with RIPA lysis
buffer that supplemented with protease inhibitor (1X, Cat# 78430, Halt Protease Inhibitor Single-Use
Cocktail, Thermo Fisher Scientific, Waltham, MA, USA) and phosphatase inhibitor (0.5X, PierceTM
Phosphatase Inhibitor Mini Tablets, Thermo Fisher Scientific, Waltham, MA, USA). After homogenization
with pellet pestle, the cells were incubated on ice for 30 min. The re-suspended cells were centrifuged
at 12.000 rpm for 10 min; then, supernatants were collected as total protein samples. PierceTM BCA
Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) was used to determine final protein
concentration. After boiling with sample buffer for 10 min and centrifuged for 10 min, the total protein
samples were loaded onto and ran by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), then blots transferred onto polyvinylidene fluoride (PVDF) membranes, followed by
blocking with 5% skimmed milk or 5% BSA in TBS-Tween-20 (TBST) for 1 h. The membranes were
then incubated in primary antibodies against CDH11 (polyclonal antibody, 1:1000, Cat# 71-7600, Thermo
Fisher Scientific, Waltham, MA, USA), β-catenin (monoclonal antibody, 1:1000, Cat# 9582P, Cell Signalling
Technology, Danvers, MA, USA), c-Myc (monoclonal antibody, 1:500, Cat# sc-40, Santa Cruz Biothecnology,
Santa Cruz, CA, USA), Met (monoclonal antibody, 1:1000, Cat# 8198, Cell Signalling Technology, Danvers,
MA, USA), SOX2 (monoclonal antibody, 1:1000, Cat# 3579P, Cell Signalling Technology, Danvers, MA,
USA), CD44 (monoclonal antibody, 1:1000, Cat# 3570, Cell Signalling Technology, Danvers, MA, USA),
KLF4 (polyclonal antibody, 1:1000, Cat# 4038P, Cell Signalling Technology, Danvers, MA, USA), c-Jun
(monoclonal antibody, 1:1000, Cat# 9165, Cell Signalling Technology, Danvers, MA, USA), MMP7
(monoclonal antibody, 1:1000, Cat# 3801, Cell Signalling Technology, Danvers, MA, USA),and β-actin
(monoclonal antibody, 1:10.000, Cat# ab6276, Abcam Biotechnology Company, Cambridge, MA, UK) at
4 ◦C overnight. After washing with TBST, membranes were probed with an HRP-labeled anti-rabbit or
anti-mouse IgG secondary antibody as appropriate. Protein bands were visualized by UVP Biospectrum
Imaging System (Vision Works LS 6.8, Level Biotechnology Inc. New Taipei City, Taiwan) using ECL
reagents (Thermo Fisher Scientific, Waltham, MA, USA).
98
J. Clin. Med. 2019, 8, 148
2.6. Transwell Matrigel Invasion and Migration Assay
We used the 24-well plate transwell system to evaluate migration ability. The upper chambers
of the transwell were pre-coated with solubilized Matrigel (BD Bioscience). After the matrigel
polymerized, MDA-MB-231 and Hs578t cell lines (2 x 104 cells/well) were seeded into the upper
chamber containing 200 μL serum-free DMEM, while 500 μL DMEM with 10% FBS in the lower
chamber served as chemoattractant. The medium was discarded after 24 h incubation and cells on
the membrane were fixed using formaldehyde (10%) for 20 min at room temperature before crystal
violet staining for 20 min. The cells on the upper side of the membrane were carefully removed with a
cotton swab. The migrated cells were observed under microscope and the total number of cells on the
lower surface counted. Migration assay was performed following same steps as the invasion assay,
but without Matrigel on the upper chamber.
2.7. Immunofluorescence Assay
The wild-type and siCDH11 MDA-MB-231 and Hs578t cells were seeded in 96-well plates
and incubated for 24 h, washed with 200 μL ice-cold PBS, then fixed using 200 μL pre-chilled 4%
formaldehyde for 15 min at room temperature before being blocked with 200 μL blocking buffer (1x
PBS/ 5% BSA/ 0.3% TritonTM X-100) for 1 h at room temperature. After washing with PBS, the cells
were incubated with 100 μL primary antibodies against CDH11 (monoclonal antibody, Cat#, 5B2H5,
1:50, Thermo Fisher Scientific, Waltham, MA, USA), or β-catenin (monoclonal antibody, Cat# 9582P,
1:50, Cell Signalling Technology, Danvers, MA, USA) at 4 ◦C overnight in a dark room. Next day, cells
were washed with 0.1% PBS, incubated with 100 μL Alexa-Flour-conjugated secondary antibodies
against rabbit and mouse for 1 h at room temperature in the dark. In this experiment, the primary
and secondary antibodies were diluted in antibody dilution buffer (1x PBS/ 1% BSA/ 0.3% TritonTM
X-100). Next, cells were washed with PBS and were counterstained with DAPI (0.5 μg/mL, Vector
Laboratories, Burlingame, CA, USA) and evaluated using fluorescence microscope.
2.8. Mammosphere Formation Assay
The wild-type and siCDH11 MDA-MB-231 and Hs578t cells were harvested and seeded in 24-well
plates (Cat# CLS3473, Corning Costar Ultra-Low Attachment Multiple Well Plates, Sigma-Aldrich,
St. Louis, MO, USA) that contained 500 μL serum-free DMEM medium, supplemented with B27
(Invitrogen, Carlsbad, CA, USA), and 10 ng/mL epidermal growth factor (BD Biosciences, Palo Alto, CA,
USA). The cells were seeded in 3 different density (1000 cells/cm2, 2000 cells/cm2, and 4000 cells/cm2)
for each group. After 5 days incubation, formed mammospheres were observed and evaluated
under microscope.
2.9. In Vivo Study
The MDA-MB-231 and Hs578t cells were treated with siRNA specific for CDH11 for 48h.
NOD/SCID mice were randomized into wild type (n = 5) and siCDH11 (n = 5) group for each cell line.
The mice were inoculated subcutaneously with 2 × 106 wild type (WT) or siCDH11 MDA-MB-231
or Hs578t cells in their hind flank. Mice tumor sizes were measured on days 6, 9, 12, 15, 18, and 27
after TNBC cell inoculation using callipers and tumor volumes calculated with a standard formula:
length × width2 × 0.5. The tumor-bearing mice were sacrificed, and the tumor mass were observed
and measured on day 27 post-inoculation. In parallel in vivo studies following same steps except
sacrificing on day 27, the mice were observed until day 45 post-inoculation to assess the effect of altered
CDH11 expression on the survival rates. For maintenance of siRNA effect, mice in the siCDH11 group
were injected intra-tumorally with 10 μmol/L of ‘siCDH11-atelocollagen’ complex on days 9, 18, 27,
and 36 after TNBC cell inoculation. The siCDH-atelocollagen complex, usually prepared the preceding
evening and stored at 4 ◦C before use, consisted of equal volumes of well mixed siCDH11 and
atelocollagen (Koken Co. Ltd., Tokyo, Japan). All tumor xenograft animal studies were approved by
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the TMU-SHH Joint Institutional Review Board and performed in accordance with protocol approved
by the TMU Institutional Animal Care and Use Committee (approval number: LAC-2015-0383).
2.10. Statistical Analysis
Kaplan Meier overall survival analysis were performed using “R2: Genomics Analysis and
Visualization Platform” and GraphPad Prism for Windows version 7.00 software (GraphPad Software
Inc., San Diego, CA, USA). Statistical significance was assumed when p ≤ 0.05. For correlation studies
between CDH11 and several components of the WNT signalling pathway SigmaPlot for Windows
version 10.0 software (Systat Software Inc., San Jose, CA, USA) was used. All cell-based assays were
performed at least three times in triplicates and results expressed as Mean ± SD. Quantitative and
qualitative analyses of western blot, mammosphere formation, migration and invasion assays data
were performed using ImageJ version 1.51j8 (Wayne Rasband National Institutes of Health, Bethesda,
MD, USA) and the graph results were created using SigmaPlot.
3. Results
3.1. High CDH11 Expression has Significant Positive Correlation with Poor Overall Survival in Patients with
Basal-Like and Triple Negative Breast Cancer
To determine existing correlation or association between CDH11 expression and prognosis of
breast cancer patients, we assessed TCGA Breast Cancer (BRCA) cohort datasets from UCSC Xena
Browser (https://xenabrowser.net/datapages/). We divided the breast cancer patients into luminal
A, luminal B, Her2-enriched, BL and TNBC subgroup. We observed that high CDH11 expression
correlated with significantly better survival rates in the luminal A (p = 0.0381) and Her-2 enriched
(p = 0.0319) subgroups, while no statistically significant correlation was observed between CDH11
expression and luminal B breast cancer patient survival (p = 0.2831) (Figure 1A–C). However, in
contrast, high CDH11 expression in the BL (p = 0.0049) and TNBC (p = 0.045) subgroups significantly
correlated with worse overall survival (Figure 1D,E). Our data is consistent with the aggressive
phenotype of TNBC cells and their poor prognosis despite initial good response to therapy and
corroborate significant overlap between the TNBC and BL breast cancer molecular subtypes [22,23].
These results indicate the prognostic nature of CDH11 expression profile and suggest its role as a
potential candidate for anti-TNBC targeted therapy.
3.2. CDH11 Positively Modulates β-Catenin Expression and Is Associated with Activation of the Canonical
WNT Signalling Pathway
β-catenin is a key component of the canonical WNT signalling pathway and has been shown
to directly bind to the cytoplasmic domain of CDH11 (13). We hypothesized that CDH11 plays
an important role in enhancing the stemness, migration, and invasion potential of TNBC cells
through activation of the canonical WNT signalling pathway. Using the METABRIC-Breast Cancer
(IlluminaHiSeq) cohort dataset (n = 1904), we investigated the correlation between CDH11 and
several components of the WNT signalling pathway in the TNBC subgroup. We found that CDH11
expression positively correlated with β-catenin, WNT2, and TCF2 expression with pearson’s r = 0.29
(p = 8.3 × 10−30), 0.60 (p = 7.8 × 10−183) and 0.48 (p = 1.3 × 10−101), respectively (Figure 2A–C).
Corroborating the results above, our IHC data demonstrated that tissues from TNBC patients
concurrently overexpressed CDH11 and β-catenin proteins, compared to the weak/non-expression in
non-tumor tissues (Figure 2D–F). In fact, correlative analysis of our local TNBC cohort (n = 38) indicate
a strong positive correlation between CDH11 and β-catenin (r = 0.62; p < 0.0001; Figure 2F, lower panel).
To reconfirm these findings and establish the functional significance of CDH11 expression and/or
activity in TNBC cells, we knocked-down CDH11 in MDA-MB-231 and Hs578t TNBC cell lines and
examined its effect on WNT signalling using western blot and immunofluorescence staining assays.
Reduced CDH11 expression in the TNBC cells altered their morphology from spindle-like to polygonal,
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reduced cell viability, and increased cell doubling time (Figure 3A,B). Additionally, our western blot
data showed that MDA-MB-231 and Hs578t cells transfected with siCDH11 exhibited significantly
decreased expression levels of CDH11, β-catenin, Met, c-Myc, c-Jun, and MMP7 (Figure 3C,D).
Furthermore, we observed that siCDH11 in MDA-MD-231 and Hs578t cells reduced β-catenin nuclear
localization and expression (Figure 4). These data corroborate the modulatory role of CDH11 on
the WNT/β-catenin signalling pathway and suggest that CDH11 plays an important role in the
maintenance of β-catenin protein in the MDA-MB-231 and Hs578t TNBC cell lines.
Figure 1. Patients with TNBC and basal-like breast cancer exhibiting high expression of CDH11 are
characterized by worse prognosis. Kaplan-Meier plots based on analyses of breast cancer cohort
(n = 1247) using the TCGA Breast Cancer (BRCA) cohort datasets show the effect of CDH11 expression
on the overall survival rates in patients regardless of molecular subtype, (A) Luminal A, (B) Luminal B,
(C) Her2-enriched, (D) Basal-like, or (E) Triple negative breast cancer.
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Figure 2. CDH11 positively modulates β-catenin expression and activates the canonical WNT signalling
pathway. Statistical analyses of the TNBC sub-group of the METABRIC Breast Cancer cohort (n = 1904)
show positive correlation between expression of CDH11 and (A) β-catenin, (B) WNT2, and (C) TCF12
mRNA. (D and E) Differential expression of CDH11 and β-catenin in non-tumor and TNBC tissue
samples demonstrated by representative IHC images and percentages of patients. Scale bar: 50 μm.
(F) Histogram showing positive correlation between CDH11 and β-catenin protein expression level in
our TNBC cohort (n = 38). * p < 0.05, ** p < 0.01, *** p < 0.001
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Figure 3. Loss of CDH11 function using siRNA changes cell morphology and inhibits activation of
the canonical WNT signalling pathway in TNBC cells. (A) The cell morphology of MDA-MB-231
and Hs578t changed from spindle-like to polygonal after loss of CDH11 expression. (B) Graphical
representation of the effect of siCDH11 on the doubling time of MDA-MB-231 and Hs578t cells as
determined by trypan-blue exclusion. (C) Western blot results show CDH11 knockdown decreased
β-catenin, Met, c-Myc, c-Jun, and MMP7 protein expression level in MDA-MB-231 and Hs578t cell
lines. (D) Graphical representation of C. Results expressed as mean ± SD of assays done 3 times in
triplicate. * p < 0.05, ** p < 0.01, *** p < 0.001; NS, not significant; Red arrow, floating non-viable cells.
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Figure 4. Knockdown of CDH11 using siRNA reduces β-catenin nuclear co-localization in TNBC cells.
Immunofluorescence staining of MDA-MB-231 and Hs578t cells with CDH11 (green), β-catenin (red),
and DAPI (blue). The results show that silencing CDH11 concurrently reduced CDH11 and β-catenin
protein expression level and their nuclear localization. The blue arrows indicate presence and absent
of CDH11 and β-catenin in the nuclear region. Images are representative of four separate assays in
triplicate. Scale bar: 50 μm.
3.3. CDH11 Inhibition Suppresses the Stem Cell-Like Phenotype of TNBC Cells
CSCs constitute a subset of cancer cells with self-renewal ability and enhanced resistance to some
chemotherapy agents [6]. We investigated whether CDH11 plays an important role in TNBC stemness.
Tumorsphere formation assays using wild-type (WT) and siCDH11 MDA-MB-231 and Hs578t cells
show that the siCDH11 cells displayed lesser tumorsphere formation efficiency compared to the WT
cells (Figure 5A–E). Measurement of tumorsphere sizes showed that all the siCDH11 tumorspheres
were significantly smaller than those formed by their WT counterparts of both cell lines except in
the lowest seeding cells of Hs578t (Figure 5B,C). The siCDH11 cells produced fewer tumorspheres
than WT cells at all seeding density, except 4000 cells/cm2 (Figure 5D,E). To further confirm the
important role of CDH11 in TNBC stemness, we assessed several CSCs markers. We observed
significantly downregulated Sox2, KLF4, CD44, and c-Myc protein expression levels in the siCDH11
group compared to the WT group (Figure 5F and Figure S1A). These data demonstrate that tumorsphere
formation efficiency is suppressed in the CDH11-deficient MDA-MB-231 and Hs578t TNBC cell
lines and suggest a role for CDH11 expression in the modulation of the stem cell-like phenotype of
TNBC cells.
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Figure 5. CDH11 inhibition suppresses the stem cell-like phenotype of TNBC cells. (A) Images showing
tumorsphere size in wild-type cells and their siCDH11 counterparts of varying cell density. Histograms
comparing the tumorsphere sizes of wild-type or si-CDH11 (B) MDA-MB-231 and (C) Hs578t. Histograms
comparing the number of tumorspheres formed by wild-type or si-CDH11 (D) MDA-MB-231 and
(E) Hs578t cells, based on ImageJ quantification. Only tumor spheres ≥40 μm in size were counted.
(F) The effect of siCDH11 on the expression Sox2, KLF4, CD44, and c-Myc proteins in MDA-MB-231
and Hs578t cells. (G) Graphical representation of the migration (upper panel) and invasion (lower panel)
of MDA-MB-231 and Hs578t cells. Results represent mean ± SD of 3 independent assays in triplicate.
* p < 0.05, ** p < 0.01, *** p < 0.001; WT, wild type; NS, not significant; Scale bar: 100 μm.
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3.4. CDH11 Inhibition Markedly Attenuate the Migration And invasion of TNBC Cells
Since the CSCs-like phenotype is often associated with enhanced oncogenicity and metastatic
traits [24], we further examined whether and how alteration in CDH11 expression affects the
characteristic aggressiveness of TNBC cells, using WT and siCDH11 MDA-MB-231 and Hs578t cells.
We demonstrated that the siCDH11 cells exhibited significantly reduced migration and invasion
ability; fewer migrated siCDH11 MDA-MB-231 and Hs579t cells were observed than for the WT
cells (Figure 5G). Similarly, siCDH11 resulted in significantly less invaded cells, compared to the WT
cells (Figure 5G and Figure S1B). Since, cell migration and invasion are objective measures of the
aggressiveness of cancerous cells; these results further corroborate the vital role of CDH11 in the
enhanced metastatic phenotype and aggressiveness of TNBC cells.
3.5. Silencing CDH11 Significantly Attenuates Tumorigenicity and Tumor Growth of TNBC Cells, In Vivo
Having previously demonstrated that silencing CDH11 suppresses the stem cell-like phenotype
of TNBC cells in vitro, to determine the probable inhibitory effect of silencing CDH11 on tumor
formation and growth in vivo, we generated tumor xenograft models derived from NOD/SCID mice
(n = 5/group) inoculated with 2 × 106 WT or siCDH11 MDA-MB-231 or Hs578t cells subcutaneously
in the hind-flank and observed for 27 days (Figure 6A). We demonstrated that the mice inoculated
with siCDH11 MDA-MB-231 or Hs578T developed very significantly smaller tumors, compared to the
WT group (MDA-MB-231: ~6.58-fold smaller, p = 0.008; Hs578t: ~5.75-fold smaller, p = 0.003 on day 27)
(Figure 6B,C). siRNA effect in the siCDH11 group was maintained by intra-tumoral injection with
10 μmol/L of ‘siCDH11-atelocollagen’ complex (Figure S2). Of translational relevance, in parallel mice
assays, survival analyses show that over 45 days, mice bearing siCDH11 MDA-MB-231 or Hs578T
cells-derived tumors enjoyed 20–50% (p = 0.027) or 16–50% (p = 0.011) survival advantage, respectively,
compared to their WT-inoculated litter-mate counterparts (Figure 6D,E). Taken together, these findings
suggest that CDH11 play an important role in tumorigenicity and tumor growth of TNBC cells in vivo.
As depicted in the schematic abstract (Figure 6F), these data showing siCDH11-associated impaired
tumorigenesis and increased survival substantiate CDH11-targeting as a potential therapeutic strategy
for patients with TNBC.
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Figure 6. Silencing CDH11 significantly attenuates tumorigenicity of TNBC cells, in vivo. (A) Schema
showing xenografts derived from NOD/SCID mice injected with 2 × 106 WT or siCDH11 MDA-MB-231
or Hs578t cells subcutaneously in the hind-flank and observed for 27 days (group A, n = 5/group) or 45
days (group B, n = 5/group). Graph showing difference in tumor volume over time for the WT or siCDH11
(B) MDA-MB-231 or (C) Hs578T tumor-bearing mice. Intergroup p-values were determined by 2-way
ANOVA. Kaplan-Meier survival curves for mice bearing WT or siCDH11 (D) MDA-MB-231 or (E) Hs578T
cell-derived tumors. WT, wild type. (F) Schematic abstract showing that CDH11 inhibition suppresses
the TNBC CSCs-like and metastatic phenotypes through WNT signalling regulation. In the presence of
WNT signal, cytoplasmic β-catenin is released from CDH11, accumulates in the perinuclear region, then
translocates to the nucleus where it activates downstream CSCs-regulating target genes, including Met,
c-Myc and Sox2 by binding to TCF/LEF. Once activated, these genes enhance self-renewal, migration, and
invasion abilities of TNBC cells. In the absence of CDH11, membranar, cytoplasmic and nuclear β-catenin
pool is diminished, WNT signalling is obtused, and the canonical WNT signalling pathway downstream
target genes remains inactivated.
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4. Discussion
Cadherin 11 is a transmembrane protein with documented conflicting roles in several types
of cancers [25–28]. Recently, it was suggested that CDH11 acts as a tumor suppressor gene as
demonstrated by its methylated and silenced status in malignant tissues such as in the nasopharyngeal,
esophageal, gastric, hepatocellular carcinoma, colon, and breast carcinoma [26]. Similarly, in vitro and
in vivo studies of murine retinoblastoma, cdh11 acted as a tumor suppressor gene through promotion
of tumor cell death [29]. Conversely, in ovarian cancer patients, CDH11 exhibited no evidence
of tumor-suppressive or oncogenic function, nor bore any prognostic / predictive relevance [27].
However, cumulative evidence supports the role of cdh11 as an oncogene, including that reported
in the present study. Higher CDH11 mRNA expression level has been shown in malignant breast
tumor than in non-malignant breast tumor or normal breast tissues [14]. Another study showed that
increased expression of CDH11 is characteristic of enhanced invasiveness in breast cancer cell lines,
in vitro [30]. In the present study, we demonstrated that high CDH11 expression positively correlates
with poor prognosis in the more aggressive breast cancers subtypes, namely BL and TNBC subtypes
(Figure 1). Thus, we posit that the high expression of CDH11 in patients with BL breast cancer and
TNBC indicates that CDH11 plays an important role in these breast cancer molecular subtypes as an
oncogene. This is consistent with the findings from prostate and renal cancers, wherein tissue samples
from the bone metastatic site exhibited higher expression levels of the CDH11 protein than observed
in primary tumor or adjacent normal tissue [15,16].
Based on breast cancer big data analyses, we showed that CDH11 expression positively correlates
with expression of WNT signalling components such as β-catenin, WNT2, and TCF2, and that tissues
from TNBC patients show concurrent high expression of CDH11 and β-catenin proteins; thus, we
demonstrate that CDH11 positively modulates β-catenin expression and activates the canonical WNT
signalling pathway (Figure 2). These findings are consistent with contemporary knowledge that
β-catenin is a core mediator of the canonical WNT signalling pathway. In the presence of WNT
molecule, β-catenin translocates from the cytoplasm to the nucleus, induces downstream target
genes, subsequently activating the canonical WNT pathway [9]; however, with absent or deactivated
WNT molecule, cytoplasmic β-catenin binds to the APC-Axin-CK1-GSK3β complex, otherwise called
destruction complex, leading to β-catenin phosphorylation [11]. The phosphorylated β-catenin is
degraded in the proteasome, thus, reducing β-catenin bioavailability [11]. Cadherin acts as a reservoir
for calcium-dependent adhesion-competent β-catenin when WNT signalling is inactivated [13].
Validating our hypothesis that CDH11 may promote β-catenin nuclear translocation and
WNT activation, we demonstrated that CDH11 modulates β-catenin expression levels and that
CDH11/β-catenin signalling axis plays a regulatory role for the canonical WNT signalling pathway in
TNBC (Figure 3), as concomitant decreased CDH11 and β-catenin in the TNBC cell was observed, with
siCDH11 cells exhibiting reduced CDH11/β-catenin nuclear co-localization compared to the control
WT cells (Figure 4). This is consistent with studies suggesting that the transcriptional suppression
of β-catenin was associated with inhibition of the WNT signalling activity in MCF-4 and A549 cell
lines [31]. Based on our immunofluorescence and IHC staining, CDH11 localizes in the membrane
and cytoplasm. In rheumatoid arthritis, matrix metalloproteinases (MMPs)- and γ-secretase- induced
cleavage induced CDH11 activity, through its release from the cytoplasmic domain and subsequent
nuclear translocation [32,33]. This in-part explains our observed nuclear co-localization of CDH11 and
β-catenin and subsequent WNT signalling activation.
Aside possessing the ability to self-renew and differentiate into heterogeneous tumor cells,
CSCs are implicated in the drug-resistance, relapse, distant metastasis and poor prognosis in TNBC
patients [34,35]. We demonstrated that CDH11 knockdown significantly reduces the size of formed
mammospheres, with concomitant downregulation of CSCs markers, Sox2, KLF4, CD44, and c-Myc
(Figure 5), which is consistent with previous findings showing that inhibition of the canonical WNT
signalling decreased Sox2 [36], CD44 [24], and c-Myc, as well as suppressed tumorsphere formation
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and inhibited tumor formation in xenograft tumor mice models [34,37]. Taken together, our results
highlight a modulatory role for the CDH11/β-catenin signalling axis in TNBC CSCs-like.
Having established the functional relevance of the CDH11/β-catenin signalling axis in TNBC
CSCs-like phenotype, we further confirmed that this axis modulates TNBC metastatic phenotype as
demonstrated by markedly suppressed migration and invasion ability of CDH-deficient TNBC cells
(Figure 5). This finding is consistent with the previously documented role of CDH11 in the promotion
of migration and invasion in colorectal and prostate cancer [38,39]. Finally, substantiating findings
from our in vitro assays, our in vivo studies highlight the putative potential of CDH11-targeting to
suppress tumorigenesis, and inhibit tumor growth in TNBC xenograft models, while concurrently
improving survival time (Figure 6 and Figure S2).
5. Conclusions
In summary, our findings highlight the critical roles CDH11 plays in TNBC. We demonstrate
for the first time, to the best of our knowledge, that by targeting β-catenin, CDH11 regulates the
canonical WNT signalling pathway, inhibits the CSCs-like and metastatic phenotypes of TNBC cells,
and represents a novel therapeutic approach in TNBC treatment. We herein provide a basis for further
exploration of CDH11 as a putative candidate for targeted therapy in triple negative breast cancer.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/2/148/s1,
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Abstract: L1 cell adhesion molecule (L1CAM) is aberrantly expressed in several tumor types where
it is causally linked to malignancy and therapy resistance, acting also as a poor prognosis factor.
Accordingly, several approaches have been developed to interfere with L1CAM function or to deliver
cytotoxic agents to L1CAM-expressing tumors. Metastatic dissemination, tumor relapse and drug
resistance can be fueled by a subpopulation of neoplastic cells endowed with peculiar biological
properties that include self-renewal, efficient DNA repair, drug efflux machineries, quiescence,
and immune evasion. These cells, known as cancer stem cells (CSC) or tumor-initiating cells,
represent, therefore, an ideal target for tumor eradication. However, the molecular and functional
traits of CSC have been unveiled only to a limited extent. In this context, it appears that L1CAM is
expressed in the CSC compartment of certain tumors, where it plays a causal role in stemness itself
and/or in biological processes intimately associated with CSC (e.g., epithelial-mesenchymal transition
(EMT) and chemoresistance). This review summarizes the role of L1CAM in cancer focusing on its
functional contribution to CSC pathophysiology. We also discuss the clinical usefulness of therapeutic
strategies aimed at targeting L1CAM in the context of anti-CSC treatments.
Keywords: L1CAM; cancer stem cells; chemoresistance; epithelial-mesenchymal transition; cancer
therapy; cell adhesion molecule
1. Background
The L1 cell adhesion molecule (L1CAM, also known as CD171) was described for the first time by
Schachner et al. in the central nervous system (CNS) [1]. In that context, L1CAM has been primarily
implicated in the development and plasticity of the nervous system, where it plays a pivotal role
in neuronal migration and differentiation, neurite outgrowth, axon guidance, fasciculation of axons
and dendrites, myelination, and synaptogenesis [2–4]. Accordingly, the knockout of the murine gene
results in profound neurological disorders [5,6], and mutations in human L1CAM are causally related
to a spectrum of CNS defects that are collectively defined as L1 syndrome [7].
Following the discovery of L1CAM, other closely related cell adhesion molecules (CAMs) have
been described, defining an L1 subfamily of which L1CAM is the archetype. In vertebrates, the L1
subfamily comprises four different members which share an analogous structural organization: Close
Homolog of L1 (CHL1), Neuronal Cell Adhesion Molecule (NrCAM), Neurofascin and L1CAM itself [8].
All these proteins, in turn, belong to the Immunoglobulin superfamily of CAMs (Ig-CAMs), which
owes its name to the presence of Ig-like domains in the extracellular portion of these proteins.
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2. Molecular Characteristics of L1CAM
2.1. Structural Determinants of L1CAM Interactions
L1CAM is a single-pass membrane glycoprotein with a molecular weight of 200–220 kDa which
exhibits three different portions: an extracellular domain, a transmembrane domain and a highly
conserved cytoplasmic domain (Figure 1a) [9].
 
Figure 1. L1 cell adhesion molecule (L1CAM) structures and interactions. (a) Schematic structure
of L1CAM, with the ectodomain comprising six Ig-like motifs (Ig1-Ig6, magenta ellipses) and
five Fibronectin type-III repeats (FN1-FN5, green squares), the transmembrane (blue line) and the
intracellular domain (black rectangle) (b) L1CAM homophilic interactions involve the FN3 repeat of
two consecutive molecules (cis) that form hydrogen bonds (red line). When the molecules are exposed
on two different cells, the involved residues can span between all the Ig-like motifs and FN2 or FN3
repeats (trans). For space limitations and clarity, only some homophilic bonds are displayed. See the
main text for more details. (c) L1CAM heterophilic interactions involve almost all extracellular domains,
with the specific domain depending on the partner. Only some examples of binding are shown here;
more details are available in the main text. A generic partner is depicted as a transmembrane protein
(violet rectangle: extracellular domain; yellow rectangle: intracellular domain). The two types of
heterophilic interaction can be concomitant (cis-trans). (d) L1CAM can acquire different conformations
during its interactions. The horseshoe structure is characterized by the bond between Ig-1 with Ig-4
and Ig-2 with Ig-3 that leads to a curvature of the molecule. Two horseshoe structures are connected by
Ig-1 and Ig-2 repeats of adjacent molecules. The extended conformation involves bonds between the
first four Ig structures of two neighbor L1CAM molecules. (e) More than two L1CAM molecules might
be connected acquiring a very complex conformation (zipper-like). The domain-swapped multimer
comprises interactions between Ig1 with Ig-4 and Ig2 with Ig-3. For space limitations and clarity, only
interactions with full-length L1CAM are displayed. See text for more details.
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The ectodomain comprises six N-terminal Ig-like motifs (Ig1–Ig6) followed by five fibronectin
type III repeats (FN1–FN5) [4,8]. These structural elements and their dynamic arrangements are crucial
to establish and drive the multiple interactions of L1CAM. Indeed, L1CAM exerts its function through
inter-molecular interactions that can be either homophilic (i.e., L1CAM-L1CAM) or heterophilic with
different partners. L1CAM can engage in cis-interactions, binding to another protein at the surface of
the same cell (Figure 1b,c), trans-interactions with a protein localized on an adjacent cell (Figure 1b,c),
or cis/trans-interactions where both events can occur simultaneously (Figure 1c) [10]. When these
interactions take place, the proteins involved may assume different structural conformations in order
to facilitate their binding that are illustrated in Figure 1. Su et al. predicted that L1CAM can acquire a
horseshoe quaternary structure (Figure 1d). Another possible conformation that L1CAM acquires is
the so-called extended quaternary structure (Figure 1d). Interestingly, these four domains are critical
for neurite outgrowth and L1CAM adhesive properties, even though additional sequences within all
the six Ig domains are required for an optimal activity [11–13]. Cryo-electron tomography studies also
revealed a more complex mode of homophilic interaction whereby horseshoes from L1CAM proteins on
opposing membranes meet as trans pairs, forming a lattice that is stabilized by protein-carbohydrate and
carbohydrate-carbohydrate interactions (Figure 1e) [14]. The existence of such horseshoe-dependent
structures is still controversial as some researchers attribute this conformation to a complicated mixture
of other quaternary structures at a higher level of complexity rather than to a structure per se [14].
2.2. L1CAM Interactions
L1CAM is devoid of enzymatic activity and, therefore, needs molecular effectors for transducing
intracellular signals and regulating the multiple processes in which it is involved. In this context,
L1CAM often couples with other cell-surface molecules that, instead, have the capability to activate a
downstream signaling. The proteins involved in a functional and/or physical interaction with L1CAM
belong to different classes including other Ig-CAMs (such as NCAM), proteoglycans (e.g., neurocan),
integrins, extra cellular matrix proteins (laminin), co-receptors (neuropilin-1), cytoskeletal proteins
(ankyrin), and Receptor Tyrosine Kinases (RTKs) such as Fibroblast Growth Factor (FGF) and Epidermal
Growth Factor (EGF) receptors. The main features of these interactions are summarized in Table 1.
Table 1. Homophilic and heterophilic L1CAM interactors. ND = not defined. *not conclusively
demonstrated but inferred from the data provided in the corresponding reference.
Interactors L1CAM Motif Involved Type of Interaction References
L1CAM Ig1-6, FN2-3 cis, trans [11,15–17]
NCAM Ig5 cis [18,19]
Neurocan Ig1 ND [20]
Integrins Ig6, FN3 cis [17,21,22]
Laminin Ig6* trans [23]
Neuropilin Ig1 cis, trans [10,24]
Ankyrin Cytoplasmic domain [25,26]
FGFR FN3, Ig1, Ig2 cis, trans [27]
EGFR FN5, Ig3* cis, trans [28]
2.2.1. L1CAM Interacting Partners and Functional Implications
L1CAM and NCAM interact with each other in cis [18,19,29]. This interaction allows L1CAM
to bind other L1CAM molecules in trans and, therefore, has been termed “assisted homophilic
binding”. This binding has synergistic effects on L1CAM-mediated cell aggregation and adhesion
in neuroblastoma cells [19,29]. L1CAM can also interact with neurocan [20,30]. The Ig6 motif of
L1CAM contains the highly conserved aminoacidic sequence Arg-Gly-Asp (RGD) that is crucial for
the cis interaction of L1CAM with αvβ3, αvβ1, α5β1, αvβ5, αIIBβ3 integrins [21,22,31]. The FN3 repeat
is also involved in the binding of L1CAM with integrins, in particular with α5β1, αvβ3, α9β1 [17].
The interaction with laminin occurs, although not exclusively, via the human natural killer-1 (HNK-1)
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carbohydrate [23]. The binding between L1CAM and Neuropilin-1 (NRP1 or NP-1) requires the
small aminoacidic motif FASNKL [10,24]. Castellani and collaborators showed that the switching of
semaphorin-3A (Sema3A)-induced axonal repulsion into attraction depends on cis vs. trans interactions
of L1CAM with NP-1, respectively. In this scenario, L1CAM and NP-1 could be considered as
co-receptors for Sema3A. Hence, this cis interaction is required as part of the Sema3A receptor complex
and is necessary for the switching mechanism [10]. The cytoskeletal protein ankyrin is a prominent
intracellular partner of L1CAM, and their interaction occurs through the highly conserved amino
acid motifs LADY and FIGQY [25,26]. In neurons, L1CAM interaction with ankyrin is critical for the
synaptic targeting of retinal axons and it also induces, in co-operation with EphrinB signaling, axon
branch attraction in vivo [32]. The first RTK proposed to interact with L1CAM (and other adhesion
molecules) is the fibroblast growth factor receptor (FGFR) [33]. Among the four members of the FGFR
family, the direct interaction with L1CAM so far has been demonstrated only for FGFR1 [27,34]. L1CAM
can also bind all the members of the EGFR family (erbB1-erbB4) [35]. When L1CAM trans interacts
with EGFR, the binding is very weak and is not sufficient per se for EGFR autophosphorylation, even
though a tyrosine kinase activity was detected at cell contact sites in D. melanogaster [36]. This implies
that cis interactions between the two types of molecules may be required to enhance L1CAM-induced
activation of EGFR. To note, a cis contact with erbB3 has been described in vivo [35].
2.2.2. The Regulation of L1CAM Interactions via Phosphorylation of the Cytoplasmic Tail
A key feature of L1CAM that can modulate its interactions is the phosphorylation of its cytoplasmic
domain. Three kinases have been implicated in this process: ERK2, c-SRC and PKCα. The first to be
identified was ERK2, a key player in the mitogen-activated protein kinase (MAPK) signaling, that
interacts physically with L1CAM. Schaefer et al. have found that ERK2 is able to phosphorylate
L1CAM at Ser1204 and Ser1248 n vitro, and suggested that this phosphorylation regulates the binding
of L1CAM to ankyrin [37]. L1CAM and ERK2 crosstalk is bidirectional, since L1CAM stimulates
ERK2 activation and MAPK signaling, most likely via FGFR. L1CAM-mediated ERK2 activation
has been proposed to occur upon L1CAM endocytosis since both L1CAM and ERK2 are present in
endocytic vesicles [37]. The second kinase implicated in L1CAM phosphorylation is the nonreceptor
tyrosine kinase c-SRC. The latter phosphorylates the Tyr1176 residue within the YRSLE motif [38] that is
required for endocytosis of L1CAM via clathrin-coated pits [39]. The authors have shown that Tyr1176
phosphorylation prevents L1CAM binding to clathrin-associated AP-2 complex, suggesting a model
whereby transient dephosphorylation of the YRSLE motif allows L1CAM endocytosis. Finally, protein
kinase C-alpha (PKCα) phosphorylates the Thr1172 residue within the L1CAM cytoplasmic domain, thus
regulating important properties of pancreatic adenocarcinoma cells such as motility [40,41]. Notably,
Thr1172 phosphorylation promotes conformational changes that, in turn, influence the interactions of
L1CAM even within its extracellular portion. For example, the binding to integrins is profoundly
affected by the phosphorylation status of Thr1172 [40,41]. It is worth mentioning, however, that these
studies relied principally on the use of recombinant proteins, and therefore need further validation in
more physiological settings.
In summary, L1CAM engages in interactions with a myriad of molecules that impinge on several
signal transduction pathways which, in turn, orchestrate fundamental aspects of cell physiology.
2.3. Proteolytic Processing of L1CAM
By analogy to other Ig-CAMs, L1CAM can be cleaved by several proteinases, a process that
regulates both the cell-autonomous and non-cell-autonomous signaling of the protein [42]. These
proteolytic events and the generated L1CAM fragments are summarized in Figure 2.
A cleavage site in the FN3 domain of L1CAM is recognized by the serine proteases PC5A, plasmin
and trypsin [43–45] (Figure 2a). The proteolytic action of these enzymes generates two fragments, one
of about 140-kDa and one of 80-kDa. Lutz and collaborators demonstrated the production of alternative
fragments of 135-kDa (soluble) and 70-kDa that comprise the intracellular and transmembrane domains
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and part of the extracellular domain (Figure 2a). The nuclear translocation of the 70-kDa fragment,
which involves sumoylation of the residue Lys1172, is mediated by importin, results from trafficking
via endosomes and depends on the presence of a nuclear localization signal encompassing Lys1147.
However, the authors did not investigate the possible role of nuclear L1CAM fragment in gene
transcription [46]. Besides the serine protease-mediated processing, the ectodomain of L1CAM
can be cleaved closer to the membrane, thus producing a bigger fragment of about 180-200 kDa
(Figure 2b). The proteases responsible for such process are Neuropsin, β-secretase 1 (BACE1) and
the metalloproteases ADAM10 and ADAM17 [47–51]. Notably, the two types of processing may
occur sequentially (Figure 2c). First, a fragment of 140-kDa is produced upon cleaving inside the FN3
domain. The remaining portion of the ectodomain is further processed to produce a soluble fragment
of 50-kDa [43]. Whatever protease accounts for the iuxtamembrane cleavage of L1CAM, in addition to
the above mentioned 180-200 kDa portion of the ectodomain, a 30-32 kDa fragment is always produced.
This, in turn, is further processed by γ-secretase resulting in a smaller fragment of 28 kDa that is released
from the membrane, translocates into the nucleus and triggers gene transcription [51]. However,
soluble L1CAM can also derive from events other than proteolytic cleavage. Indeed, Angiolini et al.
have recently described a novel, endothelial-specific isoform of L1CAM, that results from a peculiar
alternative splicing of its pre-mRNA. In particular, the splicing factor NOVA2 induces the skipping of
the exon that encodes the transmembrane domain, generating a soluble L1CAM that retains both the
extracellular and the cytoplasmic domains and is endowed with angiogenic activity [52].
 
Figure 2. Processing of L1CAM. (a) Full-length L1CAM undergoes a cleavage inside the FN3 repeat
by serine proteases PC5A, plasmin or trypsin. Thus, a soluble fragment of about 135-140 kDa (top)
and another of 75-80 kDa are produced. The former is released while the remaining fragment,
which comprises part of the ectodomain, the transmembrane domain and the cytoplasmic domain,
is internalized and imported into the nucleus via importin. (b) L1CAM is cleaved closer to the
membrane by neuropsin, BACE1 or ADAM10/17 proteases generating a soluble fragment of about
180–200 kDa (top) and one of 30 kDa. (c) The processes described in (a,b) can occur sequentially. First,
L1CAM is cleaved inside the FN3 repeat; a second cut occurs close to the membrane producing a
fragment of 50 kDa and another of 30-32 kDa, which remains anchored to the membrane. The latter is
further processed by γ-secretase and is released from the plasma membrane, eventually translocating
into the nucleus.
3. Clinical Relevance of L1CAM in Cancer Diagnosis and Prognosis
The definition of L1CAM’s role in cell motility and plasticity within the nervous system prompted
many groups to investigate whether the protein exerts an analogous role in different contexts. Numerous
studies focused on the function of L1CAM in tumor-related processes. Indeed, L1CAM has emerged
as a causal factor in tumor invasion and metastasis. Such a role is extensively described in a number
of excellent reviews [42,53,54] and will not be discussed here. We will mainly focus on the clinical
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relevance of L1CAM in cancer patients, and in particular on the correlation of its levels with the
prognosis, the diagnosis and other clinical parameters in certain cancer types (Table 2).
Table 2. L1CAM clinical relevance in cancer.




Endometrial cancer Negative (OS, DFS) High grade, lymph node metastasis, tumor relapse [55–60]
Ovarian cancer Negative (OS, DFS) Low tumor resectability, lymph node metastasis,chemoresistance, [61–64]
Melanoma Negative (DFS) Metastasis [65]
Breast cancer Negative (DFS) Larger tumor size, lymph node involvement,higher histologic grade, advanced TNM stage [66]
Gastric cancer Negative (OS, DFS) Distant metastasis [67]
Colon cancer Negative (OS) Advanced cancer stage, distant metastasis andtumor recurrence [68]
Pancreatic cancer Negative (OS) Lymph node involvement, vascular invasion,perineural invasion and higher degree of pain [69]
Non-small cell lung cancer Negative (PFS) None [70]
Kidney cancer Negative (OS) ND [71]
The potential of L1CAM as a prognostic factor has received great attention from investigators
working on gynecological tumors. Among these, the tumor in which the prognostic role of L1CAM
has been investigated most extensively is endometrial cancer.
Bosse et al. [55] evaluated L1CAM levels in a large retrospective cohort of early stage endometrial
cancer. They have found that patients with >10% tumor cells positive for L1CAM had a remarkably
shorter overall survival than those below that threshold. Smogeli et al. [56] found that, in the subgroup
of patients who did not receive adjuvant chemotherapy, L1CAM expression was significantly associated
with shorter disease-free survival and with risk of relapse in univariate analysis. In a different study
that analysed biopsies from 1134 endometrial cancer patients, L1CAM high expression predicted
poor disease-specific survival – defined as time from surgery to death – both in the entire cohort and
among low-risk patients, who normally receive no or limited adjuvant treatment [57]. Moreover, high
expression of L1CAM correlated significantly with the occurrence of lymph node metastases, both in
the whole patient population and in the low-risk subgroup. In addition, the authors evaluated the
serum level of soluble L1CAM (sL1CAM) in preoperative samples from a subgroup of 372 patients with
endometrial cancer. A higher amount of sL1CAM was detected in cancer patients with respect to healthy
controls, in line with previous studies [61]. High levels of sL1CAM predicted poor disease-specific
survival in both the entire cohort and in the low-risk group. sL1CAM levels were also predictive for
lymph node metastasis in the entire cohort. However, once adjusted for age, FIGO stage, histologic
type and grade, circulating sL1CAM levels failed to exhibit independent prognostic power.
L1CAM has also been assessed as a biomarker for preoperative risk factor stratification of
endometrial carcinoma. However, it did not significantly improve risk stratification when compared to
classical factors [72], implying that L1CAM should not be used to plan preoperative treatment. Another
study showed that L1CAM is highly expressed in recurrent respect to non-recurrent endometrial cancer
and correlates with lower disease-free survival [58].
A multicentric study named ENITEC, which involved 10 different European centers, assessed
L1CAM expression in 1199 cases that included early and late-stage endometriod endometrial cancers
(EECs) as well as non-endometriod endometrial cancers (NEECs) [59]. In early-stage EECs, L1CAM
expression was associated with grade 3 histology and lymphovascular space invasion (LVSI) while in
late-stage EECs its expression correlated also with the presence of nodal disease. Moreover, L1CAM
levels were associated with shorter disease-free and overall survival in both early and late-stage EECs.
Very recently, L1CAM expression was also found to correlate with distant recurrence in early-stage
endometrial cancer patients with negative peritoneal cytology, a subgroup that normally has a relatively
good prognosis [60].
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In the context of gynecological oncology, the clinical utility of L1CAM has also been extensively
studied in ovarian cancer (OC). In this tumor type, L1CAM shows a wide range of expression,
from a small fraction of cancer cells to high levels in most of the tumor mass (Figure 3a–c).
 
Figure 3. L1CAM levels in ovarian cancer. Three examples of high-grade serous ovarian cancer with
different levels of L1CAM are shown. L1CAM is visualized by immunohistochemistry on formalin-fixed
paraffin-embedded specimens. The protein is localized on the cancer cell membrane with levels that
range from (a) a minority of cells to (c) most of the tumor mass. The arrowheads in (b) show ovarian
cancer-associated vessels that are L1CAM-positive as previously described [56]. Scale bars: (a), 25 μm;
(b,c) 50 μm.
Fogel et al. reported the expression of L1CAM in poorly differentiated OC, where it acts as a
biomarker of worse prognosis [61]. Other groups have then confirmed the association of L1CAM
with bad outcome [42,62], although some studies have questioned the prognostic value of L1CAM in
OC [73]. Of note, L1CAM was consistently detected at the invasive front of OC [61,62,64], supporting
its role in tumor invasion.
In type-I ovarian cancer, often confined to the ovary and resulting in good prognosis, L1CAM
was assayed in patients with either endometriod or clear cell histotype [63]. The authors showed
that L1CAM levels correlated with poor disease-specific overall survival and disease-free survival
in endometrioid, but not in clear cell ovarian carcinomas. Moreover, overall survival was worse in
early-stage patients with high L1CAM levels, making L1CAM a potential stratification marker for
a high-risk subgroup among these putative good-prognosis patients. Although L1CAM alone did
not result in multivariate analysis as an independent prognostic factor for overall disease survival,
its positivity was associated with incomplete response to primary therapy in endometroid ovarian
cancer but, once again, not in the clear cell histotype [63]. Finaly, Altevogt and collaborators measured
the levels of both membrane and soluble L1CAM in a cohort of high grade serous ovarian cancer
patients [64]. They found that soluble L1CAM isolated from patients’ ascitic fluid correlated with poor
outcome in terms of PFS and showed a trend toward prolonged OS.
The correlation of L1CAM expression with poor prognosis is by no means limited to the
gynecological cancers described above. Indeed, L1CAM has been defined as a negative prognostic
factor in melanoma [65], breast cancer [66], gastric cancer [67], colon cancer [68], pancreatic cancer [69],
non-small cell lung cancer [70], kidney cancer [71], etc., as elegantly reviewed elsewhere [42,53,54].
In summary, the clinical utility of L1CAM as a diagnostic and prognostic factor has emerged from
many studies in different types of cancers, albeit with some controversial observations, which is in line
with its involvement in malignancy-associated features of tumor cells [42,53,54].
4. L1CAM Mechanism of Action in Stemness and in Stem-Related Processes
A common fate of all cancer patients, especially for those who have been diagnosed at late stage,
is that they undergo chemotherapy and/or radiotherapy. However, even in case of a satisfactory
response of the primary tumor to the treatments, many patients experience a disease relapse, and the
scenario is even worsened by the acquisition of chemoresistance which makes the recurrent tumor
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refractory to standard therapies. Tumor relapse and drug resistance are commonly attributed to a
subset of cells that, taking advantage of an armory of biological weapons, evade chemotherapy with
diverse resistance mechanisms. Such cell subpopulation appears related to cancer stem cells (CSC) [74].
This hypothesis is supported by certain characteristics of CSC such as: a low proliferative potential
that makes them insensitive to chemotherapy which usually targets actively dividing cells; increased
levels of molecular pumps that efflux drugs out of the cell; adaptation to inflammation; efficient DNA
repair; and altered apoptotic mechanisms [75].
CSC have been the subject of intense debate and controversy over the last two decades. Some
researchers refer to them as a transient state of tumor cells rather than a discrete subpopulation [76],
a concept strictly related to tumor cell plasticity; others are even questioning their existence [77,78].
According to many investigators, much of the controversy and skepticism around CSC derives from a
semantic issue, namely what criteria must be considered to define bona fide CSC [79]. As a matter of
fact, a subset of cancer cells with distinct tumor-initiating ability does evade the conventional therapies
and fuels tumor recurrence [80,81]. These features of CSC account for the common use of the term
cancer-initiating cells (CIC) as a synonym [82]. Collectively, there is a body of experimental and clinical
evidence that supports the existence and the pro-malignant function of cancer cells with stem-like
features [79].
4.1. L1CAM Function in CSC and Its Contribution to Cancer Stemness-Associated Processes
L1CAM has been linked to many CSC-related processes, yet only a few studies have demonstrated
its direct involvement in stemness. Tumor recurrence and metastasis is accompanied and fueled by
specific biological processes, such as the acquisition of chemoresistance and EMT, that have been found
to be intimately associated with cancer stemness [83]. Hence, it is not surprising that, due to its causal
role in CSC biology, L1CAM has been also implicated in these processes in cancer, even though these
studies were not always conducted on CSC subpopulations.
4.1.1. Glioblastoma
Similarly to what occurred during its discovery, the first connection of L1CAM with CSC was
found in the central nervous system [84]. Through a loss-of-function approach, the authors showed
that silencing L1CAM in glioblastoma stem cells (GSC), defined by CD133 expression, reduced their
growth and survival both in vitro and in vivo. They also described the underlying mechanism that
entails the loss of Olig2, caused by L1CAM silencing, and the upregulation of cyclin-dependent
kinase inhibitor p21WAF1/CIP1, which acts as a tumor suppressor [84]. In another study, Cheng and
coworkers showed that L1CAM regulates DNA damage responses and radiosensitivity of CD133+ or
CD15+ GSC through the nuclear translocation of its intracellular domain [85]. In particular, L1CAM
expression is induced by DNA damage, and is critical for the activation of ataxia telangiectasia
mutated (ATM) and of the downstream checkpoint proteins Chk2, Rad17, and Chk1, which repair
the DNA as part of the DNA damage response signaling pathway [86]. Mechanistically, the portion
of L1CAM involved in this process is the highly conserved cytoplasmic domain that acts as signal
transducer upon DNA damage, regulating NBS1 expression through c-Myc to enhance DNA damage
checkpoint activation. The findings discussed above might implicate L1CAM as a potential marker of
glioblastoma CSC. Indeed, L1CAM has been frequently employed to identify stem-like population
in glioblastoma [84,85,87,88]. Nevertheless, CSC-related functions, such as tumor initiation and
self-renewal abilities, have not been defined yet by comparing L1CAM-positive and L1CAM-negative
subpopulations of glioma cells [89]. Thus, the role of L1CAM as a GSC marker remains to be
conclusively demonstrated.
Glioblastoma provides also a prototypical example of L1CAM’s role in chemoresistance [90].
Held-Feindt et al. started from the earlier observation that TGF-β1 is a potent inducer of L1CAM
expression in tumor cells [91,92]. Notably, these authors employed clinically relevant models of primary
tumor cells and cultivated them as suspension neurospheres as a tool to enrich for glioblastoma stem-like
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cells. They showed that L1CAM promoted chemoresistance to temozolomide, which was mediated
by TGF-β1 and led to the down-regulation of caspase-8 in both stem-like and bulk glioblastoma cells.
These data raised the question of whether chemoresistance is restricted to CSC compartment only or
rather it can also be ascribed to non-stem subpopulations. However, it is appropriate to point out that
the cells used in the study derived from the differentiation of stem-like cells. It is conceivable, in this
case, that such differentiated cells might have retained chemoresistance as an imprinting from their
stem state.
4.1.2. Colorectal Cancer
The identification of L1CAM as a target ofβ-catenin/TCF signaling in colorectal cancer (CRC) [93,94]
paved the way to the definition of its role in CRC stem cells. Gavert et al. [95] observed initially
that, while the ectopic expression of L1CAM enhanced CRC metastasis, likely via the activation of
NF-κB signaling, L1CAM was not co-expressed with the CRC stem cell markers EpCAM, CD133 and
CD44. However, L1CAM was subsequently reported to be expressed in LGR5+ CRC stem cells, where
it promoted metastatic dissemination through the induction of the clusterin gene (CLU), an event
independent from NF-κB signaling [96]. In particular, L1CAM enhanced the transactivation of CLU by
the transcription factor STAT-1. The link between L1CAM and STAT-1, however, remains to be defined
at the molecular level. The role of L1CAM in CRC stemness has also been investigated by Basu et al.
who focused on the Wnt target gene and transcription factor Achete scute-like 2 (ASCL2), a key
regulator of stemness that is exclusively expressed in LGR5+ intestinal stem cells [97,98]. Basu et al.
implicated ASCL2 as an L1CAM effector in CRC progression [99]. Indeed, L1CAM expression in
human CRC cells dramatically increased the expression of ASCL2 which, in turn, was required for
L1CAM-induced CRC cell proliferation, motility and tumorigenesis. Finally, L1CAM and ASCL2 were
found to co-localize in human CRC tissue, suggesting a possible cooperation in conferring a more
invasive phenotype to CRC cells. A very recent study has provided compelling evidence that high
L1CAM expression marks a subpopulation of CRC cells with tumor propagation, metastasis-initiating
and chemoresistance features [100]. Intriguingly, L1CAMhigh cells partially overlapped with LGR5+
CRC stem-like cells. In this context, L1CAM expression was not only a biomarker but also a prerequisite
for metastasis initiation and chemoresistance. Ganesh et al. also provided mechanistic insights into
the upregulation of L1CAM by showing that the loss of E-cadherin-dependent epithelial integrity
releases L1CAM from the transcriptional repression operated by REST, a factor that prevents L1CAM
expression in non-neuronal tissues [100]. Very recently Fang et al. correlated L1CAM with pERK 1/2
levels in CRC lymph node metastasis [101]. The authors showed that L1CAM expression in tissue
samples increased from poorly differentiated through well differentiated CRC reaching the highest
levels in metastatic CRC tissue. The same behavior was observed for pERK 1/2. Future work should
clarify whether the positive correlation between L1CAM and pERK levels reflects a functional link and
whether L1CAM-regulated ERK signaling contributes to CRC dissemination.
4.1.3. Pancreatic Cancer
L1CAM-associated chemoresistance has also been proposed in pancreatic cancer. Lund and
collaborators generated a pancreatic carcinoma cell line resistant to the chemotherapeutic 5-Fluorouracil
(5-FU) and, upon transcriptomic profiling, identified L1CAM interaction pathway as one of the
top-ranking hits among 319 upregulated genes [102]. Silencing L1CAM resulted in decreased invasiveness
of the 5-FU resistant cell line. Driven by their microarray data and by previous observation in pancreatic
cancer [92], the authors knocked down Slug and β-catenin in chemoresistant cells and found that the
former, but not the latter, modulates L1CAM protein levels. Yet whether a Slug/L1CAM axis accounts
for chemoresistance in pancreatic carcinoma remains to be investigated.
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4.1.4. Gynecological Cancers
Among tumors of the gynecological tract, the role of L1CAM in cancer stemness has been studied
in ovarian and endometrial carcinoma. A study conducted on ovarian cancer cell lines revealed
that L1CAM, in combination with CD133, marks a subpopulation of ovarian CSCs [103]. In light of
the known correlation of L1CAM with ovarian cancer aggressiveness [61,62], these findings, once
confirmed in patient-derived tissue, might implicate L1CAM/CD133-positive CSC in the malignant
properties of this tumor type. Furthermore, the repertoire of ovarian CSC-associated markers is still a
highly debated and controversial issue [82], and L1CAM may offer a new tool for the unequivocal
identification of this elusive cell population. The study on L1CAM+/CD133+ ovarian CSCs showed
also, through the genetic manipulation of ovarian cancer cell lines, that L1CAM is causally involved
in CSC-associated radioresistance as well as in self-renewal and tumor initiation. Further research,
however, should aim at elucidating the underlying molecular mechanisms.
In ovarian cancer cells, the L1CAM gene was found to be under the regulation of TWIST1,
a transcription factor that is causally linked to increased tumorigenicity as well as resistance to
cisplatin [104]. Indeed, L1CAM was upregulated upon the forced expression of TWIST1 and, more
important, it was required for TWIST1-induced chemoresistance. Mechanistically, upon cisplatin
treatment, L1CAM silencing partially prevented Akt activation, which was a key player in cisplatin
resistance of ovarian cancer cells. These data, therefore, pointed to a TWIST1/L1CAM/Akt signaling
pathway that drives chemoresistance in ovarian cancer.
As discussed earlier, L1CAM correlates with malignancy in endometrial cancer. In agreement
with those observations, recent studies have established a link between L1CAM and endometrial
cancer stemness [105]. The authors observed first that L1CAM promotes epithelial-mesenchymal
transition (EMT) as exemplified by the concomitant downregulation of E-cadherin and induction of
vimentin. Given the well-established association between EMT and cancer stemness [83], the authors
then investigated CSC-related features. They found that L1CAM-expressing cells exhibit resistance to
anoikis and higher clonogenic potential in non-adherent conditions, two peculiar features of CSC [82].
Moreover, L1CAM expression was accompanied by the upregulation of Musashi-1 and CD133, both
considered to be CSC markers in endometrial cancer [106].
4.1.5. Retinoblastoma
Recently, L1CAM has been reported to be both sufficient and necessary for conferring
chemoresistance to retinoblastoma, the most common intraocular cancer in children [107]. Proteins
related to apoptosis and multi-drug resistance (MDR) are frequently involved in the resistance of cancer
cells and CSCs to chemotherapy [108–110]. Along this line, L1CAM depletion in retinoblastoma cells
resulted in a marked increase of the pro-apoptotic proteins which cleaved caspase-3 and cytochrome C,
whereas the anti-apoptotic proteins Bcl-2, Bcl-xL, and pro-caspase-3, were reduced. Moreover, the drug
efflux pumps ABCA1, ABCB1, ABCC2, and ABCG2 were significantly reduced in L1CAM-depleted
cells whereas L1CAM overexpression increased their levels.
4.1.6. L1CAM Impact on Stemness-Related Features of Tumor Microenvironment
The contribution of L1CAM to tumor development can also occur via the modulation of
stemness-related properties within the tumor microenvironment, which in turn modulates cancer
cell behavior in a non-autonomous manner. For example, in tumor endothelium L1CAM promotes
endothelial-to-mesenchymal transition (EndMT), a phenomenon reminiscent of EMT [111]. In this
context, L1CAM induces the expression, among many other genes, of KLF4 and CD44, both well-known
as stemness-associated factors. EndMT generates cells that retain the properties of multipotent stem
cells and can differentiate into several cell types (e.g., fibroblast, pericyte, bone, etc.) [112]. Furthermore,
EndMT produces key cellular components of the tumor microenvironment such as cancer-associated
fibroblasts that support tumor progression [113]. This might open a novel scenario whereby L1CAM
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could also orchestrate stemness in the tumor microenvironment, adding a further layer of complexity
to its role in cancer progression.
4.1.7. L1CAM Expression Obtained by Omics Data Unveiled its Involvement in CSC Processes
By comparing cancer stem cell genetic profile with their non neoplastic counterpart, L1CAM
emerged very frequently altered. These data endorse the crucial role of the adhesion molecule in cancer
stem cells.
Nakata et al. demonstrated that LGR5 gene is associated with stem features in glioblastoma [114].
A transcriptomic analysis of LGR5-silenced glioblastoma stem cells showed that L1CAM is
downregulated and therefore is regulated by LGR5, altough the molecular mechanism remains
to be elucidated. In another study, Okawa et al. profiled and compared the proteome and secretome
of glioblastoma multiforme stem cells (GNS) and normal neural stem cells [115]. The authors found
that several CSC markers were enriched in the glioblastoma stem cell population, and L1CAM was
one of them. Interestingly, L1CAM was found aberrantly expressed both in the secretome and in the
cell-associated proteome of GNS, suggesting that its function is specifically involved in the stem cell
compartment of glioblastoma.
Finally, Gemei et al. analyzed the genetic profile of the 3AB-OS osteosarcoma cell line that is an
immortalized CSC line and represents the stem component of MG63 parental cell line used for genetic
comparison [116]. L1CAM was among the genes whose expression increased in the c3AB-OS cell line
with respect to the differentiated MG63.
A transcriptomics profile combined with high-throughput flow cytometry was conducted on
self-renewing (i.e., stem-like) and non-self-renewing cells from the sonic hedgehog (SHH) subgroup
of medulloblastoma. In this case, unlike the studies reported above, L1CAM was found specifically
downregulated in CSCs at both gene and protein levels [117]. This suggests that the expression of
L1CAM as a CSC-associated marker is tumor type-dependent, and in certain tumors L1CAM can even
mark selectively the non-stem cancer cell population.
In conclusion, several studies have provided compelling evidence that implicates L1CAM, directly
or indirectly, in the regulation of CSC pathophysiology. Yet none of them have conclusively indicated
or demonstrated L1CAM to be a CSC (or CIC) marker. Therefore, the jury is still out on the use of
L1CAM for the isolation, identification and characterization of the CSC compartment in clinically
relevant settings.
4.2. Beyond Cancer: L1CAM in Normal Stem Cells
Besides the role of L1CAM in cancer stemness, it is worth mentioning that a few studies have
implicated the molecule also in normal stem cells. Son and collaborators [118] demonstrated that
the stem cell markers octamer-binding transcription factor 4 (Oct4), Nanog, sex-determining region
Y–box 2 (Sox2), forkhead box protein D3 (FoxD3), and SSEA-3 were downregulated in L1CAM-depleted
human embryonic stem cells (hESC). Conversely, the same genes resulted in being upregulated in
L1CAM-overexpressing hESC. L1CAM-depleted hESC displayed also an increased expression of
lineage markers (i.e., Olig2, GFAP, Pax6 as ectoderm marker; CD31, T-Branch, LEF1 as mesoderm
marker; FOXA2, GATA4, SOX17 as endoderm marker). Moreover, the authors showed that L1CAM is
essential for hESC pluripotency. In particular, when normal H9 cells were differentiated into embryoid
bodies (EBs) most lineage markers did not increase in L1CAM-depleted cells whereas they were
upregulated in control cells. Mechanistically, FGFR1 appeared to be involved in this process, although
the exact mechanism remains to be elucidated. L1CAM formed a complex with FGFR1 and a reduced
activation of FGFR1, ERK and AKT was observed in L1CAM-depleted cells [118]. Another study,
performed on murine ESC (mESC), showed that L1CAM is required for neuronal differentiation of
mESC and depends on the fucosyltransferase FUT9 and sialyltransferase ST3Gal4 through a signaling
pathway that involves the activation of phospholipase C-gamma (PLCγ) [119]. It remains unclear
whether the discrepancy between the impact of L1 in hESC, where it sustains stemness, and mESC,
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where it promotes differentiation, reflects a species-specific role of L1 in ESC or rather depends on
different experimental conditions between the two studies.
Further complexity is added by a recent study on L1CAM in human neural progenitors (hNP).
In this context, the ectopic expression of L1CAM extracellular domain altered differentiation and
motility in hNP without affecting cell proliferation [120]. L1CAM-expressing hNP lost their progenitor
status and became committed to differentiation. Interestingly, these authors co-cultured hNP with
chick embryo brain cells to assess phenotype alterations in a more complex microenvironment. In these
culture conditions L1CAM ectodomain again promoted the loss of the progenitor phenotype and
induced the differentiation of hNP towards astrocytes. Taken together with the stemness-sustaining
role of L1CAM in hESC (see above), these findings on promoting commitment in hNP might imply
that the outcome of L1CAM expression is cell context-dependent.
5. L1CAM as a Therapeutic Target
The expression pattern of L1CAM in cancer and its functional role in CSC point to this molecule
as a viable target for novel therapeutic strategies. While no attempts have been reported yet to test
the druggability of L1CAM in CSC, several studies have supported the potential of L1CAM-targeted
treatments in different tumor types, as summarized in Table 3. The three main strategies that have
been designed for this purpose are illustrated in Figure 4 and described below.
Table 3. L1CAM-targeted therapeutic approaches in different cancers.
Cancer Type Therapeutic Strategy Antibody Clone Effect References
Ovarian cancer Antibody alone chCE7, L1-11A ↓ Proliferation↓Migration [121]
Ovarian cancer Antibody alone CE7 ↓ Proliferation [62]
Ovarian cancer Antibody alone L1-9.3 ↓ Tumor growth↑ Survival [122]
Melanoma
Pancreatic cancer Antibody alone L1-9.3
↓ Tumor growth
EMT induction [123]
Cholangiocarcinoma Antibody alone cA10-A3 ↓ Tumor growth [124]
Pancreatic cancer Antibody + gemcitabine L1-14.10, L1-9.3 ↓ Tumor growth↑ Apoptosis [125]
Ovarian cancer Antibody + paclitaxel L1-14.10, L1-9.3 ↓ Tumor growth↑ Apoptosis [125]
Cholangiocarcinoma Antibody + gemcitabine Ab417 ↓ Tumor growth [126]
Cholangiocarcinoma Antibody + cisplatin Ab417 ↓ Tumor growth [126]
Ovarian cancer Radioimmunoconjugate 177Lu-DOTA-chCE7 ↑ Survival [127]
Ovarian cancer Radioimmunoconjugate 161Tb-chCE7 ↓ Tumor growth [128]






Ovarian cancer Radioimmunoconjugate + paclitaxel 177Lu-DOTA-chCE7
↑ Survival
Tumor growth delay [131]
Ovarian cancer Radioimmunoconjugate + proteinkinase inhibitor
177Lu-DOTA-chCE7
↓ Proliferation
↓ Tumor growth [132]
Neuroblastoma CAR-T cell CE7R Various responses [133]
Ovarian cancer CAR-T cell CE7R ↓ Tumor growth↓ Ascites [134]
Retinoblastoma CAR-T cell CE7R Cytotoxicity [135]
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Figure 4. L1CAM is a viable therapeutic target in cancer. Three strategies for targeting L1CAM in
cancer cells are depicted. Such strategies are based on neutralizing antibodies, radioimmunoconjugates
or chimeric antigen receptor-redirected T (CAR-T) cells. These treatments, alone, or in combination
with chemotherapy, result in the reduction of tumorigenicity due to increased apoptosis and cytotoxic
effects, possibly accompanied by increased immune infiltration into the tumor site. Based on the
expression and function of L1CAM in cancer stem cells, these L1CAM-targeted approaches may prove
effective anti-CSC strategies, as illustrated in the figure. See the main text for more details.
5.1. Monoclonal Antibodies
In many cases, L1CAM-targeted approaches have relied on neutralizing antibodies (Figure 4).
The latter, for example, exhibited a remarkable potential as antitumor agents in preclinical models
of ovarian cancer. Arlt et al. induced antibody-mediated reduction of proliferation and migration
in vitro as well as tumor growth in vivo using two independent anti-L1CAM monoclonal antibodies
(chCE7 and L1-11A) [121]. We have also reported a reduction of proliferation in IGROV1 cells upon
anti-L1CAM monoclonal antibody CE7 treatment [62]. Wolterink and coworkers generated novel
monoclonal L1CAM antibodies [122]. The selected clone L1-9.3 inhibited SKOV3ip tumor growth,
increasing mouse survival. The transcriptome analysis of treated mice revealed also that L1-9.3
treatment could interfere with apoptotic and tumor growth pathways. To note, the treatment with
L1-9.3 was accompanied by massive monocyte infiltration, and monocyte depletion via clodronate
liposomes abolished the therapeutic effect of the antibody. This role of monocytes in the response to
L1CAM-mediated immunotherapy would be consistent with a crosstalk between L1CAM and the
tumor immune microenvironment. Such a hypothesis was further supported in preclinical models
of pancreatic cancer. Sebens and collaborators [136] demonstrated that L1CAM induced an immune
suppressive phenotype in malignant pancreatic ductal adenocarcinoma (PDAC). In particular, T-regs,
but not T-effs, were more prone in migrating on L1CAM expressing H6c7 and Panc1 cells. Moreover,
in such microenvironment T-effs reduced their proliferation and inhibited autologous T cell proliferation.
L1CAM promoted the establishment of a microenvironment that could favor immune escape and
might contribute to tumor progression and chemoresistance [136].
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The therapeutic effects of anti-L1CAM antibodies were also assessed in melanoma and pancreatic
carcinoma. Doberstein et al. evaluated the therapeutic efficacy of anti-L1CAM treatment on the
syngeneic tumor models RET (melanoma) and Panc02 (pancreatic adenocarcinoma), both genetically
manipulated to express L1CAM [123]. They also employed the clone L1-9.3 and confirmed both the
antibody-mediated reduction of tumor growth and the involvement of immune effector mechanisms
in its anti-tumor effect. In addition, the authors showed that anti-L1CAM treatment induced EMT
via EGFR phosphorylation. Another study reported cytotoxicity and anti-tumor activity of L1CAM
chimeric antibody cA10-A3 in a mouse model of intrahepatic cholangiocarcinoma [124]. Of note,
despite L1CAM expression in the nervous system and other body districts, no signs of behavioral
changes or other signs of toxicity were reported with the use of anti-L1CAM antibodies for all the
studies presented here. This supports the potential clinical utility of such tools as antitumor strategy.
As outlined in Section 4.1, L1CAM is causally related to chemoresistance in various cancer types,
which suggests that interfering with L1CAM function may enhance the response to other treatments.
Indeed, anti-L1CAM antibodies improved the efficacy of chemotherapeutic drugs in preclinical models
of ovarian and pancreatic cancer [137]. The authors employed two different anti-L1CAM antibodies:
L1-14.10 and L1-9.3. Pancreatic adenocarcinoma Colo357 and ovarian cancer SKOV3ip cell lines
were treated with both antibodies in combination with either gemcitabine or paclitaxel, respectively.
The addition of anti-L1CAM inhibited tumor growth much more than chemotherapy alone and
increased apoptosis. Lower levels of NF-κB were observed upon combo treatment along with a
reduction in vascular endothelial growth factor (VEGF) production and CD31-positive vessels. To note,
increased monocyte infiltration was also observed in this study upon combination treatment. Along
the same line, Cho et al. have demonstrated that treating intrahepatic cholangiocarcinoma (Choi-CK)
xenograft mouse model with gemcitabine or cisplatin in combination with anti-L1CAM antibody Ab417
inhibited tumor growth [126]. The combination of L1CAM antibodies with conventional chemotherapy
or other targeted approaches remains an area of research that may have relevant implications and
deserves further investigation.
5.2. Radioimmunoconjugates
Besides these strategies for functional inactivation, the expression pattern of L1CAM in cancer
suggests that anti-L1CAM antibodies may also be harnessed to deliver cytotoxic agents to tumor cells.
It is rather surprising, in this regard, that no reports are available in the literature about antibody-drug
conjugates based on L1CAM. In fact, L1CAM undergoes endocytosis [39], which is enhanced by
antibody binding [138,139], supporting the hypothesis that antibody-drug conjugates would represent
suitable tools against L1CAM-expressing cancer cells.
Anti-L1CAM antibodies, instead, have been widely used in preclinical models of ovarian
carcinoma and other tumor types as radioimmunotherapy tools upon conjugation with different
radioactive isotopes (Figure 4). Fischer et al. used a chimeric anti-L1CAM monoclonal antibody
(chCE7) conjugated with 1,4,7,10-tetraazacyclododecane-N-N’-N’-N′′′-tetra acetic acid (DOTA) and
labeled with the low-energy β-emitter lutetium-177 (177Lu) to treat human ovarian cancer-bearing mice.
A single treatment with 177Lu-DOTA-chCE7 was able to increase mice survival upon subcutaneous
injection of SKOV3.ip1 [127]. Grünberg and coworkers showed that the treatment of nude mice
bearing IGROV1 xenografts with terbium-161-labelled chCE7 increased radiotoxicity in respect to the
radioimmunoconjugate alone [128]. In the neuroblastoma model SK-N-SH, the efficacy of Iodine-131
(131I)-labelled chCE7 was compared with that of 131I-metaiodobenzylguanidine (MIBG), currently used
for treating recurrent or refractory neuroblastoma [129]. 131I-MIBG was less effective than 131I-chCE7
in reducing tumor volume although none of them abolished tumor growth. Both treatments elicited
a transient response since, after the initial reduction, more pronounced for 131I-chCE7, the tumor
started to regrow reaching the starting volume. Interestingly, both molecules were also tested as
imaging tools in seven patients with recurrent neuroblastoma. The two imaging approaches were
complementary in targeting the tumor and therefore the authors proposed their use in a combined
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radioimmunotherapy [129]. Another group has recently conjugated the anti-L1CAM antibody cA10-A3
with 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) labelled with 177Lu and evaluated its efficacy
in cholangiocarcinoma [130]. The treatment with 177Lu-NOTA-cA10-A3 of mice xenografted with
L1CAM-overexpressing SCK-L1 cells reduced tumor volume by promoting cell apoptosis and reducing
cell proliferation.
In addition, radio-labelled L1CAM antibodies have also been employed together with other drugs.
Lindenblatt et al. coupled 177Lu-DOTA-chCE7 with paclitaxel treatment. They reported a synergistic
inhibitory effect on IGROV1 viability via cell cycle arrest in the radiosensitive G2/M phase [131].
The combined treatment prolonged survival and also delayed tumor latency in vivo. In another study,
the same group combined 177Lu-DOTA-chCE7 with protein kinase inhibitors (PKIs) to treat ovarian
cancer [132]. Among five compounds (alisertib, MK1775, MK2206, saracatinib, temsirolimus), they
selected MK1775 for further characterization due to its higher efficacy. The combination of MK1775
with 177Lu-DOTA-chCE7, administering either the PKI firstly or both compounds at the same time,
synergistically reduced IGROV1 proliferation. The treatment induced DNA double strand breaks
in IGROV1 cells, as reflected by histone H2A.X phosphorylation at Ser-139 (γH2A.X), resulting in
tumor cell apoptosis. γH2A.X foci were also found in SKOV3ip xenografts upon treatment with
either MK1775 alone or in combination with the radioimmunoconjugate. The combined treatment
reduced tumor volume in mouse xenografts with respect to the PKI alone, even if the treatment with
only 177Lu-DOTA-chCE7 was sufficient by itself to reduce tumor growth to a similar extent [132].
A comparison of these findings with those obtained by combining 177Lu-DOTA-chCE7 with paclitaxel
(see above) will help to inform future therapeutic strategies. Overall, these data support the feasibility
of combination treatments based on L1CAM radioimmunoconjugates as efficacious strategies.
Besides radioimmunotherapy, the conjugation of L1CAM antibodies with various radioisotopes
has generated reagents that found interesting applications in tumor imaging. Indeed, the successful
detection of neoplastic lesions has been reported not only in preclinical cancer models [130,140,141]
but also in patients as described above [129]. Due to the expression and function of L1CAM in cancer
stem cells for some tumors, the possibility of imaging this cell subpopulation might be of help not only
for prognostic purposes but also to monitor the evolution of the disease.
5.3. CAR-T Cells
L1CAM has also been investigated as a target for cellular therapies based on the adoptive transfer
of chimeric antigen receptor-redirected T (CAR-T) cells (Figure 4). This approach dates back to 1993
and was first published by the immunologist Zelig Eshhar [142]. Since its first application, CAR-T
cell therapy proved to be an intriguing approach and today has become of paramount importance
for liquid cancers where it offers a successful therapeutic strategy [143,144]. It is based on the ex vivo
isolation of tumor-reactive T lymphocytes engineered to express a chimeric antigen to redirect against
the tumor. However, such a strategy quickly became of interest for its potential also in solid tumors
where it was pioneered by Jensen et al. in neuroblastoma patients [133]. The authors generated CAR-T
cells co-expressing an L1CAM-specific chimeric receptor (CE7R) and the fusion gene encoding the
selection-suicide enzyme hygromycin phosphotransferase–thymidine kinase (HyTK). These CAR-T
cells were then tested in a phase-I clinical trial for children with recurrent/refractory neuroblastoma.
Treated patients did not show any sign of overt toxicity. Despite that the study’s primary endpoint
was limited to safety of the treatment, the authors also monitored patients’ response. Among the
six patients who underwent adoptive CAR-T cell therapy, one patient had first a stable disease and then
a partial response, one patient displayed a complete response and another patient had stable disease.
However, among the six patients only one experienced a prolonged survival. Subsequent studies also
supported CAR-T therapy feasibility in other neoplasms. Hong et al. evaluated the applicability of
L1CAM-based CAR-T cells in ovarian cancer [134]. The authors showed that CE7R T-cells were able
to kill a panel of human ovarian cancer cell lines. Moreover, CE7R T-cells also recognized and killed
ascites-derived primary cells. In SKOV3 xenograft mice, the treatment significantly inhibited tumor
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growth and reduced ascites production compared to control mice. Andersch et al. employed CAR-T
cells co-targeting both L1CAM and the GD2 ganglioside in retinoblastoma cell lines, and reported
that this approach led to elimination of tumor cells in vitro [135]. Interestingly, they also described
an escape mechanism whereby retinoblastoma cells downregulate the expression of both antigens
after CAR-T treatment. Further validation of this approach using in vivo preclinical models will
undoubtedly provide important insights into its clinical utility.
In summary, various studies conducted on different tumor types have shown the remarkable
potential of L1CAM-targeting strategies for the design of innovative antitumor therapies.
6. Potential Implications and Clinical Perspectives of L1CAM in Cancer and CSC
Many lines of experimental and clinical evidence support the potential relevance of L1CAM
in the management of tumor patients. For example, as outlined in Section 2.2.2, the ectodomain of
L1CAM is released into the extracellular space upon proteolytic cleavage. This raises the possibility
that shed L1CAM becomes detectable in blood and other body fluids. Indeed, several studies found
a correlation between soluble L1CAM levels in liquid biopsies from cancer patients and different
clinical parameters [57,61,144,145]. Along these lines, we have recently found a novel soluble isoform
of L1CAM, endowed with angiogenic functions, that lacks the transmembrane domain and is released
in the extracellular space. The levels of this isoform resulted in being associated with vessel density in
ovarian cancer specimens suggesting an implication also in tumor angiogenesis [52]. Thus, L1CAM is
a promising non-invasive biomarker with diagnostic and prognostic value.
The expression pattern of L1CAM in many different cancer types as well as its pivotal role in
diverse tumor-related cellular processes, including cancer stemness, makes it a suitable target for
antitumor therapies. Indeed, L1CAM-targeted therapies resulted in multiple advantages, among which
are counteracting tumor cell invasion, EMT and metastasis initiation, and pro-malignant interactions
between tumor cells and their microenvironment. Based on the studies discussed in the previous
sections, this list should also include the inhibition of CSC function.
Yet, with the exception of a phase-I trial with CAR-T cells in neuroblastoma patients ([133], see
also Section 5), to date no L1CAM-based treatments have reached clinical use, although there are
biotech companies that are actively pursuing this goal. Future efforts in this direction should take
into account various aspects, including, for example, the potential side effects of L1CAM-targeted
treatments. The protein, indeed, is abundantly expressed in the nervous system as well as in other cell
types of various organs (e.g., the hematopoietic system and various epithelia). While no studies on
preclinical models have reported signs of overt toxicity of anti-L1CAM agents, additional early-phase
clinical trials are warranted to validate these findings in humans.
Finally, by analogy to several targeted treatments, it is unlikely that any L1CAM-based strategy
would give satisfactory results as a monotherapy. We believe that L1CAM-targeted treatments should
be considered in the context of combination therapies. This view is supported, for example, by the
reported role of L1CAM in conferring chemoresistance to cancer cells (see Section 4.2), which implies
that neutralizing L1CAM would restore sensitivity to conventional antitumor drugs. Furthermore,
emerging evidence (mentioned in Section 5.1) also points to a crosstalk of L1CAM with the tumor
immune microenvironment which contributes to immune evasion. Hence, one can speculate that
L1CAM inactivation synergizes with immunotherapy in overcoming the ability of many tumors to
escape the immune attack.
So far, L1CAM has not been investigated as a target in the context of therapies directed against CSC.
Yet the expression pattern and the role of the molecule in this subpopulation of tumor cells provide the
rationale for assessing the impact of L1CAM-targeted treatments on CSC function. Indeed, L1CAM
may represent an Achilles heel for such a cell population. As outlined above, a few strategies have been
designed to either interfere with L1CAM activity or deliver antitumor agents to L1CAM-expressing
cells. Thus, it will be of interest to test whether such strategies impact on tumor stemness and on
CSC-related properties such as self-renewal, chemoresistance and cancer initiation. Given the role
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of L1CAM in CSC, it is intriguing to envisage L1CAM-based strategies to target this cancer cell
subpopulation. However, based on the functional contribution of CSC to tumor metastasis and relapse,
the therapeutic window becomes a key factor in order to achieve better efficacy. One can expect, in this
regard, a lower effect in the neoadjuvant treatment of a primary tumor as compared to the prevention
of metastatic dissemination or tumor recurrence.
Future research will clarify if and to what extent L1CAM targeting represents a suitable strategy
for innovative antitumor therapies, focusing in particular on the opportunity of defeating CSC-driven
metastasis, relapse and drug resistance, thus contributing to tumor eradication.
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Abstract: Ovarian cancers represent the deadliest among gynecologic malignancies and are
characterized by a hierarchical structure with cancer stem cells (CSCs) endowed with self-renewal
and the capacity to differentiate. The Wnt/β-catenin signaling pathway, known to regulate stemness
in a broad spectrum of stem cell niches including the ovary, is thought to play an important role
in ovarian cancer. Importantly, Wnt activity was shown to correlate with grade, epithelial to
mesenchymal transition, chemotherapy resistance, and poor prognosis in ovarian cancer. This review
will discuss the current knowledge of the role of Wnt signaling in ovarian cancer stemness, epithelial to
mesenchymal transition (EMT), and therapy resistance. In addition, the alleged role of exosomes
in the paracrine activation of Wnt signaling and pre-metastatic niche formation will be reviewed.
Finally, novel potential treatment options based on Wnt inhibition will be highlighted.
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1. Introduction
Epithelial ovarian cancer (EOC) represents the deadliest among gynecologic malignancies [1].
This is mainly due to the fact that up to 80% of ovarian cancer patients present with symptoms and are
subsequently diagnosed only at late disease stages, i.e., when metastases have already spread to pelvic
organs (stage II), the abdomen (stage III), or beyond the peritoneal cavity (stage IV) [2].
EOC is an extremely heterogeneous disease. Multiple (epi)genetic alterations at a broad spectrum
of oncogenes and tumor suppressor genes have been observed in ovarian cancer leading to deregulation
of signal transduction pathways whose functions ranges from DNA repair, cell proliferation, apoptosis,
cell adhesion, and motility. Based on these molecular alterations, ovarian cancer has been subdivided in
two major type I and type II classes of tumors [3]. Type I tumors are slow growing, mostly restricted to the
ovary, and develop from well-established precursor lesions called “borderline” tumors. Type I tumors
comprise of four different subtypes, namely low-grade serous, mucinous, clear cell, and endometrioid
cancers. The histological composition of these four types resemble normal cells present in the
fallopian tube and/or ovarian surface epithelium, endocervix, vagina, and endometrium, respectively,
thus suggesting different cells of origin for the different histotypes [3]. Type I lesions frequently carry
mutations in KRAS, BRAF, PTEN, and CTNNB1 (β-catenin), and often show a relatively stable karyotype.
Type II ovarian cancers include high-grade serous (HGS) and undifferentiated carcinomas, the vast
majority of which characterized by TP53 alterations and pronounced genomic instability [3]. Of note,
inherited and somatic BRCA1 and BRCA2 mutations are usually found in type II tumors. It is under
debate whether HGS ovarian cancers originate from the fimbria of the fallopian tube or from the
ovarian surface epithelium (OSE) [4].
Ovarian cancers are thought, because of their distinctive progression and recurrence patterns,
to be characterized by a hierarchical structure with cancer stem cells (CSCs) endowed with self-renewal
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and the capacity to differentiate, which continuously fuel the growth of the tumor mass and coexist
with more committed cell types [5,6]. Notably, the Wnt/β-catenin signaling pathway, known to regulate
stemness in a broad spectrum of stem cell niches including the ovary, is thought to play an important
role in ovarian cancer. First, 16–54% of endometrioid ovarian cancers are characterized by mutations
in β-catenin or, though at a considerably less frequency, in other members of the Wnt cascade such as
APC, AXIN1, and AXIN2 [7,8]. Second, other histotypes, and in particular serous ovarian carcinomas
where mutations in Wnt-related genes are relatively uncommon, are characterized by constitutive
Wnt signaling activation as indicated by alterations in β-catenin subcellular localization (i.e., nuclear
and cytoplastic vs. membrane-bound) [9–12]. Importantly, Wnt activity was shown to correlate
with grade [12], epithelial to mesenchymal transition (EMT) [7], chemo-resistance [13], and poor
prognosis [14] in patients with ovarian carcinomas.
Here, we will review the current knowledge of the role of Wnt signaling in ovarian cancer
stemness, EMT, and therapy resistance. The alleged role of exosomes in the paracrine activation of
Wnt signaling, and novel potential treatment options based on Wnt inhibition will also be highlighted.
2. The Wnt/β-Catenin Signaling Pathway
Stem cells are distinguished from other somatic cells by their ability to self-renew and to give rise
to distinct differentiated cell types throughout their lifetime [6]. The canonical Wnt signaling program
plays a central role in controlling the balance between stemness and differentiation in several adult
stem cell niches [15], including the ovary [7]. Accordingly, aberrant Wnt signaling is associated with
pathological conditions like cancer [15].
Wnt proteins comprise a group of evolutionary conserved, lipid-modified glycoproteins [16]
that operate at both short and long distances in order to regulate programs involved in proliferation,
differentiation and stemness [15,17]. In absence of canonical Wnt ligands, intracellular β-catenin
levels are regulated by the formation of a multiprotein “destruction complex” encompassing protein
phosphatase 2A (PP2a), glycogen synthase kinase 3 (GSK3β) and casein kinase 1α (CK1α), and the
scaffold proteins adenomatous polyposis coli (APC), and AXIN1/2. The destruction complex binds
and phosphorylates β-catenin at specific serine and threonine residues, thereby targeting it for
ubiquitination and subsequent degradation by the proteasome (Figure 1a). Instead, in the presence
of Wnt ligands, co-activation of the Frizzled and LRP5/6 (low-density lipoprotein receptor-related
proteins) receptors prevents the formation of the destruction complex, thereby stabilizing intracellular
β-catenin and eventually leading to its translocation from the cytoplasm to the nucleus. Here, β-catenin
interacts with members of the T-cell specific transcription factor/lymphoid enhancer binding factor
(TCF/LEF) family of transcription factors and modulates the expression of a broad spectrum of Wnt
downstream target genes regulating stemness, proliferation, and differentiation [15] (Figure 1b).
An illustrative example of the relevance of a tightly controlled Wnt signal regulation is provided
by the intestinal stem cell niche, i.e., the crypt of Lieberkühn. At the bottom of the crypt, where the
highly proliferative intestinal stem cells (ISC) reside, Wnt signaling is highly active due to signals from
the surrounding stromal compartment [18], as also shown by nuclear β-catenin localization in both ISCs
and the intercalating Paneth cells. Moving up along the crypt-villus axis, Wnt becomes progressively
less active, following a signaling gradient inversely proportional to the differentiation grade of the
epithelial lining [19]. In accordance with the central role played by this Wnt gradient, loss of function
mutations at the tumor suppressor gene APC or gain of function mutations in the β-catenin (CTNNB1)
oncogene leading to ligand-independent (i.e., constitutive) Wnt activation represent the main initiating
events in the vast majority of sporadic colon cancer cases. Hence, the disruption of the homeostatic
equilibrium among stemness, differentiation, and proliferation along the crypt-villus axis brought
about by constitutive Wnt activation is sufficient to trigger colon cancer development [20].
The functional relevance of the Wnt pathway in controlling stemness, proliferation,
and differentiation in organ-specific adult stem cell niches other than the intestinal tract is reflected by
the broad spectrum of cancer where its deregulation contributes to tumor initiation and/or progression.
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Accordingly, there is ample evidence from the scientific literature supporting an important role for
Wnt signaling in both the onset and progression of ovarian cancer [7].
Figure 1. The Wnt/β-catenin signal transduction pathway in homeostasis. (a) In the absence of
Wnt ligands, intracellular β-catenin levels are controlled by a destruction complex encompassing
protein phosphatase 2A (PP2a), glycogen synthase kinase 3 (GSK3β) and casein kinase 1α (CK1α),
adenomatous polyposis coli (APC), and AXIN1/2. This complex binds and phosphorylates β-catenin
at serine and threonine residues, thereby targeting it for ubiquitination and proteolytic degradation
by the proteasome. (b) In presence of Wnt, co-activation of the Frizzled and low-density lipoprotein
receptor-related protein 5/6 (LRP5/6) (low-density lipoprotein receptor-related proteins) receptors
prevents the formation of the destruction complex leading to the stabilization and consequent
translocation of β-catenin from the cytoplasm to the nucleus. Here, β-catenin interacts with members
of the T-cell specific transcription factor/lymphoid enhancer binding factor (TCF/LEF) family of
transcription factors and modulates the expression of a broad spectrum of Wnt downstream target
genes. DVL – disheveled. Adapted from [21].
3. Wnt Signaling in Ovarian Development and Tissue Homeostasis
Mammalian sex determination is a developmental process consisting of two distinct antagonistic
genetic pathways allowing XX or XY undifferentiated gonads to differentiate into two different organs,
namely the testis and the ovary [22]. The SRY-SOX9-FGF9 pathway supports testis development,
while the RSPO1-Wnt-β-catenin-FOXL2 network promotes ovarian determination [22] (Figure 2).
Before sex determination, the undifferentiated gonad is composed of the coelomic epithelium,
together with germ and mesenchymal cells. Here, both the Wnt signaling activators Wnt4 and
R-spondin 1 (RPSO1) are important regulators of proliferation of the coelomic epithelium, as indicated
by ablation of both Rspo1 and Wnt4 leading to reduced numbers of coelomic epithelial cells in XX and
XY gonads and, consequently, to hypoplastic testis in XY mutant gonads [23].
During XY sex determination, the transcription factor sex-determining region Y (SRY) together with
Splicing factor 1 (SF1) upregulate SRY-Box 9 (SOX9) gene expression. Subsequently, SOX9 upregulation
leads to the differentiation of coelomic epithelium into anti-Müllerian hormone producing Sertoli cells,
thereby stimulating testis development [24]. Sertoli cells also secrete FGF9 (Fibroblast Growth Factor
9) thus inhibiting the pro-ovarian Wnt signaling pathway [25]. Furthermore, WT1 (Wilms Tumor 1)
and ZNFR3 (Zinc Finger 3) also have been shown to downregulate Wnt signaling during male sexual
differentiation [26,27]. Accordingly, genetic ablation of Znrf3 leads to ectopic Wnt signaling in XY
gonads and consequentially in the presentation of a female phenotype [27].
In females, both granulosa cells and ovarian surface epithelium (OSE) are derived from the
coelomic epithelium. During fetal stages, Rspo1 is expressed in the mesothelial lining of the coelomic
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cavity and within the fetal ovary [28], whereas Wnt4 expression is localized to the gonad medulla and
mesonephros between the gonad and the Müllerian duct [29]. Wnt4 and RSPO1 are essential for ovarian
differentiation and oogenesis as they suppress Sox9 expression, stimulate granulosa cell differentiation,
and promote female sexual development by sustaining Müllerian duct differentiation [28,30,31].
Genetic ablation of Wnt4, Rspo1, or Ctnnb1 in XX gonads lead to premature differentiation of granulosa
cells in fetal stages and consequentially to the abrogation of ovary development at perinatal stages [32].
Figure 2. Schematic view of sex determination. In the undifferentiated gonad both Wnt4 and RSPO1
(R-spondin 1) are important regulators in particular for the proliferation of the coelomic epithelium.
In XX gonads, expression of Wnt4, and RSPO1 leads to ovarian differentiation and oogenesis as
they suppress Sox9 expression, stimulate granulosa cell differentiation, and promote female sexual
development by sustaining Müllerian duct differentiation. In XY gonads male reproductive organs
are determined by the expression of sex-determining region Y (SRY) together with Splicing factor 1
(SF1) leading to upregulation of Sox9 gene expression. In addition, Fibroblast Growth Factor 9 (FGF9),
Wilms Tumor 1 (WT1), and Zinc Finger 3 (ZNFR3) inhibit the pro-ovarian Wnt signaling pathway.
Also, anti-Müllerian hormone (AMH) prevents the development of the Müllerian duct into female
reproductive organs.
Ng et al. (2014) [33] provided additional evidence highlighting the significance of the role played
by Wnt during ovarian development and tissue maintenance and regeneration in adulthood. In this
study, Lgr5, the marker of the above-mentioned and Wnt-driven intestinal stem cells, was shown to be
broadly expressed during ovarian organogenesis, whereas it was restricted to the OSE in neonatal life.
Using in vivo lineage tracing, Lgr5+ cells were identified as stem or progenitor cells, able to contribute
to the development of the OSE cell lineage, the mesovarian ligament, and the fimbriae. In adult ovaries,
Lgr5+ cells were restricted to the proliferative regions of the OSE and the mesovarian-fimbria junctional
epithelium. In the OSE, Lgr5+ cells are thought to preserve homeostasis and to underlie repair of
the epithelial damage after ovulation [33]. Indeed, using a Wnt-reporter mouse model, the complete
coelomic epithelium overlying the undifferentiated gonad displayed β-catenin/Tcf mediated LacZ
expression gradually reduced to smaller populations during postnatal, pre-puberal, and adult life [34].
Of note, the LacZ+ OSE cells were enriched in SP (side population) positive cells, a sub-population of
stem-like cells identified by their capacity to efflux the dye Hoechst 33342 by ATP-binding cassette
super-family G member 2 (ABCG2) transporter pumps [34], a clinically relevant feature acquired by
chemotherapy resistant ovarian CSCs.
Apart from its role during embryonic development of the ovary, Wnt signaling was also shown
to be an essential regulator of ovarian homeostasis, fertility, and tumorigenesis. Knock-out of APC2,
a homologue of the APC tumor suppressor gene [35], resulted in the activation of ovarian Wnt signaling
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and in sub-fertility. The latter was due to disturbed follicular growth and the consequent reduced
ovulation rate and corpora lutea formation [36]. Notably, aged APC2-/- mice developed granulosa
cell tumors (GCT) with comparable histological features and molecular signatures to those of the
corresponding human GCTs [36].
Overall, the central role played by Wnt in regulating the delicate balance between stemness,
proliferation, and differentiation to ensure ovarian tissue homeostasis is reflected by its causal
association with ovarian cancer onset and/or progression as discussed in the next section.
4. Wnt Signaling in Ovarian Cancer
As mentioned above, CTNNB1 (β-catenin) mutations are found in 16–54% of endometrioid ovarian
cancer cases. Likewise, genetic alterations in other members of the Wnt cascade, such as APC, AXIN1,
and AXIN2, have also been detected in this specific ovarian cancer histotype [7,8]. In a conditional APC
knock-out mouse model, it was shown that constitutive activation of Wnt/β-signaling in Müllerian
duct-derived organs (i.e., fallopian tubes, uterus, cervix, and the upper two thirds of the vagina) results
in the formation of endometrioid tumors in the oviduct, reminiscent of the corresponding histotype in
man. Of note, in the same study the ovarian surface epithelium was unaffected, thus suggesting that
the oviduct, rather than the OSE, encompasses the cell of origin of (endometrioid) ovarian cancer [37].
In addition to endometrioid ovarian carcinomas, mutations in CTNNB1 are also found in rare cases
of mucinous ovarian cancer [38]. Moreover, both CTNNB1 and APC mutations have also been detected
in non-epithelial microcystic stromal tumors (MSTs) of the ovary [39–41]. Accordingly, an increased
incidence of MSTs has also been reported among patients affected by familial adenomatous polyposis
(FAP) due to germline mutations in APC [40,41]
Yet, it should be clearly stated that endometrioid tumors represent a notable exception as mutations
in Wnt-related genes are in general extremely rare in any other ovarian cancer histotype [7]. However,
even in the absence of specific mutations, Wnt signaling has been reported to be frequently activated
in the more common serous histotype as indicated by nuclear and cytoplasmic β-catenin subcellular
localization [9–12]. In addition, expression profiling data have confirmed the frequent activation of
Wnt signaling in ovarian cancer at large [42,43]. In particular, transcriptome analysis of ascites-derived
ovarian cancer cells and tumor-associated macrophages (TAMs) has revealed that both canonical and
non-canonical Wnt ligands (i.e., WNT7A, WNT2A, WNT5A, WNT9A) are expressed in tumor cells,
whereas LRP and FZD are common to both tumor cells and TAMs [43].
Pangon et al. (2016) took advantage of the Cancer Genome Atlas (TCGA) to show that the
oncogene JRK (jerky) is overexpressed in 15% of ovarian cancers in association with increased
expression of canonical Wnt target genes [44]. JRK directly interacts with the β-catenin transcriptional
complex, thereby stabilizing the β-catenin/TCF complex and ultimately resulting in increased β-catenin
transcriptional activity and cell proliferation. Consistent with this, depletion of JRK in cancer cell lines
repressed expression of β-catenin target genes and reduced cell proliferation [44].
More recently, noncoding RNAs (ncRNAs) have emerged as important post-translational regulators
of Wnt-associated gene expression in ovarian cancer (Table 1). By using orthotopic mouse models of
ovarian cancer, it was demonstrated that β-catenin plays a key role in the formation of metastasis by
controlling the endoribonuclease Dicer, a key component of the microRNA (miR)-processing machinery.
β-catenin directly targets Dicer, thereby downregulating multiple miRNAs including the miR-29 family
known for its role as a negative EMT regulator. Silencing of β-catenin or overexpression of Dicer or
mi-R29 in metastatic ovarian cancer cells reduced their migratory capacity, and attenuated metastasis
formation upon β-catenin knockdown in orthotopic mouse models [45]. Of note, reduced expression of
miR-29 is associated with ovarian cancer progression and strongly correlated with poor survival [46].
Several other miRs have been demonstrated to impact migration, invasion, and cancer progression
via Wnt signaling in ovarian cancer [47–59]. Interestingly, miR-939 has been suggested to function as a
tumor promotor by regulating Wnt signaling through direct suppression of the previously discussed
APC2 tumor suppressor [48].
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Next to miRs, several long non-coding RNAs (lncRNAs) have been described to play a causative
role in Wnt-associated cell proliferation, EMT, and chemotherapy resistance in ovarian cancer [60–65].
Table 1 summarizes the data relative to gene and non-coding RNA alterations leading to Wnt signaling
activation in ovarian cancer.
Table 1. Gene and non-coding RNA alterations leading to Wnt signaling activation in ovarian cancers.
Gene/ncRNA Ovarian Cancer Histotype* Mechanism/Target Reference
CTNNB1 Endometrioid. Oncogenic activation. [8,38,66–70]
CTNNB1 Mucinous. Oncogenic activation. [38]
CTNNB1 Microcystic Stromal Tumors (MST). Oncogenic activation. [39]
APC Endometrioid. Loss of tumor suppressor function. [8]
APC Microcystic Stromal Tumors (MST). Loss of tumor suppressor function. [40,41]
AXIN1 Endometrioid. Loss of tumor suppressor function. [8]
AXIN2 Endometrioid. Loss of tumor suppressor function. [8]
microRNA (miR)-10a) Granulosa cell tumor. miR-10a targets PTEN and indirectly activates Wnt (and AKT)signaling. Oncogenic activation. [54]
miR-15b Epithelial ovarian cancer *.
miR-15b targets WNT7A 3’-untranslated region (3’-UTR) and
thus inhibits Wnt signaling. Loss of tumor suppressor
function.
[50]
miR-16 Epithelial ovarian cancer *. miR-16 target(s) yet unknown; it inhibits Wnt signaling. Lossof tumor suppressor function. [56]
miR-21 Epithelial ovarian cancer *. miR-21 target(s) yet unknown; it activates Wnt signaling.Oncogenic activation. [57]
miR-27a Epithelial ovarian cancer *. mir-27 targets the Wnt antagonist FOXO1. Oncogenicactivation. [55]
miR-29 Serous, mucinous, and clear cellovarian cancer.
miR-29 target(s) yet unknown; it activates Wnt signaling.
Oncogenic activation. [45,46]
miR-92a-1 Epithelial ovarian cancer *. miR-92a-1 targets the Wnt antagonist Dickkopf 1 (DKK1).Oncogenic activation. [51]
miR-200c Epithelial ovarian cancer *. miR-200c target(s) yet unknown; it inhibits Wnt signaling.Loss of tumor suppressor function. [47]
miR-214 Epithelial ovarian cancer *. miR-214 target(s) yet unknown; it inhibits Wnt signaling. Lossof tumor suppressor function. [53]
miR-219-5p Epithelial ovarian cancer *. miR-219-5p targets the EMT transcription factor TWIST andinhibits Wnt signaling. Loss of tumor suppressor function. [52]
miR-654-5p Epithelial ovarian cancer *. miR-654-5p targets CDCP1 and PLAGL2. Loss of tumorsuppressor function. [58]
miR-939 Epithelial ovarian cancer *. miR-939 targets APC2. Loss of tumor suppressor function. [48]
miR-1180 Epithelial ovarian cancer *. miR-1180 targets SFRP1. Loss of tumor suppressor function. [59]
miR-1207 Epithelial ovarian cancer * miR-1207 targets SFRP1, AXIN2, and ICAT. Loss of tumorsuppressor function. [49]
HOTAIR 1 Epithelial ovarian cancer *.
HOTAIR target(s) unknown; Wnt agonist. Oncogenic
activation. [60]
SNHG20 2 Epithelial ovarian cancer *.
SNHG20 target(s) unknown; Wnt agonist. Oncogenic
activation. [61]
HOXD-AS1 3 Epithelial ovarian cancer *.
HOXD-AS1 targets the Wnt antagonist miR-133a-3p.
Oncogenic activation. [62]
CCAT2 4 Epithelial ovarian cancer *.
Targets unknown; EMT and Wnt agonist. Oncogenic
activation. [63]
MALAT1 5 Epithelial ovarian cancer *. Targets unknown; Wnt agonist. Oncogenic activation. [64]
AWPPH 6 Epithelial ovarian cancer *. Targets unknown; Wnt agonist. Oncogenic activation. [65]
HOXB-AS3 7
Serous ovarian cancer samples;
other histotypes. Targets unknown; Wnt agonist. Oncogenic activation. [71]
*, histotype not characterized; 1, HOTAIR—HOX antisense intergenic RNA; 2, SNHG20—small nucleolar RNA
host gene 20; 3, HOXD-AS1—HOXD cluster antisense RNA 1; 4, CCAT2—colon cancer-associated transcript
2; 5, MALAT1—metastasis associated lung adenocarcinoma 1; 6, AWPPH—associated with poor prognosis of
hepatocellular carcinoma; 7, HOXB-AS3—HOXD cluster antisense RNA 3.
Apart from the above alterations in genes and non-coding RNAs, Wnt signaling activation in
ovarian cancer might result from additional alternative epigenetic mechanisms, either cell-autonomous
or induced by the tumor microenvironment. Epigenetic alterations leading to autocrine overexpression
of Wnt ligands [72,73], receptors [74], and/or of other Wnt agonists like FRAT1 [12] or PYGO2 [75],
or to the inhibition of antagonists such as the secreted frizzled receptors proteins (sFRP) and Dickkopf
(DKK1) [14,76–78] have been reported in the literature. Likewise, paracrine secretion of Wnt-activating
cues was observed from either the stroma surrounding the primary ovarian cancer, or from ascites in
the case of late-stage disease. Several components of ovarian cancer ascites, known to be associated
with shorter progression free survival [79,80], have been previously implicated in promoting Wnt
signaling: leptin [81,82], urokinase-type plasminogen activator receptor (uPAR) [83], and macrophage
migrating inhibitory factor (MIF) [84]. These soluble factors may act by activating the Wnt pathway
in disseminated ovarian cancer cells present in ascites. Two additional ascites factors, namely
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osteoprotegerin (OPG) [85] and interleukin 8 (IL-8) [86], are in fact downstream Wnt targets and could
serve as markers of Wnt signaling activity in ascites. In addition, β-1 integrin-mediated adhesion to
the peritoneal mesothelium, a key step in the route to ovarian cancer metastasis, activates β-catenin
signaling [87]. Of note, it has recently been shown that extracellular vesicles such as exosomes play a
critical role in long-distance transmission of morphogens and in particular in Wnt signaling [88]. In the
context of ovarian cancer ascites, exosomes may represent a stable source of paracrine Wnt signals [89].
The role of exosomes will be discussed at more length later on in this review.
5. Wnt Signaling in Ovarian Cancer Stem Cells, EMT, and Therapy Resistance
After diagnosis, tumor debulking surgery followed by carboplatin- and paclitaxel-based
chemotherapy represent the standard first line therapy for high grade serous ovarian cancer patients.
Although at this stage the primary response to chemotherapy is extremely efficient, most patients relapse
and develop metastases locally and at distant organ sites [90]. This is mainly due to sub-populations
of tumor cells likely to have acquired stem cell features (CSCs) through EMT and, consequently,
the EMT-associated chemo-resistance [5]. In 2005, it was shown for the first time that the aggressiveness
of human ovarian cancer results from alterations in stem and progenitor-like cells in the ovary [91].
Moreover, this study demonstrated that the small subpopulation of stem-like, tumor-propagating
ovarian cancer cells were earmarked by expression of cluster of differentiation 44 (CD44) and other
stem cell and EMT markers such as KIT (CD117), SCF (stem cell factor), SLUG (SNAIL2), and VIM
(vimentin) [91]. After this initial report, several cell surface antigen markers have been identified which
allow enrichment of ovarian CSCs from immortalized cell lines, primary tumors, and ascitic fluids:
CD133, CD24, CD44, CD177, aldehyde dehydrogenase 1 (ALDH1), and SP [5]. Notably, active Wnt
signaling has been shown to play a key role in the regulation and maintenance of ovarian cancer
stemness [51,92,93].
Ovarian cancer follows a unique pattern of metastasis formation where, unlike many other cancer
types, no anatomical barrier exists between the primary site and the abdominal cavity, thus greatly
facilitating the dissemination of exfoliated malignant cells. In particular, disseminated ovarian cancer
cells secrete vascular permeability factors and can block lymphatic drainage leading to accumulation
of ascites fluid within the peritoneal cavity [94]. These malignant ascites provide a favorable tumor
microenvironment (TME) enriched in secreted inflammatory cytokines [79], growth factors [95],
and extracellular macromolecules (collagen, fibronectin, and laminin) [96]. In this environment, tumor
cells form multicellular aggregates enriched in cancer stem/progenitor cells, the so-called ‘spheroids’,
which eventually implant on the mesothelial lining of the peritoneum [97] (Figure 3). The attachment
of these floating spheroids to the peritoneal lining and associated organs represents the major route for
metastasis formation in ovarian cancer [98] where, as observed in other epithelial cancers, EMT was
shown to play a key role [99]. Interestingly, although hematogenous spread is generally thought to play
a relatively minor role in metastasis formation in ovarian cancer, it has recently been demonstrated in a
parabiosis mouse model [100]. In this study, two mice, one of which intraperitoneal transplanted with
ovarian cancer cells, were surgically connected to share blood supply. The development of ovarian
cancer in the cancer-free animal likely results from hematogenous spread [100]. Likewise, circulating
tumor cells have been identified in peripheral blood from ovarian cancer patients [101].
Overall, the naturally occurring spheroids in ascites are likely to underlie metastatic disease in
ovarian cancer patients. In the next sections, we will discuss the current experimental evidence on the
role of Wnt signaling in eliciting EMT and chemo-resistance in high grade serous ovarian cancer.
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Figure 3. Model for peritoneal metastasis formation in ovarian cancer. Ovarian cancer follows a unique
pattern of metastasis formation, where no anatomical barrier exists between the primary site and the
abdominal cavity. Multicellular aggregates enriched in cancer stem/progenitor cells, the so-called
spheroids, detach from the primary tumor and eventually implant on the mesothelial lining of the
peritoneum. EMT was shown to play a key role facilitating the acquisition of stem-like features,
anoikis resistance, and increased migration and invasion. The establishment of premetastatic niches
composed of several cell populations, including tumor-associated neutrophils, is thought to be required
for disseminating carcinoma cells to engraft at the distant site. Exosomes in ovarian cancer ascites
have been proposed as a putative mechanism to facilitate long-range distance cell–cell communication
thereby establishing both pre-metastatic niches in the peritoneal cavity and preserving stemness in
disseminated cancer cells. CAFs: cancer associated fibroblasts; MSCs: mesenchymal stem cells.
5.1. Wnt Signaling and EMT in Ovarian Cancer
EMT is a reversible developmental program exploited by cancer cells to reversibly switch from an
epithelial phenotype with apical-basal polarity and cell–cell adhesions, to a more motile mesenchymal
state with spindle like morphology and front-back-end polarity [102]. Next to the motility and invasive
features characteristic of the mesenchymal state, EMT is functionally associated with the acquirement
of stem-like features, resistance to therapy, and immune suppression [103–105]. Last, the capacity of
cells undergoing EMT to revert to an epithelial state by mesenchymal-to-epithelial transition (MET)
is rate-limiting to allow the stem- and mesenchymal-like migrating CSCs to regain proliferative and
epithelial features essential to colonize the metastatic site [102,106]. Various signaling pathways
are involved in EMT, including transforming growth factor β (TGF-β), Notch, and Wnt/β-catenin.
Activation of the Wnt/β-catenin pathway has been shown to be an important regulator of EMT in
many different types of cancers [106–108], including ovarian cancer [109–112]. In this context, ovarian
cancer cell lines with a high SNAIL to E-cadherin ratio, are characterized by enhanced CSC-like, motile,
and therapy-resistant features when compared with epithelial ovarian cancer cell lines. Accordingly,
SNAIL knockdown reversed the malignant properties and tumor burden of the more mesenchymal
ovarian cancer cell lines in xenograft models [111]. SNAIL and other EMT transcription factors
(EMT-TFs) have been shown to activate expression of the GOLPH3 (Golgi phosphoprotein 3) gene,
encoding for an oncoprotein frequently upregulated in ovarian cancer tissues and cell lines, through
Wnt/β-catenin signaling activation [112]. Induction of EMT and the consequent acquisition of migratory
and invasive cellular features downstream of Wnt activation have also been demonstrated in ovarian
carcinomas where IQGAP2, a Wnt antagonist, is frequently silenced by DNA methylation [110]. Last,
cyclin G2, an unconventional cyclin that opposes cell cycle progression and inhibits EMT, acts as a
tumor suppressor in ovarian cancer by inhibiting Wnt/β-catenin signaling [109].
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More recently, it has been suggested that, rather than being a binary process with fully opposing
epithelial and mesenchymal phenotypes, EMT generates hybrid E/M cancer cells displaying both
epithelial and mesenchymal characteristics [113,114]. Indeed, similar to the normal ovarian surface
epithelial (OSE) cells previously shown to display both epithelial and mesenchymal characteristics
and a remarkable phenotypic plasticity during post-ovulatory repair, double positive E-cadherin and
vimentin cells have been observed in ovarian cancers [115]. Accordingly, different intermediate EMT
states have been identified in ovarian cancer cell lines [116] and ascites-derived spheroids [117]. Here,
ovarian cancer cells in hybrid E/M states were shown to exhibit stem-like features, anoikis resistance,
and increased migration and invasion when compared with the fully epithelial and mesenchymal
states [116–118].
Overall, it is yet unclear whether the hybrid E/M cells represent a ‘metastable’ cell population or
are cells captured in a time frame during the transition between the epithelial to mesenchymal states.
The elucidation of the complex network of intrinsic and extrinsic mechanisms underlying EMT during
metastasis formation and the role of Wnt signaling therein represents an important future research
challenge. In the next section, the current knowledge on the role of Wnt signaling in resistance to
chemotherapy in ovarian cancer will be discussed.
5.2. Wnt Signaling and Therapy Resistance in Ovarian Cancer
As mentioned above, chemotherapy is extremely efficient in the first-line treatment of primary
ovarian cancers although it inevitably leaves behind chemo-resistant CSCs likely to underlie relapse
and metastasis in distant organ sites [90]. Wnt signaling has been associated with resistance to
chemotherapy in different tumor types including ovarian cancer [119].
Chemo-resistance can be acquired through a broad spectrum of molecular and cellular mechanisms
such as the upregulation of ATP-binding cassette (ABC) transporter pumps, the activation of EMT,
and the exosome-mediated transport of molecules controlling a broad spectrum of pathways underlying
drug resistance [120]. ABC transporters have indeed been shown to be expressed in ovarian cancer
usually in association with cancer stemness and poor prognosis [121,122]. Notably, upregulation of
the ABCG2 transporter pump and Wnt signaling activation downstream of cKIT mediate the onset of
resistance to cisplatin and paclitaxel in ovarian CSCs [13]. In the same study, ABCG2 expression and
chemo-resistance to both cisplatin and paclitaxel could be reversed by β-catenin siRNA knockdown,
once again highlighting the central role of Wnt signaling in these processes [13].
Another well-established mechanism underlying therapy resistance in ovarian cancer, as also
mentioned in the previous section, is represented by EMT [99]. Su et al. (2010) showed that
SFRP5 (secreted frizzled-related protein 5), a well-known Wnt and EMT antagonist, is frequently
downregulated in ovarian cancer by epigenetic silencing through promoter hypermethylation [123].
Accordingly, restoration of SFRP5 expression inhibits Wnt signaling and EMT thus sensitizing ovarian
cancer cells to chemotherapy. Activation of the EMT-TF TWIST and of AKT2 signaling play key roles
downstream of SFRP5 silencing [123].
In addition to the above-mentioned cell-autonomous mechanisms, ascites also forms a unique
tumor microenvironment likely to contribute to therapy resistance [124]. Malignant ascites provides a
favorable tumor microenvironment consisting of cellular and non-cellular components, each likely to
play a role in the development of resistance to carboplatin- and paclitaxel-based therapy. Among these,
cancer associated fibroblasts (CAFs) represent an important component of ovarian cancer ascites [124].
CAFs are a subpopulation of fibroblasts capable of affecting tumor progression, dissemination,
and therapy response through signaling to tumor cells and/or remodeling of the extracellular matrix
(ECM) [125]. Recently, Ferrari et al. (2019) demonstrated that Dickkopf-3 (DKK3), the stromal expression
of which is strongly associated with aggressive ovarian cancer, promotes CAFs’ aggressive behavior
by enhancing Yes-associtated protein/transcriptional co-activator with PDZ-binding motif (YAP/TAZ)
activity through Wnt/β-catenin signaling [126]. From a mechanistic perspective, DKK3 destabilizes the
Wnt-antagonist Kremen, leading to increased LRP6 localization at the cell membrane. This in turn
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stabilizes YAP/TAZ and β-catenin levels leading to more global gene expression changes enhancing
cancer stemness, malignant progression, and metastasis [126]. Other ascites cellular components such
as macrophages have also been shown to take part in tumor progression and the development of
therapy resistance. Ragahvan et al. (2019) showed that Wnt signaling participates in a bidirectional
ovarian CSC-macrophage interaction [92]. By taking advantage of hetero-spheroids composed of
macrophages and ovarian cancer cells in close contact with each other, it was shown that Wnt signaling,
activated by secretion of the Wnt5b ligand from macrophages, led to an increase of the ovarian CSC
compartment (ALDH+) and to the enhancement of the immune-suppressive characteristics of the
macrophages. Likewise, Wnt5b knockdown in macrophages resulted in a loss of the ALDH+ ovarian
CSC fraction. Most importantly, the hetero-spheroids were less sensitive to chemotherapeutics and
were more invasive in in vitro assays [92]. Hence, macrophage-initiated Wnt activation is likely to play
a central role in ovarian cancer stemness maintenance and in therapy resistance.
Notwithstanding more recent advances in chemotherapy (e.g., intraperitoneal delivery of cytotoxic
drugs and the introduction of novel, more targeted agents such as bevacizumab and imatinib) [127–129],
less than 30% of advanced ovarian cancer patients survive longer than five years after diagnosis [1].
Therefore, there is urgent need for novel therapeutic strategies based on improved understanding of
the molecular and cellular mechanisms underlying dissemination and metastasis formation by ovarian
cancer cells in the peritoneal cavity and their acquisition of dormant and chemo-resistant properties.
Recently, the role played by extracellular vesicles and in particular by exosomes in tumor progression,
dissemination, and resistance to therapy has opened new avenues in basic and translational cancer
research. In the next section we will present and discuss the current knowledge on exosomes in ovarian
cancer, especially in the context of intra-abdominal ascites and of long-range Wnt signaling activation.
6. Exosomes and Wnt Signaling in Ovarian Cancer Ascites
Malignant ascites provides a favorable tumor microenvironment and consists of a heterogeneous
mixture of cells and secreted factors that modulate cancer cell behavior during tumor progression,
metastasis formation, and acquirement of chemo-resistance. As mentioned, Wnt ligands are modified
lipids and are therefore highly hydrophobic, thereby limiting their ability for extracellular diffusion [16].
Recently however, studies have shown that Wnts can be transported across tissues by exosomes [88,130].
In the following paragraphs we will highlight the current knowledge on the role played by exosomes
in ovarian cancer ascites as a putative mechanism to activate Wnt signaling over long-range distances
both in establishing pre-metastatic niches in the peritoneal cavity and in preserving stemness in
disseminated cancer cells.
6.1. Exosomes
Exosomes are small extracellular vesicles ranging in diameter from 30 to 100 nm that are secreted
by most eukaryotic cells. Secreted exosomes are important mediators in cell–cell communication as they
carry molecules such as microRNAs, mRNAs, and both membrane-bound and secreted proteins [131].
Exosomes are thought to facilitate tumor survival and progression by stimulating angiogenesis and
tumor growth, suppressing immune responses, remodeling of the extracellular matrix, promoting
metastasis formation either directly and/or through the establishment of premetastatic niches [131]
(Figure 3). Numerous studies have demonstrated the presence of exosomes in ovarian cancer cell line
cultures, and in patient-derived serum and ascites [132–135]. Notably, it has been shown that active
Wg (Wingless) and Wnt3a ligands are membrane-bound in exosomes from Drosophila and human
cells, respectively [88]. Moreover, macrophage-derived and exosome-packaged Wnts are rate-limiting
for the regenerative response of intestine intestinal stem cells after radiation [130]. In relation to
cancer, fibroblast-derived exosomes carrying Wnt ligands increase cell migration and metastasis
formation in breast cancer [136]. Hu et al. (2019) recently found that exosomes derived from stromal
fibroblasts contain Wnt ligands capable of eliciting the de-differentiation of colon cancer cells into
therapy resistant CSCs [137]. Alternatively, activation of Wnt signaling in target cells has been shown
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to occur by exosomes encompassing β-catenin in their cargo. Here, both 14-3-3 proteins and β-catenin
were encompassed in the extracellular vesicles. 14-3-3 proteins bind to dishevelled segment polarity
protein 2 (Dvl-2) and GSK3β thereby interfering with β-catenin phosphorylation and stimulating Wnt
signaling [138].
Although to date no evidence has been presented supporting the presence of exosomes
encompassing active Wnt ligands in ovarian cancer ascites, differential expression analysis of ovarian
cancer exosomes compared with those from normal OSE cells indicate a potential involvement of
miRNAs known to target the Wnt signal transduction pathway [139]. Moreover, recently it has been
demonstrated that exosomes isolated from a highly invasive ovarian cancer cell line promote metastasis
in vivo compared to exosomes from cells with low invasive capacity [140]. Quantitative proteomic
analysis of tumor tissues of the mice treated with exosomes derived from these two different cell
lines revealed a potential role for Wnt signaling in the role played by exosomes in tumor growth
and metastasis in vivo [140]. Also, as discussed here below, ovarian cancer exosomes containing the
Wnt target and transmembrane protein CD44 have been shown to participate in the formation of
pre-metastatic niches [141].
6.2. Pre-Metastatic Niche
Ovarian carcinomas spread through the shedding of clusters of tumor cells from the primary lesion
into the peritoneal cavity. In this context, the key event in metastatic seeding is the mesothelial adhesion
of ovarian cancer cells in the intraperitoneal cavity. The establishment of premetastatic niches is thought
to be required for disseminating cancer cells to engraft at the distant site [142]. Premetastatic niches
comprise of a specialized and favorable micro-environment that facilitates colonization and promotes
survival and outgrowth of disseminated tumor cells [142] (Figure 3). The relevance of the formation of
pre-metastatic niches in ovarian cancer has been proposed by several studies [141,143]. Lee et al. (2019)
demonstrated that inflammatory factors secreted by ovarian cancer cells mobilize neutrophils and
stimulate them to create chromatin webs called ‘neutrophil extracellular traps’ (NETs) in the omentum
in both tumor-bearing mice (before metastasis occurs) and in early-stage ovarian cancer patients.
The NETs can sequentially capture ovarian cancer cells and thereby promote metastasis formation.
Reversely, inhibiting NET formation abrogated omental colonization [143].
Next to NETs, ovarian cancer exosomes have also been shown to participate in the establishment of
a pre-metastatic niche by alternative mechanisms. First, MMP1 mRNA has been found in extracellular
vesicles derived from ovarian cancer cell lines and ascites from ovarian cancer patients that promotes
apoptotic cell death of the mesothelial cells, thus resulting in the destruction of the peritoneal
barrier [144]. In addition, ovarian cancer cells’ exosomes encompassing the cell-surface glycoprotein
CD44 can transfer it to peritoneal mesothelial cells and induce their reprogramming by EMT activation.
The modified mesothelium facilitates ovarian cancer invasion and metastasis formation [141]. Of note,
CD44 is a major Wnt target gene in the intestinal epithelium [145] and is essential for Wnt induction
during colon cancer progression [146], thus suggesting yet another functional link between Wnt
signaling and ovarian cancer exosomes in pre-metastatic niche formation.
To interfere with the interaction between disseminated ovarian cancer cells and the
exosome-receiving mesothelial cells, De la Fuente et al. (2015) developed a metastatic trap (M-Trap) [147].
By embedding exosomes purified from ovarian cancer patient ascites on a 3D scaffold, the authors
showed that the M-Trap device was able to capture ovarian cancer cells in a mouse model of ovarian
cancer. This led to a more focalized disease and an increase in survival rate [147]. These results lay
the foundation for future clinical approaches to improve treatment of ovarian cancer patients with
malignant ascites [147].
Overall, notwithstanding that treatment of advanced stage ovarian cancer patients still represents
a major clinical challenge, recent advances in our understanding of the mechanisms underlying ovarian
cancer ascites formation and the role they play in metastasis formation in the peritoneal cavity are of
good auspices for the future. Exosomes in particular, may represent powerful tools in early diagnosis
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and treatment [135]. As for the latter, targeted exosome ablation or inhibition of exosome secretion may
affect tumor progression or therapy resistance (Figure 4). In this scenario, the Wnt signaling pathway
may also represent a relevant therapeutic target. In the next paragraph, treatment options based on
targeting of Wnt signaling in ovarian cancer will be discussed.
 
Figure 4. Therapeutic targets for the inhibition of Wnt signaling. (a–c) Wnt soluble receptors,
anti-R-spondin antibodies, and antibodies directed against Frizzled receptors impair the ligand/receptor
interaction and prevent downstream signaling. (d) Disheveled inhibitors block Wnt signaling by
interfering with the Frizzled/Disheveled interaction. (e) Tankyrase activates Axin through PARsylation.
Tankyrase inhibition increases Axin levels thus stimulating the formation of the β-catenin destruction
complex and reducing the intracellular β-catenin pool. (f) cyclooxygenase (COX) inhibitors increase
ubiquitination and proteasomal degradation of β-catenin. Next, COX2 inhibition leads to reduced levels
of prostaglandin E2 (PGE2) known to positively affect Wnt signaling. (g) Disruption of its interaction
with TCF inhibits β-catenin-mediated transcriptional activity. CREB-binding protein (CBP) inhibitors
instead interfere with the interaction between TCF/LEF and CBP thereby reducing transcriptional
activity. (h) PORCN-inhibitors hamper the palmitoylation of Wnt before its extracellular release.
(i) Exosome secretion inhibitors reduce the transport of biomolecules like active Wnt ligands, RNAs and
proteases that contribute to angiogenesis, tumor growth, immune response suppression, the remodeling
and degradation of the extracellular matrix (ECM). Additional abbreviatons: RNF43 = RING finger
43; LGR4/5/6 = Leucine-rich repeat-containing G-protein coupled receptor 4/5/6; RSPO = R-spondin;
ZRNF3 = Zinc RING finger 3; GSK3β = glycogen synthase kinase 3β; LRP5/6 = LDL Receptor Related
Protein 5/6; TCF/LEF = T-cell specific transcription factor/lymphoid enhancer binding factor.
7. Targeting Wnt in Ovarian Cancer: Opportunities for Treatment?
During the last decade, the therapeutic response rate of ovarian cancer patients has improved
through optimization of chemotherapy strategies, their intraperitoneal administration, and the
introduction of targeted therapies [127–129]. However, despite these developments, the overall
survival of ovarian cancer patients has not significantly improved [1]. Because of the role played in
cancer stemness and in therapy resistance, the Wnt signaling pathway forms a candidate target for
therapeutic intervention as different segment of this cascade are suitable for therapeutic targeting
(Figure 4; Table 2).
Although R-spondins (RSPO) are unable to initiate Wnt signaling, they can, by binding to
leucine-rich repeat-containing G-protein coupled receptors (LGR) enhance responses to low-dose Wnt
proteins [148]. Functional RSPOs have been found in multiple human tumor types and anti-RSPO
monoclonal antibodies shown to reduce the tumorigenicity of cancer cells in patient-derived tumor
xenograft models of several malignancies including ovarian cancer [149]. Porcupine (PORCN) inhibitors
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form another relevant target to inhibit Wnt signaling. The acetyltransferase PORCN is responsible
for post-translational modifications of Wnt proteins essential for the transport, secretion, and activity
of the ligands. WNT974 is a selective PORCN inhibitor that has been shown to exert cytostatic
effects on ascites-derived ovarian cancer cells as a consequence of Wnt signaling inhibition [150].
When combined with the conventional chemotherapeutic drug carboplatin, WNT974 administration
led to increased cytotoxic effects and cell cycle arrest in ascites samples when compared with single
drug treatments [150].
The FDA (Food and Drug Administration)-approved anti-helminth compound niclosamide
represents yet another powerful Wnt inhibitor shown to repress ovarian CSC growth through
downregulation of both the disheveled protein DVL2 and the surface receptor LRP6 [151]. Next to Wnt,
niclosamide targets additional signaling pathways known to play a role in cancer stemness, including
Notch, mTORC1, and Stat3 [152].
Besides the above mentioned Wnt targets and inhibitory compounds, inhibition of Wnt ligands
secretion, inactivation of the extracellular portion of Frizzled receptors, and interference with the
TCF/β-catenin complex represent additional and presently under investigation strategies [153] (Figure 4;
Table 2).
Currently, different Wnt inhibitors are being evaluated in clinical trials for different cancer types
including ovarian cancer. As a notable example, Ipafricept is a recombinant fusion protein that
competes with the FZD8 receptor for its ligand thereby antagonizing Wnt signaling. Ipafricept reduces
cancer stem cells, promotes differentiation, and synergizes with taxanes in ovarian cancer xenografts.
More recently, a phase 1B trial was conducted with ipafricept in combination with carboplatin and
paclitaxel in patients with recurrent platinum-sensitive ovarian cancer [154]. Unfortunately, although
generally well-tolerated by patients, bone toxicity at efficacy doses limited ipafricept treatment [154].
Nonetheless, other Wnt inhibitors targeting PORCN and β-catenin are now being tested in clinical
trials in different tumor types [155].
Table 2. Wnt inhibitors in ovarian cancer.
Molecular Targets Inhibitors Activity Reference
Extracellular targeting Anti-Rspondin
anti-RSPO monoclonal antibodies reduce tumorigenicity of




Recombinant fusion protein that competes with the
membrane-bound Frizzled 8 (FZD8) receptor for its ligand;
leads to tumor regression in combination with taxane in
ovarian xenograft models; currently under clinical trial.
[154]
LRP6 inactivation Salinomycin
Small molecule blocking Wnt induced LRP6 phosphorylation




Small molecule disrupting the frizzled-disheveled interaction
by targeting the PDZ domain; chemo-sensitizes
paclitaxel-resistant ovarian cancer cells.
[158]
PORCN WNT974
Small molecule inhibitors of Wnt acetyltransferase porcupine;




Small molecule that selectively potentiates CK1α kinase
activity leading to increased β-catenin phosphorylation;




Small molecule inhibitor promoting FZD1 endocytosis and
suppressing LRP6 expression; inhibits growth and increases
cell death in ovarian cancer.
[161–163]
COX-inhibitors Aspirin lowers the risk of ovarian cancer development; in caseof ovarian cancer underlying mechanism yet unknown. [164]
8. Conclusive Remarks
In conclusion, a considerable body of evidence supports the relevance of the role played by Wnt
signaling in ovarian cancer stemness, progression to malignancy, and resistance to chemotherapy.
Notwithstanding the potential and innovative therapeutic strategies currently in development to
specifically target the Wnt pathway, plasticity of cancer cells still represents an escape mechanism
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leading to therapy resistance. Moreover, because of Wnt’s essential role in tissue homeostasis and
regeneration upon damage, its inhibition is likely to result in adverse events. Therefore, the identification
and elucidation of the complex network of intrinsic and extrinsic mechanisms driving ovarian cancer
progression and therapy resistance represent the major future research challenge in the translation of
the fundamental understanding of metastasis and therapy.
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Abstract: The classical cancer stem cell (CSC) model places CSCs at the apex of a hierarchical scale,
suggesting different genetic alterations in non-CSCs compared to CSCs, since an ill-defined number of
cell generations and time intervals separate CSCs from the more differentiated cancer cells that form
the bulk of the tumor. Another model, however, poses that CSCs should be considered a functional
state of tumor cells, hence sharing the same genetic alterations. Here, we review the existing literature
on the genetic landscape of CSCs in various tumor types and as a case study investigate the genomic
complexity of DNA obtained from matched CSCs and non-CSCs from five ovarian cancer patients,
using a genome-wide single-nucleotide polymorphism (SNP) microarray.
Keywords: ovarian cancer; cancer stem cell; genetic heterogeneity; SNP array
1. Cancer Stem Cell (CSC) Theory
It has been established and it is well accepted that tumors are composed of heterogeneous cell
populations. According to the classical hierarchical model, tumors arise from a small population of cells,
called CSCs, derived from the malignant transformation of a normal stem cell. One of the main features
of stem cells is their unlimited proliferative potential to sustain renewal and repair needs of normal
tissues after injury. However, following exposure to environmental carcinogens or due to stochastic
effects, normal stem cells can accumulate genetic mutations in cancer-associated genes (e.g., oncogenes
and onco-suppressor genes), as well as defects in the DNA repair machinery. These mutated stem cells
can become resistant to apoptosis and undergo malignant transformation in CSCs [1]. According to this
model, CSCs inherit all the key features from their normal stem counterparts, including the unlimited
proliferation rate and self-renewal capability. This implies that CSCs can accumulate a number of
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genetic or epigenetic changes, subsequently inherited by tumor cells derived from CSC asymmetric
division and differentiation (Figure 1A, left panel) [2,3]. Due to the genetic heterogeneity of cancer, it is
likely that the mutational burden of CSCs varies among different tumors, as occurs in non-CSCs. On the
other hand, other studies indicate that CSCs develop mechanisms to lower radical oxygen species
(ROS) accumulation and to extrude drugs, thus reducing the risk of damage to their genetic content [4].
These features let us speculate a reduced number of genetic alterations in CSCs compared to non-CSCs
(Figure 1A, right panel). Moreover, non-CSCs could possibly accumulate private mutations—defined
as mutations not shared by CSCs—during subsequent rounds of proliferation of trans-amplifying cells
and bulk tumor cells (Figure 1A).
Figure 1. The classical (A) and the alternative (B) “Cancer Stem Cell (CSC)” models and hypothetical
implications for the tumor mutational burden of transient-amplifying (T-A) and bulk tumor cells
(non-CSCs). In the right panels, examples of CSC with different levels of genetic alterations
(low, intermediate, high) are represented.
In contrast to the hierarchical model, an alternative theory poses CSC as a functional state of a tumor
cell (reviewed in [5]). According to this alternative model (Figure 1B, left panel), stemness can not only
be a cellular intrinsic property but also the result of extrinsic stimuli and of the cross-talk between CSCs
and the complex network of cells, matrices, and vesicles that cooperate to maintain a tumor permissive
160
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microenvironment [6]. For example, in a study on breast cancer in which cell lines were used as models,
only one subpopulation of cells out of three (stem cell-like, basal-like, and luminal-like cells) was
tumorigenic in vivo, whereas in another setting, in which irradiated stromal cells were provided, all three
considered subpopulations where equally tumorigenic [7]. Within the tumor microenvironment, CSCs,
as their normal adult counterpart, reside in specialized niches, since they need to receive cues
from the surrounding cells in order to activate and maintain their stemness program (self-renewal,
proliferation and apoptosis resistance) and stemness regulating pathways (i.e., Notch, Wnt/β-catenin
and Hedgehog). The niche consists of different cell types, including tumor-associated fibroblasts (TAFs),
endothelial cells, pericytes, and immune cells, especially tumor-associated macrophages (TAMs) and
myeloid-derived suppressor cells (MDSCs), as well as non-cellular elements, such as the extracellular
matrix and the complex network of growth factors and cytokines [6,8]. All these components regulate
stemness in different ways, i.e., by secreting cytokines which activate signaling pathways and stimulate
self-renewal [6], or by promoting epithelial-to-mesenchymal transition [9].
According to this alternative model, the genetic profile of CSCs and non-CSCs is predicted to be
quite similar (Figure 1B, right panel).
2. Genetic Profile of Cancer Stem Cells Versus the Bulk of Tumor Cells
In the last decade, CSCs have been identified in most tumor types (both solid and liquid) based on
the expression of specific surface markers, lack of certain differentiation markers and high tumorigenic
potential. In addition, CSCs have the ability to grow in vitro under serum-free conditions as rounded
structures called spheroids and undergo asymmetric cell division, thus originating one daughter cell
(maintaining stemness features) and one differentiated cell.
To date, only a few attempts have been made to describe the cytogenetic complexity of CSCs,
mainly comparing their karyotype to that of non-CSCs (Table 1). Most studies analyzed either tumor
cell lines or a small number of primary samples, due to the difficulty of obtaining enough genomic
DNA from CSCs. Moreover, CSC isolation was often not performed according to stemness marker
expression, but rather by using in vitro specific cell culture protocols. Along this line, Gasparini and
colleagues performed a complete cytogenetic characterization of sphere-growing stem-like cells from
six different cell lines of melanoma, breast, lung, and ovarian cancer [10].
Results indicated a more rearranged karyotype of CSCs, compared to the parental cell lines
maintained under standard adhesion culture conditions. CSCs showed a higher number and complexity
of chromosomal alterations in all cell lines evaluated. One bias of this study, acknowledged by the
authors, was the use of immortalized cell lines and in vitro culture techniques for CSC isolation and
expansion. Indeed, CSC-enriched spheroids are mainly composed of highly dividing progenitors that
could affect results of genetic analysis. In any case, the main finding of this study was that growth
culture conditions affect the genetic landscape of tumor cells.
In another study, Lee and colleagues demonstrated that glioblastoma (GBM) cells from primary
tumor samples, cultured in serum-free spheroid-forming conditions, harbored extensive genotype
similarity to parental tumor cells [13]. In contrast, when cultured in serum-supplemented media,
glioblastoma cells underwent genomic rearrangements in terms of loss of heterozygosity (LOH),
pseudo-tetraploidy and chromosomal deletions, suggesting a key role of in vitro culture conditions in
the acquisition of genetic instability. Unfortunately, it is unknown whether these in vitro findings can
be relevant to CSCs from patients.
Few other studies were performed in different tumor types, including GBM, breast cancer,
head-and-neck squamous cell carcinoma (HNSCC), and bladder cancer, in order to compare either
FACS-sorted CSCs or spheroid-forming cells with either their non-CSC counterpart or the tumor bulk
(Table 1). Piccirillo et al. analyzed 12 primary GBM tumor sample-derived neurospheres by single
nucleotide polymorphism (SNP) array and found that four out of 12 presented at least three copy
number alterations (CNAs). Then, the authors analyzed one of these samples in detail, by using
whole-exome sequencing (WES) and single-cell analysis. They concluded that the selected somatic
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mutations and CNAs highlighted in the primary tumor were also present in the derived neurospheres.
Moreover, some genetic alterations were subclonal and correlated with different tumorigenic potential
of single tumor cells in mice. Thus, conclusions suggest that CSCs and bulk tumor cells share the same
genetic alterations but GBM presents substantial intra-tumor genetic heterogeneity [11].
Table 1. Studies on genetic alterations in CSCs.





CNAs found in primary tumor
cells are also present in
neurospheres in different
subclones
Piccirillo S.M. et al.,
2015 [11]
GBM Primary tumorcells aCGH
High similarity between GBM
mass and spheroids
Pesenti C. et al.,
2019 [12]












Mutations are shared between
tumor bulk and spheres
Klevebring D. et al.,
2014 [14]
Breast Tumor cells frompleural effusions
low-coverage
WGS
Same alteration in sorted CSCs
and bulk tumor





No differences in VAF between
monolayer and spheres
Tong M. et al., 2018
[16]
HNSCC Primary tumorcells WES
From LOH analysis, it is
hypothesized that CSCs may
originate either from normal
tissue or from tumor cell
dedifferentiation
Salazar-Garcia L.






SNPs are mainly shared by sorted
CSCs and bulk tumor cells; a
small number is enriched either in
CSCs or in bulk cells
Prado K. et al., 2017
[18]
Various Cell lines SKY
More rearranged genotype of
spheres compared to parental cell
lines
Gasparini P. et al.,
2010 [10]
Abbreviations: CSCs, cancer stem cell; GBM=glioblastoma multiforme; SNP= single nucleotide polymorphism; WES
= whole exome sequencing; can = copy number alteration; aCGH = array comparative genomic hybridization; SKY
= spectral karyotyping imaging; WGS =whole genome sequencing; VAF = variant allele frequency; HNSCC = head
and neck squamous cell carcinoma; LOH = loss of heterozygosity.
In an independent study, Pesenti et al. obtained spheroids from three out of 10 primary GBM
tumor samples and analyzed them by array comparative genomic hybridization (aCGH). In each case,
they observed that tumor cells and their derived spheres shared the same genetic alterations [12],
in line with previous findings [19]. Altogether, all these studies demonstrated that neurospheres share
mutations and alterations with parental GBM cells.
Three other studies focused on breast cancer. Kleverbring and colleagues compared bulk tumor
cells and spheroids in ten primary samples, sorted CD44+/CD24− and CD44−/CD24− cells, and sorted
aldehyde dehydrogenase positive (ALDH+) and negative (ALDH−) cells in two additional samples,
by WES, and validated their findings by ultra-deep amplicon sequencing [14]. In all the analyses,
the Authors observed that CSCs and non-CSCs shared most mutations; thus, they concluded that the
existence of CSCs and non-CSCs is the result of a continuous dynamic transition between a stem- and
a non-stem functional state due to cell plasticity, rather than being distinct cell populations irreversibly
characterized by different genomic landscapes.
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Tiran et al. compared FACS-sorted CD44+/CD24− and ALDH+ cells with bulk tumor cells, obtained
from pleural effusions, by low-coverage whole genome sequencing (WGS), thus demonstrating that
FACS-sorted CSCs and the bulk tumor shared the same alterations [15].
Tong and colleagues compared, by WGS, MDA-MB-231 cells maintained either in adherent
culture conditions or in spheroid-forming conditions and validated their findings by target deep DNA
sequencing [16]. They demonstrated that the observed SNVs were characterized by a similar allelic
frequency in both cell culture conditions, thus indicating that no variant was specifically associated with
the stem status in their experimental model. Rather, spheroid-forming cells distinguished themselves
from the adherent counterpart for a distinct gene expression profile.
Once again, putative breast CSCs, either sorted on the basis of surface markers or enzymatic
activity or enriched by serum-free conditions, seem to be genetically similar to the bulk tumor cells,
even though they differ for the functional properties or their transcriptomic profile.
Finally, sporadic studies reported the CSC genomic profile of other tumor types. Salazar-Garcia
et al. tried to rebuild the CSC evolutionary history by WES analysis of ALDH+ and ALDH− cells
FACS-sorted from four HNSCC primary tumors, as well as normal cells. By evaluating LOH, they
hypothesized that in some patients CSCs derived from the neoplastic transformation of normal tissue,
whereas in other patients they derived from dedifferentiation of tumor cells. Indeed, if a variant was
present in normal cells and in CSCs in heterozygosity, but heterozygosity was lost in the differentiated
tumor cells, it is likely, according to the authors, that tumor cells derived from CSCs, which derived
from normal tissue. On the contrary, if a variant was present in heterozygosity in both normal and
tumor cells, but not in CSCs, such cells probably derived from tumor cell dedifferentiation. Thus,
in HNSCC, the authors observed a certain extent of genetic difference between CSCs and non-CSCs.
In one case of invasive urothelial bladder carcinoma, Prado et al. FACS-isolated
CD44+/CD49f+/EpCAM+ CSCs from both primary tumor and lymph node metastases and analyzed
them by WES, comparing results with the bulk tumor cells and normal lymph nodes [18]. They found
51 SNVs, of which the majority was shared by CSCs and tumor cells. Only a small number were
uniquely found in the bulk tumor cells or in CSCs. The authors concluded that the SNVs unique
in bulk were the result of clonal evolution and the SNVs unique in CSCs belonged to a quiescent
subpopulation that had not yet generated a progeny big enough to be detectable among the other
bulk cells.
3. The Case of Ovarian Cancer
Ovarian cancer is the fifth most frequent female cancer and the most common cause of death from
gynecological tumors [20]. Epithelial ovarian cancer (EOC) comprises almost 90% of all cases [21].
Even if several models have been proposed to explain EOC pathogenesis [22], origin of EOC is still
debated. Indeed, although serous tubal intraepithelial carcinoma (STIC)—a non-invasive tumor formed
preferentially in the distal fallopian tube epithelium—has been considered by the scientific community
as a precursor of high-grade serous carcinoma, in many cases it is unclear whether advanced stage
disease results from progression from an early stage.
Known risk factors for ovarian cancer include the number of ovulations [23], inflammatory
conditions [23,24], factors of hormonal nature [25], and genetic predisposition. Indeed, women with
Lynch syndrome and with germline mutations in BRCA-1 and BRCA-2 have increased lifetime risk of
several cancers, including EOC [19].
As for other tumors, CSCs in ovarian cancer has been identified according to the expression of
specific surface markers. One of the most widely used markers is CD133 or Prominin, introduced by
Curley and colleagues who demonstrated the higher tumorigenic potential of CD133+ cells, compared
to CD133−, isolated from primary samples of EOCs and injected into immunocompromised mice [26].
However, more recently, the use of CD133 has been debated and novel markers were added for CSCs
identification, such as ALDH, a detoxifying enzyme that enables CSCs to survive chemotherapeutic
drugs. Recently, CD44 and CD117 (c-kit) have been proposed by Zhang and colleagues as markers
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for CSCs in EOCs [27]. These results were also confirmed by Pastò et al., who demonstrated that
CD44+CD117+ double positive cells presented all canonical features of CSCs including ability to grow
as spheroids, expression of stemness-associated markers (e.g., Nanog, Sox2 and Oct4), expression of
multidrug-resistant pumps involved in drug extrusion, and high tumorigenic potential when injected
into immunocompromised mice [28].
With regard to ovarian cancer, it is unknown whether CSCs disclose a genetic fingerprint similar
to non-CSCs. We consider this question important, as its answer can help to discriminate whether
epithelial ovarian CSCs fit the standard CSC hierarchical model or whether they are to be considered a
functional state of tumor cells, as has been advanced for other tumor types. This lack of knowledge
motivated our choice to investigate in a pilot experiment the genomic complexity of DNA obtained
from matched CSCs and non-CSCs from ovarian cancer patients using a genome-wide SNP microarray.
We performed karyotype profile analysis on CSCs isolated from human primary cultures of EOC
established from high grade serous ovarian cancer ascitic fluid samples. The study was approved
by the local ethical committee. CSCs were FACS-sorted as CD44+CD117+ from the ascitic effusions
of eight patients and the extracted DNA was analyzed by high-density SNP arrays (CytoScan® HD
Array, Affymetrix, Santa Clara, California, USA) and compared to CD44+CD117− cells (non-CSCs).
The essential clinical features of these patients are summarized in Table 2.
Table 2. Clinical features of EOC patients involved in the study.
Sample Histotype Stage Grade Chemotherapy
CD117
enrichment *
49 III Serous-papillary 3C 3 Yes 7.08
49 V Serous-papillary 3C 3 Yes 2.41
84 IV Serous-papillary 3C 3 Yes 4.02
98 Serous 3B 1 No 21.53
101 Serous 3C 3 Yes 4.37
106 Bilateralserous-papillary 4 3 No 5.99
* CD117 mRNA expression (fold change) between CD44+CD117+ and CD44+CD117− FACS-sorted populations.
This parameter is used to check by an orthogonal technique CSC enrichment after sorting, EOC, Epithelial
ovarian cancer.
In three out of eight pairs of CSCs and non-CSCs analyzed quality of the DNA samples was too
low and precluded comparison of the genetic fingerprints of the two subpopulations. In the remaining
five pairs (49, 84, 98, 101, and 106), SNP analysis was successful and did not disclose any genetic
difference between CSC and non-CSC DNA samples, with the exception of a mosaic rearrangement on
chromosome 2 (arr[GRCh37] 2p21p11.2(45744391_84671244)× 2-3) detected in sample 84_CSC which
was not detected in the matched 84_non-CSC sample. Additional genetic studies, such as mutation
profiling of matched CSC and non-CSC samples could not be performed, due to limited amount
of tumor gDNA. Finally, in the case of patient #49, it was possible to obtain two samples of ascitic
fluid at a 12 month-interval (#49_III and #49_V) and SNP array analysis was performed in both cases
confirming an identical genotype of the CSC and non-CSC subpopulations. Notably, although within
each pair no or only marginal genetic differences were found, each tumor sample presented multiple
genetic alterations in terms of LOH, deletions or amplifications, compared with normal genomes.
The representative profile of one of these samples is shown in Figure 2.
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Figure 2. Comparison of chromosomal alterations in CSCs versus non-CSCs by Cytoscan SNP-array in
one representative ovarian cancer patient (#49 V).
In summary, although the number of pairs analyzed was low, we found that patient-derived
ovarian CSCs present very similar genetic features compared with non-CSCs. Therefore, it is likely that
epigenetic differences account for the marked functional differences between these two sub-populations
described elsewhere [28].
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4. Conclusions
The classical CSC model places CSCs at the apex of a hierarchical scale, implying different genetic
alterations in non-CSCs compared to CSCs, since a number of cell generations and time intervals
separate CSCs from the more differentiated cancer cells that form the bulk of the tumor (Figure 1).
In addition, CSCs seem to be endowed with more efficient DNA repair mechanisms, which partially
shield their genome from genotoxic events. In this study, we tested this prediction in the case of ovarian
cancer. Our results suggest that CSCs are genetically very similar to more differentiated cancer cells.
Altogether, our findings agree with the majority of previous studies in other tumor types (Table 1)
and support the alternative theory which poses CSC as a functional state of a tumor cell rather than a
specific cell type.
How is this functional state of CSCs induced? Although a full answer to this question is currently
not possible and is beyond the scope of this article, several intriguing hypotheses deserve to be
mentioned. In a recent work, Canova described three stemness-associated genes: Nanog, Sox2,
and Oct4 [29]. Each one controls the differentiation into a specific cell lineage, repressing the alternative;
when co-expressed, they actually block differentiation in all lineages, thus promoting a stemness
phenotype. We and others have found that ovarian CSCs co-expressed Nanog, Sox2, and Oct4,
whereas expression of these genes is reduced or absent in tumor non-CSCs. Thus, stemness seems to
be maintained because the differentiation pathways are blocked, rather than because the stemness
pathways are activated. In addition, it has been demonstrated that some cells (i.e., hepatocytes and
pancreatic islet cells) can de-differentiate under specific stimuli [30]. These results imply that tumor cells
(non-CSCs) could potentially be forced to stemness by pressure from surrounding cells (i.e., within the
tumor microenvironment) or stress conditions (i.e., anti-tumor drug treatment, metabolic substrate, or
oxygen restriction). In order to survive, these cells block differentiation pathways and de-differentiate
into CSCs, thus acquiring the ability to enter quiescence, overexpress multi-drug resistant pumps to
extrude toxic compounds, or activate altered metabolic pathways, all canonical features of CSCs [28,31].
In conclusion, our results, albeit limited to a small number of cases, support the alternative CSC
model shown in Figure 1 and suggest stemness as a dynamic state, a state of plasticity between tumor
cells and CSCs. The genetic similarity of CSCs and non-CSCs should be taken into account in the
development of successful new therapeutic approaches for ovarian cancer.
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Abstract: Resistance to therapy in patients with solid cancers represents a daunting challenge that
must be addressed. Indeed, current strategies are still not effective in the majority of patients;
which has resulted in the need for novel therapeutic approaches. Cancer stem cells (CSCs), a subset
of tumor cells that possess self-renewal and multilineage differentiation potential, are known to
be intrinsically resistant to anticancer treatments. In this review, we analyzed the implications
for CSCs in drug resistance and described that multiple alterations in morphogenetic pathways
(i.e., Hippo, Wnt, JAK/STAT, TGF-β, Notch, Hedgehog pathways) were suggested to be critical for
CSC plasticity. By interrogating The Cancer Genome Atlas (TCGA) datasets, we first analyzed the
prevalence of morphogenetic pathways alterations in solid tumors with associated outcomes. Then,
by highlighting epigenetic relevance in CSC development and maintenance, we selected histone
deacetylase inhibitors (HDACi) as potential agents of interest to target this subpopulation based on the
pleiotropic effects exerted specifically on altered morphogenetic pathways. In detail, we highlighted
the role of HDACi in solid cancers and, specifically, in the CSC subpopulation and we pointed out
some mechanisms by which HDACi are able to overcome drug resistance and to modulate stemness.
Although, further clinical and preclinical investigations should be conducted to disclose the unclear
mechanisms by which HDACi modulate several signaling pathways in different tumors. To date,
several lines of evidence support the testing of novel combinatorial therapeutic strategies based on
the combination of drugs commonly used in clinical practice and HDACi to improve therapeutic
efficacy in solid cancer patients.
Keywords: cancer stem cells; solid cancer; chemo-resistance; HDAC inhibitors
1. Introduction
Drug resistance is a well-known phenomenon that arises when a disease becomes tolerant to
treatment. This concept was described first in bacteria when they became resistant to antibiotics,
but since then, this phenomenon has been observed in other diseases, including cancer. Although
many types of cancers are initially susceptible to antitumor approaches including chemotherapy
and target-therapy and immunotherapy, over time, cancers can develop resistance through several
mechanisms, such as DNA mutations or metabolic changes that promote drug inhibition and
degradation [1]. Solid tumors are biologically complex structures with strong intratumor heterogeneity
that arises among cancer cells within the same tumor as a consequence of genetic changes, environmental
differences, and epigenetic and reversible changes in cell features [2]. Two main conceptual frameworks
have been elaborated to conceptualize the link between intratumor heterogeneity and therapy
resistance [3]. The first and most supported idea is clonal evolution, where a single mutated cell
creates a tumor and over time acquires additional mutations, resulting in several subpopulations with
evolutionary advantages [4]. An example of this comes from the analysis of circulating tumor DNA
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in the blood of colorectal cancer (CRC) patients with primary or acquired resistance to epidermal
growth factor receptor (EGFR) blockade [5]. Siravegna and colleagues exploited the circulating
tumor DNA to genotype colorectal tumors and tracked clonal evolution during treatment with
EGFR-specific antibodies, discovering that the percentage of mutated KRAS clones declines in blood
when EGFR-specific antibodies are withdrawn. This result suggests that resistant cell populations are
highly dynamic and that specific resistant clones arise in specific therapeutic conditions [5].
The second concept is the cancer stem cell (CSC) model. In the last decade, several lines of
evidence have suggested the presence of CSCs within the plethora of heterogeneous cells in solid
cancers. The CSC paradigm implies that the tumor is organized into a hierarchy of subpopulations
of tumorigenic CSCs and their non-tumorigenic progeny [6]. Among other described CSC features,
self-renewal potential and the capability to generate progenitor/daughter cells with various degrees
of differentiation make CSCsresponsible for tumor heterogeneity, drug resistance and tumor relapse
(Figure 1) [7]. However, although several papers have identified CSCs as being responsible for drug
resistance, the evidences are based on the identification and characterization of CSCs made with
numerous non-homogeneous experiments that are difficult to compare. Thus, to confirm this theory,
different approaches (in vitro, in vivo and in silico) must be implemented. Moreover, understanding
the features and the complex signaling mechanisms that underlie the CSC state is a key point in
highlighting new possible therapeutic strategies to target CSCs and to overcome resistance (Figure 1).
Figure 1. Cancer stem cells (CSCs) model of drug resistance:CSCs are responsible for tumor
heterogeneity, drug resistance and tumor relapse. Indeed, they may survive chemotherapy lead
to tumor relapse. Only by taking advantages of a CSCs specific targeted therapy, the outcome could
result in tumor regression and patients’ complete survival.
To date, it is widely recognized that alterations of the “epigenome” are therapeutically relevant
as well as DNA mutations. Indeed, in contrast to DNA mutations, “epimutations” must be actively
maintained through DNA replication for their dynamic nature; thus, their functional effects are
reversible and, consequently, targetable [8,9].
Increasing evidence supports the significance of the epigenetic regulation of CSCs’ features [10].
DNA methylation as well as histone acetylation are two epigenetic modifications that participate in the
modulation of expression of many genes, regulating important cellular activities such as proliferation,
differentiation and migration. While the role of DNA methylation in CSCs is relatively well established,
the role of histone and non-histone protein acetylation is still not completely clear.
It has been suggested that, globally, hypoacetylated chromatin is associated with cancer [11].
In detail, as reviewed by Liu et al. [12], the dysregulation of two classes of enzymes, histone
acetyltransferases (HAT) and histone deacetylases (HDAC), implicated in the regulation of acetylation
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levels is related to carcinogenesis and the regulation of the stemness properties of both normal
and cancer cells. Thus, acetylation and deacetylation of histones and non-histone proteins regulate
important signaling pathways involved in the maintenance of cancer stem-like cell traits such as
self-renewal or differentiation.
In invasive breast cancer patients, Sulaiman et al. recently observed a direct link between HDAC
expression and CSCs. By analyzing 887 samples, they found that high Wnt and HDAC activity was
associated with estrogen receptor 1 (ESR1) and progesterone receptor (PGR) repression, poor survival
and increased relapse. Interestingly, clinically achievable doses of Wnt, HDAC, and ESR1 inhibitors
were able to inhibit both bulk and CSC subpopulations, inducing the differentiation of CSCs in
non-CSCs without affecting normal mammary epithelial cells (MCF-10A) [13]. The overexpression of
individual HDACs has been correlated to predict poor patients’ prognosis independently of tumor
type and disease stage and a role of specific HDACs has been also reported in CSCs. The genetic
knockdown of individual isoforms such as HDAC1, 2, 3 and 6 have been shown to induce cell cycle
arrest and apoptosis in several tumor types including breast, lung, colon cancer and leukemia as
review by West et al. [14]. Witt et al. [15] taking advantage of two independent pairs of genetically
matched immortalized breast cancer cell lines, derived one from normal human breast precursor
epithelial cells with a mixed luminal-myoepithelial phenotype resembling CSC characteristics, and the
one from normal human mammary epithelial cells that exhibit a more differentiated myoepithelial
phenotype, demonstrating that HDAC1 and HDAC7 play an essential role in the stem-like phenotype,
maintaining the CSC population in breast and ovarian cancer models. Another work reported that the
levels of HDAC 1, 7 and 8 were overexpressed in pancreatic ductal adenocarcinoma (PDAC) compared
to those of adjacent non-tumor tissues and that patients with high levels of HDAC 1, 7 or 8 had
significantly worse overall survival compared to those with low expression levels [16]. A specific role
of HDAC8 was also demonstrated in breast cancer, where a selective HDAC8 inhibitor suppressed
Notch 1 expression [17]. Moreover, An et al. reported that, in triple negative breast cancer, HDAC8
induced cell migration by Hippo–Yap signaling. In detail, HDAC8 suppressed the phosphorylation of
YAPSer127 to promote its nuclear localization [18].
In contrast, Zimberlin et al. taking advantage of a mouse model in which HDAC1 and HDAC2
were simultaneously deleted in the intestine of adult mice, showed a rapid loss of intestinal homeostasis
and a decrease in stem-like features when both HDACs were deleted [19]. This latter observation
suggests a rationale for the intestinal side effects often observed during treatment with HDAC inhibitors
(HDACi). Similarly, Jamaladdin et al. by conditional knock-down in embryonic stem cellsdemonstrated
the essential role of HDAC1 and 2 in cellular proliferation and stem cell self-renewal throughthe
regulation of key pluripotent transcription factors [20]. Indeed, severe phenotypes were observed
following specific deletion of both HDAC1 and HDAC2 in the heart, brain, smooth muscle and neuronal
endocrine cells, suggesting a fundamental role for these HDACs in organ maintenance [21]. However,
the hypothesis of positive or negative effect exerted by HDACi on normal stem cells is controversial.
In this regard, Yusoff and colleagues published a systematic review about preclinical studies evaluating
the organ protection effects of HDACi. They conclude that HDACi reduce mortality in experimental
models by conferring multi-organ protection, often following a single treatment administered in some
cases post injury, suggesting the design of early phase clinical trials in order to confirm the protective
role exerted by these agents [22].
From this perspective, the increased dependency of tumor cells on HDACs and their upregulation
during transformation could help identifying the therapeutic window’s width of HDACi. At the same
time, we should be aware of the potential toxicity induced by this class of agent.
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Below, we provide an overview of promising therapeutic strategies based on HDACi, to sensitize
CSCs to antitumor approaches including chemotherapy and target and immunotherapy. We first
outlined the multiple alterations within morphogenetic pathways that show a critical role in CSC
plasticity and are potentially targeted by HDACi. Then, considering all intrinsic and extrinsic features
of CSCs responsible for chemo-toxicity escape, we discuss the capability of HDACi, alone or in
combination, to overcome chemo-resistance.
2. Morphogenetic Pathways Are Dysregulated in Solid Cancers
As extensively demonstrated, stem cell proliferation and cell fate are under the control of
several morphogenetic pathways. Among them, we focused on those that have been extensively
characterized in cancer: Wnt/β-catenin, Notch, Hedgehog, TGF-β/BMP, JAK-STAT and Hippo pathways
(Figure 2). These pathways can be altered in solid cancer and participate in phenomena such as
drug resistance. However, these pathways undertake a different role depending on which solid
cancer is considered. To identify specific morphogenetic pathways that are more relevant than others
in specific solid tumors, we performed a bioinformatics analysis, taking advantage of 16 public
solid tumor expression datasets (Table 1 reports The Cancer Genome Atlas (TCGA) Id, the sample
size and the patient status for each dataset) by using the online tool R2 Genomics Analysis and
Visualization Platform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). R2 calculates, for all the genes in
the differentiation-related KEGG pathways (718), whether they are differentially expressed considering
overall survival, which is the best endpoint to consider to compare multiple cancer types with the goal
of identifying common themes that transcend the tissue of origin and may inform precision oncology,
as described in a recent publication by Liu et al. [23].
We are aware that our pan-cancer systematic analysis is performed across all TCGA tumor types
without considering patients clinical features. In details, we did not considered age of diagnosis and
grade, when available in TCGA datasets. Thus we anticipated that ouranalysis hassome limitations.
In a subsequent calculation, the overrepresentation of these genes in the individual pathways was
determined. A valuewas reported depending on how many related genes were identified withineach
pathway as compared with all 718 differentiation-KEGG pathways analyzed. In detail, we tested the
significance of the 6 chosen morphogenetic pathways described above. In Table 1, the significance
values are reported for the 6 pathways for each solid cancer, and the differences among the 6 pathways
analyzed are represented by a color scale. From the resulting list, it is obvious that any specific
pathway can be indicated as most relevant in the poor prognosis of patients for all cancer types.
Notably, the Hippo pathway had a strong over-representation in patients with a poor prognosis
among solid tumors (first in 7/16 tumors), playing a critical role in pancreatic, prostate, stomach
adenocarcinomas, lung squamous and cervical cell carcinomas, sarcoma and skin cutaneous melanoma.
Similarly, the Wnt/β-catenin pathway seems to play a very important role, representing the most
important pathway in 4/16 cases, such as mixed colon adenocarcinoma, liver hepatocellular, head and
neck and bladder urothelial carcinomas and third most-important pathway in 8/16 cases (Table 1).
Jak/ STAT resulted as key pathway in rectum adenocarcinoma and glioblastoma, while TGFβ in
lung adenocarcinoma, Notch in kidney renal clear cell carcinoma and finally Hedgehog in breast
invasive cancers.
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2.1. Wnt Signaling
Wnt signaling is one of the main pathways regulating development and stemness, and it has
also been closely related to cancer. The canonical Wnt signaling pathway, which through β−catenin
modulates the expression of specific target genes, is an important regulator of stem cells and CSCs and
is aberrantly activated during the development of various human cancers as reviewed by Fodde et
al. [24]. Gain-of-function mutations of the CTNNB1 gene (encoding β−catenin) and loss-of function
mutations of APC and AXIN genes were identified as the main mechanisms associated with Wnt
signaling dysfunction in cancers [25]. The role of this pathway in carcinogenesis has been most
prominently described for colorectal cancer (CRC). In the gut, the Wnt pathway is essential for
sustaining cell proliferation within the crypt base and shows a gradient in expression along the crypt
axis. Manipulation of Wnt signaling can drastically alter crypt integrity, while the stimulation of Wnt
activity by, for instance, R-spondin leads to crypt proliferation [6], and its inhibition leads to the loss of
crypt formation and progenitor offspring [7]. Moreover, the presence of Wnt in conjunction with other
morphogenetic pathways is critical for maintaining normal and cancer cycling stem cells and Paneth
cells, as reviewed by Reya and Clevers [26].
2.2. Hippo Pathway
In mammals, cell–cell junctions and apicobasal polarity are involved in upstream activation
of the Hippo cascade. The core of the Hippo pathway is a kinase cascade: the nuclear result is
that Lats1/2, nuclear dbf2-related family kinases, phosphorylate two major downstream effectors,
Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), resulting
in their ubiquitination and proteolysis [27]. Nguyen et al. showed that YAP1 induced transcriptional
changes and resulted in age-related prostate tumors in mice [28]. Similarly, Zhang et al. showed a
significant upregulation and hyperactivation of YAP in castration-resistant prostate tumors compared
to their levels in hormone-responsive prostate tumors. They claimed that the enhanced expression of
YAP was able to transform immortalized prostate epithelial cells and promote migration and invasion
in both immortalized and cancerous prostate cells [29].
2.3. Stats
Stats are a family of transcription factors with additional functions in the cytoplasm,
the mitochondria and the nucleus. They participate in chromatin conformation and epigenetic
marking in the nucleus. In addition, they affect oxidative metabolism in the mitochondria and
in the cytoplasm, and they interact with microtubule components to regulate cellular motility [30].
However, in our bioinformatics analysis, the JAK/STAT pathway was highly represented in glioblastoma
and rectum adenocarcinoma (Table 1). Signal transducer and activator of transcription 3 (STAT3)
is aberrantly activated in glioblastoma and has been identified as a relevant therapeutic target in
this disease and many other human cancers [31]. Moreover, Gangulyand colleagues demonstrated
high levels of STAT 3-phosphorylation in Tyrosine 705 and Serine 727 in glioma-initiating cells
compared to their differentiating counterparts, suggesting a clear involvement of STAT pathway
activation in gliomagenesis [32]. In addition, a strong link between IL-6-STAT3 signaling and
O6-methylguanine DNA methyl transferase expression and methylation and to temozolomide
sensitivity in glioblastoma was found, suggesting a possible combination therapeutic approach
based on IL-6/STAT3 inhibitors [33,34]. Nevertheless, STAT3 is over-activated in many breast cancers,
while STAT5 promotes both survival and differentiation of mammary epithelium. Moreover, it is
known that, in the context of breast cancer, STAT3 activity can be modulated through STAT5 activity,
and their combined functions can have an impact on breast cancer progression [35].
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2.4. TGF-β Signaling
TGF-β signaling controls the cell cycle, differentiation and the microenvironment in epithelial
cells through both the SMAD protein family and non-SMAD signaling pathways. In colon cancer,
Yusra et al. showed that the expression levels of TGF-β receptor genes, TGFBR1 and TGFBR3, were
higher in CD133 positive (+) colon CSCs, suggesting that CD133+ colon CSCs have increased sensitivity
to TGF-β [36]. They showed high expression of the TGFBR1 gene in the tumor budding structures
derived from the mouse xenograft with TGF-β transfected cells. Importantly, Yu and colleagues
showed that TGFBR2 was responsible for triggering the TGF-β signaling pathway through recruitment
and phosphorylation of Type I receptor, which has been shown to act as a tumor suppressor by assisting
in the regulation of stemness through downregulated signaling effects of the Wnt/β-catenin signaling
pathway [37].
2.5. Notch Pathway
Regarding the Notch pathway, the literature provides many data about its fundamental role in
development and maintenance of the hematopoietic system. Less is available on its role in solid cancers.
In hematopoiesis, Notch plays a central role in cell fate proliferation and differentiation of stem cells.
There is also evidence demonstrating that the Notch pathway can leads hematopoietic stem cells and
common lymphoid precursors to undergo T- or B-cell differentiation [38]. Moreover, Notch alteration
has been associated with tumorigenesis, since it can be considered, depending on cell model, as an
oncogene or a tumor suppressor [39].
2.6. Hedgehog Pathway
Finally, the Hedgehog (Hh) pathway is mainly involved in tissue repair, embryonic development,
and epithelial-to-mesenchymal transition in cells. In the signaling cascade, Hh ligands, such as Sonic
Hedgehog (Shh), Indian Hedgehog (Ihh), and Desert Hedgehog (Dhh), undergo cleavage and produce
a signaling protein with dual lipid modifications. Subsequently, the signaling cascade initiated by
smoothened (SMO) leads to activation and nuclear localization of GLI transcription factors, which drive
the expression of Hh target genes, mostly involved in proliferation, survival, and angiogenesis [40].
This signaling transduction pathway has been shown to be required for self-renewal and proliferation
of cerebellar, retinal, and pancreatic CSCs [41]. Recently, Duan et al. have shown that Hh signaling
is upregulated in breast cancer cells through nuclear factor-κB (NF-κB) activation and promoter
hypomethylation. In addition, overexpression of Shh enhances the self-renewal capacity and migration
ability of breast cancer cells and is a poor prognostic indicator in breast cancer [42].
Because of a clear deregulation is described in multiple cancer types, various clinical approaches
have been aimed to target the aforementioned pathways. Although several types of inhibitors
of the Wnt-pathway are under development as single-agent anticancer therapies, they have not
led to exciting results thus far. Indeed, even if PRI-724 (CBP/β-catenin antagonist), LGK-974
(Porcupine inhibitor), vantictumab (anti-Frizzled-1/2/5/7/8 antibody), OMP-54F28 (Frizzled-8–Fc
decoy fusion protein) and TSA101 (a radiolabeled anti-Frizzled-10 antibody) are all currently in
early clinical development, the results obtained in three concluded studies in monotherapy with
PRI-724 (NCT01302405), vantictumab (NCT01345201) and OMP-54F28 (NCT01608867) are not very
promising [42].
In solid tumors, several clinical trials are ongoing to test the efficacy of two major classes of Notch
inhibitors such as γ-secretase inhibitors, which obstruct Notch receptor cleavage, and monoclonal
antibodies that interfere with the Notch ligand-receptor interaction, as reviewed by Venkatesh et al. [38].
Thus far, the best results have been obtained in a clinical trial that ended in 2012, where a γ-secretase
inhibitor (MK-0752) was used in adult patients with advanced solid tumors, mostly gliomas. Only one
objective complete response and stable disease longer than 4 months in 10 patients were observed
among 113 patients enrolled [43].
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Figure 2. CSCs-activated signaling pathways: Schematic representation of the signaling pathway
responsible for induction and maintenance of CSC state. The transcription factors, co-factors, main nodes
reported are targetable by drugs. (Adapted from Pattabiraman and Weinberg, Nat Rev Drug Discovery,
2014 [44]).
Limited results have been obtained with vismodegib, an Hh pathway inhibitor, which was
approved by the European Medicines Agency (EMA) in 2013 for the treatment of metastatic basal
cell carcinoma (BCC) or locally advanced BCC in patients who are not candidates for surgery or
radiotherapy. Indeed, the gain in overall survival in these patients compared to standard therapy,
is only 0.8 years [42].
Currently, several other attempts are ongoing, targeting CSCs to deplete the tumor; however,
to date, no specific CSC targeted therapy is yet available. In contrast, it may be more effective to use
an approach based on pushing CSCs to differentiate and on sensitizing them to chemotherapy by
modulating their epigenetic profile. Indeed, by highlighting the significance of the epigenetic profile in
CSC maintenance, in the next sections we reviewed the role of HDACi to target CSCs, both directly and
through the modulation of the morphogenetic pathways described above. Actually, by demonstrating
that morphogenetic pathway alterations correlating with poor prognosis often coexist in a solid cancer
type, we anticipated the limited efficacy of targeted agents inhibiting a single pathway as reported
above. This could shed a new light on therapeutic agents with pleiotropic effect such as HDACi.
Therefore, we next discussed how HDACi could play a role in overcoming resistance to some of the
most commonly used chemotherapeutics and their ability to enhance specific cancer therapeutic agents
by targeting CSCs.
3. Histone Deacetylase (HDAC) Inhibitors Target Cancer Stem Cells (CSCs) and
Morphogenetic Pathways
It is well known that the morphogenetic pathways described above are frequently dysregulated in
cancer by epigenetic mechanisms as reviewed by Munozet al. [45]. Since trichostatin A (TSA), a natural
product isolated from Streptomyces hygroscopicus, was described as an HDACi [46], several agents of this
class of epigenetic drugs have been synthetized and tested as anticancer agents, both in preclinical and
clinical models. HDACi are truly pleiotropic agents, which act through a wide variety of disparate and
mutually interactive mechanisms. Indeed, by influencing the chromatin structure, HDACi regulate
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gene expression. Moreover, by acting on non-histone proteins deacetylation, HDACi can also modulate
cellular functions independent of gene expression. In this way, HDACi regulate different altered
pathways in cancer, such as apoptosis, DNA repair, growth arrest, terminal differentiation, senescence,
apoptosis, anti-angiogenesis, anti-metastasis and immune responses, all of which represent hallmarks
of cancer and critical characteristics of CSCs [11]. Finally, HDACi have a strong effect on CSCs by
pushing them from a stem-like and resistant phenotype to a more differentiated and sensible phenotype
(Figure 3).
 
Figure 3. Histone deacetylase inhibitors (HDACi) pleiotropic effects toward CSCs: HDAC are described
to modulate several pathways involved in cell cycle, metabolism, stress adaptation, intrinsic and
extrinsic apoptosis, motility and immunity through chromatin modeling and non histone proteins
modulation. The plasticity of epigenetic regulation makes HDAC inhibition a good strategy to target
CSCs chemo-resistant subpopulation in solid cancer pushing the CSCs to differentiate and so gain a
chemo-sensible phenotype.
In recent years, we demonstrated that HDACi, such as vorinostat and valproic acid (VPA),
were able to induce selective death of the CSC subpopulation in non-small-cell lung cancer (NSCLC)
and CRC models, as evaluated by colony and sphere formation assays [47,48].
Similar results were obtained by Salvador et al. who demonstrated that the HDACi abexinostat
induced cytotoxicity in 16 breast cancer cell lines (BCLs), as evaluated by Aldefluor and tumorsphere
formation assays. They found that abexinostat induced CSC differentiation, identifying the long
non-coding RNA Xist (Xinactive specific transcript) as a biomarker that can predict the BCL response to
HDACi [49]. In line with these findings, Cai et al. demonstrated that TSA or vorinostat, downregulating
HDACs 1, 7 and 8, repressed epithelial to mesenchymal transition (EMT) in PDAC and targeted
well-known CSC phenotypes, including resistance to therapy and metastasis. Notably, they also
suggested that HDACi such as mocetinostat, which specifically inhibits isoforms 1, 2, 3 and 11 HDACs,
were not good candidates for PDAC treatment [16]. Moreover, we obtained preliminary data showing
that HDACi sensitized cancer cells to chemotherapeutics by pushing them in a differentiation state in
colorectal and prostate cancer cell models by modulating morphogenetic pathways [50].
In addition to the preclinical studies that focused on HDACi and their functional effects on
modulating CSC subpopulations, several attempts are aiming to explain the molecular mechanisms
underlying HDACi effects of HDACi on them. We most likely believe that HDACi strongly modulate
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the CSC phenotype through their ability to modulate one or more morphogenetic pathway main
components, as described above.
Similarly, several data support the close connection between HDAC6 and multiple components
of the Wnt, Hippo, TGFβ and Hh pathways. Concerning the Wnt pathway, two papers showed that
HDAC6 inhibition led to a decrease in β-catenin nuclear localization, resulting in a strong inhibition of
cell proliferation [51,52]. In breast cancer, the involvement of HDAC6 in the Hippo pathway-regulating
network was demonstrated by downregulation of YAP protein levels [53] and by a strong acetylation
and destabilization of the tumor suppressor MST1 [54]. Some evidence suggests that HDAC6 plays
a role in theTGFβ−SMAD activation pathway, and thus its inhibition establishes a decrease in EMT
induction [55,56]. Finally, most recently, it has been shown that HDAC6 inhibition leads to inactivation
of Gli1, resulting in glioma cancer cell radio-sensitization [57]. In the same manner, HDAC1 has been
shownto be essential for SMAD2-3 and Gli1 transcriptional activation, consequently also quenching
related pathways [58,59]. As expected, the molecular mechanism becomes complicated when we
consider the effect of HDACi, which target more than one HDAC isoform and, simultaneously,
more than one morphogenetic pathway.
For example, valproic acid (VPA), a class I- II HDAC inhibitor, is clearly able to inhibit TGF-β,
Yap and Notch signaling by dual suppression of SMAD4 and SMAD3 [60], by depletion of nuclear
YAP [61] and by downregulation of the transcription factor Notch1 and its target gene HES-1 [62].
Moreover, it has been reported that the pan-HDAC inhibitor trichostatin A (TSA) and the selective
HDAC inhibitor entinostat (isoforms 1, 2 and 3) are able to reduce Wnt pathway activation by induction
of DKK1, a negative regulator of β−catenin [63] and by inhibition of HDAC1-2 [19].
Finally, as VPA and TSA, vorinostat modulates SMAD4 localization and Nocth3 expression [64,65],
but Fan and colleagues also showed that a small molecule SMO-HDAC antagonist was able to retain
inhibitory activity for Gli transcription induced in SMO-dependent and SMO-independent ways [66].
Furthermore, TSA and domatinostat, two specific class I and II HDAC inhibitors, switched off Gli
signaling by downregulating a transcriptional factor of FoxM1 [67] in the first case and by inhibition of
HDAC1/2/3 in the second case [68]. However, it should be noted that some papers have reported that
VPA treatment is responsible for Wnt pathway activation by β−catenin nuclear stabilization [13,69].
However, the exact function and interactions governing HDACi activity remain elusive. Thus,
further investigationsare necessary to understand the mechanism by whichHDACi target CSCs. Only a
clear view of their actions will lead to the identification of a biologically efficacious dose. Thus,
it should always be considered that the effects of HDACi depend not only on the cancer type but also
on the context, dosing and schedule of treatment. For example, the association of entinostat with
the aromatase inhibitor exemestane has been designated as a breakthrough therapy for the treatment
of recurrent/metastatic estrogen receptor-positive breast cancer based on the results of a phase II
randomized trial [70]. In contrast, the clinical activity of mocetinostat, tested in phase I/II in association
with gemcitabine in patients with solid tumors including pancreatic cancer, has been considered
insufficient to merit further testing in this setting [71], as well as due to the significant toxicities in the
phase II cohort [71].
4. CSC Chemo-Toxicity Escape Mechanisms
Cancer drug-resistance can be due to intrinsic or acquired factors. The intratumor heterogeneity
of tumor cells and the tumor microenvironment and the presence of cancer stem cells are all
intrinsic characteristics involved in cancer drug resistance. But latter, has also been observed in
most drug-sensitive tumor types for most classes of drugs as an acquired mechanism.
Several mechanisms of cancer drug resistance are well described in both tumor cells and CSCs,
and the most important and targetable ones, such as multidrug resistance [72], resistance to apoptosis
program, increased repair of drug-induced DNA damage and quiescence phenotype induction [73],
are presented schematically in Figure 4. In addition to the common and well-known mechanisms by
which normal stem cells and CSCs overcome drug toxicity, some others have recently been described,
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such as metabolism adaptation or activation of the immune escape program, while others remain to
be uncovered.
Figure 4. CSCs model of drug resistance: CSCs features mostly responsible for drug resistance.
The CSC-resistant phenotype is likely to be the result of a complex but specific mixture of molecular
circuitries, and it is the complex nature of this phenomenon that explains the difficulties encountered
in trying to overcome drug resistance by targeting this specific cell population.
4.1. Multidrug Resistance
Over 40 years ago, multidrug resistance, the high expression of drug efflux pumps, such as
ATP-binding cassette (ABC) transporter family proteins, was the first described innate resistance
mechanism. Overexpression of ABCB1 confers cancer cell resistance to multiple drugs (i.e., DNA-toxic
antitumor agents, reactive oxygen species –ROS- inducers), including colchicine, doxorubicin, etoposide,
vinblastine and paclitaxel [74]. The critical role of ABC transporters in CSC drug resistance was
reported by Chau et al. in c-Kit+ ovarian CSCs. The authors demonstrated that Wnt/β-catenin regulates
ABCG2 expression and resistance to cisplatin/paclitaxel. LEF/TCF binding sites are within the ABCG2
gene promoter, indicating that ABCG2 is a transcriptional target of β-catenin [75].
Moreover, in a prospective clinical study of 142 CRC patients, Guo et al. found that ABCB5
mRNA transcripts are significantly enriched in patient peripheral blood specimens compared with
those in non-CRC controls and correlate with CRC disease progression. Notably, ABCB5 regulates CRC
invasiveness, at least in part by enhancing AXL receptor tyrosine kinase signaling [76]. Additionally,
in glioblastoma and melanoma, high expression of drug efflux pumps, such as ABCG2 and ABCB5,
is reported in CSCs [77,78].
4.2. Apoptosis
In addition to other mechanisms, CSC resistance to drug cytotoxicity is commonly associated
with intrinsic or acquired defects and/or inefficient signaling in either the extrinsic or intrinsic pathway
of apoptosis. Regarding the extrinsic pathway, lung, pancreatic, breast and glioma CSC models exhibit
resistance to TRAIL-induced apoptosis by genetic and epigenetic silencing of pro-apoptotic factors,
such as caspase 8 or c-FLIP, or by upregulation of TRAIL-R2 receptor, as reviewed by Fulda [79].
Regarding the intrinsic pathway, the role of Bcl-2 family members in tumorigenesis and cancer cell
survival has been known for a long time, and its effects on CSC biology are well described. Bcl-2 is
highly expressed in CD44+/CD24-/low breast CSCs [80] and in quiescent leukemic CD34+ progenitor
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cells [81]. Similarly, in colon CSCs, high levels of Bcl-xL activity were found in a BH3 mimetic
screen [82]. Reductions of Bcl-xL expression resulted in increased sensitivity to oxaliplatin and
5-fluorouracil (5-FU) [83]. Other members of the Bcl-2 family can be involved in CSC apoptotic
escape, such as MCL-1, that was found to be downregulated by MiR-519d in cisplatin-resistance breast
CSCs [84]. However, it is clear that the plethora of intrinsic and extrinsic apoptosis factors involved
in the fine-tuning of the apoptotic process could be affected. Indeed, Rouhrazi et al., performing a
quantitative real-time polymerase chain reaction (qRT-PCR) screen for 84 key apoptosis-related genes
in zoledronic acid-resistant CD133+/CD44+ prostate CSCs, showed significant over/underexpression
of a cluster of anti-apoptotic and pro-apoptotic genes [85]. Our group confirmed the increase in
expression of antiapoptotic proteins in another preclinical model of zoledronic acid resistant prostate
cancer cells in which the acquisition of CSCs features has been described. Interestingly, activation of
the p38-MAPK in these cells was found to be a crucial mechanism in the regulation of several biological
processes, such as antiapoptotic, prosurvival, proinflammatory and proangiogenic events, as well
as EMT and invasion [86,87]. Similarly, a proteomic analysis of colonosphere cultures derived from
resection specimens of liver metastases in patients with colon cancer highlighted that 20 of 32 proteins
upregulated two-fold in CSCs were classified as regulating "Cell Death" [88]. From this perspective, in
contrast to the observed CSC high apoptotic threshold, only combination therapies and drugs with
pleiotropic effects could be effective at targeting the multiple resistance mechanisms.
4.3. Alteration of DNA Damage Repair System
Since radiotherapy and the majority of chemotherapeutic agents induce DNA damage, perturbation
of the DNA damage repair system is another well-described mechanism of CSCs to escape genotoxic
effects. As reviewed by Vitale et al. various molecular alterations lead to a robust DNA damage response
(DDR) in CSCs compared with the relatively more differentiated malignant cells in glioblastoma,
breast, lung and CRC [73]. However, each CSC could establish a specific alteration that increases the
basal dependence on specific DDR components for proliferation and survival. Moreover, each DDR
protein is under the control of several factors and in turn modulates several phenomena such as
ATM (ataxia-telangiectasia mutated). Indeed, Bao et al. highlight that the CSC population exhibits
an upregulation of phosphorylated ATM, Chk2, RAD51 and RAD17, either at baseline or in response
to radiation [89]. Moreover, Carruthers et al. indicated that CSCs possessed ATM-independent
mechanisms for activation and maintenance of the G2/M checkpoint, whereas differentiated tumor
cell populations appeared to be more reliant on ATM function for G2/M checkpoint integrity [90].
In addition, Zhang et al. showed that ZEB1 participated in an ATM-dependent mechanism in the DDR
response in breast CSCs by stabilizing CHK1 [91].
4.4. Quiescence State
In addition to a robust DDR, CSCs display a persistent quiescence state. The notion that standard
chemotherapeutic resistance results from the persistence of quiescent CSCs has emerged recently
by genetic-fate mapping in several solid tumor types. A slow proliferative state is essential for
the survival of cells (resistance) in the presence of oxaliplatin or temozolomide treatments in CRC
and in glioblastoma, respectively [92,93]. Knowledge concerning activated or silenced mechanisms
relying on this state could be useful to employ combinatorial therapeutic strategies to manipulate
and to sensitize CSCs to chemotherapeutics. For example, activated TGF-β signaling (among others,
responsible for triggering cytostatic signals) drives the dormancy of CSCs in mouse squamous cell
carcinoma, leading to cisplatin resistance [94]. Similarly, a subpopulation of CSCs undergoing EMT
is associated with a slow proliferative state that confers resistance to anti-proliferative drugs in a
model of breast and skin cancer [95]. Moreover, Soeda et al. reported that inhibition of the p38 MAPK
pathway led to an increase in EGFR expression but reduced proliferation and cell death induction
and promoted maintenance of an undifferentiated state [96]. Recently, it has been demonstrated that
leukemia stem cells express the highest levels of enhancer of zeste homolog 1 (EZH1) and 2 (EZH2),
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two histone-lysine N-methyltransferases that mediate methylation of histone H3 at lysine 27 (H3K27),
to maintain the quiescent state. The key role of these two enzymes was confirmed, showing that
inactivation of EZH1/2 eradicated quiescent leukemia stem cells, inducing cell cycle progression and
differentiation [97]. Notably, EZH2 was also associated with radioresistance of glioma stem cells [98]
as well as CD24–/lowCD44+ population amplification in breast cancer upon treatment [99].
4.5. Metabolism Adaptation
In recent years, conventional wisdom indicates that CSC metabolism adaptation could play a main
role in chemoresistance and radioresistance. Metabolism based on oxidative phosphorylation is crucial
for the generation of energy needed to support the maintenance of tumors; however, this process
also produces reactive oxygen species (ROS), which have the potential to cause stem cell dysfunction.
For this reason, CSCs usually grow in a hypoxic niche and employ a glycolytic metabolism [100,101].
Additionally, CSCs are characterized by increased ROS levels, reduced oxidative damage and, thus,
longer survival, potentially due to a combination of mechanisms that arise in the tumor, including the
modulation of multiple antioxidative enzyme systems or redox-sensitive signaling pathways, such as
NRF2, NF-κB, c-Jun, and HIFs, leading to increased expression of antioxidant molecules, as recently
reviewed in detail by our group [102].
Another altered metabolic feature described in the CSC subpopulation is the high glycolytic
metabolism recently demonstrated to be related to the high mitochondrial mass in MCF-7 breast cancer
cells [103]. In detail, an unbiased proteomic approach has allowed the establishment that mitochondrial
proteins are among the most strongly upregulated in cells overexpressing WNT1 and FGF3, which
are responsible for the stemness phenotype. Interestingly, the mito-high MCF7 cells are also resistant
to paclitaxel, resulting in little or no DNA damage [103]. Moreover, an enrichment in mitochondrial
content has been associated with a higher DNA repair capacity in human breast cancer stem cells,
suggesting that an increased mitochondrial mass may enable CSCs to cope efficiently with the action
of certain anticancer drugs [104]. In line with these findings, a metabolic profile of CD34+ and CD34−
chronic myeloid leukemia (CML) cells, derived from fourindividuals by recording steady-state levels
of 70 metabolites through liquid chromatography–mass spectrometry (LC–MS), highlighted a selective
increase in glucose oxidation and anaplerosis, the process of replenishment of depleted metabolic
pathway intermediates, in CML cells resistant to imatinib treatment [105].
4.6. Immune Evasion
Finally, a recently described CSC-resistance feature is immune evasion. CSCs have evolved
sophisticated strategies to escape host immune surveillance that are targets of current therapeutic efforts
(as reviewed by Fiori and Maccalli) [106,107]. A bioinformatic approach using The Cancer Genome Atlas
(TCGA) revealed an enrichment of tumor-intrinsic WNT/β-catenin signaling in non-T cell inflamed
tumors, providing a strong rationale for the development of pharmacologic inhibitors of this pathway
with the aim of restoring immune cell infiltration and augmenting the immunotherapeutic response [108].
Molecularly, Agudo et al. showed that cycling epithelial stem cells, including Lgr5+ intestinal stem
cells, as well as ovary and mammary stem cells, were eliminated by activated T cells, but quiescent
stem cells in the hair follicle and muscle were resistant to T cell killing. Mechanistically, the authors
highlighted that the quiescent stem cells downregulated the antigen presentation machinery, including
MHC class I and TAP proteins, through the trans-activator NLRC5 [109]. Similarly, the slow-cycling
CSC subpopulation in CRC, with the loss of the major histocompatibility complex by overexpression of
costimulation molecules and CSC-specific antigens, were resistant to the cytotoxic effect of dendritic and
cytokine-induced killer cells [110]. Interestingly, Peng et al. found that myeloid-derived suppressor
cells (MDSC) promoted tumor formation by enhancing breast CSC-like properties as well as by
suppressing T cell activation, claiming a cross-talk between MDSC and breast CSCs. Specifically,
MDSC inducing IL6-dependent phosphorylation of STAT3 and activation of NOTCH through nitric
oxide lead to prolonged STAT3 activation in CSCs [111]. However, our knowledge about specific
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immunological properties of distinct CSC populations is still limited and requires further study to
implement new targetingtherapeutic strategies.
Overall, these observations suggest that CSCs have several ways to escape anti-tumor approaches
and that it is critical to identify CSC-specific alterations for targeting within a single tumor or rather to
use drugs with pleiotropic effects to successfully target this difficult to kill subpopulation.
5. HDAC Inhibitors Are Able to Overcome Chemo-Resistance
As pleiotropic agents, HDACi can modulate a wide variety of molecules and target several related
molecular pathways. Thus, it is obvious that this class of drug could affect many escape chemotoxicity
strategies implemented by tumor cells and CSCs, which are described above.
Indeed, it has been demonstrated that entinostat, as a type of HDACi, reverses cisplatin resistance,
among various mechanisms, by the induction of apoptosis with an increase in cleaved PARP and a
decrease in MDR1 in esophageal squamous cell carcinoma [112]. Similarly, Zhao et al. observed that
specific inhibition of HDAC8 mediates the upregulation of miR-137 and inhibition of MDR1 to sensitize
neuroblastoma cells to doxorubicin (Dox) [113]. In a lung cancer cell model, To et al. demonstrated
that belinostat reverts cisplatin resistance by the inhibition of both ABCC2 and the DNA repair gene
ERCC1 [114].
Concerning P-glycoprotein (P-gp), another crucial drug efflux transporter, although it has been
reported that HDACi upregulates P-gp in colorectal cancer cells through STAT3 induction and ABCB1
posttranscriptional stabilization [115], Tomono et al. demonstrated that HDACi inhibited Snail-induced
activation of P-gp in lung cancer Snail-overexpressing cells [116]. Moreover, in squamous carcinoma
cell lines, Chikamatsu et al. reported that the expression of CSC markers, such as CD44 and ABCG2,
decreased upon vorinostat and TSA treatment and that the combination of these HDACi with cisplatin
or docetaxel had a synergistic cytotoxic effect [117].
As pointed out above, HDACi usually work as sensitizers and modulators of the entire gene pattern,
synergizing with several chemotherapeutics and molecular targeted agents. Thus, the doses used in
in vitro and in vivo experiments are not expected to provide clear apoptosis induction. Nevertheless,
Aztopal et al. reported that relatively low doses (2.5 and 5 mM) of VPA prevented mammosphere
formation, inducing apoptosis [118]. Similarly, Di Pompo et al. reported that new compounds with
selective HDACi activity affect CSCs generated from three different histotypes of human sarcomas,
inducing, among others, apoptosis [119]. The author demonstrated that concurrent class I and IIb
HDAC inhibition is crucial to obtain anticancer effects. In pancreatic CSCs, vorinostat epigenetically
restores the expression of miR-34a, leading to apoptosis through caspase-3/7 activation [120]. Moreover,
HDAC1 inhibition contributes to NANOG-mediated TRIM17 and NOXA gene expression, leading to a
downregulation of antiapoptotic MCL-1, conferring immuno- and chemo-sensitization [121].
Since a clear characterization of CSCs has not yet been defined completely, we believe that the
majority of findings regarding overcoming chemoresistance were not described in a specific cell
subpopulation; therefore, we have also reviewed the literature on HDACi and their ability to sensitize
resistance in subpopulations in many cancer types regardless of stem-like features.
Fluoropyrimidine-based therapy still represents a classic therapeutic strategy in several solid
tumors, such as colorectal, breast and pancreatic cancers; however, chemo-resistance remains a big
open question to resolve. Resistance to 5-FU or to its pro-drugs may result from deficient drug uptake,
alterations of targets, activation of DNA repair pathways, resistance to apoptosis andalterations of the
tumor microenvironment.
We and others have previously demonstrated synergistic antitumor effects of different HDACi in
combination with fluoropyrimidines in different tumors, such as breast, colorectal [48,122–125] and
head and neck squamous cell carcinomas (HNSCC) [126]. Our results demonstrated that the synergistic
interaction between HDACi and 5-FU is dependent on both the downregulation of thymidylate synthase
(TS), the key enzyme in the mechanism of action of 5-FU, and on the upregulation of thymidine
phosphorylase (TP), the key enzyme converting capecitabine to 5-FU. Interestingly, HDAC3 is the
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HDAC isoform principally involved in TP upregulation. These observations could be clinically relevant
since HDAC3 hasrecently emerged as a critical anticancer target [127–129], and more selective HDAC3
inhibitors may have a more favorable side-effect profile compared with class-I or non-selective HDACi.
Intrinsic or acquired resistance to 5-FU is often related to TS protein overexpression. Indeed, high levels
of TS expression have been correlated with poorer overall patient survival in several tumors [130].
Interestingly, we have previously demonstrated a synergistic antitumor effect of vorinostat with 5-FU
in CRC cells selected for resistance to 5-FU (HT29FU cells) and in cells carrying an amplification of the
TS gene (H630-R10 cells), suggesting a potential mechanism by which vorinostat may overcome the
resistance to 5-FU [122]. Similarly, we recently showed that VPA/capecitabine combination treatment
synergizes with radiotherapy (RT), confirming the modulation of both TS and TP protein levels by
VPA in CRC models, even in the presence of RT [48]. Based on these data, a phase 1/2 study is
currently ongoing exploring VPA at an antiepileptic dosage, in combination with capecitabine, during
preoperative radiotherapy in locally advanced rectal cancers patients (V-shoRT-R3 trial) [131]. Notably,
data from the completed phase 1 of the study support the feasibility of VPA in combination with
chemoradiotherapy [132].
In the same context, Huang et al. demonstrated that TSA was able to decrease colon CSC properties
and, in combination with 5-FU, suppress colon cancer viability in vitro and colon tumorigenesis
in vivo [133].
Another challenging class of chemotherapeutics is represented by the “platinum complexes”,
which includes anticancer drugs such as oxaliplatin, cisplatin and carboplatin. Cisplatin is currently
employed for several tumors, such as testicular, ovarian, bladder, head and neck, esophageal, small and
non-small-cell lung, cervical, stomach and others, regiments containing oxaliplatin, with or without
a biologic agents in combination, are the optimal choice for metastatic CRC treatment, leading to
sufficient disease reduction and allowing patients to become eligible for resection of metastatic diseases.
However, cisplatin or oxaliplatin treatments are associated with drug resistance and several
adverse side effects. For these reasons, a combinational strategy aimed to revert resistance, improve
outcomes and reduce side effects, could be of great benefit. Unpublished results from our group
demonstrated that VPA induces cellular differentiation and sensitization of colorectal CSCs to
oxaliplatin. In details, by using CRC primary spheroid cultures, transduced with a TOP-GFP
Wnt reporter, we monitored apoptosis and cell proliferation in both differentiated cells and CSCs
within the same population, treated with VPA alone and/or standard chemotherapy [50]. Based on
these preliminary results, a randomized phase II trial has been designed by our group to evaluate
whether the combination of VPA with bevacizumab and oxaliplatin/fluoropyrimidine regimens
(mFOLFOX6/mOXXEL) prolongs progression-free survival (PFS) compared with bevacizumab and
oxaliplatin/fluoropyrimidine regimens alone, as the first-line treatment in patients with metastatic
CRC with mutation of RAS (Revolution Trial–Randomized phase II study of VPA in combination with
bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients with ras-mutated metastaTIc
cOlorectal cancer). Correlative studies will be performed on patient materials to study the impact of
the treatment on the CSCs population.
Cisplatin resistance has been reported in HNSCC cells to be related to enhanced stem cell properties,
tumor metastasis, and increased HDACs expression [134]. Wang et al. demonstrated that cisplatin
treatment, but not paclitaxel and doxorubicin treatment, result in the enrichment of CSCs, conferring
multidrug resistance in NSCLC cell lines by the induction of TRIB1 and HDACs [135]. It has been
demonstrated that TRIB1 enhances histone deacetylase 1 (HDAC1)-mediated p53 deacetylation and
decreases DNA binding of p53, decreasing its tumor suppressor activity [136]. Moreover, high levels of
TRIB1 show a significantly poorer prognosis in CRC patients, in NSCLC cisplatin-treated patients and
in a Chinese Han population with pancreatic cancer [135,137,138]. In metastatic NSCLC, pancreatic
and bladder cancer cisplatin treatment is associated with gemcitabine. In this regard, it has been
described that the pan-HDACi CG200745, decreasing the transcript for multidrug resistance protein
(MRP) 4, a member of the MRP/ABCC subfamily of the ATP-binding cassette, controls drug efflux and
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sensitivity in gemcitabine-resistant pancreatic cancer cells [139], for which gemcitabine-based regimens
are still the major treatment. Moreover, the inhibition of HDACs 1, 7 and 8 by TSA or vorinostat results
in an upregulation of e-cadherin in PDAC cells and downregulation of Oct-4, Sox-2, and Nanog, as
well as inhibition of PDAC tumor sphere formation, resulting in a strong potentiation of gemcitabine
therapeutic activity [16]. Interestingly, overexpression of HDAC7 has been demonstrated in pancreatic
cancer and suggested as clinical biomarker for pancreatic cancer diagnosis and prognosis [140].
Additionally, CG200745, by inducing miR-509-3p expression, selectively targets Hippo signaling
in cholangiocarcinoma cells and synergistically interacts with conventional chemotherapeutic
drugs, including gemcitabine, cisplatin, oxaliplatin and 5-FU, even enhancing the sensitivity of
gemcitabine-resistant cholangiocarcinoma cells to these drugs [141]. However, although co-treatment
of biliary tract cancer cells with HDACi, including TSA, VPA or vorinostat, and gemcitabine suppresses
EMT with tolerable cytotoxicity [62,142], it has also been reported that HDACi increase the expression
of both e-cadherin and vimentin in different cholangiocarcinoma cell lines, suggesting that further
analyses are needed before using these drugs in the clinic for the treatment of this tumor [142].
The preclinical synergistic interaction between HDACi and gemcitabine has also been described in
leiomyosarcoma, for which Lopez et al. demonstrated that the selective class I/IV HDACi mocetinostat
combined with gemcitabine exhibits synergistic effects in vitro and in vivo [143].
Interestingly, in a phase I study in which vorinostat was combined with carboplatin and
gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or
peritoneal cancer, despite no maximum tolerated dose determined due to toxicities, six of the seven
patients evaluable for RECIST (Response Evaluation Criteria in Solid Tumours) assessment had partial
responses (PR) [144]. These results indicate that the use of other HDACi with a better safety profile, such
as VPA, could be further investigated in combination with gemcitabine and/or platinum compounds.
It has been already described in the literature that HDACi modulate the EGFR family in several
ways, as also reported by our group [145,146]. This evidence explains how HDACi improve the
EGFR-based target therapy and how they overcome the drugresistance that is commonly reported
after the first anti-EGFR target therapy cycles of treatment. Indeed, Wang et al. showed that HDAC6
overexpression confers resistance to gefitinib via the stabilization of EGFR. Moreover, inhibition of
HDAC6 by CAY10603, a selective inhibitor, represses the proliferation and synergizes with gefitinib
to induce apoptosis in lung adenocarcinoma cell lines, via the destabilization of EGFR [147]. In the
same model of NSCLC, it has been reported that the knockdown of HDAC1 sensitize resistant cells to
paclitaxel in vitro and that SNOH-3, a selective HDAC1 inhibitor, induces apoptosis and suppresses
angiogenesis in preclinical models [148]. In addition, we found that vorinostat or VPA sensitize primary
NSCLC cell lines to anti-ErbB3 monoclonal antibody by modulating the EGFR family also in 2D and in
3D culture models, enriched in CSCs [47]. Interestingly, a phase I study of CUDC-101, a multitarget
inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with HNSCC,
showed an increase of 1.5 years in median duration of response and 9/15 patients free with increased
PFS [149]. Other examples of combined treatment of HDACi with targeted drugs have also been
reported. For example, Gruber et al. showed that 4SC-202, a class I HDACi, abrogates GLI activation
and Hh target gene expression in both SMO-inhibitor-sensitive and -resistant cells. Significantly, it has
been reported that treatment with SMO inhibitors leads to rapid and frequent development of drug
resistance in basal cell carcinoma and medulloblastoma [68].
Finally, it is important to highlight that, despite a good and durable clinical benefit obtained by
immune checkpoint blockers (ICB) in several tumors, particularly “hot” or “immunogenic tumors”,
in other solid tumors, the responses with ICB are quite modest, representing a critical therapeutic
challenge [150]. A possible solution to address such challenges could be to combine ICB with specific
drugs aimed to prime the immune response and increase the tumor immune profile. Published data
suggest that HDACi enhance the immunogenicity of cancer cells. Indeed, HDACi are involved in the
regulation of NK cell-activating ligands, MHC class I and II molecules, elevation of NK and CD8+
cytotoxicity and proinflammatory cytokines, and modulation of Treg and Treg Foxp3 expression [151].
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Terranova-Barberio et al. showed that HDACi treatment leads to a significant decrease in tumor
growth through epigenetic priming of the immune system, with increased tumor antigen presentation
and immune cell activation. Interestingly, both pan-HDACi and class-selective HDACi promote an
upregulation of PD-L1 and HLA-DR in triple negative breast cancer cell models when co-cultured
with peripheral blood mononuclear cells, associated with a downregulation of CD4+ Foxp3+ Treg
in vitro and in vivo [152]. In line with this finding, Miyashita et al. found that the combination of
low-dose VPA and gemcitabine enhances the susceptibility of the PANC-1 cell line to γδT cell-mediated
tumor cell lysis through the upregulation of major histocompatibility complex class 1-related chain
molecules [153]. Interestingly, several phase I and II clinical trials, based on HDACi treatment in
combination with immunotherapy, are recruiting with the aim to identify optimal biological dosing
strategies [151]. The first results are not yet available, and additional preclinical studies need to be
performed to disclose the mechanisms underlying the controversial HDACi-dependent effects.
6. Conclusions and Future Perspectives
In solid cancers, multiple factors contribute to the failure of commonly used therapies, leading to
relapse. Here, we emphasized the aspects related to CSCs and their involvement in this phenomenon,
reviewing what is known in the literature. By highlighting the pathways and mechanisms responsible
for the resistance to the commonly used chemotherapeutics, we suggest that only the addition of
pleiotropic molecules will target the CSCs population efficiently. From this perspective, HDACi could
be among the best candidate drugs. We have reviewed the role of HDACi in solid cancers, specifically
in the CSC subpopulation, and have pointed out some mechanisms by which HDACi are able to
overcome drug resistance. In clinicaltrials.gov, 377 registered studies in solid tumors with HDACi
were retrieved. Most of them are phase-I and phase-II trials and several are currently recruiting as
a single agent or in combination therapies (Table 2). Only seven phase-III studies are reported and
only one have published results (Table 3). In the latter study, the vorinostat effect was evaluated
in monotherapy, in a double-blind, randomized placebo-controlled trial, involving 90 international
centers and enrolling 661 patients with measurable advanced malignant pleural mesothelioma and
disease progression after one or two previous systemic regimens. The study was negative, with no
statistical significant difference (median overall survival of 30.7 weeks; 95% CI 26.7–36.1) versus the
placebo arm (27.1 weeks; 95% 23.1–31.9) [154] confirming negative results obtained by this class of
agent in monotherapy in several solid tumor types [155]. Another phase -III trial (ClinicalTrial.gov
identifier: NCT00473889) exploring the combination of vorinostat plus carboplatin and paclitaxel in
NSCLC patients was terminated due to negative results and increased toxicity, although a phase II trial
demonstrated that vorinostat was able to improve the efficacy of chemotherapy [156]. Even as single
agent, drug-induced side-effects of HDACi were observed, associated with several toxicities including
cardiotoxicities, hematological and gastrointestinal toxicities [157]. However, despite being able to
affect a multitude of physiological cellular process, thus being potentially very toxic, several HDACi
have gained FDA approval for use in hematological malignancies [155].
Table 2. Phase and status of HDACi clinical trials: clinical trials registered in https://clinicaltrials.gov/










Early Phase 1 2 0 0 0 0 0 1 1 4
Phase 1 24 34 8 109 45 2 5 3 230
Phase 2 15 16 3 55 37 0 1 3 130
Phase 3 1 2 0 1 1 0 0 2 7
Not
Applicable 0 1 0 4 0 0 1 0 6
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Moreover, we strongly believe that HDACi should be use in clinical practice as biological modifiers
and not as cytotoxic drugs. Consequently, by contrast with clinical trials conducted so far, low doses of
these drugs should be used to avoid direct cytotoxic effects. In addition, we believe that the therapeutic
window of this class of drug is only in combination with standard chemotherapeutics.
On these bases, further clinical and preclinical investigations should be conducted to better
disclose the mechanisms by which HDACi modulate several signaling pathways in different tumors.
In summary, as highlighted in this review, the promising data obtained until now could represent the
foundation to test novel combinatorial therapeutic strategies, where HDACi would be combined with
commonly used drugs to improve therapeutic efficacy in solid cancer tumors.
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